<SEC-DOCUMENT>0001628280-22-029499.txt : 20221110
<SEC-HEADER>0001628280-22-029499.hdr.sgml : 20221110
<ACCEPTANCE-DATETIME>20221110161808
ACCESSION NUMBER:		0001628280-22-029499
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221110
DATE AS OF CHANGE:		20221110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36579
		FILM NUMBER:		221377492

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>advm-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:915153f8-5dd7-44a4-84da-67d592863439,g:2581671a-d3ba-4d70-a3e7-003e900c7a5c,d:d78fc84db2574938a52c2b619c0c6019--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:advm="http://www.adverum.com/20220930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>advm-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80L2ZyYWc6NzlkMGU4NzA1Y2Y2NDBhOGEyMGJlNjY3MGNmZDAwMzcvdGFibGU6MGNkOWRjYTYxODMzNDZhM2JkNTk4NmU2OWYwYjdmY2EvdGFibGVyYW5nZTowY2Q5ZGNhNjE4MzM0NmEzYmQ1OTg2ZTY5ZjBiN2ZjYV8zLTEtMS0xLTI5MDk1_a12e8df2-1891-44ab-a846-f4458e58748b">false</ix:nonNumeric><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80L2ZyYWc6NzlkMGU4NzA1Y2Y2NDBhOGEyMGJlNjY3MGNmZDAwMzcvdGFibGU6MGNkOWRjYTYxODMzNDZhM2JkNTk4NmU2OWYwYjdmY2EvdGFibGVyYW5nZTowY2Q5ZGNhNjE4MzM0NmEzYmQ1OTg2ZTY5ZjBiN2ZjYV80LTEtMS0xLTI5MDk1_01ca5eb1-efb3-4197-94f8-686b94ad1c74">2022</ix:nonNumeric><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80L2ZyYWc6NzlkMGU4NzA1Y2Y2NDBhOGEyMGJlNjY3MGNmZDAwMzcvdGFibGU6MGNkOWRjYTYxODMzNDZhM2JkNTk4NmU2OWYwYjdmY2EvdGFibGVyYW5nZTowY2Q5ZGNhNjE4MzM0NmEzYmQ1OTg2ZTY5ZjBiN2ZjYV81LTEtMS0xLTI5MDk1_bbfcb86e-493c-4a9e-892c-b3175c40ba66">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80L2ZyYWc6NzlkMGU4NzA1Y2Y2NDBhOGEyMGJlNjY3MGNmZDAwMzcvdGFibGU6MGNkOWRjYTYxODMzNDZhM2JkNTk4NmU2OWYwYjdmY2EvdGFibGVyYW5nZTowY2Q5ZGNhNjE4MzM0NmEzYmQ1OTg2ZTY5ZjBiN2ZjYV82LTEtMS0xLTI5MDk1_95a93698-8ecb-4387-8342-46f473319bd2">0001501756</ix:nonNumeric><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80L2ZyYWc6NzlkMGU4NzA1Y2Y2NDBhOGEyMGJlNjY3MGNmZDAwMzcvdGFibGU6MGNkOWRjYTYxODMzNDZhM2JkNTk4NmU2OWYwYjdmY2EvdGFibGVyYW5nZTowY2Q5ZGNhNjE4MzM0NmEzYmQ1OTg2ZTY5ZjBiN2ZjYV83LTEtMS0xLTI5MDk1_e5f83fef-4899-4849-968c-9fbd0324de5d">12-31</ix:nonNumeric><ix:nonNumeric contextRef="ifcc1c37af20f4e43b05ad926c9e5ef3b_I20220930" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMzg0ODI5MDcwMTczOQ_6a3d187e-f234-4fd7-9010-35776946dddc">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="advm-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f50a0d4c90547b5a6e67d46b4c5995e_I20221104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ieb2df3a435684436bddd5c51c154a23a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i44433fe8d4104d3a83fe0df026333455_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d6f32550ba1434c9e67090a8d16b28e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9842733bcbb49b2ac6dd8ef51160cf1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67846955d203444991996f8db5938a69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fc4612654aa4870acef5f852550d561_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0eb628814a04ad8971209780bc02232_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc0d4ed39fb04b2089aee2f3e0739e42_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00ced84e48d142babc4e6edcc897094a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22a80d1fae54e15bac4c1582f12e26e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d3a4780987e4e9692fdafbb646d0e5a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5d6b6204c994327981fb6f38ee2e5ff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e35090827424e029a917e87a3044012_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib90a0153e711486598954353cda4c4f6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia61c0616a34746bf8b0475dd12eece06_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f8b7aaa691944a4a550b8ced951db24_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i972d3044b3264665a366176257e6f0a4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65bbe7741c5844b19b5542e8c5caf343_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46e83442dc5749b0a5d1ad0026c402d2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4af61eabf3d42e09f408fb99c2367e5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f851ab82a443b5a834a5415c2880e0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65c2b4e4a1b54fdf897b4c3015a17e3f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id191c6d1957d4719b9c5e156e348e8db_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbb610db5124447a81519c9fddb553ad_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19622582a11f4462a48573d5c32fb7c5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6388d78a0f704f1c86da5e1f4c37aa33_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47c31b7bd48c4503a19ac8602ddba6ff_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic047966dbeb843b496329bb693a66b72_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice288f0d914a4d95915117eb965b9fc7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib238c3743368488b9eb8ed8b364431e9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i480b594590b940cd851f225ae27fd622_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90ba8498524046978db9a015fa44aeab_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4af913e76594eaa821e5e62c4699428_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbfe14fd14dc46eeae6028be0bedb756_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dda90e2dcb84f4abf4d236b758309c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic53d2c3285b2405c89747aede88daf77_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2061f8740354460fbd6fa9e20be2522a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6353d7b319d44289aff3a0e8fcae2bac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe95493f3b5a4dc5b74fbbfe667afede_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i121cdd6f1a6b4029901948f5a1c143d5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idebb246dffde4b12a9cd6c4cf9a7f620_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaefcad51308b4b3790bcf428575004c3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94109faeb1f44d1da072d36ea355382d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i841267b2dc374ac3ad96e04341fb587a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5269eef549e4b18bb64d22f1b54e0ca_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37097774df59414a8b4fe74f0511d45f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23eb60965e1a4ce59cc12982fa1fc9fa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe7ae56850e4431a1e91bc6167ef963_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475232b6968b4298945132136bd68a2d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1230d7a79cd43ca8b3d88d5b06de1db_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i609ae2740da044548ec7c4c368af7b51_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceda05b2f1b4410faf5aca6a1f9cb9c0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9921ca0a5094f0bac938ac91d53078a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07da0e72c1be41e7aaf42551fd516c9f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bd7d22674a0458b874208ec2cf0c887_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i851c8e2358684ae6b21b416e2330cb70_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d43fd4cf2a549a0b04c2f34890cb7ff_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e6eb7bc0bbc467bbdb22d47d409103f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a18ede15a1b47778e90d6d5c7bb304f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45935ce9978f46239a14318be6d6f2ae_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9809e3ed4b544acb18ad2a9ef94d4fa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5ff1d37342b4c27865fff03a63c60c8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c37575b017e43bf9a8ac40ac84a9957_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021fc47f853242c2be3df72c455d228f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b517ce4be034b4db4fafa152857e3ae_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if94ce7427b6d4ad3bf65c204029b5bb5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b38d8b71f5349f99b74f3e4bd7dfb70_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a51274da0d34c37ad110f512dfb6c25_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib282142f99284b73981803c872356bd9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i873db4f7c8b74c7fadbdceb695e76de6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3979c9c68184f3089401c14ce8a48c1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i791b55383c7c4814974ebaa3df5a5e64_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15d7519e0368492d811f7889f8f65003_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ebe063f5210487eb63855bfa84821b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8a5bca20fd4ab780190fe9cbc37eb6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45214185b5144da5833b2593032606d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcc1c37af20f4e43b05ad926c9e5ef3b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i516fa99e52e24c8d83b6da7334ab3f9a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6877ebb93e445a3a2cefb8eb73f1d51_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica79f5395f3b4b1ba885cad3da2e3411_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b8bf7bd53f54d4c801f071028410a38_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic95b4f1bc3f54077994fca5c6a6559a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9da0b7851f7b452aa126439ff59ef51a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b828ba25c3d418d8eda881a27399aa8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20efbf626199415a933fd647730ef5bf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8313d8ae20774ec3899f99bacdb83cf8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3befe5528eac478382c46f05cfe1a877_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i073bece618d24b9dade2383ac940ee3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79d4b72dd8084e709d360860964f3246_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i576e4bb113d94eed83356af145669908_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac1959e2c1824ece92a8a5edf1bfaac6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29b93864200e4683b63e032b6c30feaa_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d0ce2c0d4824b3893f8f9741ffe6466_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65531dff90074634acb629953b46148e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74b15a520ab64b8ba0d52607a8761034_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5cc515fb7324c88b70e0087f46cd446_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8482f95dee2f458a9ec19baa5f1da9dc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ee3bd88ea5a4bfab2257c3d73958b7a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d9330c6a204905a56b7b28a34889ae_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e1fbe5196e04b16b259d139c7ef556a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie986bf5a8039432c815e7e22b77b230a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i849c716b759343fb82104acfaafcf33f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i027ecc53eb374b44b0ff45c72b438658_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i058b41effd8f43b9be1d05aaf73dfe08_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d479b8fb7b044e3aa6c6ab883f2dd7a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16076e8ab5354387af2ac1ec6fc8cbdc_I20220706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>advm:employee</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i71258ef0094f45c882375b7e1010e7ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58f2678ad14b4a3d881b892b268a77d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22948541eb864302a316aae361adb856_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0c3eb26c891436cabc497ed5bd59128_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ad217fa80da4c1da3ead4e449ee044e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id96f08f18d8844938eb17eab71c615ff_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id78fc84db2574938a52c2b619c0c6019_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDM2_edbf2aa1-3869-4380-97d9-5d95d5b8b3ff">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6MTZmZTBmNmI2NzcwNGY5YWE1M2QzNzc4YzRhN2Y5NjUvdGFibGVyYW5nZToxNmZlMGY2YjY3NzA0ZjlhYTUzZDM3NzhjNGE3Zjk2NV8wLTAtMS0xLTI5MDk1_672a6606-d7df-482e-a507-27a89cc2388f">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNjY_2ecef4d1-cb57-400e-baf2-84fb56e65884">September&#160;30, 2022</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6NzFmZjQ3MWEzZDgyNDg2NmI1Njc2ZmRiMTE1MzZhNzAvdGFibGVyYW5nZTo3MWZmNDcxYTNkODI0ODY2YjU2NzZmZGIxMTUzNmE3MF8wLTAtMS0xLTI5MDk1_b08ef748-9c34-4e44-a0a1-b106e4dfdac2">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDI5_270306e0-2f1e-4171-a0d7-b9dbcad8a7bd">001-36579</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDI1_7547b97a-d594-4a26-b4c3-d668ac7bfb09">Adverum Biotechnologies, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6MTk4M2I4NmYyZDFhNGZiMDgyZTQzNzgyZGNhYmM1ZTkvdGFibGVyYW5nZToxOTgzYjg2ZjJkMWE0ZmIwODJlNDM3ODJkY2FiYzVlOV8wLTAtMS0xLTI5MDk1_34c5dfc8-3de4-4719-8792-17db3eada0fb">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6MTk4M2I4NmYyZDFhNGZiMDgyZTQzNzgyZGNhYmM1ZTkvdGFibGVyYW5nZToxOTgzYjg2ZjJkMWE0ZmIwODJlNDM3ODJkY2FiYzVlOV8wLTItMS0xLTI5MDk1_d327d595-ecd6-464b-b21e-28280e59fbf9">20-5258327</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDI2_cae1fad2-1797-40c7-aa3b-a62b0492a811">100 Cardinal Way</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDIz_99eb7f8b-4a4f-4920-a431-a2ffb0508d78">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDI4_095698d0-2bb3-4dec-a8bd-d3f422d91534">CA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDMx_33967b27-0e85-49a1-82be-7676cc44bb7b">94063</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF82OTk_1cc551f3-a9b7-4616-9f05-5ddd9863c569">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDMy_a5554e08-5062-4131-81e6-754d51c255b7">656-9323</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Trading symbol</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6NmM4MzU4N2QzMjYwNDU0Yjg0MjNlZDFkOTljYmQxOTgvdGFibGVyYW5nZTo2YzgzNTg3ZDMyNjA0NTRiODQyM2VkMWQ5OWNiZDE5OF8xLTAtMS0xLTI5MDk1_b191dac3-3609-4c3b-ac4a-91e57451c381">Common Stock, $0.0001 par value</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6NmM4MzU4N2QzMjYwNDU0Yjg0MjNlZDFkOTljYmQxOTgvdGFibGVyYW5nZTo2YzgzNTg3ZDMyNjA0NTRiODQyM2VkMWQ5OWNiZDE5OF8xLTEtMS0xLTI5MDk1_c01c513d-1cbe-44c7-ab61-0d845a18ba68">ADVM</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6NmM4MzU4N2QzMjYwNDU0Yjg0MjNlZDFkOTljYmQxOTgvdGFibGVyYW5nZTo2YzgzNTg3ZDMyNjA0NTRiODQyM2VkMWQ5OWNiZDE5OF8xLTItMS0xLTI5MDk1_d100bb3b-8e75-49b3-ad5c-9424813fd249">The Nasdaq Global Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDI0_3ceb31ec-b409-4b07-95e8-a608bca6bc10">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDMz_d665cd6c-8d7e-423c-a22a-3c2cba99326f">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6MGI1NzYxZjlmMGYxNDQ2YWI3NmU1NzU5Mzg0NzRlNTkvdGFibGVyYW5nZTowYjU3NjFmOWYwZjE0NDZhYjc2ZTU3NTkzODQ3NGU1OV8xLTAtMS0xLTI5MDk1_918c0deb-e2c9-482b-8dde-f9f7a64481db">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6MGI1NzYxZjlmMGYxNDQ2YWI3NmU1NzU5Mzg0NzRlNTkvdGFibGVyYW5nZTowYjU3NjFmOWYwZjE0NDZhYjc2ZTU3NTkzODQ3NGU1OV8xLTQtMS0xLTI5MDk1_125fbfe3-0830-4252-a3e7-035191748232">x</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6MGI1NzYxZjlmMGYxNDQ2YWI3NmU1NzU5Mzg0NzRlNTkvdGFibGVyYW5nZTowYjU3NjFmOWYwZjE0NDZhYjc2ZTU3NTkzODQ3NGU1OV8yLTQtMS0xLTI5MDk1_f55838ed-4149-41e9-9303-2a31b3e3018a">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDM1_24c902ab-5f09-4964-9460-cb001b60bf5f">x</ix:nonNumeric></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of November&#160;4, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i0f50a0d4c90547b5a6e67d46b4c5995e_I20221104" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yMzM4_5a9f4961-781d-4146-8602-4d75f6062782">99,729,025</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_13">PART I&#8212;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_13">5</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_16">Item 1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_19">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_19">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_19"> 30, 2022 and December 31, 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_22">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_22">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_22"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_22">September </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_22">30, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_25">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_25">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_25">S</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_25">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_25">ptember</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_25"> 30, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_28">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_28">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_28"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_28">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_28"> 30, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_28">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_31">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_31">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_70">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_70">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_100">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_100">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_103">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_103">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_106">PART II&#8212;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_106">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_109">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_109">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_112">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_112">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_139">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_139">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_142">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_142">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_145">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_145">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_148">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_148">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_151">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_151">66</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_154">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id78fc84db2574938a52c2b619c0c6019_154">67</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="id78fc84db2574938a52c2b619c0c6019_10"></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS SUMMARY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in common stock involves numerous risks, including the risks described in &#8220;Item 1A. Risk Factors&#8221; of this Quarterly Report on Form 10-Q. Below are some of these risks, any one of which could materially adversely affect our business, financial condition, results of operations, and prospects. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs for at least twelve months from the date of this filing. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to comply with Nasdaq&#8217;s continued listing standards.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of our product candidates, either in nonclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of nonclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to successfully develop and maintain robust and reliable manufacturing processes for our product candidates, we may be unable to advance clinical trials or licensure applications and may be forced to delay or terminate a program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet clinical or potential commercial demand, lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have relied, and expect to continue to rely, on third parties to conduct some or all aspects of our vector production, process development, assay development, product manufacturing, product testing, protocol development, and research, and these third parties may not perform satisfactorily.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will rely on third parties to conduct some nonclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Final marketing approval for our product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from its sales, if any, could be limited.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The coronavirus (&#8220;COVID-19&#8221;) pandemic has impacted our business practices and the effects of its continued impact on our business, results of operations, and financial condition will depend on future developments, which cannot be predicted.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure or perceived failure to comply with existing or future laws, regulations, contracts, self-regulatory schemes, standards, and other obligations related to privacy, data protection, and data security (including security incidents) could harm our business.  Our compliance or the actual or perceived failure to comply with such obligations could increase the costs of our services, limit their use or adoption, and otherwise negatively affect our operating results and business.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="id78fc84db2574938a52c2b619c0c6019_16"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span><br/></span></div><div id="id78fc84db2574938a52c2b619c0c6019_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMy0xLTEtMS0yOTA5NQ_ec4c2eac-bd5e-4ac5-80d2-ae1f387a6fab">84,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMy0zLTEtMS0yOTA5NQ_52796e2a-eeb6-4c51-a66e-81e0e997dc45">34,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNC0xLTEtMS0yOTA5NQ_39b3e7a4-fdfe-4087-ba6f-1b7411c76a70">118,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNC0zLTEtMS0yOTA5NQ_8c39aa29-c8d7-4f72-9eaa-4c60afaf155a">270,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease incentive receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:IncentiveToLessee" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNS0xLTEtMS0yOTA5NQ_328bc2b4-79dd-4074-a35c-f3ba7679714d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:IncentiveToLessee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNS0zLTEtMS0yOTA5NQ_aa6022f3-c59f-45af-9fb3-d2267422b4aa">5,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNi0xLTEtMS0yOTA5NQ_dbbb45e4-1394-4eee-a7e8-41b2ee566d9e">9,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNi0zLTEtMS0yOTA5NQ_266f8abc-a4f3-48c3-ae85-a8065194d24e">6,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNy0xLTEtMS0yOTA5NQ_d2bdd80d-2af4-4a1a-8e0d-0013a6f53978">213,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNy0zLTEtMS0yOTA5NQ_b815d198-5a54-4c9e-85f6-b06108fc43e8">317,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfOC0xLTEtMS0yOTA5NQ_30792cbb-1436-4e43-99c0-5804c037aa77">79,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfOC0zLTEtMS0yOTA5NQ_1838b8df-22ae-46c5-98a9-dbb220e00a89">86,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfOS0xLTEtMS0yOTA5NQ_756221b5-674b-438c-89da-d6972f4afcc3">36,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfOS0zLTEtMS0yOTA5NQ_174230e6-d74d-4f85-910e-4625cf3c2207">33,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTEtMS0xLTEtMjkwOTU_c3d080fa-94ec-4913-affe-930783dd24c0">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTEtMy0xLTEtMjkwOTU_9145fa0d-6a6f-44f2-baac-b19b62213714">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred rent receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:DeferredRentReceivablesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTItMS0xLTEtMjkwOTU_818ed79a-7f16-44ed-b7ef-a7f5d197865f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:DeferredRentReceivablesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTItMy0xLTEtMjkwOTU_88367ff5-95c9-4185-9668-ae095ccec11a">769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposit and other long-term assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTMtMS0xLTEtMjkwOTU_1dabfcb0-d74c-4d5f-bd57-3c1967416609">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTMtMy0xLTEtMjkwOTU_be0710f9-2f6a-4cb6-95d1-16cfd9fd194a">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTQtMS0xLTEtMjkwOTU_83e7dc5f-f94e-4ed4-823f-faca1cdbb946">332,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTQtMy0xLTEtMjkwOTU_e84ba44c-7d51-4370-aed4-5050efc6f198">439,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTctMS0xLTEtMjkwOTU_20e16617-20ef-4622-a495-09c87f2b39f3">846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTctMy0xLTEtMjkwOTU_4bdca73c-bb0b-48e6-8fd0-beba9acf68b3">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTgtMS0xLTEtMjkwOTU_8b5bc63c-e91c-44aa-be18-a30047be86a5">16,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTgtMy0xLTEtMjkwOTU_ae6d318b-84ad-47d4-8dc1-5fb1bc577cf5">18,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability, current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTktMS0xLTEtMjkwOTU_48aecddf-6c7b-4efc-abad-7bd42c860dbb">11,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTktMy0xLTEtMjkwOTU_b9fa5a71-9c0c-4436-ba51-fec591796a84">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjEtMS0xLTEtMjkwOTU_041df0ab-6acb-4071-8a3d-95d8c273485a">28,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjEtMy0xLTEtMjkwOTU_fb78e248-4c6a-4a6b-a857-fda791bebfa3">21,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability, net of current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjMtMS0xLTEtMjkwOTU_b1b35117-ef9f-4314-92d3-8a5964550bda">94,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjMtMy0xLTEtMjkwOTU_ea363306-b87b-4cb5-a356-6f6b2449052f">101,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjQtMS0xLTEtMjkwOTU_e30dca1c-393c-455b-a93f-1404601f5c5d">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjQtMy0xLTEtMjkwOTU_7b606c20-b086-45ce-9e2d-744ddec73d2c">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjUtMS0xLTEtMjkwOTU_6cd4d663-c4c0-4e3c-acc8-52b282a8ea00">124,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjUtMy0xLTEtMjkwOTU_0bc27ce4-af20-4dbf-a778-4eee28b57f7c">123,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjgtMS0xLTEtMjkwOTU_00b4f3ab-02de-489b-a579-d68233936258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjgtMy0xLTEtMjkwOTU_97f01ba9-37cb-4eda-ac00-67b481e7b8f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjktMS0xLTEtMjkwOTU_14fdd95e-d806-4891-8289-18fb1fadbdbb">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjktMy0xLTEtMjkwOTU_78bb62ef-1f41-4abf-a12a-c8c6e8b38e15">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzAtMS0xLTEtMjkwOTU_558efbaf-35ec-4084-88bf-b3a8be631d0f">980,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzAtMy0xLTEtMjkwOTU_9b1753b0-ea10-4bc7-a8a7-83a7c9a8b537">964,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzEtMS0xLTEtMjkwOTU_9ab7e53b-6102-402a-90d0-7fefa53e5e57">1,953</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzEtMy0xLTEtMjkwOTU_c432ea06-6cad-4e8d-ba4c-6f46adc9e4d9">714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzItMS0xLTEtMjkwOTU_d385ec9b-dd44-441b-a5f1-2ca07b7eed78">769,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzItMy0xLTEtMjkwOTU_5aa2d20f-a895-4d78-aa34-d83985fc87bc">648,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzMtMS0xLTEtMjkwOTU_f8397829-e444-43ac-ad5e-95c9d9e7dbb0">208,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzMtMy0xLTEtMjkwOTU_7d9ef787-e573-4e2a-8b07-91e6c0df43c8">316,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzQtMS0xLTEtMjkwOTU_d59174dc-886b-4f7d-ac03-c4c0f3f30504">332,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzQtMy0xLTEtMjkwOTU_6ee60376-5be1-4441-b30a-cea7235ec0a4">439,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMi0xLTEtMS0yOTA5NQ_0d48ed87-f510-4aac-9074-aefe8d11b650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMi0zLTEtMS0yOTA5NQ_4b5fc55d-b3f5-4ea4-91a3-25d52b247182">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMi01LTEtMS0yOTA5NQ_9d6e9f00-0f3c-4248-9aee-34cf350c6ee9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMi03LTEtMS0yOTA5NQ_b3b82786-8d9d-4586-99cc-4ca257680861">7,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNS0xLTEtMS0yOTA5NQ_e13068d4-97b2-48a1-91a6-3284ae939c55">23,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNS0zLTEtMS0yOTA5NQ_4bc07b2e-848c-435b-8d2f-571d565afd53">24,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNS01LTEtMS0yOTA5NQ_8ca5d464-c7cc-48d2-86f0-c5f41cf8470c">77,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNS03LTEtMS0yOTA5NQ_27cd5993-4480-4f20-91b5-51d6114fe0ff">66,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNi0xLTEtMS0yOTA5NQ_17f1031b-ef7f-43cd-8b49-4fad25d0d5fb">17,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNi0zLTEtMS0yOTA5NQ_791e2f91-f4aa-4915-9b7f-3d1bac060d9c">14,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNi01LTEtMS0yOTA5NQ_a0dfe16a-8213-43ef-ba53-ad9d18d71fbd">46,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNi03LTEtMS0yOTA5NQ_a6bf5ba1-3dae-4075-a520-e4f28eb49e0c">52,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOC0xLTEtMS0yOTA5NQ_63ad6567-7ca4-4c74-a35d-fb5586bdda86">41,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOC0zLTEtMS0yOTA5NQ_7a5bc699-ee77-414e-a060-727dd03d1a30">38,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOC01LTEtMS0yOTA5NQ_2a555d1b-2dbb-4c6a-9f89-8102ee1204c0">123,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOC03LTEtMS0yOTA5NQ_eddb10cc-4223-4e6b-876c-4b115f895c53">119,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOS0xLTEtMS0yOTA5NQ_074f1292-1050-476b-8662-4f73b20cd65f">41,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOS0zLTEtMS0yOTA5NQ_f219954b-ab9a-4ec5-826b-f18e3492084c">38,522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOS01LTEtMS0yOTA5NQ_e051fd47-e852-4b74-8946-84c4c5dec871">123,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOS03LTEtMS0yOTA5NQ_67cd23f1-47c2-4204-aba2-1a3a3f504612">111,703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTAtMS0xLTEtMjkwOTU_8f1c2721-232d-4a44-bd00-d8443ccb9f13">923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTAtMy0xLTEtMjkwOTU_0a3ba30e-53ff-4753-accf-78e8749f1295">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTAtNS0xLTEtMjkwOTU_4d55c4ea-5ba1-4f76-9d8c-e62f5edfb2f8">1,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTAtNy0xLTEtMjkwOTU_02fe2dfd-0626-498b-bd9f-64f679d08aee">572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTEtMS0xLTEtMjkwOTU_f7257971-9912-4c2c-afbb-77a4ea66b307">40,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTEtMy0xLTEtMjkwOTU_ebb8d85e-b77c-4b0f-ad6d-99b59e483392">38,362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTEtNS0xLTEtMjkwOTU_e66df4c4-5802-424c-b80d-08b3fff07db1">121,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTEtNy0xLTEtMjkwOTU_d938fde0-c151-44cf-9300-4e703cd58b34">111,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTItMS0xLTEtMjkwOTU_38b4037e-7531-48cf-9120-a9376407b454">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTItMy0xLTEtMjkwOTU_a079a649-34ed-4894-b263-aa9def733354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTItNS0xLTEtMjkwOTU_b16b67ee-f628-42da-a169-441223b27fae">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTItNy0xLTEtMjkwOTU_0e94ca4a-8b3f-4523-92dc-dde61f0c040f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTMtMS0xLTEtMjkwOTU_977de856-65a9-4cfe-97dd-c1cf30e58e59">40,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTMtMy0xLTEtMjkwOTU_ad932a15-5871-41ce-93bc-c5208b858b71">38,362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTMtNS0xLTEtMjkwOTU_f6e85814-d86c-491b-b4bb-c2aedadf02aa">121,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTMtNy0xLTEtMjkwOTU_82b5ae9b-cc26-48ac-a06b-feaa4acfb1ae">111,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTUtMS0xLTEtMjkwOTU_1c51e3b5-01ff-44d9-8445-ac5236504036">127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTUtMy0xLTEtMjkwOTU_61dba675-992a-4340-90ca-b3c3636a78bd">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTUtNS0xLTEtMjkwOTU_4e21c159-dbe2-4191-8b06-9a386fde6486">1,189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTUtNy0xLTEtMjkwOTU_6f566f6e-5e34-44da-94e8-5a327d11b21d">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTYtMS0xLTEtMjkwOTU_c5265520-df49-4bfe-ac1f-6da712014957">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTYtMy0xLTEtMjkwOTU_e9977933-baa0-4e4a-8905-c261458aceb8">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTYtNS0xLTEtMjkwOTU_c062cdd4-47f8-48f4-9a92-a8ea8d8edc7d">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTYtNy0xLTEtMjkwOTU_495c353c-c3dc-4eb6-b23f-9e7e75dc69df">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTctMS0xLTEtMjkwOTU_862dcc9d-1dc4-4fce-a0d5-57d0136ef53a">40,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTctMy0xLTEtMjkwOTU_14951c3b-496d-438c-8e82-770875cc21ac">38,468</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTctNS0xLTEtMjkwOTU_66f285dd-82c5-40c2-868b-4d28dc9b4918">123,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTctNy0xLTEtMjkwOTU_6502e029-1214-419c-b29f-b552afb09a6e">111,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtMS0xLTEtMjkwOTU_87336572-c005-4bf0-a9ea-d8612ac2276f"><ix:nonFraction unitRef="usdPerShare" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtMS0xLTEtMjkwOTU_dd3d7927-521d-450f-afd3-e2eb89d6febb">0.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtMy0xLTEtMjkwOTU_c6c36f6c-cb08-4c8c-98fb-d5c588e1f1ed"><ix:nonFraction unitRef="usdPerShare" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtMy0xLTEtMjkwOTU_d38d2c3a-0bab-4e58-8b89-a7e457c35839">0.39</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtNS0xLTEtMjkwOTU_388d3821-d037-4f2f-a7df-6b29ef710b8e"><ix:nonFraction unitRef="usdPerShare" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtNS0xLTEtMjkwOTU_7aca5ad0-0c00-4a29-8c05-fc70c0527583">1.23</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtNy0xLTEtMjkwOTU_178a4d38-a704-4cf4-8c08-c2b1c2f76937"><ix:nonFraction unitRef="usdPerShare" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtNy0xLTEtMjkwOTU_426f18de-801b-43de-8489-33d80961f8ea">1.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares used to compute net loss per share - basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktMS0xLTEtMjkwOTU_0cfc1c88-da0b-489f-aec1-2b38ac010361"><ix:nonFraction unitRef="shares" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktMS0xLTEtMjkwOTU_26f5fd44-9a5a-4b70-98cb-207ddbb803c5">99,475</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktMy0xLTEtMjkwOTU_4b8aca36-25ed-4fee-ae36-5c1119cc156a"><ix:nonFraction unitRef="shares" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktMy0xLTEtMjkwOTU_6c4cf9b6-fa1f-40ba-a38e-f29b9151f2fc">98,126</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktNS0xLTEtMjkwOTU_7d190921-2df8-465d-b4d2-0de853075651"><ix:nonFraction unitRef="shares" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktNS0xLTEtMjkwOTU_d6b51eaa-52bb-4625-a2ff-65d821f186d5">99,027</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktNy0xLTEtMjkwOTU_778deac0-d98b-47db-96f0-b757b89222ec"><ix:nonFraction unitRef="shares" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktNy0xLTEtMjkwOTU_b04a61fc-5bf8-4b14-a36b-d3be385099e6">97,966</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>(Loss)/Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44433fe8d4104d3a83fe0df026333455_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMi0xLTEtMS0yOTA5NQ_1975b64b-2eac-4efa-971a-699a0262393e">98,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44433fe8d4104d3a83fe0df026333455_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMi0zLTEtMS0yOTA5NQ_753ce4f0-c319-4ff9-8cee-af3f6434bae8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d6f32550ba1434c9e67090a8d16b28e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMi01LTEtMS0yOTA5NQ_5ccbad72-4cc3-4632-b870-93bdd78d9b82">964,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9842733bcbb49b2ac6dd8ef51160cf1_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMi03LTEtMS0yOTA5NQ_01e908b8-3009-441a-9bae-9e38a678ec58">714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67846955d203444991996f8db5938a69_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMi05LTEtMS0yOTA5NQ_8f91ced4-2a72-4c3e-9593-bbf8cdd2fe8d">648,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMi0xMS0xLTEtMjkwOTU_47aa9302-c088-4b41-a3a5-9c0d3273b6c8">316,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc4612654aa4870acef5f852550d561_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMy01LTEtMS0yOTA5NQ_84468aa3-3b70-46e3-b1d8-96aa16a4ab2e">5,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0eb628814a04ad8971209780bc02232_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMy0xMS0xLTEtMjkwOTU_6da03428-1471-41b4-9ad1-b44cccea277b">5,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc0d4ed39fb04b2089aee2f3e0739e42_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfNC0xLTEtMS0yOTA5NQ_57c50263-e270-471a-afed-92dfb812d2e5">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc4612654aa4870acef5f852550d561_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfNC01LTEtMS0yOTA5NQ_49663a3a-9e60-4bb7-b8bb-66c947a2273d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0eb628814a04ad8971209780bc02232_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfNC0xMS0xLTEtMjkwOTU_47cdde7b-df8f-4cc1-a1d2-15274662a585">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc0d4ed39fb04b2089aee2f3e0739e42_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfNS0xLTEtMS0yOTA5NQ_ea3e701e-96bc-43a7-b1be-cf5c6814f0d8">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ced84e48d142babc4e6edcc897094a_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfNy03LTEtMS0yOTA5NQ_90ed6fc4-b90c-4724-a684-5de51d16f544">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0eb628814a04ad8971209780bc02232_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfNy0xMS0xLTEtMjkwOTU_fa6c3368-da30-4c96-b55f-0b47840977c7">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ced84e48d142babc4e6edcc897094a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfOC03LTEtMS0yOTA5NQ_ebc801db-c729-4e97-a08a-61b255801f49">723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0eb628814a04ad8971209780bc02232_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfOC0xMS0xLTEtMjkwOTU_1223aaca-d91b-4296-8694-7b6ce447f058">723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia22a80d1fae54e15bac4c1582f12e26e_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfOS05LTEtMS0yOTA5NQ_f916a30c-17db-4d8d-93b5-b8e305e32625">37,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0eb628814a04ad8971209780bc02232_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfOS0xMS0xLTEtMjkwOTU_6248fc5b-7129-43e4-a3db-267248f81bd8">37,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d3a4780987e4e9692fdafbb646d0e5a_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTAtMS0xLTEtMjkwOTU_b400c8fb-cc8a-4059-a08f-ca6bc2861918">98,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3a4780987e4e9692fdafbb646d0e5a_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTAtMy0xLTEtMjkwOTU_5b39e6a4-6112-4075-853c-c035c9559ed8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d6b6204c994327981fb6f38ee2e5ff_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTAtNS0xLTEtMjkwOTU_c0dd3e76-afe3-439c-beec-d780ff9c7921">970,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e35090827424e029a917e87a3044012_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTAtNy0xLTEtMjkwOTU_62f8dcda-3ffe-4e22-932d-d790746c48fa">1,423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib90a0153e711486598954353cda4c4f6_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTAtOS0xLTEtMjkwOTU_54437c00-0d09-4c4d-9fb0-c26f707acae5">685,984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61c0616a34746bf8b0475dd12eece06_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTAtMTEtMS0xLTI5MDk1_bce61f29-717a-4cd0-95b2-180115291da3">282,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f8b7aaa691944a4a550b8ced951db24_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTEtNS0xLTEtMjkwOTU_4b8bf62c-2bd9-4707-b5ea-2f21ce60bfae">4,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972d3044b3264665a366176257e6f0a4_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTEtMTEtMS0xLTI5MDk1_e13aa7ad-267a-45cd-9479-d5faae0cc208">4,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65bbe7741c5844b19b5542e8c5caf343_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTItMS0xLTEtMjkwOTU_90c71ff2-ae19-4ed0-9911-0f90e3280ac2">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65bbe7741c5844b19b5542e8c5caf343_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTMtMS0xLTEtMjkwOTU_27a59080-074b-458a-a3ce-9ffcc30a9969">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f8b7aaa691944a4a550b8ced951db24_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTMtNS0xLTEtMjkwOTU_6b899923-39fc-4f5a-93cd-c7c0ffa8bedc">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972d3044b3264665a366176257e6f0a4_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTMtMTEtMS0xLTI5MDk1_af4f9bdb-aa7a-4350-99fb-32609e0efaa4">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46e83442dc5749b0a5d1ad0026c402d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTQtNy0xLTEtMjkwOTU_614a2bed-aa21-4fb6-ad5a-c6a30f93c0c4">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i972d3044b3264665a366176257e6f0a4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTQtMTEtMS0xLTI5MDk1_fb38f468-159f-43dd-a290-54b023f90851">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46e83442dc5749b0a5d1ad0026c402d2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTUtNy0xLTEtMjkwOTU_266f30d1-7008-46cb-848e-052059318b51">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i972d3044b3264665a366176257e6f0a4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTUtMTEtMS0xLTI5MDk1_bf983ae2-b13b-4004-b138-06a4b37faefc">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4af61eabf3d42e09f408fb99c2367e5_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTYtOS0xLTEtMjkwOTU_d4040716-fe6d-4f22-935c-2545f35cfda9">43,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i972d3044b3264665a366176257e6f0a4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTYtMTEtMS0xLTI5MDk1_351c2913-9c99-4adb-b5ca-d82c0f5b3335">43,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96f851ab82a443b5a834a5415c2880e0_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTctMS0xLTEtMjkwOTU_8dc3686f-e395-4f76-9d40-49ce15e68c69">99,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f851ab82a443b5a834a5415c2880e0_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTctMy0xLTEtMjkwOTU_4efc0dca-1030-48db-8040-c0af0bb61a76">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c2b4e4a1b54fdf897b4c3015a17e3f_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTctNS0xLTEtMjkwOTU_bdd6d3ef-d6db-414b-ad2c-f3eb05a2c889">975,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id191c6d1957d4719b9c5e156e348e8db_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTctNy0xLTEtMjkwOTU_6723965b-2c01-4a07-9cc1-13a01bdb1980">1,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb610db5124447a81519c9fddb553ad_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTctOS0xLTEtMjkwOTU_06adf5b3-8933-4c23-97cb-4bc82066e66e">729,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19622582a11f4462a48573d5c32fb7c5_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTctMTEtMS0xLTI5MDk1_7cee192b-973d-4e7d-ab02-1a972b08fb23">244,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6388d78a0f704f1c86da5e1f4c37aa33_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTgtNS0xLTEtMjk4MjQ_b4c83de9-b82b-4a77-add8-4349cdf9d773">4,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTgtMTEtMS0xLTI5MzAz_d497c69c-3baf-4c66-bf48-8736f9dbc3ba">4,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47c31b7bd48c4503a19ac8602ddba6ff_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTktMS0xLTEtMjkzMDY_ab150423-a615-4fd9-a024-f2560f33b680">457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic047966dbeb843b496329bb693a66b72_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjAtNy0xLTEtMjk4NDY_7904c80b-f5e6-4aeb-a98a-f395a1654acb">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjAtMTEtMS0xLTI5MzA4_3179e21d-2bec-49cb-8858-aa8a24b4cafb">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic047966dbeb843b496329bb693a66b72_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjEtNy0xLTEtMjk4NDY_c65aa521-904c-4ce0-ac86-68f49efdab4b">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjEtMTEtMS0xLTI5MzEw_80ab23f0-6aac-4c53-9486-dd0853724da3">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice288f0d914a4d95915117eb965b9fc7_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjItOS0xLTEtMjk4NTU_f6a01d57-10af-4cbc-8a0a-365d0a638635">40,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjItMTEtMS0xLTI5MzEy_1c23e973-0d33-4d02-8ea8-5db6efe8a8ec">40,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib238c3743368488b9eb8ed8b364431e9_I20220930" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjMtMS0xLTEtMjkzMTQ_7ba3507e-d62b-45f5-8eca-8af2c245d2cc">99,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib238c3743368488b9eb8ed8b364431e9_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjMtMy0xLTEtMjkzMTY_c2f17496-0050-4948-8c3b-1ebf9933ea78">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480b594590b940cd851f225ae27fd622_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjMtNS0xLTEtMjkzMTg_24517356-bc7c-496f-b7d0-0c610e7a7f12">980,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90ba8498524046978db9a015fa44aeab_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjMtNy0xLTEtMjkzMjA_93aa4dfc-d611-4215-a5c5-87b9f89c64ae">1,953</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4af913e76594eaa821e5e62c4699428_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjMtOS0xLTEtMjkzMjI_48b48c71-807e-4418-b2b4-e43a5f6cb87b">769,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjMtMTEtMS0xLTI5MzI0_20cd1880-68d9-4eaa-bdd2-19544d5d720d">208,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity - continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>(Loss)/Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbfe14fd14dc46eeae6028be0bedb756_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMi0xLTEtMS0yOTA5NQ_3e9fb6af-9a21-4ac1-925a-9885f84cf0f4">97,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfe14fd14dc46eeae6028be0bedb756_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMi0zLTEtMS0yOTA5NQ_1d505e16-a229-4e77-9cb1-8a0d6950aa22">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dda90e2dcb84f4abf4d236b758309c0_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMi01LTEtMS0yOTA5NQ_fa5a64c4-d063-4ce3-8fa3-d33939f22ca1">937,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic53d2c3285b2405c89747aede88daf77_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMi03LTEtMS0yOTA5NQ_aad74802-edc3-4510-bab4-a17217e6a064">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2061f8740354460fbd6fa9e20be2522a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMi05LTEtMS0yOTA5NQ_bb7e26ed-848c-433b-b58e-4ca692f9bf81">502,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6353d7b319d44289aff3a0e8fcae2bac_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMi0xMS0xLTEtMjkwOTU_99f5564d-4a9e-4c67-95e2-8455fef03fe6">434,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe95493f3b5a4dc5b74fbbfe667afede_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMy01LTEtMS0yOTA5NQ_1df77aad-d560-46ca-aaf6-0860a7089532">7,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMy0xMS0xLTEtMjkwOTU_6a565d7a-7527-48c7-9287-6c2cb2d2e176">7,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNC0wLTEtMS0yOTA5NS90ZXh0cmVnaW9uOmIzNTE3ZDE2Nzk3MzQ5YjNiNDkzOWE4NzkzMzcwOGMyXzU1_be037e27-9d6a-40aa-a473-db28686e9b45">5</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i121cdd6f1a6b4029901948f5a1c143d5_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNC0xLTEtMS0yOTA5NQ_f43cec6f-7f66-4c36-8aa7-3c85c275c235">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe95493f3b5a4dc5b74fbbfe667afede_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNC01LTEtMS0yOTA5NQ_69ff93b8-a048-4757-af22-67758b91e10a">1,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNC0xMS0xLTEtMjkwOTU_bb970618-95d8-4895-945c-7edfc608b930">1,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i121cdd6f1a6b4029901948f5a1c143d5_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNS0xLTEtMS0yOTA5NQ_ee1c39e9-9046-4496-856d-eacc9e2c98a2">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe95493f3b5a4dc5b74fbbfe667afede_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNS01LTEtMS0yOTA5NQ_1ba60f99-c026-4cff-9453-6497416fa0d1">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNS0xMS0xLTEtMjkwOTU_9aed5d37-2e04-4918-8130-fc60407ea1d8">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i121cdd6f1a6b4029901948f5a1c143d5_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNi0xLTEtMS0yOTA5NQ_c02921d8-8d48-4567-a704-e7f40930d60a">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idebb246dffde4b12a9cd6c4cf9a7f620_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfOC03LTEtMS0yOTA5NQ_c664420f-99bd-446d-90f4-91dae100e2d2">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfOC0xMS0xLTEtMjkwOTU_426c5cb5-bb42-415a-bfd0-74ea37965a6d">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idebb246dffde4b12a9cd6c4cf9a7f620_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfOS03LTEtMS0yOTA5NQ_bf7fb061-d876-47bb-959b-7d64c5b36cce">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfOS0xMS0xLTEtMjkwOTU_3947c8c6-67dc-4d7e-bf9e-590406d0be63">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaefcad51308b4b3790bcf428575004c3_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTAtOS0xLTEtMjkwOTU_6c38d698-f475-467b-95f5-6c85af3a475d">28,436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTAtMTEtMS0xLTI5MDk1_44f311a7-4ac1-45b3-a07e-afa2fe0d997e">28,436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94109faeb1f44d1da072d36ea355382d_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTEtMS0xLTEtMjkwOTU_de825947-4983-4a93-88e6-077501641bcf">97,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94109faeb1f44d1da072d36ea355382d_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTEtMy0xLTEtMjkwOTU_b32075ef-80c4-44c0-9e9a-dbf6a0dee36f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841267b2dc374ac3ad96e04341fb587a_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTEtNS0xLTEtMjkwOTU_80b733be-60f9-4b97-8c88-02c489987845">946,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5269eef549e4b18bb64d22f1b54e0ca_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTEtNy0xLTEtMjkwOTU_e88c2580-279a-44e9-9800-566c8148212a">316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37097774df59414a8b4fe74f0511d45f_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTEtOS0xLTEtMjkwOTU_edbf1c70-74be-4132-b145-611bb59bee3a">530,972</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23eb60965e1a4ce59cc12982fa1fc9fa_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTEtMTEtMS0xLTI5MDk1_7bc3ecb3-f5c5-4ef9-9531-f72371a8b1ab">414,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe7ae56850e4431a1e91bc6167ef963_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTItNS0xLTEtMjkwOTU_0416bbe6-7da1-42b3-a869-4682d471ce84">8,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475232b6968b4298945132136bd68a2d_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTItMTEtMS0xLTI5MDk1_4b5f3380-3476-4864-a2e0-b11393948dfe">8,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, additional issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fe7ae56850e4431a1e91bc6167ef963_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTMtNS0xLTEtMjkwOTU_b1933c61-22c9-4316-bd0f-fb7250b3fe60">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i475232b6968b4298945132136bd68a2d_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTMtMTEtMS0xLTI5MDk1_56ef8baf-2877-4fab-a0f0-44069c92087e">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1230d7a79cd43ca8b3d88d5b06de1db_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTQtMS0xLTEtMjkwOTU_59bfd43c-7f79-4110-9cc9-31188b2920f7">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1230d7a79cd43ca8b3d88d5b06de1db_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTUtMS0xLTEtMjkwOTU_4c1cbd3e-3213-4de8-8755-ebe6148705de">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe7ae56850e4431a1e91bc6167ef963_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTUtNS0xLTEtMjkwOTU_4a429a0f-43b2-41bf-b9a3-c8d18bbb9ba3">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475232b6968b4298945132136bd68a2d_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTUtMTEtMS0xLTI5MDk1_b97c7168-60d8-4a13-9af4-be8cd793dba3">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609ae2740da044548ec7c4c368af7b51_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTYtNy0xLTEtMjkwOTU_f9ebc2e0-6b54-415c-8e68-40a2a12ae459">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i475232b6968b4298945132136bd68a2d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTYtMTEtMS0xLTI5MDk1_78a05e89-d9f6-402d-8c04-220a141cc1bc">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609ae2740da044548ec7c4c368af7b51_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTctNy0xLTEtMjkwOTU_ad440136-6105-4d61-ba10-19fd077677db">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i475232b6968b4298945132136bd68a2d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTctMTEtMS0xLTI5MDk1_a5742f7a-e39c-4ee8-8043-af68947fb85b">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iceda05b2f1b4410faf5aca6a1f9cb9c0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTgtOS0xLTEtMjkwOTU_1acd7a30-cad8-47b5-8b14-4eb9eb464f53">44,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i475232b6968b4298945132136bd68a2d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTgtMTEtMS0xLTI5MDk1_48e04c93-1016-44c0-9f37-9d63da884dcd">44,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9921ca0a5094f0bac938ac91d53078a_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTktMS0xLTEtMjkwOTU_357fb94f-94c2-4514-9dfa-8ce074338722">98,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9921ca0a5094f0bac938ac91d53078a_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTktMy0xLTEtMjkwOTU_646a2f74-d7d9-447f-b666-51aa877b4ba0">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07da0e72c1be41e7aaf42551fd516c9f_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTktNS0xLTEtMjkwOTU_f3c5ecf5-4bb2-4dad-806f-ea0eb004870d">954,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bd7d22674a0458b874208ec2cf0c887_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTktNy0xLTEtMjkwOTU_74ac510b-4d64-46d2-8709-276aac0884fc">417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i851c8e2358684ae6b21b416e2330cb70_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTktOS0xLTEtMjkwOTU_a499971e-b6ef-4566-8a39-5fe97d87ee7a">575,305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d43fd4cf2a549a0b04c2f34890cb7ff_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTktMTEtMS0xLTI5MDk1_36f95dc9-494d-459a-9a91-95244c7e5f53">379,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6eb7bc0bbc467bbdb22d47d409103f_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjAtNS0xLTEtMjkwOTU_0b0ed41d-3c8d-4d32-b0af-91674927a246">5,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjAtMTEtMS0xLTI5MDk1_8f0923c4-df50-43cb-b333-b6c411928b62">5,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a18ede15a1b47778e90d6d5c7bb304f_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjEtMS0xLTEtMjkwOTU_75f659c0-5829-4a66-b613-b0076d3651b1">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45935ce9978f46239a14318be6d6f2ae_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjItNy0xLTEtMjkwOTU_60c3aec6-a789-483b-bc19-a0311d69b6d9">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjItMTEtMS0xLTI5MDk1_ed49b07c-74bc-42c4-9c96-ce8cd44d4c0b">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45935ce9978f46239a14318be6d6f2ae_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjMtNy0xLTEtMjkwOTU_26bb5663-491e-430b-b82a-52e157a64f14">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjMtMTEtMS0xLTI5MDk1_5e4ec806-60d6-4a57-88ef-8b27a15991ff">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9809e3ed4b544acb18ad2a9ef94d4fa_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjQtOS0xLTEtMjkwOTU_89632904-950b-4105-8669-a5b2b133a0ef">38,362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjQtMTEtMS0xLTI5MDk1_b4795c7d-f068-4d50-96e6-bdf7eaf642ef">38,362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5ff1d37342b4c27865fff03a63c60c8_I20210930" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjUtMS0xLTEtMjkwOTU_3101166c-7fb9-463d-8d23-63f2e14e8708">98,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ff1d37342b4c27865fff03a63c60c8_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjUtMy0xLTEtMjkwOTU_6ef57696-cd15-4d75-afdc-be9f2004ddc5">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c37575b017e43bf9a8ac40ac84a9957_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjUtNS0xLTEtMjkwOTU_26d55a47-bd49-477f-9ba0-06793034ef84">960,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i021fc47f853242c2be3df72c455d228f_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjUtNy0xLTEtMjkwOTU_b60857d4-7f95-40e3-af52-d3ccdbaf7426">523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b517ce4be034b4db4fafa152857e3ae_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjUtOS0xLTEtMjkwOTU_f19af3df-fed7-46b5-a93d-d08dfa78d77b">613,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if94ce7427b6d4ad3bf65c204029b5bb5_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjUtMTEtMS0xLTI5MDk1_e7b0d22e-e0ae-45fa-9421-42155998753e">346,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMy0xLTEtMS0yOTA5NQ_63f4b250-7a9c-40f3-b69d-cd674a31daf8">121,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMy0zLTEtMS0yOTA5NQ_b809aa24-2cab-40c8-8a66-d2b5e315e460">111,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNS0xLTEtMS0yOTA5NQ_5c6e94dd-6c2f-4b96-a345-60b329fc8f96">4,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNS0zLTEtMS0yOTA5NQ_517834f3-ad97-48a7-88ae-7e293128c99b">3,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNi0xLTEtMS0yOTA5NQ_1f9c7bf8-31b5-408f-9a2f-396a4db62de6">14,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNi0zLTEtMS0yOTA5NQ_c31aa103-d4ee-489f-80c1-71416d8716f5">20,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of premium and accrued interest on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNy0xLTEtMS0yOTA5NQ_a34e5e40-94c8-4bbb-b1dd-4ddbac7b68b1">277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNy0zLTEtMS0yOTA5NQ_cc2931f5-cd22-4756-887c-2dbf2a2131cb">2,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfOC0xLTEtMS0yOTA5NQ_76f33bf0-bd78-4645-a233-493f85d2fb0d">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfOC0zLTEtMS0yOTA5NQ_2a8b3ec9-bb74-45c1-9ec6-b970556d6e39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfOS0xLTEtMS0yOTA5NQ_6e383f38-d3c2-4272-8742-cb0881baa0d7">2,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfOS0zLTEtMS0yOTA5NQ_6e4f4f8d-4de1-4cc8-918d-02b723bc922d">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTAtMS0xLTEtMjkwOTU_a33b8573-97e5-4e39-a350-3bfab19852c3">1,526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTAtMy0xLTEtMjkwOTU_38c100c2-dffd-4574-a535-a190f79a695c">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTItMS0xLTEtMjkwOTU_39582ba3-54c2-4860-b55b-877c562ad25e">3,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTItMy0xLTEtMjkwOTU_ea0a29da-2947-4017-b7e9-4dfc135e7985">3,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTMtMS0xLTEtMjkwOTU_30778753-6fa5-4c7c-b4b7-190b6d435ecc">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTMtMy0xLTEtMjkwOTU_c859b3ec-9a45-4d24-a28f-c05ac0927555">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" sign="-" name="advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTQtMS0xLTEtMjkwOTU_4ec6f1cf-03a1-4b3c-b436-53c7e7e42dd0">3,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" sign="-" name="advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTQtMy0xLTEtMjkwOTU_46856dc6-5478-4071-b831-5fdfa73a683e">2,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTUtMS0xLTEtMjkwOTU_ad987c60-034c-434a-9b8a-0962ae8a6b3a">543</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTUtMy0xLTEtMjkwOTU_c31f8061-5772-4a82-ade5-a8c12c3de845">587</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTYtMS0xLTEtMjkwOTU_913d41dc-8fb7-4bbd-b9fc-e89267f708e9">272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTYtMy0xLTEtMjkwOTU_f129cf61-2d82-4b80-921b-588e2f8396f2">3,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTctMS0xLTEtMjkwOTU_fb734276-15cf-4ed7-9d8a-35c6cce18ea7">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTctMy0xLTEtMjkwOTU_89e0b514-ec22-450c-a372-0f0c9970d6f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability and lease incentive receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTktMS0xLTEtMjkwOTU_002b9111-7509-455e-913d-cb77989440f6">12,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" sign="-" name="advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTktMy0xLTEtMjkwOTU_7c0c063e-cdbf-4d10-a4e1-5575672975a3">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjEtMS0xLTEtMjkwOTU_72f66449-1f7e-49b2-8c46-b3c7147caf84">89,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjEtMy0xLTEtMjkwOTU_f024d51d-47e8-4d24-a685-35203c2db8cf">82,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjMtMS0xLTEtMjkwOTU_05703e48-1e33-4537-992b-37a652386a1e">81,782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjMtMy0xLTEtMjkwOTU_e88d68a0-de63-4393-b03f-f4e7a957e0e1">328,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjQtMS0xLTEtMjkwOTU_41108a6d-100e-49cf-98fe-db78dab18748">232,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjQtMy0xLTEtMjkwOTU_c0ee0ab0-d40c-4e70-ba50-839cf5d33d07">384,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjUtMS0xLTEtMjkwOTU_2bde1e81-7dc6-4370-bb13-ab7a1e66f9d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjUtMy0xLTEtMjkwOTU_e38cbd83-ead1-4bc6-a88c-403baa68fae9">8,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjYtMS0xLTEtMjkwOTU_8ffe9ba2-3e1d-4682-92ce-28df806cbae9">11,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjYtMy0xLTEtMjkwOTU_0d8f9142-89bf-43fe-ba94-e08ac0322199">10,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjctMS0xLTEtMjkwOTU_0ecdc441-aba3-423b-a415-cb8cf477f7b7">139,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjctMy0xLTEtMjkwOTU_85f81818-0c6f-4414-807c-2a70c5e49b1e">54,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from offerings of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjktMS0xLTEtMjkwOTU_1a3ba636-b0c1-4653-958c-3bdaf42b979d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjktMy0xLTEtMjkwOTU_f142dbce-621e-4205-8eb5-148c455efcd2">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock pursuant to option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzEtMS0xLTEtMjkwOTU_36125926-2e11-4ae1-933f-5544866d6969">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzEtMy0xLTEtMjkwOTU_7e276c20-524b-400a-b5b7-97b60ef845fa">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzMtMS0xLTEtMjkwOTU_1f643ed9-8bd7-4267-9ad7-6fcb0eb8bca5">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzMtMy0xLTEtMjkwOTU_84d2bbf5-e150-4a30-a420-7af69812e594">526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzUtMS0xLTEtMjkwOTU_73835443-f49e-4c03-9b8e-68370c39ef9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzUtMy0xLTEtMjkwOTU_85c53074-09a5-4517-a330-472b0c251fb6">240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzYtMS0xLTEtMjkwOTU_80844789-eb63-464a-bf4c-69460ef58b01">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzYtMy0xLTEtMjkwOTU_ce550b35-cb67-4f88-8670-2da7fcc3498c">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzctMS0xLTEtMjkwOTU_fe1a41a4-bbb6-46b2-819a-c28230b12f5a">50,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzctMy0xLTEtMjkwOTU_106fd9ce-763e-45b2-a2ec-931daa230f47">25,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzgtMS0xLTEtMjkwOTU_f3aa056e-0117-45a2-88b8-1e81bd614158">36,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6353d7b319d44289aff3a0e8fcae2bac_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzgtMy0xLTEtMjkwOTU_444fcef1-98fa-4690-8a86-6ba50f7d4927">63,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzktMS0xLTEtMjkwOTU_0e56c017-221d-4a8f-8cc4-d308ce486b7e">86,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if94ce7427b6d4ad3bf65c204029b5bb5_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzktMy0xLTEtMjkwOTU_1370bd70-31e4-49c7-9a1a-672722ef0f43">38,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDAtMS0xLTEtMjkwOTU_ec4c2eac-bd5e-4ac5-80d2-ae1f387a6fab">84,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if94ce7427b6d4ad3bf65c204029b5bb5_I20210930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDAtMy0xLTEtMjkwOTU_d7b93652-3fda-4127-96e9-fb21d0e9ab74">32,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDEtMS0xLTEtMjkwOTU_c3d080fa-94ec-4913-affe-930783dd24c0">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if94ce7427b6d4ad3bf65c204029b5bb5_I20210930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDEtMy0xLTEtMjkwOTU_1aa7c103-ce82-49ee-82f0-ed63b865905f">5,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDItMS0xLTEtMjkwOTU_52f86187-d213-4821-921b-7e8188a64ad4">86,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if94ce7427b6d4ad3bf65c204029b5bb5_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDItMy0xLTEtMjkwOTU_62c94155-e8d0-40f5-8065-2defa8f4b2d4">38,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental schedule of noncash investing and financing information</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDQtMS0xLTEtMjkwOTU_121e14a1-c176-497d-bcf1-e9b532c603a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDQtMy0xLTEtMjkwOTU_ceb54b6a-4474-4525-af14-c8939781123f">84,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of operating right-of-use assets</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="advm:RemeasurementOfOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDUtMS0xLTEtMjk4Nzc_a1fff18b-dc01-4432-911e-b5b9e2ea350a">2,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="advm:RemeasurementOfOperatingLeaseRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDUtMy0xLTEtMzAxNzI_0c1cf60d-0d9b-41f6-ac0e-75150ee35e44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets in accounts payable, accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDUtMS0xLTEtMjkwOTU_b141db96-8bc2-44bc-ae0a-1e09e20a9942">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDUtMy0xLTEtMjkwOTU_a274bb80-5252-43cd-acf0-9a3eab28c208">2,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="id78fc84db2574938a52c2b619c0c6019_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNC9mcmFnOjVmNmM5OGY2NjM3ZDQ3OTk5ZjY2MWM4YWY3OWZiODM2L3RleHRyZWdpb246NWY2Yzk4ZjY2MzdkNDc5OTlmNjYxYzhhZjc5ZmI4MzZfMjU4MA_cab10002-dd28-405e-a19e-7add333ce81c" continuedAt="i0fb99f70035e4a959d3fce32ad139794" escape="true">Organization and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i0fb99f70035e4a959d3fce32ad139794"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or &#8220;Adverum&#8221;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNC9mcmFnOjVmNmM5OGY2NjM3ZDQ3OTk5ZjY2MWM4YWY3OWZiODM2L3RleHRyZWdpb246NWY2Yzk4ZjY2MzdkNDc5OTlmNjYxYzhhZjc5ZmI4MzZfNjg2_4a7f27b1-b2bc-4c5b-ba8c-0a7224801d6e">769.9</ix:nonFraction> million as of September&#160;30, 2022. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of September&#160;30, 2022, the Company had cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNC9mcmFnOjVmNmM5OGY2NjM3ZDQ3OTk5ZjY2MWM4YWY3OWZiODM2L3RleHRyZWdpb246NWY2Yzk4ZjY2MzdkNDc5OTlmNjYxYzhhZjc5ZmI4MzZfOTM1_8bf1afef-22ec-42b7-aff0-b5ccdc54a435">203.3</ix:nonFraction> million, which the Company believes will be sufficient to fund its operations for at least twelve months from the date of issuance of these financial statements.</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNC9mcmFnOjVmNmM5OGY2NjM3ZDQ3OTk5ZjY2MWM4YWY3OWZiODM2L3RleHRyZWdpb246NWY2Yzk4ZjY2MzdkNDc5OTlmNjYxYzhhZjc5ZmI4MzZfMjU4MQ_113d2d55-005e-478d-9b15-ae991b3592c7" continuedAt="ia55a368dc1c54f829c50e746af1847e1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s consolidated financial information. The results of operations for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2021 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. </span></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia55a368dc1c54f829c50e746af1847e1">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC</ix:continuation>.</span></div></ix:continuation><div id="id78fc84db2574938a52c2b619c0c6019_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNy9mcmFnOjQwMDM1NTI3ZTRjNTQyOGNiNjBhOTJhMTIyNjNjN2UwL3RleHRyZWdpb246NDAwMzU1MjdlNGM1NDI4Y2I2MGE5MmExMjI2M2M3ZTBfMjI1Mw_8e73c07b-d40e-42d6-9f21-3b79cf02ed36" continuedAt="i10e897ef09c24373a3bad4f940a4f6e3" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i10e897ef09c24373a3bad4f940a4f6e3"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNy9mcmFnOjQwMDM1NTI3ZTRjNTQyOGNiNjBhOTJhMTIyNjNjN2UwL3RleHRyZWdpb246NDAwMzU1MjdlNGM1NDI4Y2I2MGE5MmExMjI2M2M3ZTBfMjI1MA_6c6ab359-2e40-40da-984a-8b9a9de75fdd" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNy9mcmFnOjQwMDM1NTI3ZTRjNTQyOGNiNjBhOTJhMTIyNjNjN2UwL3RleHRyZWdpb246NDAwMzU1MjdlNGM1NDI4Y2I2MGE5MmExMjI2M2M3ZTBfMjI1MQ_397b21be-efe8-4422-b6fe-a0dbc9174010" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topic 326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company on January 1, 2023. Early adoption is permitted. The Company does not expect the effect of adoption to be material.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMjg3MQ_8dcd6cdc-207a-4456-91a3-816ef90d6d23" continuedAt="i2aec707b77834aac91de53fdd1a3290a" escape="true">Fair Value Measurements and Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i2aec707b77834aac91de53fdd1a3290a" continuedAt="i160bc34128ca4822b2e66d4429048b4a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance on the fair value hierarchy for disclosure of fair value measurements is as follows:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, and corporate bonds are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2. </span></div><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMjg3Mg_7c3c2ed7-d3f4-49f9-833c-376c3ec9391b" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b38d8b71f5349f99b74f3e4bd7dfb70_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNC0xLTEtMS0yOTA5NQ_1914152a-293e-44f4-8fee-6faef96356e3">10,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b38d8b71f5349f99b74f3e4bd7dfb70_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNC0zLTEtMS0yOTA5NQ_4c9a23cd-2815-4d3e-9aaf-a6d2ce09de01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b38d8b71f5349f99b74f3e4bd7dfb70_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNC01LTEtMS0yOTA5NQ_f94854a2-3f24-49fc-a2a3-ad57358c6c61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b38d8b71f5349f99b74f3e4bd7dfb70_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNC03LTEtMS0yOTA5NQ_cd1755b3-3d3e-44ab-9075-54cc3c79f2a5">10,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a51274da0d34c37ad110f512dfb6c25_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNi0xLTEtMS0yOTA5NQ_9dd54f37-2856-4233-a322-db737491b844">81,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a51274da0d34c37ad110f512dfb6c25_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNi0zLTEtMS0yOTA5NQ_4386ed42-2b49-4d1c-845b-e46a5d788aff">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a51274da0d34c37ad110f512dfb6c25_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNi01LTEtMS0yOTA5NQ_9241cbb6-59cf-463a-a671-8a6934a94a17">1,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a51274da0d34c37ad110f512dfb6c25_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNi03LTEtMS0yOTA5NQ_41b325ce-ce6f-45e0-ba61-22e1b26f63b1">80,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib282142f99284b73981803c872356bd9_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNy0xLTEtMS0yOTA5NQ_c579d60a-7387-42c5-a9ea-c54928530a4d">99,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib282142f99284b73981803c872356bd9_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNy0zLTEtMS0yOTA5NQ_839f5c76-d0d2-4a93-a704-b8d42dee2416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib282142f99284b73981803c872356bd9_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNy01LTEtMS0yOTA5NQ_f0b6c498-1706-47b1-bee4-e32c1bc7be81">294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib282142f99284b73981803c872356bd9_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNy03LTEtMS0yOTA5NQ_2930bab6-f275-440e-980b-c4279879eeab">99,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i873db4f7c8b74c7fadbdceb695e76de6_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOC0xLTEtMS0yOTA5NQ_c2e225e9-3692-4619-b2c7-ed50ca82a212">2,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i873db4f7c8b74c7fadbdceb695e76de6_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOC0zLTEtMS0yOTA5NQ_758e059d-345c-4d67-b278-01aa4a6741bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i873db4f7c8b74c7fadbdceb695e76de6_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOC01LTEtMS0yOTA5NQ_e2bcd36b-c95e-4be9-aada-6b07c0b38767">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i873db4f7c8b74c7fadbdceb695e76de6_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOC03LTEtMS0yOTA5NQ_3cc57d66-8350-4a2b-bb6b-c6109ecb6335">2,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3979c9c68184f3089401c14ce8a48c1_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOS0xLTEtMS0yOTA5NQ_cf689aff-08e4-4ebf-9fca-63c3bb13c78a">193,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3979c9c68184f3089401c14ce8a48c1_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOS0zLTEtMS0yOTA5NQ_4f47668f-ce2d-4d18-9364-636b06f49f9f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3979c9c68184f3089401c14ce8a48c1_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOS01LTEtMS0yOTA5NQ_22368786-52b1-4ee4-a52d-eb0bc4f18b30">1,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3979c9c68184f3089401c14ce8a48c1_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOS03LTEtMS0yOTA5NQ_63eff477-ece1-4cc3-bd9d-2c9ee2565f89">191,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="advm:CashAndCashEquivalentAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTAtMS0xLTEtMjkwOTU_cd3ee2b0-4694-491a-86fa-11b3cdf6b259">72,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTAtMy0xLTEtMjkwOTU_351c34a0-808d-49ae-825d-5fc064dc2857">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTAtNS0xLTEtMjkwOTU_e40d30fc-0d59-4c91-8fd0-51b2063cdc5d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTAtNy0xLTEtMjkwOTU_03f035c5-2869-43dd-8ef5-a109be317fbd">72,983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTEtMS0xLTEtMjkwOTU_69dfd962-e273-46c2-9cc9-bcbc404cdac1">120,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTEtMy0xLTEtMjkwOTU_dde1acbd-665a-4198-b9d5-0faedee330ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTEtNS0xLTEtMjkwOTU_c8597a7d-3e64-4fef-a535-e89cf3e998dd">1,502</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTEtNy0xLTEtMjkwOTU_b444dec6-8e23-456a-880b-c30cc96c426c">118,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791b55383c7c4814974ebaa3df5a5e64_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNC0xLTEtMS0yOTA5NQ_c1042386-d6c5-48c3-b4e5-f844d45020b8">10,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791b55383c7c4814974ebaa3df5a5e64_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNC0zLTEtMS0yOTA5NQ_fb6006c9-21d4-4f87-926f-5efc4a91249f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791b55383c7c4814974ebaa3df5a5e64_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNC01LTEtMS0yOTA5NQ_321fe48c-ca7b-4863-80d7-a6f39cd6b192">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791b55383c7c4814974ebaa3df5a5e64_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNC03LTEtMS0yOTA5NQ_bbe3c309-1139-4ecf-8920-946d51ae604e">10,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d7519e0368492d811f7889f8f65003_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNi0xLTEtMS0yOTA5NQ_fab60d24-4631-489b-bea7-a30c5129ed01">62,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d7519e0368492d811f7889f8f65003_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNi0zLTEtMS0yOTA5NQ_56eb0168-3b8c-4f78-a874-509acd9213e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d7519e0368492d811f7889f8f65003_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNi01LTEtMS0yOTA5NQ_2dd532b7-e8b9-4815-a804-4d5cdef9cfc6">218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d7519e0368492d811f7889f8f65003_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNi03LTEtMS0yOTA5NQ_19e59563-c20c-4eb4-9d01-c486a48c9090">62,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ebe063f5210487eb63855bfa84821b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNy0xLTEtMS0yOTA5NQ_a92f7566-4147-4020-a329-bbd8c0ffc86c">177,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ebe063f5210487eb63855bfa84821b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNy0zLTEtMS0yOTA5NQ_449ec846-3eaa-44cb-9005-e36200e29e52">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ebe063f5210487eb63855bfa84821b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNy01LTEtMS0yOTA5NQ_89293f57-ca9e-4010-b61e-f28c4d5b2c3c">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ebe063f5210487eb63855bfa84821b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNy03LTEtMS0yOTA5NQ_83edf786-8078-4c08-8f39-7d8728c8fc18">177,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8a5bca20fd4ab780190fe9cbc37eb6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfOC0xLTEtMS0yOTA5NQ_93eb4cf4-4c59-4ba8-971a-5c938a75d4c0">47,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8a5bca20fd4ab780190fe9cbc37eb6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfOC0zLTEtMS0yOTA5NQ_bfe94d0b-af8e-4b72-a0b0-c81d461bbf60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b8a5bca20fd4ab780190fe9cbc37eb6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfOC01LTEtMS0yOTA5NQ_98ec34cb-79f9-40b6-8be0-2494d598fd3b">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8a5bca20fd4ab780190fe9cbc37eb6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfOC03LTEtMS0yOTA5NQ_982cbb28-fa92-4df5-9b23-4b8f365182d1">47,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45214185b5144da5833b2593032606d2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTAtMS0xLTEtMjkwOTU_350a6fdd-5839-4077-aca0-fb815f641a18">297,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45214185b5144da5833b2593032606d2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTAtMy0xLTEtMjkwOTU_d26f7a66-20f8-4d3e-83cc-56465a246879">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45214185b5144da5833b2593032606d2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTAtNS0xLTEtMjkwOTU_b8f47752-eacd-491f-bbd4-44d1c8f262a8">318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45214185b5144da5833b2593032606d2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTAtNy0xLTEtMjkwOTU_0644256e-6df5-48be-b56f-324baf567176">296,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="advm:CashAndCashEquivalentAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTEtMS0xLTEtMjkwOTU_2c70c894-356f-4ce6-938c-59fe4845f5f2">25,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTEtMy0xLTEtMjkwOTU_b9e6bf0b-2d47-4d59-9810-5018b91d8b34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTEtNS0xLTEtMjkwOTU_321dc26e-bc0d-4863-a424-15708723822d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTEtNy0xLTEtMjkwOTU_6fa078b6-f805-4a59-b1da-d657b081dd59">25,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTItMS0xLTEtMjkwOTU_a061fc74-bfe7-456f-8bfa-83b53c2ec273">271,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTItMy0xLTEtMjkwOTU_20e087a3-9593-461c-ac8a-e0519539d8ee">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTItNS0xLTEtMjkwOTU_b7d5bc10-0323-4903-b87c-c24dcb469906">317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTItNy0xLTEtMjkwOTU_4b86c8a1-7b4b-4677-80a6-d5f286ae3c3a">270,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><ix:continuation id="i160bc34128ca4822b2e66d4429048b4a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-5" name="advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfNTQ5NzU1ODE2NzYz_0dd88c63-7553-4bfe-88c1-c920d772e5ed">9.6</ix:nonFraction> million of marketable securities have a remaining maturity between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMzg0ODI5MDcwMTczOQ_6a3d187e-f234-4fd7-9010-35776946dddc">one</span> and <ix:nonNumeric contextRef="i516fa99e52e24c8d83b6da7334ab3f9a_I20220930" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMzg0ODI5MDcwMTc0MA_d66b1efe-662b-4342-93e3-6844a6959377">two years</ix:nonNumeric>. The remainder of the marketable securities have a remaining maturity of less than one year. Management regularly reviews all of the Company&#8217;s investments for other-than-temporary declines in estimated fair value. The aggregate fair value of the marketable securities in an unrealized loss position as of September&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMjc0ODc3OTA3Mzk0OA_fe93a4bc-041f-4d03-9e89-7b3403bd8789">167.9</ix:nonFraction>&#160;million, which are highly liquid funds with high credit ratings that have final maturity of less than two years from date of purchase. Management determined that the gross unrealized losses on the Company&#8217;s marketable securities as of September&#160;30, 2022 were temporary. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. Management concluded that <ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="INF" name="advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMjM3Mw_85c842eb-f0e5-43bc-a613-002a6b236a5c">none</ix:nonFraction> of the Company&#8217;s marketable securities were other-than-temporarily impaired as of September&#160;30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, the Company performed an impairment test to measure certain laboratory equipment at fair value. The assets are measured at fair value using Level 3 inputs on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable. Refer to Note 4, Balance Sheet Components for additional information.</span></div></ix:continuation><div id="id78fc84db2574938a52c2b619c0c6019_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RleHRyZWdpb246Y2RiNzZkYTRiMzRmNDE4MmE4MDVmNzNjMjBlZjc1NDJfNzM2_de8e30ba-5a02-42c3-9501-d7672ae6747c" continuedAt="i851c278d0ca043d28ccd6a0287c557dd" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="i851c278d0ca043d28ccd6a0287c557dd"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RleHRyZWdpb246Y2RiNzZkYTRiMzRmNDE4MmE4MDVmNzNjMjBlZjc1NDJfNzM3_8908bf50-eae8-449a-a37a-41bb82811a48" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6877ebb93e445a3a2cefb8eb73f1d51_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfMi0xLTEtMS0yOTA5NQ_40d3787a-cb5c-4b88-b438-785825ae3b5e">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica79f5395f3b4b1ba885cad3da2e3411_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfMi0zLTEtMS0yOTA5NQ_d2dbba9e-1ab1-444c-914f-17dcdb7ff2c9">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b8bf7bd53f54d4c801f071028410a38_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfMy0xLTEtMS0yOTA5NQ_cce88107-a2c4-4d18-b816-1bc13efe9830">16,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic95b4f1bc3f54077994fca5c6a6559a4_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfMy0zLTEtMS0yOTA5NQ_c40fcd74-178f-4954-b007-102bb4f130e0">12,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da0b7851f7b452aa126439ff59ef51a_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNC0xLTEtMS0yOTA5NQ_f1b079af-9c4a-40a7-9605-54cd04029ec5">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b828ba25c3d418d8eda881a27399aa8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNC0zLTEtMS0yOTA5NQ_169d5c2d-16c5-4aba-970b-3900d7d239bb">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20efbf626199415a933fd647730ef5bf_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNS0xLTEtMS0yOTA5NQ_ea5d71aa-e59b-46e1-afca-d84e4010526f">34,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8313d8ae20774ec3899f99bacdb83cf8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNS0zLTEtMS0yOTA5NQ_19da7c73-6865-4d6e-8276-06b29534bf2f">26,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3befe5528eac478382c46f05cfe1a877_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNi0xLTEtMS0yOTA5NQ_1a14fbdc-c531-4699-8eeb-4a07df715780">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i073bece618d24b9dade2383ac940ee3b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNi0zLTEtMS0yOTA5NQ_b8001ddc-d1e0-4c89-85dd-a98bcacc8c4c">4,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNy0xLTEtMS0yOTA5NQ_79b83b94-e0f6-426e-9e37-5a0f75e58dd8">53,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNy0zLTEtMS0yOTA5NQ_c4db7dc0-b84d-4198-bd08-b3416ea47ef1">46,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfOC0xLTEtMS0yOTA5NQ_1fca1225-9a90-41ce-aaf3-86e317ece564">17,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfOC0zLTEtMS0yOTA5NQ_51ff52db-9bdc-4a4a-949e-a23bfd2997ae">13,174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfOS0xLTEtMS0yOTA5NQ_8acd5199-9b9b-48d9-81c0-ac65c987a0a8">36,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfOS0zLTEtMS0yOTA5NQ_34c6f6b4-9248-4ae3-b484-25649343b626">33,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an impairment analysis for certain laboratory equipment assets based on the identification of impairment indicators during the nine months ended September&#160;30, 2022. The analysis determined that the fair value of the assets, which was determined using a market approach, was lower than the carrying value. As a result of the evaluation, an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RleHRyZWdpb246Y2RiNzZkYTRiMzRmNDE4MmE4MDVmNzNjMjBlZjc1NDJfNDg0_8371a063-0b36-4ebf-8439-2ffc97044f7c">2.0</ix:nonFraction> million was recognized for the nine months ended September&#160;30, 2022. The assets indicated as impaired were written down to their estimated fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RleHRyZWdpb246Y2RiNzZkYTRiMzRmNDE4MmE4MDVmNzNjMjBlZjc1NDJfNzM1_035b2838-1771-41c8-a358-d456bb6bae93" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfMi0xLTEtMS0yOTA5NQ_3d58b01f-ce35-4c19-8acb-c527894cb05b">8,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfMi0zLTEtMS0yOTA5NQ_a8dc7491-3c3f-4dd1-b080-cff0d4da72ec">9,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical, clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfMy0xLTEtMS0yOTA5NQ_abb8cc09-2f21-4ba3-95a7-0f9cf341c4f0">6,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfMy0zLTEtMS0yOTA5NQ_fd61b5db-a44a-42d1-9ffc-cdf0ce748745">4,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNC0xLTEtMS0yOTA5NQ_97536b62-867e-41ad-bef8-7e23d03bd578">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNC0zLTEtMS0yOTA5NQ_990ccc23-3078-4d96-89ba-7e17b213da73">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNS0xLTEtMS0yOTA5NQ_46a32900-03fc-408e-b839-2faff05dc61b">469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNS0zLTEtMS0yOTA5NQ_e1a5a4af-a43d-4e9e-ba8d-da41f29554a7">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNi0xLTEtMS0yOTA5NQ_4fbe26dc-afb0-4e78-a606-59816993ef4c">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNi0zLTEtMS0yOTA5NQ_dfbf2927-9aa5-4f94-b6eb-83eba38edeb7">2,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNy0xLTEtMS0yOTA5NQ_d0f2b3a9-f39f-456e-a3fe-fa7305f458f1">16,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNy0zLTEtMS0yOTA5NQ_8157ade0-f587-4a96-98c5-de4caea45c7c">18,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_1186"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xMTg2L2ZyYWc6NmQ4NzQ0NWE4YjkyNGU4MThmYzlhNjQzZjI3MzlhN2YvdGV4dHJlZ2lvbjo2ZDg3NDQ1YThiOTI0ZTgxOGZjOWE2NDNmMjczOWE3Zl8yNzQ4Nzc5MDcxOTM5_1b6a8e02-f6ab-4e59-9d6c-94a882f71333" continuedAt="iaf3f75a26b3f44cea3dc97d2ddb311de" escape="true">Leases</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaf3f75a26b3f44cea3dc97d2ddb311de">Sublease income for operating leases is recognized on a straight-line basis over the lease term and is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. In the three months ended September&#160;30, 2022, the Company reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. The Company assessed the collectability to be less than probable and recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses in the three and nine month periods ended September&#160;30, 2022. The deferred rent receivable as of December 31, 2021 and September 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-5" name="us-gaap:DeferredRentReceivablesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xMTg2L2ZyYWc6NmQ4NzQ0NWE4YjkyNGU4MThmYzlhNjQzZjI3MzlhN2YvdGV4dHJlZ2lvbjo2ZDg3NDQ1YThiOTI0ZTgxOGZjOWE2NDNmMjczOWE3Zl8xNjQ5MjY3NDQ0MjIx_5e80dc58-0f6f-4822-bc2a-74ad79d9b986">0.8</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-5" name="us-gaap:DeferredRentReceivablesNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xMTg2L2ZyYWc6NmQ4NzQ0NWE4YjkyNGU4MThmYzlhNjQzZjI3MzlhN2YvdGV4dHJlZ2lvbjo2ZDg3NDQ1YThiOTI0ZTgxOGZjOWE2NDNmMjczOWE3Zl8yNzQ4Nzc5MDcxOTQw_2655a5aa-69ab-4ba1-a2c3-a91b9e57f3fc">zero</ix:nonFraction>, respectively. As a result of the adjustment to eliminate the deferred rent receivable, sublease income for the three and nine months ended September 30, 2022 was a negative $<ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xMTg2L2ZyYWc6NmQ4NzQ0NWE4YjkyNGU4MThmYzlhNjQzZjI3MzlhN2YvdGV4dHJlZ2lvbjo2ZDg3NDQ1YThiOTI0ZTgxOGZjOWE2NDNmMjczOWE3Zl8yNzQ4Nzc5MDcxOTQ4_2349e8bc-f14e-48a4-ba4f-6bea265bad87">4.1</ix:nonFraction>&#160;million and a negative $<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xMTg2L2ZyYWc6NmQ4NzQ0NWE4YjkyNGU4MThmYzlhNjQzZjI3MzlhN2YvdGV4dHJlZ2lvbjo2ZDg3NDQ1YThiOTI0ZTgxOGZjOWE2NDNmMjczOWE3Zl8yNzQ4Nzc5MDcxOTY0_5d7f4bba-70c0-45ed-a2a5-3a995714d790">0.8</ix:nonFraction>&#160;million, respectively</ix:continuation>.</span></div><div id="id78fc84db2574938a52c2b619c0c6019_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RleHRyZWdpb246NzkxMTFiZDUxZWY5NDUxYzk3NTNjYWVhYzZjYzRjMGZfNjg0_b11f362c-8e43-4fb7-8d30-6f15fe230288" continuedAt="i85819326de1e4b85a8d05402210806e4" escape="true">Equity Incentive Awards</ix:nonNumeric></span></div><ix:continuation id="i85819326de1e4b85a8d05402210806e4" continuedAt="i831d88a36cd149e6be37007751ee44cb"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RleHRyZWdpb246NzkxMTFiZDUxZWY5NDUxYzk3NTNjYWVhYzZjYzRjMGZfNjgx_0c175639-bafe-4607-891e-c73bc67c8622" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s option activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfMS0xLTEtMS0yOTA5NQ_48a03442-a3ac-414d-9f70-cbc5f0d1114c">13,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfMS0zLTEtMS0yOTA5NQ_c4173c18-4b9a-47cc-8cf8-89bdf81b36ba">9.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfMi0xLTEtMS0yOTA5NQ_2c497bf6-5888-47cb-9660-ce88dc1761c0">10,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfMi0zLTEtMS0yOTA5NQ_b3cb5763-4c44-4329-a0fc-9af2be7bd57f">1.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfMy0xLTEtMS0yOTA5NQ_c4b011e2-8776-4084-9e93-dbfdda1f4be1">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfMy0zLTEtMS0yOTA5NQ_c618f739-c3b3-4c26-ba04-b8528ba5555f">0.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfNC0xLTEtMS0yOTA5NQ_b9fc145f-2ae9-4052-bd15-c19cd608cc20">4,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfNC0zLTEtMS0yOTA5NQ_1400d636-d32a-4387-ba91-478c2d6581de">5.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfNS0xLTEtMS0yOTA5NQ_c3d1e135-be04-4064-bff3-b356dd21d911">19,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfNS0zLTEtMS0yOTA5NQ_97ef3c0d-c64e-47ce-a026-a989ded1f6ae">5.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfNi0xLTEtMS0yOTA5NQ_81359fcf-374f-4b6f-b09a-e832058c55ac">5,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfNi0zLTEtMS0yOTA5NQ_3e9f2366-1d17-4003-b662-eb4a8cd77a1f">11.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the nine months ended September&#160;30, 2022 include <ix:nonFraction unitRef="shares" contextRef="i79d4b72dd8084e709d360860964f3246_D20220101-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RleHRyZWdpb246NzkxMTFiZDUxZWY5NDUxYzk3NTNjYWVhYzZjYzRjMGZfMTg4_9d427ba1-007c-44b2-aad5-fd393b98104a">2.5</ix:nonFraction>&#160;million shares of performance-based non-qualified options with both performance and service vesting conditions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;)</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RleHRyZWdpb246NzkxMTFiZDUxZWY5NDUxYzk3NTNjYWVhYzZjYzRjMGZfNjgy_aabd97e1-d433-46a5-99d8-d1901c2dabc6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSUs activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant-<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i576e4bb113d94eed83356af145669908_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfMS0xLTEtMS0yOTA5NQ_d251ea09-a4d0-47a7-9c21-e70d9e1e1af5">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i576e4bb113d94eed83356af145669908_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfMS0zLTEtMS0yOTA5NQ_cf8d8063-4a35-41d2-8a64-eb55964e37c9">3.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfMi0xLTEtMS0yOTA5NQ_9e0f1673-f3a6-4bbc-896c-5f1a0154ff6f">857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfMi0zLTEtMS0yOTA5NQ_d84343cb-5d94-437b-a434-6e582073f760">1.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfMy0xLTEtMS0yOTA5NQ_1f1342cd-e75c-4ae7-a8e6-60686cf97cce">833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfMy0zLTEtMS0yOTA5NQ_d09dcd1c-fa86-4872-a8b6-e21ed9e077f6">3.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfNC0xLTEtMS0yOTA5NQ_a4029860-4b21-443f-ac8d-a850b67373bc">426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfNC0zLTEtMS0yOTA5NQ_b2603026-7433-44e2-b427-fb838684bba8">3.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac1959e2c1824ece92a8a5edf1bfaac6_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfNS0xLTEtMS0yOTA5NQ_f048c02d-b6b0-45da-afaf-61afee3b9d74">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iac1959e2c1824ece92a8a5edf1bfaac6_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfNS0zLTEtMS0yOTA5NQ_95397f98-01d5-4b34-b145-f5aa45457895">2.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted during the nine months ended September&#160;30, 2022 include <ix:nonFraction unitRef="shares" contextRef="i79d4b72dd8084e709d360860964f3246_D20220101-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RleHRyZWdpb246NzkxMTFiZDUxZWY5NDUxYzk3NTNjYWVhYzZjYzRjMGZfNDYz_e625cc40-3f5f-41b7-b973-68c97b9150e0">0.4</ix:nonFraction> million shares of performance units with both performance and service vesting conditions.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><ix:continuation id="i831d88a36cd149e6be37007751ee44cb"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RleHRyZWdpb246NzkxMTFiZDUxZWY5NDUxYzk3NTNjYWVhYzZjYzRjMGZfNjgz_a8bd42ca-55ac-4da7-9fea-1139870e7221" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.332%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b93864200e4683b63e032b6c30feaa_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfMy0xLTEtMS0yOTA5NQ_5b41d156-02e8-4849-a6ae-81cef1a7e34a">1,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d0ce2c0d4824b3893f8f9741ffe6466_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfMy0zLTEtMS0yOTA5NQ_8cf22146-d2be-41f2-8be9-8d01bd02099a">2,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65531dff90074634acb629953b46148e_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfMy01LTEtMS0yOTA5NQ_49c10927-9032-4e6e-a6f9-679c39450dce">5,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74b15a520ab64b8ba0d52607a8761034_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfMy03LTEtMS0yOTA5NQ_d8660514-876b-494e-9a26-92dab99ddf1b">7,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5cc515fb7324c88b70e0087f46cd446_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNC0xLTEtMS0yOTA5NQ_278ba22e-e757-4d3a-9bc3-6ed315962738">3,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8482f95dee2f458a9ec19baa5f1da9dc_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNC0zLTEtMS0yOTA5NQ_f17b8bbd-1ab9-44ba-b904-1c49e87201e8">3,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee3bd88ea5a4bfab2257c3d73958b7a_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNC01LTEtMS0yOTA5NQ_b9915ce1-f01e-4f06-9a96-49daeffa164c">9,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d9330c6a204905a56b7b28a34889ae_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNC03LTEtMS0yOTA5NQ_73cdb347-bd99-49fd-a23c-7e8fec76bccd">13,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNS0xLTEtMS0yOTA5NQ_30e0bcda-6d9e-44b5-afd4-267ebd2519a2">4,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNS0zLTEtMS0yOTA5NQ_a3e04ea6-7eba-4ffd-95e0-b228bad5a1ea">5,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNS01LTEtMS0yOTA5NQ_4d8e6841-5fd8-476f-ab7f-d97343e3a7dc">14,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNS03LTEtMS0yOTA5NQ_a57734fa-51d1-4e6c-8896-cd2d2942404c">20,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div id="id78fc84db2574938a52c2b619c0c6019_52"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RleHRyZWdpb246MmMyYjZkYzBhYjUzNGM4MzgxZjY1ZTk4ZDY2ZTcwNGFfODM1_b23930b8-88f6-4ec9-a9ef-45936df99d8c" continuedAt="id041e2f7a7eb4bcf810f795ce074acdb" escape="true">Net Loss per Share</ix:nonNumeric></span></div><ix:continuation id="id041e2f7a7eb4bcf810f795ce074acdb"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, rights under the employee stock purchase plan (&#8220;ESPP&#8221;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RleHRyZWdpb246MmMyYjZkYzBhYjUzNGM4MzgxZjY1ZTk4ZDY2ZTcwNGFfODM2_0eb6bd34-c3ad-4863-ac8c-e080639053ba" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e1fbe5196e04b16b259d139c7ef556a_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfMi0xLTEtMS0yOTA5NQ_34a90b08-6fce-4776-a875-341a1c1f9800">19,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie986bf5a8039432c815e7e22b77b230a_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfMi0zLTEtMS0yOTA5NQ_1ca23b86-a707-4dbb-84d0-6eca939b9f74">13,859</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i849c716b759343fb82104acfaafcf33f_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfMy0xLTEtMS0yOTA5NQ_3fb88740-dc43-46ca-8a7d-1496cc60e35a">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i027ecc53eb374b44b0ff45c72b438658_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfMy0zLTEtMS0yOTA5NQ_963f3b70-c87a-46af-b53b-bd0bb3cf9ff7">2,593</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i058b41effd8f43b9be1d05aaf73dfe08_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfNC0xLTEtMS0yOTA5NQ_5623aaeb-8c07-473c-b9c6-002bb5128cc9">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d479b8fb7b044e3aa6c6ab883f2dd7a_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfNC0zLTEtMS0yOTA5NQ_51e64d7d-884d-4bbe-b9c8-464bffb39050">400</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfNi0xLTEtMS0yOTA5NQ_3cd7eed3-d392-40e1-8416-6843c50bab52">21,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfNi0zLTEtMS0yOTA5NQ_508c9f40-c7e6-41ba-921e-aa0dc2b7069d">16,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="id78fc84db2574938a52c2b619c0c6019_55"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfODk4_36ffea94-0a4b-4d54-a8f8-f135ca91f0cc" continuedAt="i3828138f498347ae8e06d917e31388bc" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="i3828138f498347ae8e06d917e31388bc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize its clinical development of ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, and focus its pipeline strategy on certain highly prevalent ocular diseases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the restructuring plan, the Company reduced its workforce by <ix:nonFraction unitRef="employee" contextRef="i16076e8ab5354387af2ac1ec6fc8cbdc_I20220706" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfNjUy_2ca24d4e-9401-4b3e-a43d-b179ea658e09">75</ix:nonFraction> employees (approximately <ix:nonFraction unitRef="number" contextRef="i16076e8ab5354387af2ac1ec6fc8cbdc_I20220706" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfNjgw_65ef25d2-795f-4327-9fed-0ca34ee8b43c">37</ix:nonFraction>%) as of July 6, 2022. <ix:nonNumeric contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfMjc0ODc3OTA3NDA0NQ_d874e181-da6e-4262-97aa-f359ebe5ce42" continuedAt="i73a03a1996c847439b81c9e772670742" escape="true">Below is a summary of restructuring costs during the nine months ended September&#160;30, 2022 and accrued restructuring costs as of September&#160;30, 2022 :</ix:nonNumeric></span></div><div><ix:continuation id="i73a03a1996c847439b81c9e772670742"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Benefits Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock-Based Compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71258ef0094f45c882375b7e1010e7ef_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfMi0yLTEtMS0zMDkxOQ_dea720e9-f40a-4f25-a0cb-457969a1143d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f2678ad14b4a3d881b892b268a77d9_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfMi00LTEtMS0zMTEzMQ_cecc875d-08cc-4647-901d-d2c52400ec3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfMi02LTEtMS0zMTEzMQ_bd91ebbc-e490-4677-9478-38b01647443f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22948541eb864302a316aae361adb856_D20220101-20220930" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfMy0yLTEtMS0zMDkxOQ_d48e9edb-0b1b-4356-ae51-d841222c70da">4,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0c3eb26c891436cabc497ed5bd59128_D20220101-20220930" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfMy00LTEtMS0zMTEzMQ_eeb89bd0-52d5-4564-bce3-525c6759d43a">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfMy02LTEtMS0zMTEzMQ_29ddf2e2-a907-4a64-861c-2f0e92bd2262">4,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments made</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22948541eb864302a316aae361adb856_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNC0yLTEtMS0zMDkxOQ_78452f18-f021-4ed4-b916-4550dfb220f3">4,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0c3eb26c891436cabc497ed5bd59128_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNC00LTEtMS0zMTEzMQ_6cbdb3e5-ce67-4d64-868e-bbde9e4c4261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNC02LTEtMS0zMTEzMQ_bf43f571-9164-4b48-b713-016d0bf4abc8">4,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22948541eb864302a316aae361adb856_D20220101-20220930" decimals="-3" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNS0yLTEtMS0zMDkxOQ_3e08ebca-1af2-40a8-991a-48fe57075b25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0c3eb26c891436cabc497ed5bd59128_D20220101-20220930" decimals="-3" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNS00LTEtMS0zMTEzMQ_e1b710c4-304a-4dc4-8dc1-74e1038546bd">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-3" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNS02LTEtMS0zMTEzMQ_560855db-2a5d-433d-b9ba-af2f91471deb">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad217fa80da4c1da3ead4e449ee044e_I20220930" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNi0yLTEtMS0zMDkxOQ_3eb624ad-1d6d-4e3e-b585-caf7fbfa424a">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id96f08f18d8844938eb17eab71c615ff_I20220930" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNi00LTEtMS0zMTEzMQ_14cc7934-ce40-4c52-97c4-080e59cc3e8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNi02LTEtMS0zMTEzMQ_5e96048f-a80a-4d1f-b03c-d26928eef18b">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the three and nine months ended September 30, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfMTY0OTI2NzQ0Nzk5Mg_d2d30699-e9b4-4bcd-9a77-489043b67181">4.7</ix:nonFraction>&#160;million of restructuring costs, of which $<ix:nonFraction unitRef="usd" contextRef="i65531dff90074634acb629953b46148e_D20220101-20220930" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfMjc0ODc3OTA3NTcyNg_34be0018-a38a-44b1-b146-2350e4781c21">3.7</ix:nonFraction>&#160;million was classified as research and development expenses and $<ix:nonFraction unitRef="usd" contextRef="i5ee3bd88ea5a4bfab2257c3d73958b7a_D20220101-20220930" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfMjc0ODc3OTA3NTc0MA_2746e95d-409e-42a3-9edf-97091a9b727e">1.0</ix:nonFraction>&#160;million was classified as general and administrative expenses. Substantially all of the restructuring costs were incurred during the three months ended September&#160;30, 2022, of which $<ix:nonFraction unitRef="usd" contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfMjc0ODc3OTA3MzY0OA_d3dc6574-8b70-4a2d-ba0d-8c784173091f">4.5</ix:nonFraction>&#160;million were paid. The Company expects the restructuring to be completed in the fourth quarter of 2022.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The interim financial statements included in this Quarterly Report on Form 10-Q and this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December&#160;31, 2021, and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, contained in our Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission (SEC) on March&#160;29, 2022. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (&#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These forward-looking and other statements are subject to risks and uncertainties, including those discussed in the section titled &#8220;Risk Factors,&#8221; set forth in Part II &#8211; Other Information, Item&#160;1A below and elsewhere in this report that could cause actual results to differ materially from historical results or anticipated results. </span></div><div id="id78fc84db2574938a52c2b619c0c6019_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases. We develop gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include novel vector discovery, nonclinical and clinical development, and pre-commercial planning. In addition, we have in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (&#8220;GMP&#8221;) quality control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ixo-vec (ADVM-022)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), which we previously referred to as ADVM-022, is a single, in-office intravitreal (&#8220;IVT&#8221;) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent bolus anti-vascular endothelial growth factor (&#8220;VEGF&#8221;) IVT injections. Ixo-vec utilizes an engineered, proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette capable of transducing retinal cells after a single in-office IVT injection. This product is intended to improve both real-world vision and quality of life outcomes for patients. Ixo-vec is currently being developed for the treatment of patients with wet age-related macular degeneration (&#8220;wet AMD&#8221;) who are responsive to anti-VEGF therapy. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with wet AMD. Age-related macular degeneration (&#8220;AMD&#8221;) is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately ten percent of those cases.  In recognition of the need for new treatment options for wet AMD, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted Fast Track designation for Ixo-vec for the treatment of wet AMD.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we initiated the OPTIC trial, designed as a multi-center, open-label, dose-ranging, safety and efficacy trial of Ixo-vec in patients with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Patients in OPTIC are treatment experienced, and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision. We completed enrollment for OPTIC in July 2020 and continue to regularly present updated efficacy, aflibercept protein levels and safety data from the trial out to two years and have initiated an extension study to continue to follow our patients for an additional three years for a total of five years.  To date, we have seen strong signals of therapeutic efficacy in OPTIC in both the 6 x 10&#94;11 vg/eye (&#8220;6E11&#8221;) and 2 x 10&#94;11 vg/eye (&#8220;2E11&#8221;) doses, including continuous stable aflibercept protein levels from 10 weeks to three years, maintenance to improvement in best-corrected visual acuity and central subfield thickness (&#8220;CST&#8221;), a measure of fluid in and beneath the retina, as well as a reduction in CST fluctuations. Ixo-vec has been generally well tolerated, with the most common adverse events being</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dose-dependent adeno-associated virus (&#8220;AAV&#8221;) associated ocular inflammation that has been responsive to topical corticosteroid therapy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonclinical studies have indicated that a 6 x 10&#94;10 vg/eye (&#8220;6E10&#8221;) dose has the potential to achieve therapeutic levels of aflibercept. In April 2022, we announced having received feedback via a Type C meeting written response from the FDA related to our planned Phase 2 trial of Ixo-vec in wet AMD. We requested the FDA&#8217;s feedback to ensure alignment with the regulatory agency ahead of filing the Investigational New Drug (&#8220;IND&#8221;) amendment for our Phase 2 trial, which IND amendment was submitted on May 26, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we dosed the first subject in our Phase 2 LUNA (&#8220;LUNA&#8221;) trial of Ixo-vec. The LUNA trial is a multicenter, double-masked, randomized, parallel-group Phase 2 trial evaluating two doses of Ixo-vec, including 2E11 and a new, lower 6E10 dose, in up to 72 subjects with wet AMD. The LUNA trial will assess four new enhanced prophylactic steroid </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regimens, including local steroids and combinations of local and systemic steroids to test the relative contribution of local versus systemic AAV exposure on ocular inflammation. Specific regimens include topical difluprednate (&#8220;Durezol&#174;&#8221;), dexamethasone intravitreal implant (&#8220;Ozurdex&#174;&#8221;), or a combination of either topical Durezol&#174; or IVT Ozurdex&#174; with oral prednisone.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial will randomize the participants equally between the 2E11 and 6E10 Ixo-vec doses across four prophylactic steroid regimens and will be conducted at approximately 40 sites in the U.S. and Europe. The primary endpoints will be similar to the OPTIC trial and focus on mean change in best-corrected visual acuity and central subfield thickness (&#8220;CST&#8221;) from baseline to one year, and incidence and severity of adverse events. Other data points will include protein expression of aflibercept starting at 10 weeks and an interim analysis at 26 weeks, including fluctuations in CST. The study will also evaluate the effectiveness and tolerability of the prophylactic steroid regimens.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we announced that the European Medicines Agency (&#8220;EMA&#8221;) has granted Ixo-vec Priority Medicines (&#8220;PRIME&#8221;) designation. PRIME is a program launched by the EMA to enhance support for research on and development of medicines that have demonstrated preliminary safety and efficacy and thus the potential to target a significant unmet medical need.  This regulatory program offers developers of promising medicines enhanced interaction and early dialogue and is designed to optimize development plans and speed evaluation ensuring these medicines reach patients as early as possible. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we initiated the INFINITY trial, a multi-center, Phase 2, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of Ixo-vec in patients with diabetic macular edema (&#8220;DME&#8221;). A dose limiting toxicity at the 6E11 dose in this diabetic population was identified in April of 2021. Consequently, we are no longer pursuing Ixo-vec for DME, nor are we evaluating the 6E11 dose in wet AMD. We have not seen similar patient safety concerns in any of our patients at either the 2E11 dose in the INFINITY or OPTIC trials or the 6E11 dose in the OPTIC trial. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunogenicity to AAV therapy has been broadly reported to be associated both with systemic and ocular gene therapies. Based on an extensive evaluation of data from all of our subjects treated with Ixo-vec and all of our nonclinical data by internal and external experts, we believe new enhanced prophylactic steroid regimens, which includes local steroids and a combination of local and systemic steroids, will allow us to minimize post-prophylaxis inflammation in our trial subjects going forward. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance Ixo-vec for wet AMD, we are continuing to develop our manufacturing expertise for ongoing supply. We maintain control of key aspects of the manufacturing process, specifically in scalable process development, assay development, and GMP quality controls.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADVM-062</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a novel gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (&#8220;BCM&#8221;) via a single IVT injection. ADVM-062 utilizes Adverum&#8217;s propriety vector capsid, AAV.7m8.  In January 2022, we announced that the FDA granted Orphan Drug Designation to ADVM-062.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCM affects approximately 1 to 9 in 100,000 males, worldwide. This X-linked recessive hereditary condition is caused by mutations in either the L or the M opsin gene(s) and can manifest in loss of visual acuity, photosensitivity, myopia and infantile nystagmus that can persist into adulthood. Consequently, individuals with BCM have visual impairments to important aspects of daily living such as facial recognition, learning, reading, and daylight vision. Currently, there is no cure for BCM and to our knowledge, no other therapies to treat BCM are in development. We are collaborating with the families of patients affected with BCM to help advance our therapies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Restructuring</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we announced we had taken measures to restructure our operations, including reductions in both headcount and expenses to prioritize Ixo-vec&#8217;s clinical development, and focus our pipeline strategy on certain highly prevalent ocular diseases. We expect these restructuring measures will be sufficient to fully support our Ixo-vec development plan and extend our expected cash runway into 2025. We expect the restructuring to be completed in the fourth quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations and financial condition for the three and nine months ended September&#160;30, 2022 were not significantly impacted by the COVID-19 pandemic. However, the full extent to which the COVID-19 pandemic will directly or indirectly impact these areas in the future is unknown at this time and will depend on future developments that are unpredictable. We are actively monitoring and managing our response and assessing actual and potential impacts to these areas. Please refer to the &#8220;Risk Factors&#8221; section for further discussion of the risks we face as a result of the COVID-19 pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuously evaluating and addressing potential impacts of the COVID-19 pandemic on our operations. To date, we have experienced limited impact due to COVID-19 on our operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to the health and safety of our employees and their families and to doing our part to slow the spread of COVID-19. We have reopened our offices to allow our employees more flexibility to mix virtual and in-person work and to advance our culture and corporate goals. We believe this will also enable greater balance and well-being of our employees. We continue to update our policies and implement new practices to align with the current guidance from state and federal governments and health authorities. We believe these measures and others have allowed us to mitigate, but not eliminate, the effects and risks on our on-site operations posed by the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Clinical Trials</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the COVID-19 pandemic on our ongoing and planned clinical trials is uncertain and subject to change. To date, we believe we have experienced limited impact due to COVID-19 on our ongoing clinical programs, including the OPTIC and LUNA clinical trials. We are working closely with our clinical trial sites to monitor and attempt to address or limit the potential negative impacts of the evolving COVID-19 outbreak and the emergence of COVID-19 variants on patient safety, trial enrollment, continued participation and follow-up of patients already enrolled in our clinical studies, protocol compliance, data quality, and overall study integrity. Despite these efforts, we are unsure as to whether the COVID-19 pandemic will significantly impact future trial enrollment or completion of our current or planned clinical studies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Supply Chain and Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not yet experienced significant disruptions to our supply chain and manufacturing as a result of the COVID-19 pandemic, we cannot be certain that this trend will continue. Based on current information, we believe that our partners in our supply chain have been and will continue to serve us continuously during the COVID-19 pandemic. The COVID-19 pandemic and other factors have also adversely impacted the global supply chain for other supplies and materials which could impact our future operations. To mitigate against future potential delays in supplies and materials we use in our operations, including product supply, we are continuously implementing additional measures to address potential risks as we identify them, including securing additional supplies and manufacturing capacity reserve, which have resulted in additional expenses and may result in other additional expenses in the future. Given the uncertainty regarding the impact delays and disruption in the global supply chain may have on our operations, we are unable to quantify the ultimate impact on our future results at this time.</span></div><div id="id78fc84db2574938a52c2b619c0c6019_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated positive cash flow or net income from operations since our inception and, as of September&#160;30, 2022, we had an accumulated deficit of $769.9 million. We expect to incur substantial expenses and continuing losses from operations in the foreseeable future as we conduct our research and development efforts, advance our product candidates through nonclinical and clinical development, manufacture clinical study materials, seek regulatory approval, and prepare for and, if approved, proceed to commercialization. We are at an early stage of development and may never be successful in developing or commercializing our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we may in the future generate revenue from a variety of sources, including license fees, milestone and research and development payments in connection with strategic partnerships, and potentially revenue from product sales if any of our product candidates are approved, to date we have not generated any revenue from product sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no operational clinical or commercial manufacturing facilities, and all of our clinical manufacturing activities are currently contracted out to third parties. Additionally, we use third-party contract research organizations (&#8220;CRO&#8221;) to carry out our clinical development and we do not have a sales organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of our product candidates. We will need substantial additional funding in the future to support our operating activities as we advance our product candidates through nonclinical and clinical development, seek regulatory approval and prepare for and, if approved, proceed to commercialization. Adequate funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital, or to do so on acceptable terms, when needed, or to form additional collaboration partnerships to support our efforts, we could be forced to delay, reduce or eliminate our research and development programs or potential commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had $203.3 million in cash, cash equivalents and short-term investments. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have not generated any revenue from the sale of our products. We have generated revenue through research, collaboration and license arrangements with strategic partners. Our ability to generate product revenue and become profitable depends upon our ability to successfully develop and commercialize our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the amount or timing of product revenue. Even if we are able to generate revenue from the sale of our products, our sales may not be sufficient to generate cash from operations, in which case we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting a significant amount of research and development is central to our business model. Research and development expenses primarily include personnel-related costs, stock-based compensation expenses, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical study materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We defer and expense advance payments for goods or services for future research and development activities as the goods are delivered or the related services are performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate nonclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and CROs that conduct and manage nonclinical studies and clinical trials on our behalf. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. We estimate the amounts incurred through communications with third party service providers and our estimates of accrued expenses as of each balance sheet date are based on information available at the time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate the nature, timing or aggregate costs of the efforts that will be necessary to complete the development of any of our product candidates. The successful development and commercialization of a product candidate is highly uncertain, and clinical development timelines, the probability of success, and development and commercialization costs can differ materially from expectations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses primarily include personnel-related costs, stock-based compensation, professional fees for legal, consulting, audit and tax services, overhead expenses, such as rent, equipment depreciation, insurance and utilities, and other general operating expenses not otherwise included in research and development expenses. Our general and administrative expenses may increase in future periods if and to the extent we elect to increase our investment in infrastructure to support continued research and development activities and potential commercialization of our product candidates. We will continue to evaluate the need for such investment in conjunction with our ongoing consideration of our pipeline of product candidates. We may require increased expenses related to audit, legal and regulatory functions, as well as director and officer insurance premiums and investor relations costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize our clinical development of Ixo-vec and focus our pipeline strategy on certain highly prevalent ocular diseases, which included a reduction in our workforce by approximately 37%. Substantially all of the restructuring costs were incurred and recorded in the operating expenses in the Condensed Statements of Operations during the three months ended September&#160;30, 2022. We expect the restructuring to be completed in the fourth quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net primarily comprises interest income on our cash equivalents and investments in marketable securities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Judgments and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an on-going basis, we evaluate our critical accounting judgments and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions. Except as noted below, there have been no significant changes in our critical accounting judgments and estimates during the nine months ended September 30, 2022 as compared to the critical accounting judgments and estimates disclosed in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our most recent Annual Report on Form 10-K filed with the SEC on March 29, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for leases under Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, Leases (Topic 842) effective January 1, 2019. For our long-term operating leases, we recognize a right-of-use asset and a lease liability on our consolidated balance sheets. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that we would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the incremental borrowing rate, we estimate our credit rating, adjust the credit rating for the nature of the collateral, and benchmark the borrowing rate against observable yields on comparable securities with a similar term. We base the right-of-use lease asset on the lease liability adjusted for any prepaid or deferred rent. We determine the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income for operating leases is recognized on a straight-line basis over the lease term and is classified as a reduction of rent expense in operating expenses.  The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable.  In the three months ended September&#160;30, 2022, management reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease.  Management assessed the collectability to be less than probable and we recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses in the three and nine month periods ended September&#160;30, 2022. The deferred rent receivable as of June 30, 2022 and September 30, 2022 was $4.1&#160;million and zero, respectively.</span></div><div id="id78fc84db2574938a52c2b619c0c6019_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three and Nine Months Ended September&#160;30, 2022 and 2021</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September&#160;30,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,037)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,522)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,515)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,195)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,703)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,492)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,114)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,362)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,752)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,745)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,131)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,614)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,131)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,362)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,769)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,800)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,131)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,669)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $7.5 million license revenue for the nine months ended September&#160;30, 2021 was related to an upfront payment received in January 2021 upon execution of a license agreement entered with Lexeo Therapeutics, Inc (&#8220;Lexeo&#8221;). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased $0.2 million to $23.8 million for the three months ended September&#160;30, 2022 from $24.1&#160;million for the three months ended September&#160;30, 2021. The overall decrease was primarily due to a $2.0 million decrease in facilities related expenses and a $1.5 million decrease in salaries due to lower headcount following the restructuring, $1.0&#160;million lower consultant costs and $0.8 million lower laboratory expenses; partially offset by $3.7&#160;million of restructuring costs and a $1.1 million increase in clinical trial-related expenses in preparation for the Phase&#160;2 LUNA trial. Stock-based compensation expense included in research and development expenses was $1.4&#160;million for the three months ended September&#160;30, 2022, compared to $2.2 million for the three months ended September&#160;30, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased $10.4 million to $77.1 million for the nine months ended September&#160;30, 2022 from $66.7&#160;million for the nine months ended September&#160;30, 2021. The overall increase was primarily related to a $4.4&#160;million increase in clinical trial-related expenses as we prepared to initiate our LUNA trial; $3.7&#160;million in restructuring costs; $2.1&#160;million recognition of impairment costs associated with certain laboratory equipment; a $2.0&#160;million increase in license costs arising from amounts due under a sublicense agreement; and $1.8 million in personnel-associated costs including higher salaries and bonuses as a result of higher average number of employees during 2022 in the period prior to the restructuring compared to same period last year as well as retention efforts for continuing employees. These increases were partially offset by a $1.6&#160;million decrease in material production and bioanalytical expenses; $1.3 million decrease in outside research and development services driven by nonclinical research; and $1.3 million in lower laboratory expenses. Stock-based compensation expense included in research and development expenses was $5.2&#160;million for the nine months ended September&#160;30, 2022, compared to $7.1&#160;million for the nine months ended September&#160;30, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, our research and development expenses were attributable to our wet AMD, DME, and rare disease programs, as well as earlier-stage research programs. We expect that research and development expenses will decrease in future periods as we focus on advancing our gene therapy product candidate Ixo-vec for the treatment of wet AMD.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense increased $2.7&#160;million to $17.2 million for the three months ended September&#160;30, 2022 from $14.5&#160;million for the three months ended September&#160;30, 2021, primarily related to a $4.1&#160;million reversal of sublease income and $1.0&#160;million in restructuring costs. These increases were partially offset by a $0.8 million decrease in personnel-associated costs driven by lower headcount; and a $0.9 million decrease in facilities related expenses. Stock-based compensation expense included in general and administrative expenses was $3.1&#160;million for the three months ended September&#160;30, 2022, compared to $3.1 million for the three months ended September&#160;30, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense decreased $6.4 million to $46.1 million for the nine months ended September&#160;30, 2022 from $52.5&#160;million for the nine months ended September&#160;30, 2021, primarily related to decreases of a $5.7&#160;million in personnel-associated costs driven by lower headcount and lower fair value of equity related awards and forfeiture of equity awards as part of the restructuring and $5.2 million in professional services mainly related to investor relations and legal fees incurred in connection with the prior year's proxy contest. These decreases were partially offset by $4.6&#160;million in facilities related expenses, $1.0&#160;million in restructuring costs and $0.8 million reversal of sublease income. Stock-based compensation expense included in general and administrative expenses was $9.6&#160;million for the nine months ended September&#160;30, 2022, compared to $13.7 million for the nine months ended September&#160;30, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that general and administrative expenses will decrease in future periods as we streamline our operations. We anticipate decreased expenses related to the human resources, legal, and finance functions brought about by the restructuring measures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net were $0.9 million and $1.5 million for the three and nine months ended September&#160;30, 2022, respectively and $0.2 million and $0.6 million for the three and nine months ended September&#160;30, 2021, respectively. The increases are from higher average yields in investments and unrealized foreign currency gain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Provision</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized an income tax provision of $17,000 and $55,000 for the three and nine months ended September&#160;30, 2022, respectively, related to foreign operations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized no income tax provision for the three and nine months ended September&#160;30, 2021.</span></div><div id="id78fc84db2574938a52c2b619c0c6019_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated positive cash flow or net income from operations since our inception and as of September&#160;30, 2022, we had an accumulated deficit of $769.9 million. As of September&#160;30, 2022, we had $203.3 million in cash, cash equivalents and short-term investments compared to $305.2 million as of December 31, 2021. We believe that our existing cash and cash equivalents and short-term investments as of September&#160;30, 2022 will be sufficient to fund our operations and meet our existing contractual obligations and other cash requirements into 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of our product candidates and ongoing internal research and development programs. At this time, we cannot reasonably estimate the nature, timing or aggregate amount of costs for our development, potential commercialization, and internal research and development programs. However, in order to complete our planned nonclinical trials and current and future clinical trials, and to complete the process of obtaining regulatory approval for our product candidates, as well as to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional funding in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when we seek additional funding, we will do so through equity or debt financings, collaborative or other arrangements with corporate sources or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital in the future could have a negative impact on our financial condition and our ability to pursue our business strategies. To complete development and commercialization of any of our product candidates, we anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing, costs and results of nonclinical studies and any clinical trials for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing of and costs involved in, seeking and obtaining approvals from the FDA and other regulatory authorities, including the potential for the FDA and other regulatory authorities to require that we perform more studies than those that we currently expect;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our product candidates to progress through clinical development activities successfully;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to expand our research and development activities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of progress and cost of our commercialization of our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of preparing to manufacture our products on a larger scale;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities including product sales, marketing, manufacturing and distribution;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree and rate of market acceptance of any products launched by us or future partners;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional infrastructure and internal systems;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to hire additional personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies or other adverse market developments; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of the COVID-19 pandemic on our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license other technologies or clinical product candidates or programs that we would prefer to develop and commercialize ourselves.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,235&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,168)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Used in Operating Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, net cash used in operating activities was $89.6 million, primarily as a result of net loss of $121.8 million due to the continued activities developing our product candidates partially offset by $20.0 million of non-cash charges mainly related to $14.8 million of stock-based compensation expense, $4.8 million of depreciation and amortization expenses, and $2.0 million of impairment of long-lived assets and by $12.2 million of change in operating assets and liabilities, which fluctuate due to timing of expenses and payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, net cash used in operating activities was $82.0 million, primarily as a result of net loss of $111.1 million due to the continued activities developing our product candidates and $1.8 million of net decrease in operating assets and liabilities, partially offset by $27.3 million of non-cash charges mainly related to $20.8 million of stock-based compensation expense, $3.3 million of depreciation and amortization expenses, $2.3 million of amortization of premium (discount) and accrued interest on marketable securities, and $1.1 million of impairment of long-lived assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Provided by Investing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the nine months ended September&#160;30, 2022 consisted of $151.1 million of net maturities from our marketable securities, partially offset by $11.6 million of purchases of property and equipment primarily related to laboratory equipment and facility construction. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the nine months ended September 30, 2021 consisted of $65.6 million of net proceeds from marketable securities, partially offset by $10.8 million of purchases of property and equipment primarily related to laboratory equipment and facility construction.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Provided by Financing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the nine months ended September&#160;30, 2022 consisted mainly of $0.4 million of proceeds from our employee purchase plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the nine months ended September 30, 2021 consisted of $1.7 million of net proceeds from the sale of our common stock pursuant to our then available "at-the-market" sales agreement and $0.5 million proceeds from employee stock purchase plan, partially offset by $0.2 million for repayment of a loan.</span></div><div id="id78fc84db2574938a52c2b619c0c6019_100"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item.</span></div><div><span><br/></span></div><div id="id78fc84db2574938a52c2b619c0c6019_103"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of disclosure controls and procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Management, including our Chief Executive Officer and Acting Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of September&#160;30, 2022. The evaluation of our disclosure controls and procedures included a review of our processes and implementation and the effect on the information generated for use in this Quarterly Report on Form 10-Q. We conduct this type of evaluation quarterly so that our conclusions concerning the effectiveness of these controls can be reported in our periodic reports filed with the SEC. The overall goals of these evaluation activities are to monitor our disclosure controls and procedures and to make modifications as necessary. We intend to maintain these disclosure controls and procedures, modifying them as circumstances warrant.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three-months ended September&#160;30, 2022, we identified a deficiency in the operating effectiveness of controls in our financial statement close process that we considered to be a material weakness. An immaterial non-cash lease accounting error was identified in previously issued financial statements. While the identified error was not material, we considered the potential magnitude of the error(s) that could arise from the operating deficiency as potentially material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We discussed these matters with our independent registered public accounting firm and our Audit Committee. Our remediation activities are not complete and we continue to seek ways to strengthen the operation of our controls over our financial statement close process, and we may need to continue effective operation of these controls for one or more quarters before we can conclude that the material weakness has been corrected.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the existence of the material weakness, our Chief Executive Officer and Acting Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of September 30, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in internal control over financial reporting. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other changes in our internal control over financial reporting during the three months ended September&#160;30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the Effectiveness of Controls</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Acting Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within Adverum have been detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but there can be no assurance that such improvements will be sufficient to provide us with effective internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="id78fc84db2574938a52c2b619c0c6019_109"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="id78fc84db2574938a52c2b619c0c6019_112"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should consider carefully the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and prospects. Further, the current coronavirus (&#8220;COVID-19&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pandemic and actions taken to address the pandemic may exacerbate the risks described below.</span></div><div><span><br/></span></div><div id="id78fc84db2574938a52c2b619c0c6019_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Capital</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses since we were founded in 2006 and expect to incur significant losses for the foreseeable future as we continue development of our product candidates. Losses have resulted principally from costs incurred in our research and development programs and from our general and administrative expenses. In the future, we intend to continue to conduct research and development, regulatory compliance activities and, if any of our product candidates is approved, sales and marketing activities that, together with anticipated general and administrative expenses, will likely result in us incurring significant losses for the next several years or longer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently generate no revenue from sales, and we may never be able to commercialize any of our product candidates. We do not currently have the required approvals to market any of our product candidates, and we may never receive such approvals. We may not be profitable even if we or any of our future development partners succeed in commercializing any of our product candidates. Because of the numerous risks and uncertainties associated with developing and commercializing our product candidates, we are unable to predict the extent of any future losses or when we will become profitable, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs for at least twelve months from the date of this filing. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect our cash, cash equivalents and short-term investments to fund our planned operations into 2025. However, this estimate is based on a number of assumptions that may prove to be wrong, including our expectations about the timing of planned clinical trials, forecasted employee attrition, investments into our manufacturing capabilities, continued receipt of rent under our sublease, and changing circumstances beyond our control, that may cause capital to be consumed more rapidly than currently anticipated. As a result, our operating plan may change, and we may need to seek additional funds sooner than planned through collaboration agreements and public or private financings. If we run low on capital and are unable to successfully raise additional funds on terms acceptable to us, we may need to significantly curtail some or all of our development activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require substantial future capital in order to complete the nonclinical and clinical development for our product candidates and potentially to commercialize these product candidates. Any future clinical trials or ongoing clinical trials of our product candidates could cause an increase in our spending levels, as would other corporate activities, such as expenses related to manufacturing supply of our product candidates. The amount and timing of any expenditure needed to implement our development and commercialization programs will depend on numerous factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the type, number, scope, progress, expansion costs, results of and timing of any future nonclinical studies and clinical trials of any of our product candidates which we are pursuing or may choose to pursue in the future;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need for, and the progress, costs and results of, any additional clinical trials or nonclinical studies of our product candidates we may initiate based on the results of any clinical trials that we may plan or discussions with the U.S. Food and Drug Administration (&#8220;FDA&#8221;), including any additional clinical trials or nonclinical studies the FDA or other regulatory authorities outside the U.S. may require evaluating the safety of our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of obtaining or maintaining manufacturing for our product candidates, including internal and external commercial manufacturing;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing sales and marketing capabilities and enhanced internal controls over financial reporting;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of establishing collaborations, license agreements and other partnerships;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with any new product candidates that we may develop, in-license or acquire;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain partnering arrangements for development; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these factors are outside of our control. We do not expect our existing capital resources to be sufficient to enable us to fund the completion of our clinical trials and remaining development programs through commercial introduction. We expect that we will need to raise additional funds in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no product candidate approved by any regulatory authority, have not sold any products, and we do not expect to sell or derive revenue from any product sales for the foreseeable future. We may seek additional funding through collaboration agreements and public or private financings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional funding may not be available to us on acceptable terms or at all and the terms of any financing may adversely affect the holdings or the rights of our stockholders. General market conditions resulting from rising interest rates, inflation, global supply chain issues, Russia&#8217;s invasion of Ukraine, the COVID-19 pandemic, as well as other market conditions, as well as our ability to maintain our Nasdaq listing, may make it difficult for us to obtain adequate additional financing when needed or on attractive terms, or at all. In addition, the issuance of additional shares by us, or the possibility of such issuance, may cause the market price of our shares to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain funding on a timely basis, we will be unable to complete any future clinical trials for our product candidates and we may be required to significantly curtail some or all of our activities. We also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to our product candidates or some of our technologies or otherwise agree to terms unfavorable to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to comply with Nasdaq&#8217;s continued listing standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on The Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;ADVM.&#8221; There is no guarantee we will be able to perpetually satisfy Nasdaq&#8217;s continued listing requirements to maintain our listing on Nasdaq for any periods of time. Among the conditions required for continued listing on Nasdaq, we are required to maintain a minimum closing bid price of over $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2). Our closing bid price has been below $1.00 per share every business day from October 7, 2022 to the filing date of this report. Accordingly, we may not be able to maintain a minimum closing bid price over $1.00 per share and could face the risk of our common stock being delisted if the closing bid price for our common stock is below $1.00 per share for 30 consecutive business days and we are unable to regain compliance. In addition, even if we demonstrate compliance with the requirement above, we will have to continue to meet other objective and subjective listing requirements to continue to be listed on Nasdaq, which we may not be able to continue to meet. </span></div><div id="id78fc84db2574938a52c2b619c0c6019_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of Our Product Candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are in the early stages of development and will require substantial nonclinical and/or clinical development and testing, manufacturing process improvement and validation, clinical studies and regulatory approval prior to commercialization. It is critical to our business to successfully develop and ultimately obtain regulatory approval for one or more of these product candidates. Our ability to commercialize our product candidates effectively will depend on several factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of nonclinical studies and clinical trials, including the ability to demonstrate safety and efficacy of our product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals for any future products for which we complete clinical trials, including securing regulatory exclusivity to the extent available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities, for example, by engaging third-party manufacturers or developing our own manufacturing capabilities that can provide products and services to support clinical development and the market demand for our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful launch and commercial sales of the product, whether alone or in collaboration with potential partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of the product as a viable treatment option by patients, the medical community and third-party payers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing market share while competing with other therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety profile of our products following regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining compliance with post-approval regulations and other requirements; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">qualifying for, identifying, registering, maintaining, enforcing and defending intellectual property rights and claims covering our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to commercialize our product candidates, which would materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of biologics and drugs in development in the pharmaceutical industry, only a small percentage result in the submission of a biologics license application (&#8220;BLA&#8221;) to the FDA or marketing authorization application (&#8220;MAA&#8221;) to the European Medicines Agency (&#8220;EMA&#8221;) and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval to market any of our product candidates, any such approval may be subject to limitations on the indicated uses for which we may market the product, or limitations related to its distribution. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, there can be no assurance that any of our product candidates will be successfully developed or commercialized. If we or any of our future development partners are unable to develop, or obtain regulatory approval, or, if approved, successfully commercialize, any of our product candidates, we may not be able to generate sufficient revenue to continue our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development has inherent risk. Our lead product candidate, ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;) for the treatment of wet age-related macular degeneration (&#8220;wet AMD&#8221;) uses a proprietary vector, AAV.7m8, which has undergone limited human testing, and may experience unexpected results in clinical trials in the future, such as the dose-limiting toxicity at the 6 x 10&#94;11 vg/eye (&#8220;6E11&#8221;) dose tested in the INFINITY trial in diabetic macular edema (&#8220;DME&#8221;) patients. Although we will be bound by the generally applicable laws governing approval, the fact that our product is a gene therapy and the broad patient population that it is intended to treat means that the safety and efficacy of our product and the related clinical data will be under increased scrutiny by competent authorities. There have been several significant adverse side effects in gene therapy treatments in the past, including reported cases of leukemia and death seen in other trials using other genomic therapies. Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of significantly delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration that, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, or any licensee or development partner, will be required to demonstrate through adequate and well-controlled clinical trials that our product candidate or another party&#8217;s product candidate containing one of our proprietary viral vectors is safe and effective for use in its target indications before seeking regulatory approvals for commercial sale. Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors. Any such delay or failure could significantly harm our business prospects, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of our product candidates, either in nonclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the conduct of nonclinical studies and clinical trials, animal models and patients may experience changes in their health, including illnesses, injuries and discomforts. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. In addition, patients may not comply with the requirements of the study, such as missing physician visits or not taking eye drops as prescribed, which may result in changes to their health or vision that are then attributed to the product candidate. Various illnesses, injuries, and discomfort may be reported from time-to-time in clinical trials of our product candidates. For example, a dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial in DME patients resulted in our announcement on July 22, 2021 that we were discontinuing development of Ixo-vec for the DME indication. It is possible that as we test Ixo-vec and other product candidates, in current and future clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomfort and other adverse events that were observed in earlier trials, including the dose-limiting toxicity at the 6E11 dose tested in the INFINITY trial, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or later stage clinical trials, or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that one or more of our product candidates causes serious or life-threatening side effects, or side effects that outweigh the therapeutic benefit of the product candidate, the development of one or more of our product candidates may fail or be delayed, or, if one or more of our product candidates has received regulatory approval, such approval may be revoked, which would severely harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a patient experiences a negative health event during a clinical trial, we must determine if it is related to our product candidate in order to understand the safety of our product candidates. The patients we enroll in our clinical trials for our current product candidates are generally less healthy than the general population, which increases the likelihood that a negative health event, unrelated to our product candidate, may occur. These health events may be misattributed to our product candidate, either by us, our investigators, or by regulators. Such misattribution could cause regulatory approval of our product candidates to be denied or delayed. For example, the patients enrolled in our wet AMD trials are often geriatric and have other health conditions unrelated to wet AMD. We cannot assure you that we will be able to accurately determine whether or not a negative health event experienced by a patient in any of these or subsequent trials was related to Ixo-vec, nor can we assure you that the FDA or other regulatory authorities outside the U.S. responsible for reviewing the safety of Ixo-vec will agree with our determination. If a patient in one of our clinical trials experiences a negative health event, and that event is misattributed to Ixo-vec, the trial and other trials of Ixo-vec may be placed on clinical hold, and regulatory approval of Ixo-vec may be delayed or denied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if a patient enrolled in one of our clinical trials experiences a negative health event, they may be forced to withdraw from our trial, or may become temporarily unavailable for follow-up visits, which may impact the amount or quality of data we obtain from our trial, which in turn may delay or prevent regulatory approval of our product candidate. Because patients we enroll in our clinical trials for any of our product candidates are likely to be less healthy than the general population, and particularly in trials like OPTIC that enroll a small number of patients, this risk is increased.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates built on adeno-associated viral vector (&#8220;AAV&#8221;) vectors have similar risks to other gene therapy vectors, including inflammation, cytotoxic T-cell responses, anti-AAV antibodies and immune response to the transgene product, such as T-cell responses and/or antibodies against the expressed protein. For example, based on our current clinical experience, dose-related ocular inflammation is a known side effect of Ixo-vec administration, but the duration of inflammation caused by Ixo-vec, our ability to prevent or manage that inflammation using steroids or other anti-inflammatory or immunomodulatory treatments, and any potential clinical sequelae of that inflammation and treatments used to manage inflammation are not fully understood. The primary purpose of our LUNA trial is to identify the best combination of a prophylactic steroid regimen and dose of Ixo-vec that minimizes post-prophylactic inflammation while at the same time providing efficacy. If we are unable to manage this inflammation appropriately, we may not be able to further develop Ixo-vec and the FDA or other regulatory authorities outside the U.S. may not approve Ixo-vec. Even if we achieve marketing approval, doctors may not prescribe, and patients may not use, Ixo-vec or our other product candidates if they deem the levels or risk of inflammation to be unacceptable. Further, patients treated with Ixo-vec could develop antibodies against AAV.7m8 capsid and/or aflibercept protein. These antibodies could preclude these patients from receiving other AAV-based gene therapies in the future. In addition, patients previously treated with or exposed to other AAV-based gene therapies could develop antibodies against AAV.7m8 and/or the aflibercept protein, which could reduce or eliminate the effectiveness of Ixo-vec or could cause unanticipated adverse reactions to Ixo-vec. Studies have also found that intravenous delivery of certain AAV vectors at high doses may result in adverse events and have prompted the recommendation that studies involving high doses of AAV vectors should be monitored carefully for such adverse events. In addition, patients given infusions of any protein or injection of gene therapies that express a therapeutic protein may develop severe hypersensitivity reactions, infusion reactions, or serious side effects including transaminitis. With respect to our product candidates that are being or may be studied in diseases of the eye, there are additional potential serious complications related to intravitreal injection, such as retinal detachment, endophthalmitis, ocular inflammation, cataract formation, glaucoma, damage to the retina or cornea, and bleeding in the eye. Serious complications or serious, unexpected side effects in connection with the use of our product candidates could materially harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our lead product candidate, Ixo-vec, is designed for long-term, sustained expression of an exogenous protein, aflibercept. Even though EYLEA&#174; (aflibercept) has been approved by several regulatory authorities, including the FDA, for the treatment of wet AMD, there may be side effects associated with aflibercept being expressed as a gene therapy treatment modality. If such side effects are serious or life threatening, the development of our product candidate and future product candidates may fail or be delayed, or, if such product candidate(s) have received regulatory approval, such approval may be revoked, which would severely harm our business prospects, financial condition and results of operation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of nonclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are not shown to be safe and effective, we may not realize the value of our investment in our technology. Promising nonclinical results generated with a product candidate in animal models do not guarantee similar results when the candidate is tested in humans. For example, the levels of protein expression achieved from a vector in a nonclinical model, including non-human primate models, may be significantly higher than the level of protein expression achieved in humans. Similarly, human subjects administered our product candidates may develop side effects that were not observed in animal models and/or are more severe than those observed in animal models. In addition, even industry-accepted animal models may not accurately replicate human disease. Success in nonclinical studies or in early clinical trials does not mean that later clinical trials will be successful, because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through nonclinical and initial clinical testing. Further, safety and/or efficacy issues with a product candidate may only become apparent when the candidate is tested in human patients suffering from the relevant disease. Furthermore, the initiation of future trials for a product candidate will be dependent upon demonstrating sufficient safety and efficacy to the relevant regulatory authorities in preceding or other ongoing trials using the same product candidate. We will still need to conduct Phase 3 pivotal trials in which Ixo-vec will need to be compared to available therapies and utilize longer term endpoints in order to support submission and approval of a BLA. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. In addition, only a small percentage of products under development result in the submission of a marketing application and even fewer are approved for commercialization. Even if our clinical trials successfully meet their endpoints for safety and efficacy, the FDA and/or other regulatory authorities outside the U.S. may still conclude that the product candidate has not demonstrated a beneficial risk/benefit profile or otherwise does not meet the relevant standard for approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that results from any clinical trials that we plan will be successful, and any safety or efficacy concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our gene therapy platform is based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concentrated our research and development efforts on our gene therapy platform and our future success depends on the successful development of product candidates based on this platform. There can be no assurance that any development problems we have experienced or may experience in the future related to our platform will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to external commercial manufacturing sites, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the clinical trial requirements of the FDA, EMA and other regulatory authorities outside the U.S. and the criteria these regulators may use to determine the quality, safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel gene therapy products such as ours can be more expensive and take longer than for other product types, which are better known or more extensively studied to date. The FDA only recently approved the first in vivo gene therapies, LUXTURNA&#174; and ZOLGENSMA&#174;, and FDA approvals of gene therapy products to date have been generally for rare diseases with limited treatment options. Because we are targeting a broad population of patients with wet AMD, the benefit-risk profile of Ixo-vec may be subject to greater scrutiny by regulatory authorities. Regulatory approaches and requirements for gene therapy products continue to evolve, and any changes could create significant delay and unpredictability for product development and approval as compared to technologies with which regulatory authorities have more substantial experience.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, before a clinical trial can begin to enroll at a site, each clinical site's Institutional Review Board (&#8220;IRB&#8221;) and its Institutional Biosafety Committee will have to review the proposed clinical trial to assess appropriateness to conduct the clinical trial at that site. In addition, adverse events in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory authorities outside the U.S. to change the requirements for human research on or for approval of any of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulatory review committees and advisory groups, and the guidelines they promulgate, may lengthen our regulatory review process, require us to perform additional studies, increase our development costs, increase or otherwise change chemistry, manufacturing, and controls requirements, lead to changes in our regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will usually be required to consult with these, and potentially other, regulatory and advisory groups and comply with applicable guidelines or recommendations. If we fail to do so or the consultations take longer than we expect, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs incurred in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in our clinical trials will be critical to our success. The timing of current and future clinical trials will depend on the speed at which we can recruit patients to participate in future testing of these product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials, clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating and patient&#8217;s safety concerns over participating in a clinical trial, including during a pandemic. We will be required to identify and enroll a sufficient number of patients for any clinical trial for our product candidates. Potential patients may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for our trials. Additionally, some patients may have neutralizing antibodies at titer levels that would prevent them from being enrolled in a clinical trial for any of our product candidates, or may meet other exclusion criteria. As a consequence, enrollment in our clinical trials may be limited or slowed. We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for such future clinical trials. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of rare diseases, a relatively small number of individuals in the U.S. (fewer than 200,000) are impacted, and therefore, there is a limited patient pool from which to draw for clinical trials. Enrollment of eligible patients with rare or orphan diseases may be limited or slower than we anticipate in light of the small patient populations involved.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek initial marketing approval of our product candidates in the U.S. and/or Europe and we may not be able to successfully conduct clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA or the EMA or other regulatory authorities outside the U.S. In addition, the process of finding and diagnosing patients may prove costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if patients and investigators are unwilling to participate in our gene therapy studies because of the dose-limiting toxicity at the 6E11 dose tested in the INFINITY trial, or because of negative publicity from other adverse events in the biotechnology or gene therapy industries or inadequate results in our nonclinical studies or clinical trials or for other reasons, including competitive clinical trials for similar patient populations or available approved therapies, our recruitment of patients, or conduct of clinical trials and ability to obtain regulatory approval of our product candidates may be hindered.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Our product candidates use an AAV delivery system, with which host integration has been less of a concern. Nonetheless, if patients negatively associate our product candidates with the adverse events caused by previous gene therapy products, they may choose not to enroll in our clinical trials, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have difficulty enrolling a sufficient number of patients to conduct clinical trials on our product candidates as planned, we may need to delay, limit or terminate future clinical trials, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nonclinical and clinical development, manufacturing, analytical testing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA and by comparable regulatory authorities outside the U.S. In the U.S., we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved, as well as the target indications and patient population. Approval policies or regulations may change, and the regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or comparable regulatory authorities outside the U.S. can delay, limit or deny approval of a product candidate for many reasons, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with the design or implementation of our or any of our future development partners&#8217; clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our future development partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities outside the U.S. that a product candidate is safe and effective for any indication;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities outside the U.S. may not accept clinical data from trials which are conducted at multinational clinical facilities or in countries where the standard of care is potentially different from that of the U.S. or the other regulatory authorities outside the U.S.;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not demonstrate the safety or efficacy required by such authorities for approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our future development partners may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with our interpretation of data from nonclinical studies or clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may find deficiencies in the manufacturing processes, analytical testing, our facilities, or facilities of third-party manufacturers or testing laboratories with which we or any of our future development partners contract for clinical and commercial supplies; or</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our future development partners&#8217; clinical data insufficient for approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to foreign markets, approval procedures vary among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of related products, including those already on the market, may result in increased cautiousness by the FDA and comparable regulatory authorities outside the U.S. in reviewing our product candidates based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our future development partners from commercializing our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical trials that we may announce or publish from time to time may change as each clinical trial progresses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may announce or publish preliminary or interim data from our clinical trials. Preliminary and interim results of a clinical trial are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues or further patient follow up occurs and more patient data become available. For example, although we have periodically announced interim data from patients in our OPTIC trial, which showed all Ixo-vec related adverse events as mild to moderate in severity, there is no guarantee that in the future, we will not have more severe drug- or treatment-related adverse events in patients treated with Ixo-vec, such as the dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial. In addition, in certain clinical trials, such as our OPTIC trial, individual cohorts of patients are enrolled with different dosages and other treatment conditions under our protocol. These different doses, populations, and other treatment conditions may affect clinical outcomes, including safety profiles or efficacy, such as the number of supplemental injections required, in each of the cohorts. As a result, preliminary and interim data should be viewed with caution and not relied upon until the final data from a locked database for the entire clinical trial are available. Material changes in the final data compared to preliminary or interim data could significantly harm our business prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track designation for ADVM&#8209;022 may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood that ADVM&#8209;022 will receive marketing approval in the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received Fast Track designation for Ixo-vec in September 2018 for the treatment of wet AMD. The FDA may grant Fast Track designation to a drug that is intended to treat a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical needs. The FDA provides opportunities for frequent interactions with the review team for a Fast Track product, including pre-investigational new drug application (&#8220;IND&#8221;) meetings, end-of-phase 1 meetings, and end-of-phase 2 meetings with the FDA to discuss study design, extent of safety data required to support approval, dose-response concerns, and use of biomarkers. A Fast Track product may also be eligible for rolling review, where the FDA reviews portions of a marketing application before the sponsor submits the complete application.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, Fast Track designation for Ixo-vec may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, the FDA may rescind the Fast Track designation for Ixo-vec if FDA later determines that Ixo-vec no longer meets the qualifying criteria for Fast Track designation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our platform technology. Our research programs may fail to identify other potential product candidates for clinical development for a number of reasons. For example, our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to lack efficacy, have harmful side effects, or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that may ultimately prove to be unsuccessful.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully develop and maintain robust and reliable manufacturing processes for our product candidates, we may be unable to advance clinical trials or licensure applications and may be forced to delay or terminate a program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of commercially viable manufacturing processes typically is very difficult to achieve, is often very expensive and may require extended periods of time. As we develop, seek to optimize, and operate the Ixo-vec manufacturing process, we will likely face technical and scientific challenges, considerable capital costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical manufacturing campaigns or process validation campaigns. For example, all Good Manufacturing Practices (&#8220;GMP&#8221;) activities at our Redwood City facility, and external manufacturing, testing, and distribution partners are subject to significant health authority regulation with respect to manufacturing and testing our product candidates. If we are unable to satisfy these regulatory requirements, or if we are unable to solve the technical, scientific, and other challenges described above, we may be unable to manufacture a sufficient supply of our product candidates for our clinical trials and may be forced to delay or terminate our development programs. Additionally, changes in manufacturing processes (including cell lines), equipment or facilities (including moving manufacturing or testing from one of our facilities to another one of our facilities or a third-party facility, or from a third-party facility to one of our facilities) may require us to conduct additional studies to demonstrate comparability in order to receive regulatory approval of any manufacturing modifications. As a result, we could experience manufacturing delays that prevent us from completing our clinical studies in a timely manner, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may revise the process that we use to manufacture Ixo-vec for clinical trials. Before we use a revised process in clinical trials, we must submit analytical comparability data to the FDA to demonstrate that the process changes have not altered Ixo-vec in a manner that undermines the applicability of the clinical data from our Phase 1 clinical trial. If the FDA does not find our analytical comparability data sufficient, the FDA could place our IND on clinical hold until we conduct additional nonclinical or clinical comparability studies demonstrating that the Ixo-vec manufactured by our revised process and our previous process are materially equivalent, which could substantially delay the development process. If we make further changes to the manufacturing process, equipment or facilities of Ixo-vec in the future, the FDA may require us to demonstrate comparability between Ixo-vec manufactured before and after the change. For example, the FDA could require comparability studies to demonstrate that Ixo-vec manufactured in its current facilities is comparable to Ixo-vec manufactured at future commercial supply sites.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know whether any required comparability studies will begin as planned, will need to be restructured or will be completed on schedule, or at all. If the results of these comparability studies are not positive or are only modestly positive or if there are safety concerns, we may be delayed in obtaining marketing approval for Ixo-vec or not obtain marketing approval at all. Our product development costs also will increase if we experience delays in testing or regulatory approvals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet clinical or potential commercial demand, lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the complexity of manufacturing our products, we may not be able to manufacture sufficient quantities to meet clinical or potential commercial demand. Our inability to produce enough of a product meeting all release acceptance criteria at acceptable costs may cause us to be unable to meet clinical or potential commercial demand, to lose potential revenue, to have reduced margins, or to be forced to discontinue such product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we develop, seek to optimize and operate the Ixo-vec manufacturing process, we will likely face technical and scientific challenges, considerable costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical or commercial manufacturing campaigns. As a result, we could experience manufacturing delays that prevent us from commercializing Ixo-vec, if approved, on a profitable basis, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our manufacturing processes will subject us to a variety of U.S. federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of hazardous materials and wastes resulting from their use, as well as comparable legislation and regulations outside of the U.S. We will incur significant costs in complying with these laws and regulations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy products are novel and complex and have only in limited cases been manufactured at scales sufficient for pivotal trials and commercialization. Few pharmaceutical contract manufacturers specialize in gene therapy products and those that do are still developing appropriate processes and facilities for large-scale production. If we are unable to secure adequate manufacturing capacity from our contract manufacturing partners, or if our currently contracted slots are cancelled or delayed in order to prioritize other projects, we may be unable to produce sufficient quantities of our product candidates for our development programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have relationships with a limited number of suppliers for the manufacturing and testing of our vector product candidates. Our suppliers may require licenses to manufacture or test such components if such processes are not owned by the suppliers or in the public domain, and we may be unable to transfer or sublicense the intellectual property rights we may have with respect to such activities, and may be unable to acquire such rights, to the extent that we do not already have them.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract vendors for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product used in clinical trials or approved for commercial sale must be manufactured and tested in accordance with GMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s GMP regulations enforced by the FDA through its facilities inspection program as well as other regulations enforced by other regulatory authorities outside the U.S. Our contract manufacturers have not produced a commercially-approved AAV product and therefore have not yet demonstrated compliance with GMP regulations to the satisfaction of the FDA or other regulatory authorities outside the U.S. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. If the facility does not pass a pre-approval plant inspection, the FDA or other regulatory approval of the products will not be granted. In addition, the regulatory authorities may, at any time, audit or inspect any manufacturing facility we may have or those of our third-party contractors involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Should the FDA or other regulatory authorities outside the U.S. determine that the facility is not in compliance with applicable regulations, the manufacture and release of our product candidates may not be possible, and our business could be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in laws and governmental policies may have an effect on regulations. For example, on January 31, 2020, the United Kingdom (&#8220;UK&#8221;) withdrew from the European Union (&#8220;EU&#8221;), commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the UK and the EU, the UK was subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules continued to apply. The UK-EU Trade and Cooperation Agreement, which has applied since the end of the Transition Period, provides for tariff-free trade of goods, but not services, between the UK and the EU, but there may however be additional non-tariff costs which did not exist prior to the end of the Transition Period. Further, should the UK further diverge from the EU from a regulatory perspective in relation to medical products, tariffs could be put into place in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the body of the UK-EU Trade and Cooperation Agreement includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the Agreement. The Annex provides a framework for the recognition of GMP inspections and for the exchange and acceptance of official GMP documents. The regime does not, however, extended to procedures such as batch release certification. Among the changes that will now occur are that Great Britain (England, Scotland and Wales) will be treated as a third country. Northern Ireland will, with regard to EU regulations, continue to follow the EU regulatory rules. As part of the UK-EU Trade and Cooperation Agreement, the EU and the UK will recognize GMP inspections carried out by the other Party and the acceptance of official GMP documents issued by the other Party. The UK-EU Trade and Cooperation Agreement also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK has unilaterally agreed to continue to accept EU batch testing and batch release, two years notice will be provided of any change to such a policy. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use. As regards marketing authorizations, Great Britain will have a separate regulatory submission process, approval process and a separate national marketing authorization. Northern Ireland will, however, continue to be covered by the marketing authorizations granted by the European Commission (&#8220;EC&#8221;).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are currently delays on cross-border trade between the UK and the EU as businesses and governmental bodies adapt to the arrangements. We and our contract vendors currently rely on other contractors based in the UK. The implementation of new governmental policies associated with Brexit may affect our UK-based contractors&#8217; ability to comply with applicable regulations, including existing EU regulations. If they are unable to return to compliance, or if an acceptable substitute vendor cannot be identified, it may negatively impact our business. Further, to the extent that our UK-based contractors have supply relationships with vendors in the EU, these contractors may experience difficulties, delay or increased costs in receiving materials from their vendors in the EU, which could have a material adverse effect on our UK-based contractors&#8217; ability to provide the services or materials to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory authorities also may, at any time, inspect any manufacturing facility we may have or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if we become aware of a violation of our product specifications or applicable regulations, independent of an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and which may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Such violations could also result in civil and/or criminal penalties. Any such remedial measures or other civil and/or criminal penalties imposed upon us or third parties with whom we contract could materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our third-party contractors fail to maintain regulatory compliance, the FDA or other regulatory authorities outside the U.S. can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new biologic product, revocation of a pre-existing approval, injunction, seizure of product, or other civil or criminal penalties or closing one or more manufacturing or testing facilities. As a result, our business, financial condition and results of operations may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the service provided by an approved manufacturing or testing contractor is interrupted, there could be a significant disruption in commercial supply. Alternative contractors could need to be qualified through a BLA supplement which could result in further delay. The regulatory authorities may also require additional studies showing comparability between approved product or testing, and product or testing provided after a contractor change, if a new manufacturing or testing contractor is relied upon for commercial production. Changing contractors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, causing us to incur higher costs, and preventing us from commercializing our product candidates successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our product candidates is complex, highly regulated and subject to several risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Due to the complexity of manufacturing our product candidates, we may not be able to manufacture sufficient quantities to support our clinical trials. Delays in manufacture and supply by our contract manufacturing partners, including as a result of the COVID-19 pandemic, may also cause delays in their ability to supply the amount of our product that we have ordered and on which we have based our expected development timelines. Our inability to produce enough of a product candidate at acceptable costs may result in the delay or termination of development programs. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing and distribution of biologics is extremely susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, or transportation or storage conditions of the product. Even minor deviations from prescribed manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facility in which our product candidates are made, such manufacturing facility may need to be closed for an extended period of time to investigate and remedy the contamination.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, contaminants, raw materials shortages, natural disasters, power failures, and numerous other factors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our contract manufacturers must comply with the FDA&#8217;s GMP regulations and guidelines. We and our contract manufacturers may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We and our contract manufacturers are subject to inspections by the FDA and comparable regulatory authorities in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow GMP or other regulatory requirements or any delay, interruption, or other issues that arise in the manufacture, fill-finish, packaging, storage, or distribution of our product candidates as a result of a failure of our facilities, or the facilities or operations of third parties, to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates. This may lead to significant delays in the availability of sufficient supply of the product candidate substance for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions, and criminal prosecutions, any of which could be costly and damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates, if approved, and/or may be subject to product recalls, seizures, injunctions or criminal prosecution.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates are biologics and require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as our product candidates generally cannot be adequately characterized prior to manufacturing the final product. As a result, an assay of the finished product is not sufficient to ensure that the product will perform in the intended manner. Accordingly, we expect to employ multiple steps to attempt to control our manufacturing process and assure that the product or product candidate is made strictly and consistently in compliance with the process.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to develop the manufacturing process for late-stage clinical product, and our current process has not been fully characterized and therefore is open to potential variations that could lead to defective product substance that does not meet specification.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Problems with the manufacturing, storage or distribution of our product candidates, including even minor deviations from our established parameters, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims and insufficient inventory.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Some of the raw materials required in our manufacturing process are derived from biological sources. Such raw materials are difficult to procure and may also be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt commercialization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates. We may also have to take inventory write-offs and incur other charges and expenses for product that fails to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. We may encounter problems manufacturing sufficient research-, clinical-, or commercial-grade materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable production yields and costs.</span></div><div><span><br/></span></div><div id="id78fc84db2574938a52c2b619c0c6019_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have relied, and expect to continue to rely, on third parties to conduct some or all aspects of our vector production, process development, assay development, product manufacturing, product testing, protocol development, and research, and these third parties may not perform satisfactorily.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to independently conduct all aspects of our vector production, product manufacturing, product testing, protocol development, protocol performance, and research. We currently rely, and expect to continue to rely, on third parties with respect to these items. We may not be able to enter into agreements with these third parties and if we do enter into agreements with these third parties, any of these third parties may not be successful at fulfilling their contractual obligations or may choose to terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities. Our reliance on these third parties for vector production, process development, assay development, product manufacturing, product testing, protocol development, protocol performance, and research activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations. If any of these third parties on which we rely do not perform satisfactorily, we will remain responsible for ensuring that:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our nonclinical studies and clinical trials are conducted in accordance with the study plan and protocols and applicable regulatory requirements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vector production, product manufacturing, and product testing are conducted in accordance with applicable GMP requirements and other applicable regulatory requirements; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other research, process development, and assay development are conducted in accordance with applicable industry and regulatory standards and norms</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any of which we may not be able to do.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to rely on third-party manufacturers, which entails risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced control as a result of using third-party manufacturers for some or all aspects of manufacturing activities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the acquisition, change in control, or bankruptcy of the manufacturer or supplier, or their commitments to COVID-19 vaccine and therapeutics production projects that may reduce available manufacturing capacity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could lead to clinical trial delays, failure to obtain regulatory approval, or impact our ability to successfully commercialize future products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will rely on third parties to conduct some nonclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct all aspects of our nonclinical testing, clinical testing, or clinical trials ourselves. We are dependent on third parties to conduct nonclinical studies and clinical trials for our product candidates, and, therefore, the timing of the initiation and completion of these studies or trials is controlled in part by these third parties and may occur at times substantially different from our estimates. Specifically, we use and rely on medical institutions, clinical investigators, contract research organizations (&#8220;CROs&#8221;) and consultants to conduct our trials in accordance with our clinical protocols and regulatory requirements. Our CROs, investigators and other third parties play a significant role in the conduct of these trials and subsequent collection and analysis of data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that any CROs, investigators or other third parties on which we rely for administration and conduct of our clinical trials will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fails to meet expected deadlines, fails to adhere to our clinical protocols, fails to meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer those patients to another qualified clinical trial site.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the utility of certain data from the clinical trial may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any IND or BLA we submit to the FDA, or equivalent submissions to other regulatory authorities outside the U.S. Any such delay or rejection could prevent us from commercializing our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets and other confidential information, which increases the possibility that a competitor will discover them or that our confidential information, including trade secrets, will be misappropriated or disclosed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on third parties to conduct research and to develop and manufacture our product candidates, we must, at times, share confidential information, including trade secrets, with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements containing confidentiality provisions with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that they become known </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by our competitors, are purposefully or inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Public disclosure of our confidential information also prevents us from seeking patent protection for that or related discoveries. Given that our proprietary position is based, in part, on our know-how and trade secrets, the unauthorized use or disclosure of our trade secrets would impair our competitive position and may have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our confidential information and trade secrets, although our agreements may contain certain limited publication rights. For example, academic institution that we collaborate with often require rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential information or trade secrets from any such publication. However, we may fail to recognize or identify to our collaborator such confidential information or trade secrets during the appropriate timeframe prior to publication, and they may be publicly disclosed without us filing for patent or other protection. In the future we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development or similar agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets could impair our competitive position and have an adverse impact on our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div id="id78fc84db2574938a52c2b619c0c6019_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Intellectual Property</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies, and their uses as well as our ability to operate without infringing upon the proprietary rights of others. There can be no assurance that any of our product candidates will have patent protection, that our patent applications or those of our licensors will result in patents being issued or that issued patents, if any, will afford sufficient protection against competitors with similar technology, nor is there any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Issued patents may later be found unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and license certain composition-of-matter patents and applications covering components of our product candidates. Composition-of-matter patents on the biological or chemical active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our patent applications covering composition-of-matter of any of our product candidates will be considered patentable by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) and courts in the U.S. or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued composition-of-matter patents will not be found invalid or unenforceable if challenged.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and license certain method-of-use patents and applications covering methods of treating certain diseases with our product candidates. Method-of-use patents protect the use of a product for the specified method or for treatment of a particular indication. However, methods of treating human diseases are considered unpatentable in many jurisdictions, and even where available this type of patent does not prevent a competitor from making and marketing a product that is identical to our product candidate for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications may not result in any patents being issued;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents may expire before or soon after the product they cover is commercialized;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make, use, and sell our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">countries other than the U.S. may have patent laws less favorable to patentees than those upheld by the U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on the protection of our trade secrets and know-how. Although we have taken steps to protect our trade secrets and know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information independently.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets do not provide any protection against the independent development of the trade secret by a competitor or other third party. If a competitor independently obtains or develops our trade secret, either by reverse engineering our product or other legal means, we would be unable to prevent them from using the trade secret, and our competitive position would be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary know-how, the value of this information may be greatly reduced.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology industry expands, especially in the field of gene therapy, and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization of our product candidates. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming to defend against and could:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in costly litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divert the time and attention of our technical personnel and management;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cause development delays;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidate or processes could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market our product candidates. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we could redesign our product candidate or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will depend in part on our ability to acquire, in-license, or use these proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sometimes collaborate with U.S. and foreign academic institutions to accelerate our research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently are heavily reliant upon licenses of certain patent rights and proprietary technology from third parties that are important or necessary to the development of our technology and products, including technology related to our manufacturing process and our gene therapy product candidates. These and other licenses may not provide adequate rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future, or may contain other limitations on our ability to use such intellectual property or technology. As a result, our ability to develop or commercialize our processes and product candidates may be limited by the terms of such agreements. Further, the third parties from whom we license certain patent rights and proprietary technology may attempt to terminate their agreements with us. For example, in 2019 we received from Virovek a notice of intent to terminate our non-exclusive license to certain Virovek technology and know-how related to methods and materials for manufacturing adeno-associated virus. Although no further action has been taken in that matter, it illustrates that if one of our licenses were to be terminated, we may be unable to obtain a new license to that technology on commercially reasonable terms, if at all.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we need to develop or acquire alternative manufacturing technology, our product development activities may be significantly delayed, and if we were unable to develop or acquire alternative manufacturing technology, it could have a material adverse effect on our business. In addition, we may not be able to prevent competitors from developing and commercializing competitive products to the extent our licenses to patents are non-exclusive or limited with respect to fields of use or territories.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that licenses to additional third-party technology will be required to advance our current development programs, as well as additional development programs we may initiate in the future. If these licenses are not available on commercially reasonable terms or at all, we may not be able to commercialize our current and future development programs, which will have a material adverse effect on our business and financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we normally seek to obtain the right to control the prosecution and maintenance of the patents relating to our product candidates, there may be times when the filing and prosecution activities for platform technology patents that relate to our product candidates are controlled by our licensors. For example, we do not have the right to prosecute and maintain the patent rights licensed to us under agreements with Regents of the University of California, Cornell University, and Virovek, and our ability to have input into such filing and prosecution activities is limited. If these licensors or any of our future licensors fail to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We require all employees to sign proprietary information and invention assignment agreements, but they may fail to do so, or our agreements may be found invalid or unenforceable. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patent rights held by third parties that could be construed to cover certain aspects of our product candidates. In addition, changes to our product candidates or their uses or manufacture may cause them to infringe patents held by third parties. A patent holder has the right to prevent others from making, using, or selling a drug that incorporates the patented compositions while the patent remains in force. While we believe that third party patent rights will not affect our planned development, regulatory clearance, and eventual marketing, commercial production, and sale of our product candidates, there can be no assurance that this will be the case. In addition, the Hatch-Waxman exemption provided by U.S. patent law permits uses of compounds and biologics in clinical trials and for other purposes reasonably related to obtaining FDA approval of drugs and biologics that will be sold only after patent expiration, so our use of our product candidates in those FDA-related activities does not infringe any patent holder&#8217;s rights. However, were a patent holder to assert its rights against us before expiration of such patent holder&#8217;s patent for activities unrelated to seeking FDA approval, the development and ultimate sale of our product candidates could be significantly delayed, and we could incur the expense of defending a patent infringement suit and potential liability for damages for periods prior to the patent&#8217;s expiration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, obtaining and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Further, following Russia&#8217;s invasion of Ukraine in February 2022, the U.S. government has levied sanctions against Russia and Belarus, Russia has issued a decree that removes protections for some patent holders who are registered in unfriendly countries, including the U.S., and the USPTO has terminated its engagement with officials from intellectual property agencies in Russia, Belarus and Eurasia, so we are not currently maintaining certain intellectual property filings in these jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded to us, if any, may not be commercially meaningful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, Congress may pass patent reform legislation that is unfavorable to us. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or product candidates. Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. As a result, our owned and in-licensed patent portfolio provides us with limited rights that may not last for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. For example, given the large amount of time required for the research, development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extensions of patent term may be available, but there is no guarantee that we would have patents eligible for extension, or that we would succeed in obtaining any particular extension&#8212;and no guarantee any such extension would confer patent term for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. If we are able to secure FDA marketing approval for one of our product candidates that is covered by an issued U.S. patent, that patent may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (&#8220;Hatch-Waxman Act&#8221;). Depending upon the timing, duration and specifics of FDA marketing approval of product candidates, the Hatch-Waxman Act permits a patent restoration term of up to five years beyond the normal expiration of the patent, which is limited to the approved product or approved indication. In the United States, patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval; only one patent may be extended; and extension is available for only those claims covering the approved drug, a method for using it, or a method for manufacturing it. Similar extensions of patent term are available in Europe and other jurisdictions. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial conditions and results of operations may be materially and adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interpretation by the regulatory authorities in the EU of applicable EU regulations governing data and market exclusivity may impact our entitlement to data and market exclusivity. The revisions to the orphan drug legislation in the EU and the EU rules governing Supplementary Protection Certificates that are currently being discussed may also impact our entitlement to this exclusivity. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged administratively or in court.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our future development partners were to initiate or threaten legal proceedings against a third party to enforce a patent directed at one of our product candidates, or one of our future product candidates, the accused infringer could claim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, as are claims seeking declaratory judgment of invalidity. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a false or misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our defense of litigation or patent office proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research and development programs, license necessary technology from third parties, or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal or patent office proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some intellectual property that we have in-licensed may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property rights we have licensed, including certain rights related to our proprietary AAV.7m8 capsid, were generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability, or that of our sublicensees, to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to comply with any of our obligations under existing agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing of intellectual property is of critical importance to our business and involves complex legal, business, and scientific issues. Disputes may arise regarding our rights to intellectual property licensed to us from a third party, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement, what activities satisfy those diligence obligations, and to what extent those obligations are relieved or delayed by external factors beyond our control, such as the COVID-19 pandemic;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and duration of our payment obligations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our rights upon termination of such agreement; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and duration of exclusivity obligations of each party to the agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make gene therapies that are similar to our product candidates but that are not covered by the claims of any patents that we own or have exclusively licensed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patent applications that we have filed or may file in the future may not lead to issued patents;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of the issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of the issued patents that we have filed or may file in the future may expire before or shortly after commercialization of the covered product;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where, or for products for which, we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of our employees and consultants were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that our company, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could materially and adversely impact our business, financial condition, results of operations, or prospects.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can initiate clinical trials in the U.S. for our product candidates, we need to submit the results of nonclinical testing to the FDA, along with other information including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND. We may rely in part on nonclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions for our product candidates. If these third parties do not provide timely data for our product candidates, it will delay our plans for our IND submissions and clinical trials. If those third parties do not make this data available to us, we will likely have to develop all necessary nonclinical and clinical data on our own, which will lead to significant delays and increase development costs of the product candidate. In addition, the FDA may require us to conduct additional nonclinical testing for any product candidate before it allows us to initiate clinical testing under any IND, or at any stage of clinical development based on concerns that arise as the clinical program progresses or if significant manufacturing change are made to the product during the program, which may lead to additional delays and increase the costs of our nonclinical development. Delays with any regulatory authority or agency may significantly affect our product development timeline. Delays in the commencement or completion of any clinical trials that we plan for our product candidates could significantly affect our product development costs. We do not know whether any clinical trials that we plan will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed or terminated for a number of reasons, including delays or terminations related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities outside the U.S. failing to grant permission to proceed or placing the clinical trial on hold;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients failing to enroll or remain in our trial at the rate we expect;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients experiencing severe or unexpected drug-related adverse effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a facility manufacturing any of our product candidates or any of their components being ordered by the FDA or other government or regulatory authorities outside the U.S. to temporarily or permanently shut down due to violations of GMP or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process, or in the manufacturing facilities in which our product candidates are made;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes to our manufacturing process that may be necessary or desired;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, lacking the ability or resources to appropriately handle our product candidates, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, Good Clinical Practice or regulatory requirements, or other third parties not performing data collection or analysis in a timely and accurate manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspections of clinical trial sites by the FDA or other regulatory authorities outside the U.S., or the finding of regulatory violations by the FDA or other regulatory authorities outside the U.S., or an IRB that require us to undertake corrective action, result in suspension or termination of one or more clinical sites or the imposition of a clinical hold on the IND or that prohibit us from using some or all of the data in support of our marketing applications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities outside the U.S. for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one or more IRBs refusing to approve, suspending or terminating the trial at a clinical site, precluding enrollment of additional patients, or withdrawing its approval of the trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product development costs will increase if we have delays in testing or approval of any of our product candidates, or if we need to perform more or larger clinical trials than planned. Additionally, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for review and approval, which may impact the costs, timing or successful completion of a clinical trial. If we experience delays in completion of our clinical trials, or if we, the FDA or other regulatory authorities outside the U.S., the IRB, other reviewing entities, or any of our clinical trial sites suspend or terminate any of our clinical trials, the commercial prospects for our product candidate may be harmed and our ability to generate product revenue may be delayed. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials, may also ultimately lead to the denial of regulatory approval of a product candidate. If we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Further, if one or more clinical trials are delayed or terminated, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Final marketing approval for our product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to successfully complete our clinical trials and submit a BLA, and/or an MAA, we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates, and we cannot, therefore, predict the timing of any future revenue. We cannot commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the applicable applications. We cannot assure you that the regulatory authorities will complete their review processes in a timely manner or that we will obtain regulatory approval for our product candidates. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in policies from the FDA or other regulatory authorities outside the U.S. during the period of product development, clinical trials and FDA regulatory review. If marketing approval for any product candidate is delayed, limited or denied, our ability to market the product candidate, and our ability to generate product sales, would be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from its sales, if any, could be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payers or the medical community. Coverage and reimbursement of our product candidates by third-party payers, including government payers, is also generally necessary for commercial success. The degree of market acceptance of our product candidates will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstration of clinical efficacy, including duration of efficacy, and safety compared to other more-established products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limitation of our targeted patient population and other limitations or warnings contained in any labeling approved for our products by the FDA or other applicable regulatory authorities outside the U.S., including the possible inclusion of a &#8220;black box warning&#8221; from the FDA or other applicable regulatory authorities outside the U.S. alerting health care providers to potential serious side effects associated with using a product or the imposition of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of new therapeutic options by health care providers and their patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new procedures or methods of treatment that may be more effective in treating or may reduce the incidences of wet AMD, or other conditions that our product candidates are intended to treat;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost-effectiveness;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators&#8217; sales and marketing strategies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain sufficient third-party coverage and reimbursement from government health care programs, including Medicare and Medicaid, private health insurers and other third-party payers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable publicity relating to the product candidate; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out-of-pocket in the absence of third-party coverage and reimbursement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payers or patients, we may not generate sufficient revenue from that product candidate and may not become or remain profitable. Our efforts to educate the medical community and third-party payers on the benefits of such a product candidate may require significant resources and may never be successful. In addition, our ability to successfully commercialize any of our product candidates will depend on our ability to manufacture our products, differentiate our products from competing products and defend and enforce our intellectual property rights relating to our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in highly competitive segments of the biopharmaceutical markets. We face competition from many different sources, including larger and better-funded pharmaceutical, specialty pharmaceutical, biotechnology, and gene therapy companies, as well as from academic institutions, government agencies and private and public research institutions. Our product candidates, if successfully developed and approved, will compete with established therapies as well as with new treatments that may be introduced by our competitors. There are a variety of drug candidates and gene therapies in development or being commercialized by our competitors for the indications that we intend to test. Many of our competitors have significantly greater financial, product candidate development, manufacturing, and marketing resources than we do. Large pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for drugs. In addition, universities and private and public research institutes may be active in our target disease areas, and some could be in direct competition with us. We also may compete with these organizations to recruit management, scientists, and clinical development personnel. We will also face competition from these third parties in establishing clinical trial sites, registering patients for clinical trials, and in identifying and in-licensing new product candidates. For example, REGENXBIO is developing RGX-314, an AAV-based gene therapy delivering a gene encoding a therapeutic antibody fragment similar to ranibizumab (LUCENTIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of wet AMD and diabetic retinopathy, which competes for the same patients, study site resources, and personnel as Ixo-vec. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New developments, including the development of other biotechnology and gene therapy technologies and methods of treating disease, occur in the pharmaceutical, biotechnology and gene therapy industries at a rapid pace. Developments by competitors may render our product candidates obsolete or noncompetitive. Competition in drug development is intense. In addition, we believe that duration of efficacy is an important consideration by physicians and patients when choosing a therapy. However, we do not know and may not know prior to any potential approval the duration of efficacy of our product candidates. We anticipate that we will face intense and increasing competition as new treatments enter the market and advanced technologies become available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for our product candidates, the availability and price of our competitors&#8217; products could limit the demand, and the price we are able to charge, for our product candidates. For example, LUCENTIS and EYLEA are currently available in the U.S. for treatment of wet AMD. We will not achieve our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug products or choose to reserve our product candidates for use in limited circumstances. Our inability to compete with existing or subsequently introduced drug products or other therapies would have a material adverse impact on our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our potential competitors in these diseases may be developing novel therapies that may be safer or more effective or easier to administer than our product candidates. For example, if we continue clinical development of, and seek to commercialize, Ixo-vec for the treatment of wet AMD, it will compete with a variety of therapies currently marketed and in development for wet AMD, using therapeutic modalities such as biologics, small molecules, long-acting delivery devices and gene therapy. LUCENTIS and EYLEA are anti-VEGF therapies that are well established and widely accepted by physicians, patients and third-party payers as the standard of care for the treatment of wet AMD. There are several other companies with marketed products or products in development for the treatment of wet AMD, including 4D Molecular Therapeutics, Bayer, Graybug Vision, Hoffmann-La Roche Ltd., Kodiak Sciences, Novartis, Opthea, Regeneron and REGENXBIO. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if U.S. regulatory approval is obtained, the FDA may still impose significant restrictions on a product&#8217;s indicated uses, marketing or distribution or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials. Following approval, if at all, of any of our product candidates, such candidate will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of safety and other post-market information. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities outside the U.S. for compliance with GMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requesting recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or the manufacturing facilities for any product candidate that may receive regulatory approval fail to comply with applicable regulatory requirements, a regulatory agency may:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters or untitled letters;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or withdraw regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements or applications filed by us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">institute import holds;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products, refuse to permit the import or export of product or request us to initiate a product recall.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. The FDA has the authority to require a REMS plan as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if any of our product candidates is approved, our product labeling, advertising and promotion would be subject to regulatory requirements and ongoing regulatory review. The FDA and other regulatory authorities outside the U.S. strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the competent regulatory authority as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and regulatory and enforcement authorities outside the U.S. actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or be subject to permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payers for any of our product candidates and may be affected by existing and future health care reform measures. Government authorities and third-party payers, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement by a third-party payer may depend upon a number of factors including the third-party payer&#8217;s determination that use of a product candidate is:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement approval for a product candidate from a government or other third-party payer is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of the applicable product candidate to the payer. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. While there is no uniform coverage and reimbursement policy among payers in the United States, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Further, reimbursement amounts may reduce the demand for, or the price of, our product candidates. If reimbursement is not available or is available only in limited levels, we may not be able to commercialize certain of our product candidates profitably, or at all, even if approved.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of cell and gene therapy products recently have been approved by the FDA. Although the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) approved its first method of coverage and reimbursement for one such product, the methodology has been subject to challenge by members of Congress. CMS&#8217;s decision as to coverage and reimbursement for one product does not mean that all similar products will be eligible for analogous coverage and reimbursement. As there is no uniform policy for coverage and reimbursement amongst third-party payers in the United States, even if CMS approves coverage and reimbursement for any of our product candidates, it is unclear what affect, if any, such a decision will have on our ability to obtain and maintain coverage and adequate reimbursement from other private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans. or, if they do, the level of payment may not be sufficient to allow the company to sell its products at a profit. The United States government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;Affordable Care Act&#8221;), was enacted with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. The Affordable Care Act, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations and established annual fees and taxes on manufacturers of certain prescription drugs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the Affordable Care Act have been subject to executive, Congressional, and judicial challenges as well as efforts to repeal, replace, or otherwise modify them or alter their interpretation and implementation. For example, the Tax Cuts and Jobs Act of 2017 included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, policies that undermine protections for people with pre-existing conditions, demonstrations and waivers under Medicaid and the Affordable Care Act that may reduce coverage or undermine the programs thereunder, including work requirements, and policies that make it more difficult to access health benefits through Medicaid or the Affordable Care Act. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#8220;Inflation Reduction Act&#8221;) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan year 2025. The Inflation Reduction Act also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. Any such changes could affect the number of individuals with health coverage. It is possible that the Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to successfully commercialize our product candidates, if approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have also been proposed and adopted in the U.S. since the Affordable Care Act was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This included aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year, which went into effect on April 1, 2013 and due to subsequent legislative changes to the statute, will stay in effect until 2031 unless additional congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester from May 1, 2020, through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. Further, Congress is considering additional health reform measures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These cost reduction initiatives could decrease the coverage and reimbursement that we receive for any approved products and could seriously harm our business. The Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. Further, the Inflation Reduction Act, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the Inflation Reduction Act will be implemented but is likely to have a significant impact on the pharmaceutical industry.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal, state and foreign governments will pay for healthcare products and services, which could result in reduced demand for our product candidates, if approved, or additional pricing pressures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of health care may adversely affect:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for any product candidates for which we may obtain regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price that we believe is fair for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional governmental action could be taken in response to the COVID-19 pandemic, and that such action could affect our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If the market for our product candidate, if approved, in the treatment of wet AMD or any other indication we seek to treat is smaller than we believe it is, or if our product candidate is approved with limitations that reduce the market size, our future revenue may be adversely affected, and our business may suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing the development of Ixo-vec for the treatment of wet AMD, a disease we believe to be the most common cause of vision loss in adults over the age of 50 in developed countries. If the size of the market for wet AMD or any other indication we seek to treat is smaller than we anticipate (including in our rare disease programs), we may not be able to achieve profitability and growth. Our projections of the number of people who have wet AMD and other indications, as well as the subset of people with the disease who have the potential to benefit from treatment with Ixo-vec or other future product candidates, are based on estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations and market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effort to identify patients with diseases we seek to treat is in early stages as we conduct the OPTIC trial of Ixo-vec for the treatment of wet AMD, and we cannot accurately predict the number of patients for whom treatment might be possible or whether the FDA or other regulatory authorities may approve indications for Ixo-vec that are more limited than we expect due to efficacy or safety concerns. For example, some patients have neutralizing antibodies at titer levels that may prevent them from benefiting from Ixo-vec. If this patient population is larger than we estimate, the market for Ixo-vec may be smaller than we anticipate, and our future revenue may be adversely affected. In addition, we expect prophylactic steroid treatment will be required to manage inflammation associated with treatment with Ixo-vec, and certain patients cannot be treated with prophylactic steroids. If this proportion of patient population is larger than we estimate, the market for Ixo-vec may be smaller than we anticipate. Additionally, the potentially addressable patient population may be limited or may not be amenable to treatment with our product candidates for other reasons, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, even if we obtain significant market share for any of our rare disease programs, because the potential target population is very small, we may never achieve profitability despite obtaining such significant market share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, because the target patient population for any of our rare disease programs is relatively small, the pricing and reimbursement of these product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell any of our product candidates targeting such rare disease will be adversely affected. The manner and level at which reimbursement is provided for services related to this product candidate (e.g., for administration of such product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates targeting such rare disease.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates, if approved, may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of, or the availability of data from, scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones will be based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the novel nature of our technology and the potential for our product candidates to offer therapeutic benefit in a single administration, we face uncertainty related to pricing and reimbursement for these product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are designed to provide potential therapeutic benefit after a single administration and, therefore, the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to our product candidates (e.g., for administration of our product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in establishing and maintaining development or other strategic collaborations, which could adversely affect our ability to develop and commercialize product candidates and receive milestone and/or royalty payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into development or other strategic collaborations with biotechnology and pharmaceutical companies in the past and may do so again in the future. Research activities under our collaboration agreements are subject to mutually agreed-on research plans and budgets, and if we and our strategic partners are unable to agree on the research plan or research budget in a timely fashion or at all, performance of research activities will be delayed. In addition, some of our strategic partners may terminate any agreements they enter into with us or allow such agreements to expire by their terms. If we fail to maintain our current or future strategic collaborations, we may not realize milestone and royalty payments or other revenues under the collaboration agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments may impose price controls, which may adversely affect our future profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the U.S. and in foreign jurisdictions. If we obtain approval in one or more jurisdictions, we will be subject to rules and regulations in those jurisdictions relating to our product candidates. In some countries, including Member States of the European Economic Area (&#8220;EEA&#8221;), the pricing of prescription pharmaceuticals is subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. There can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between low-priced and high-priced countries, can further reduce prices. Publication of discounts by third-party payers or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may form strategic alliances in the future, and we may not realize the benefits of such alliances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our existing business, including for the continued development or commercialization of our product candidates. These relationships or those like them may require us to incur non-recurring and other charges, increase our near-and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because third parties may view the risk of failure in future clinical trials as too significant, or the commercial opportunity for our product candidate as too limited. We cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Even if we are successful in our efforts to establish development partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such development partnerships if, for example, development or approval of a product candidate is delayed or sales of an approved product candidate are disappointing. Any delay in entering into development partnership agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no sales, marketing or distribution capabilities, and we would have to invest significant resources to develop these capabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no internal sales, marketing, or distribution capabilities. If any of our product candidates ultimately receive regulatory approval, we may not be able to effectively market and distribute the product candidate. We would have to invest significant amounts of financial and management resources to develop internal sales, distribution and marketing capabilities, some of which will be committed prior to any confirmation that any of our product candidates will be approved, if at all. We may not be able to hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms or at all. Even if we determine to perform sales, marketing and distribution functions ourselves, we could face a number of additional related risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to attract and build an effective marketing department or sales force;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing a marketing department or sales force may exceed our available financial resources and the revenue generated by any product candidates that we may develop, in-license or acquire; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our direct sales and marketing efforts may not be successful.</span></div><div><span><br/></span></div><div id="id78fc84db2574938a52c2b619c0c6019_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing symptomatic treatments they are already familiar with and for which greater clinical data may be available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Although none of our current product candidates utilize retroviruses and we believe AAVs used in our product candidates have low-integrating potential and are not known to cause disease in humans, our product candidates do use a viral vector delivery system. The risk of serious adverse events, such as the dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial, remains a concern for gene therapy and we cannot assure that it will not occur in any of our current or future clinical trials. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events in trials or studies conducted by us or other parties, in particular involving the same or similar AAV serotypes to the ones we are using, even if not ultimately attributable to our product candidates or to an AAV serotype that we employ, and resulting publicity, could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. Similarly, our lead product candidate, ADVM&#8209;022 expresses the aflibercept protein, which is also the active component in EYLEA. If safety or efficacy issues occur relating to EYLEA, even if not ultimately attributable to aflibercept, this may negatively impact our product candidate. If any such adverse events or issues occur, development and commercialization of our product candidates or advancement of any potential clinical trials could be halted or delayed, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on the principal members of our management, clinical and scientific staff. The loss of service of any of our management or clinical or scientific staff could harm our business. In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management, and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. Although we have executed employment agreements with each member of our current executive management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to attract or retain qualified management, scientific and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly in the San Francisco Bay Area. Our industry has experienced a high rate of turnover of management and scientific personnel in recent years. If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we implemented a restructuring of operations, including reductions in both headcount and expenses. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize expected operational efficiencies and the cost savings from the restructuring, our operating results and financial condition would be adversely affected. Due to our restructuring, we may not be able to effectively manage our operations or retain qualified personnel, which may result in weaknesses to our infrastructure and operations, increased risk that we may be unable to comply with legal and regulatory requirements, increased risks to our internal controls and disclosure controls, and loss of employees and reduced productivity among remaining employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restructuring resulted in the loss of institutional knowledge and expertise and the reallocation of and combination of certain roles and responsibilities across the organization, all of which could adversely affect our operations. Further, the restructuring and possible additional cost-containment measures may yield unintended consequences, such as attrition beyond our intended workforce reduction and reduced employee morale. We may be required to rely more heavily on temporary or part-time employees, third party contractors and consultants to assist with managing our operations. These consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. We will have only limited control over the activities of these consultants and can generally expect these individuals to devote only limited time to our activities. Failure of any of these persons to devote sufficient time and resources to our business could harm our business. Employee litigation related to the headcount reduction could be costly and prevent management from fully concentrating on the business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our management is unable to successfully manage this transition and restructuring activities, our expenses may be more than expected and we may be unable to fund our Ixo-vec development plan or implement our business strategy. As a result, our business, prospects, financial condition and results of operations could be negatively affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we will need to grow our organization, or certain functions within our organization, substantially to continue development and pursue the potential commercialization of our product candidates, as well as function as a public company. As we seek to advance our product candidates, we may need to expand our financial, development, regulatory, manufacturing, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Future growth will impose significant added responsibilities on members of management and require us to retain or otherwise manage additional internal capabilities. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate any additional management, clinical and regulatory, financial, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish them could prevent us from successfully growing our company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Russia&#8217;s invasion of Ukraine and current adverse economic conditions could adversely affect our revenue, financial condition, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global disruption to, and potential impacts on, the health of the global economy arising from, related to, or resulting from Russia&#8217;s invasion of Ukraine in February 2022 could affect our business and operations. For example, the credit and financial markets may be adversely affected by the war and measures taken in response thereto, potentially impacting our ability to raise adequate additional capital when needed or on favorable terms. In addition, current economic conditions, such as recent global supply chain disruptions, labor shortages, rising interest rates and inflation, may adversely impact our operations, for example by increasing our costs, disrupting our suppliers&#8217; ability to provide us with materials and supplies needed for both our manufacturing and clinical trials, or causing delays to our clinical trial and manufacturing timelines, which may negatively impact our business. These economic conditions make it more difficult for us to accurately forecast and plan our future business activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The coronavirus (&#8220;COVID-19&#8221;) pandemic has impacted our business practices and the effects of its continued impact on our business, results of operations, and financial condition will depend on future developments, which cannot be predicted. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and the emergence of new variants has caused us to modify our business practices (including the adoption of a hybrid mix of virtual and in-person work, updating our policies and implementing new practices to align with guidance from state and federal governments and health authorities). We believe these measures and others have not allowed us to eliminate the effects and risks on our on-site operations posed by the COVID-19 pandemic, so we may take further actions that may be required by government authorities or that we determine are in the best interests of our employees, customers, and business partners. We are uncertain that such measures will be sufficient to mitigate future risks posed by the virus and its variants or otherwise be satisfactory to government authorities and how long we will be required to continue these measures. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, an increased reliance by us and the companies with which we do business on information technology systems to support a hybrid workforce may increase cyber security risk, create data accessibility issues, increase the risk for communication disruptions, or otherwise disrupt or delay normal business operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may also affect our current and planned trials and development programs, possibly affecting our timelines for commercialization. We and our CROs and contract manufacturing organizations (&#8220;CMOs&#8221;) may face disruptions that may affect our ability to conduct and timely complete ongoing clinical trials including disruptions in procuring items that are essential for our development activities, such as materials used in the manufacturing of Ixo-vec. We and our CROs and CMOs, as well as clinical trial sites, may face disruptions that affect our ongoing clinical trials arising from staffing disruptions and limitations on our activities and the activities of our CROs and CMOs, and delays in the ability to obtain necessary institutional review board or other necessary site approvals or delays in site initiations or site monitoring visits, as well as other delays at clinical trial sites. We may also face limitations on enrollment and patients withdrawing from our clinical trials or not complying with the protocol procedures, which could delay completion of our clinical trials or adversely affect the data generated by our clinical trials. The current general reluctance of some people to make in-person visits to healthcare providers for treatment of non-life-threatening ailments may make initiating clinical trial sites, identifying potential patients and enrolling them in our clinical trials, retaining any such patients, ensuring that such patients comply with treatment protocols, and collecting sufficient trial data to progress our clinical programs more difficult. For example, patient concerns related to COVID-19 caused some of our OPTIC trial patients to miss scheduled appointments for fear of contracting the virus which, if this were to be repeated over longer periods of time, could impact our ability to collect data we need. Additionally, our ability to recruit and retain patients and principal investigators and site staff who believe they have heightened risks if exposed to COVID-19 may be limited which may adversely impact our clinical trial operations. The response to the COVID-19 pandemic also could redirect resources with respect to regulatory and intellectual property matters in a way that could adversely impact our ability to progress regulatory approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and approvals due to measures that are intended to limit in-person interactions. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, due to the limited ability to access our facilities and our reliance on outside vendors who may be similarly affected, our development programs may not proceed along the timelines we previously anticipated. We rely on third-party research facilities, manufacturers, suppliers, and other service providers from other countries and from different parts of the U.S. to provide services and resources necessary to support our research and development plans, to produce our product candidates, and support our clinical trials. Our ability to obtain this necessary support or supplies could be disrupted, or the cost of this support or these supplies could increase, if the operations of these suppliers or service providers, or national and international supply chains, including transportation carriers and transportation hubs, are affected by the COVID-19 pandemic. In addition, if our relationships with our manufacturers, service providers, suppliers, or other vendors are terminated, materially altered, or scaled back as a result of the COVID-19 pandemic or other health epidemics, we may not be able to enter into arrangements with alternative manufacturers, service providers, suppliers, or other vendors or do so on commercially reasonable terms or in a timely or cost-effective manner. Further, we may be subject to the inability or unwillingness of clinical investigators or patients to follow our research protocols as a result of the COVID-19 pandemic. As a result, delays could occur which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. The COVID-19 pandemic may also affect the operations of the FDA or other health regulatory authorities outside the U.S., which could result in delays of meetings, reviews and approvals, including with respect to our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19 and the emergence of new variants, which have caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, the widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are taking steps to mitigate all of these effects, the occurrence of any of these disruptions, including of our own operations, could delay our clinical trials and development programs, and otherwise harm our operations and financial condition and increase our costs and expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic continues to impact our business, results of operations, and financial condition will depend on future developments, which are uncertain and cannot be predicted, including, but not limited to, the duration and spread or any future resurgence of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. Even after the COVID-19 outbreak has subsided, we may experience materially adverse impacts to our business as a result of its global human and economic impact, or as a result of our actions taken and not taken as mitigation measures during the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; significant fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; material disruption of our product development programs; and other adverse consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of our business, we and other third parties on which we rely collect, receive, use, process, generate, transfer, make accessible, protect, secure, dispose of, transmit, share, and store sensitive, confidential, and proprietary information, including personal information (such as health-related information and medical information), intellectual property, trade secrets, research and development information, financial information, and other business information. We may rely upon third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, encryption and authentication technology, employee email, and other functions. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. We may share or receive sensitive, confidential, and proprietary information with or from third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent and continue to increase.  These threats are becoming increasingly difficult to detect. These threats come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities.  During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations and supply chain. We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, and other similar threats. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Similarly, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised or that they do not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contain exploitable defects or bugs that could result in a breach of or disruption to our information technology or the third-party information technology systems that support us and our services. The secure processing, storage, maintenance, and transmission of this critical information is vital to our operations and business strategy. We use third parties for our business, may share personal information with them, and rely on them to manufacture our product candidates and conduct clinical trials, and similar events relating to their systems could also have a material adverse effect on our business. Despite the implementation of security measures to protect against unauthorized access or disclosure, we and our CROs, contractors, consultants, collaborators, and other related third parties are vulnerable to damage or attacks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, disruptions of clinical trials, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting payments. Further, the COVID-19 pandemic and remote workforce poses increased risks to our information technology systems and data, as more of our employees work from home, utilizing network connections outside our premises. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption. A security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information. A security incident or other interruption could result in delays to the development and commercialization of our product candidates, disruption of our programs, negative publicity and financial loss. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents.  Certain privacy, data protection, and data security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and sensitive information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems (including our products), our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. While we are not aware of any such material system failure, accident, or any other security incident to date, any such event could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable privacy, data protection, and data security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal information); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A security incident could also disrupt our operations, including our ability to conduct research and development activities, process and prepare company financial information, manage various general and administrative aspects of our business, delay or impede the development of our products, and damage our reputation, any of which could adversely affect our business. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security incident were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. In addition, there can be no assurance that we will promptly detect any such disruption or security incident, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy, data protection, and data security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy, data protection, and data security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable state and federal healthcare laws and regulations, we may be subject to civil or criminal penalties and/or exclusion from federal and/or state healthcare programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on the marketing of pharmaceutical products, several other types of state and federal healthcare fraud and abuse laws restrict certain practices, including research and marketing, in the pharmaceutical industry. These laws include anti-kickback, false claims, and healthcare professional payment transparency laws and regulations. Because of the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of these laws.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering, arranging for, or recommending the purchase, lease or order of any healthcare item or service for which payment may be made, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced-price items and services. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formula managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices may be subject to scrutiny if they do not qualify for an exception or safe harbor. Liability may be established under the federal Anti-Kickback Statute without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Many states have similar laws that apply to their state health care programs as well as private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers; knowingly and willfully embezzling or stealing from a healthcare benefit program; willfully obstructing a criminal investigation of a healthcare offense; and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the False Claims Act can result in significant monetary penalties and treble damages. Pharmaceutical and other healthcare companies have faced enforcement actions under the federal civil False Claims Act for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for allegedly causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses. In addition, a claim can be deemed to be false due to failure to comply with legal or regulatory requirements material to the government&#8217;s payment decision. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false claim or statement. Pharmaceutical and other healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Affordable Care Act, among other things, imposed new reporting requirements on drug manufacturers, under the federal Physician Payments Sunshine Act, for payments and other transfers of value made by them to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain other healthcare professionals (such as a physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in significant civil monetary penalties, for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Certain states and localities also mandate implementation of commercial compliance programs, restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs, impose restrictions on drug manufacturer marketing practices, require the tracking and reporting of gifts, compensation and other remuneration to physicians and/or require the registration of pharmaceutical sales representatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to build and maintain a robust compliance program with different compliance and/or reporting requirements. We cannot ensure that our compliance controls, policies, and procedures will be sufficient to protect against acts of our employees, vendors, or other third parties that may violate such laws. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participation in federal and state healthcare programs, imprisonment, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly caused or cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability, and a breach of warranties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims could also be asserted under state consumer protection acts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decline in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently hold $10 million in product liability insurance, which may not adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we plan to maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to evolving and increasingly stringent obligations related to privacy, data protection, and data security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits, interruption of our clinical trials, and other adverse business consequences. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share sensitive, proprietary, and confidential information, including personal information, business data, trade secrets, intellectual property, and data we collect about trial participants in connection with clinical trials. Our processing activities subject us to numerous privacy, data protection, and data security obligations, such as laws, regulations, guidance, industry standards, external and internal policies, contractual requirements, and other obligations that govern processing of personal information by us or on our behalf, including information that we collect or will collect about patients and healthcare providers in connection with clinical trials. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal, state, and local governments have enacted numerous privacy, data protection, and data security laws and regulations, including those relating to data breach notification, personal information privacy, and consumer protection (e.g., Section 5 of the Federal Trade Commission Act). The legislative and regulatory landscape for privacy, data protection, and data security continues to evolve, and there has been an increasing focus on privacy, data protection, and data security issues which may affect our business. Many of these laws differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Federal regulators, state attorneys general, and plaintiffs&#8217; attorneys, including class action attorneys, have been and will likely continue to be active in this space. For example, HIPAA, as amended </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information, upon health plans, healthcare clearinghouses and certain healthcare providers, and their respective business associates that perform services for them involving individually identifiable health information, as well as their covered subcontractors. We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to penalties if we, our affiliates, or our agents obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States have begun to introduce comprehensive privacy, data protection, and data security laws and regulations. For example, California enacted the California Consumer Privacy Act ("CCPA"), which took effect on January 1, 2020. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal information.  The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). Although the CCPA exempts some data processed in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal information we maintain about California residents. Additionally, the CCPA will be expanded substantially on January 1, 2023, when the California Privacy Rights Act (&#8220;CPRA&#8221;) becomes fully operative. The CPRA will, among other things, give California residents the ability to limit use of certain sensitive personal information, expand the types of data breaches subject to the CCPA&#8217;s private right of action, establish a new California Privacy Protection Agency to implement and enforce the new law, and apply to personal information of business representatives and employees. Other states have enacted privacy, data protection, and data security laws. For example, Virginia recently enacted a comprehensive privacy, data protection, and data security law, the Consumer Data Protection Act, Colorado similarly enacted the Colorado Privacy Act, Utah recently enacted the Utah Consumer Privacy Act, and Connecticut enacted the Act Concerning Personal Data and Online Monitoring. Each of these state laws will become effective in 2023 and share similarities with but differ from the CCPA and CPRA. The obligations to comply with the CCPA and other evolving legislation may require us, among other things, to update our notices and develop new processes internally and with our partners.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations, and industry standards apply to privacy, data protection, and data security. For example, the EU GDPR, the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing personal information, and violators of these laws face significant penalties. The processing of sensitive personal information, such as physical health condition and medical information, may impose heightened compliance burdens under the EU GDPR and is a topic of active interest among foreign regulators. The EU GDPR and UK GDPR confer a private right of action to data subjects and consumer associations, the right to lodge complaints with supervisory authorities, the right to seek judicial remedies, and the right to obtain compensation for damages. The obligations under the EU GDPR and UK GDPR may be onerous and adversely affect our business, financial condition, results of operations and prospects. Compliance with the EU GDPR and UK GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with any European activities. In the event we enroll subjects in our ongoing or future clinical trials in Europe, we may be subject to additional privacy, data protection, and data security restrictions, including restrictions relating to the collection, use, storage, transfer, and other processing of personal information, including personal health data, regarding individuals in Europe as governed by the EU GDPR and UK GDPR.  Furthermore, in Europe, there is a proposed regulation related to artificial intelligence (&#8220;AI&#8221;) that, if adopted, could impose onerous obligations related to the use of AI-related systems.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain jurisdictions have enacted data localization laws and cross-border personal information transfer laws, which could make it more difficult to transfer information across jurisdictions (such as transferring or receiving personal information that originates in the EU or in other foreign jurisdictions). Existing mechanisms that facilitate cross-border personal information transfers may change or be invalidated. For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal information to countries outside the EEA that the EC does not consider to provide an adequate level of data privacy and security, such as the United States. The EC released a set of Standard Contractual Clauses (&#8220;SCCs&#8221;), which is a valid mechanism to transfer personal information outside of the EEA. In addition, Switzerland and the UK similarly restrict personal information transfers outside of those jurisdictions to countries such as the United States that do not provide an adequate level of personal information protection, and certain countries outside Europe (e.g. Russia, China, Brazil) have also passed or are considering laws requiring local data residency or otherwise impeding the transfer of personal information across borders, any of which could increase the cost and complexity of doing business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot implement a valid mechanism for cross-border data transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal information from Europe or other jurisdictions. In the event that we expand our operations abroad, the inability to import personal information to the United States could significantly and negatively impact our business operations, including by limiting our ability to conduct clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials in Europe or elsewhere, limiting our ability to collaborate with contract research organizations, service providers, contractors, and other companies subject to such cross-border data transfer or localization laws, or requiring us to increase our personal information processing capabilities and infrastructure in foreign jurisdictions at significant expense. European privacy, data protection, and data security laws may decrease demand for our products and services if affected customers seek alternatives that do not involve such transfers. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the UK&#8217;s departure from the EU, has created uncertainty with regard to data protection regulation in the UK. In particular, it is unclear how data transfers to and from the UK will be regulated. On June 28, 2021, the EC issued an adequacy decision under the EU GDPR which allows transfers of personal information from the EEA to the UK to continue without restriction for a period of four years ending June 27, 2025. If the adequacy decision is withdrawn or not renewed, transfers of personal information from the EEA to the UK will require a valid transfer mechanism and companies making such transfers may be required to implement new processes and put new agreements in place to continue making such transfers. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations related to privacy, data protection, and data security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires significant resources and may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal information on our behalf.  In addition, these obligations may require us to change our business model. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. Any failure or perceived failure by us or our partners, CROs, CMOs, collaborators, and other related third parties to comply with privacy, data protection, and data security obligations, may result in significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; bans on processing personal information; orders to destroy or not use personal information; and imprisonment of company officials (for example, under HIPAA). Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, clinical trials); inability to process personal information or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, &#8220;Trade Laws&#8221;). We can face serious consequences for violations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, Trade Laws prohibit companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, provide, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else or anything of value to or from recipients in the public or private sector. Violations of Trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax assessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We engage third parties for clinical trials and/or obtain necessary permits, licenses, registrations, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our development partners, third-party manufacturer and suppliers use biological materials and use or may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our development partners, third-party manufacturer and suppliers use or may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and any of our future development partners will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and any of our future development partners or CROs are successful in commercializing our products, the FDA and foreign regulatory authorities would require that we and any of our future development partners report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our future development partners may fail to report adverse events we become aware of within the prescribed timeframe. We and any of our future development partners may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our product candidates. If we and any of our future development partners fail to comply with our or their reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of the product and delay in approval or clearance of other products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with our code of conduct or regulatory standards and requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct including code of conduct violations, fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct, or disclosure of unauthorized activities to us that violates: (1) FDA regulations, including those laws requiring the reporting of true, complete and accurate information to regulatory authorities, (2) manufacturing standards, (3) federal and state health care fraud and abuse laws and regulations or (4) laws that require the reporting of financial information or data accurately. Specifically, sales, marketing, and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislation enacted on December 22, 2017, known as the Tax Cuts &amp; Jobs Act (&#8220;TCJA&#8221;) enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the TCJA may affect us, and certain aspects of the TCJA could be repealed or modified in future legislation. In addition, in response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law in March 2020. The CARES Act modifies certain of the changes made by the TCJA. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, and the deductibility of expenses under the TCJA, as amended by the CARES Act, or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years, and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition, or results of operations. For example, the recently enacted Inflation Reduction Act of 2022 includes provisions that will impact the U.S. federal income taxation of corporations, including imposing a minimum tax on the book income of certain large corporations and an excise tax on certain corporate stock repurchases that would be imposed on the corporation repurchasing such stock. In addition, it is uncertain if and to what extent various states will conform to the TCJA, as amended by the CARES Act, the Inflation Reduction Act, or other newly enacted federal tax legislation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and other tax attributes may be limited by the Code. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, except as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the TCJA, federal NOLs incurred in taxable years beginning after 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal NOLs for taxable years beginning after 2020 is limited. In addition, under Section 382 of the Code, our ability to utilize NOL carryforwards or other tax attributes, such as research tax credits, in any taxable year may be limited if we experience an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. In connection with our acquisition of Annapurna in May 2016, we determined that certain NOLs and research and developments tax credits for both federal and state purposes were severely limited and therefore we removed a significant amount of NOLs and research and development tax credits from our deferred tax assets. In addition, we may have experienced an ownership change as a result of the February 2018 underwritten public offering of our common stock, and may in the future experience ownership changes from future offerings or other changes in the ownership of our stock. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the amount of the NOLs and research credit carryforwards presented in our financial statements could be limited and may expire unutilized. In addition, state suspensions of the ability to use NOLs, and research credits, may limit our ability to use our NOLs and research credits to offset state taxable income and taxes.</span></div><div><span><br/></span></div><div id="id78fc84db2574938a52c2b619c0c6019_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including those discussed above and others such as:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enroll and dose patients in any clinical trials that are on-going, or that we plan to conduct in the future;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain regulatory approvals for our product candidates and delays or failure to obtain such approvals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to conduct additional nonclinical studies to determine the best gene therapy candidates to advance in development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of any clinical trials, and the results of trials of our competitors or those of other companies in our market sector;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investor perception and analysis of the results of our clinical trials, which may be different than our own;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the U.S. and foreign countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain our existing third-party license and collaboration agreements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in manufacturing adequate supply of our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity relating to the gene therapy market generally, including with respect to other products and potential products in such markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors and issuance of securities analysts&#8217; reports or recommendations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our Nasdaq listing;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our stock by insiders and stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing effects of the COVID-19 pandemic;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions other events or factors, many of which are beyond our control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property, product liability or other litigation against us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, stockholders have initiated class action lawsuits against biotechnology and pharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock, and similar litigation has been instituted against us. Such litigation could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, licensing, collaboration or similar arrangements, grants and debt financings. We do not have any committed external source of funds. As a result, we may from time to time issue additional shares of common stock or securities convertible into or exercisable for shares of our common stock. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends or other distributions. Furthermore, we may issue common stock as consideration in acquisitions. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through licensing, collaboration or similar arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research and development programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authorization of the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limitation of the removal of directors by the stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a staggered board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prohibition of stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of the ability of stockholders to call a special meeting of stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to accelerate the vesting of outstanding option grants, restricted stock units or other equity awards upon certain transactions that result in a change of control; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified a material weakness in our internal control over financial reporting. If we fail to remediate this material weakness or if we discover or develop additional material weaknesses or otherwise fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected and our financial statements may need to be restated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. During the three-months ended September 30, 2022, we identified a deficiency in the operating effectiveness of controls in our financial statement close process that we considered to be a material weakness. An immaterial non-cash lease accounting error was identified in previously issued financial statements. While the identified error was not material, we considered the potential magnitude of the error(s) that could arise from the operating deficiency as potentially material. The material weakness existed prior to December 31, 2021. In Management's Annual Report on Internal Control over Financial Reporting included in our Form 10-K for the year ended December 31, 2021, filed on March 29, 2022, our management concluded that we maintained effective internal control over financial reporting as of December 31, 2021. If management had been aware of this material weakness prior to the filing of our Form 10-K for the year ended December 31, 2021, management could not have concluded that our internal control over financial reporting was effective as of December 31, 2021. Management has performed procedures and has concluded that, notwithstanding the existence of this material weakness, our financial statements included in our Form 10-K for the year ended December 31, 2021 and in subsequent Quarterly Reports on Form 10-Q do not contain any material errors and may be relied upon. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to assert that our internal control over financial reporting is effective, or when required in the future, if our independent registered public accounting firm is unable to express an unqualified opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be adversely affected and we could become subject to litigation or investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been subject to securities class action lawsuits in the past, and could be subject to additional such lawsuits in the future, which could result in substantial losses and may divert management&#8217;s time and attention from our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we and certain of our former officers were involved in purported securities class action lawsuits, which have since been settled. The purported securities class action lawsuits asserted that the defendants violated the Exchange Act and the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and alleged that the defendants who are no longer at Adverum made materially false and misleading statements and omitted allegedly material information related to, among other things, the Phase 2a clinical trial for AVA&#8209;101, a program which was discontinued in 2015, and the prospects of AVA-101. We settled these lawsuits for $13.0 million, of which $1.0 million we contributed to cover our indemnification obligations to the underwriters, and the remainder was contributed by our insurers. Any future litigation of this type could result in payment of damages or settlement fees and diversion of management&#8217;s attention and resources, any of which could adversely impact our business. Monitoring and defending against legal actions are time-consuming for our management and detracts from our ability to focus fully on our business activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our clinical trial and development programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or addition of cohorts to clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit or other litigation in which we may become involved;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements and the timing of payments we may make or receive under these arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">nature and terms of stock-based compensation grants; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">derivative instruments recorded at fair value.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation and bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a breach of fiduciary duty;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us arising under the Delaware General Corporation Law; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws provide</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our certificate of incorporation and bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our certificate of incorporation or bylaws to be inapplicable or unenforceable in an action, we may incur </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further significant </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional costs associated with resolving the dispute in other jurisdictions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all of </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could seriously harm our business.</span></div><div id="id78fc84db2574938a52c2b619c0c6019_139"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="id78fc84db2574938a52c2b619c0c6019_142"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id78fc84db2574938a52c2b619c0c6019_145"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="id78fc84db2574938a52c2b619c0c6019_148"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:10pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>OR ITEM<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 9, 2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312520182655/d917807dex31.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reference is made to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> through </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312520182655/d917807dex31.htm">3.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20220930ex311.htm">Certification of Principal Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20220930ex312.htm">Certification of Principal Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20220930ex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20220930ex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL tags for the cover page from the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2022, are embedded with the Inline XBRL document.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Adverum Biotechnologies, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="id78fc84db2574938a52c2b619c0c6019_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id78fc84db2574938a52c2b619c0c6019_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADVERUM BIOTECHNOLOGIES, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr></table></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Rakow</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Rakow</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acting Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></div></td></tr></table></div><div style="padding-left:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Nancy Pecota</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nancy Pecota</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Controller</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>advm-20220930ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if554260aaad4468daf01c2e9d04b4e39_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Laurent Fischer, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Adverum Biotechnologies, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;10, 2022 </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.844%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>advm-20220930ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9aeedbed8b4740528583ebc1c5a600da_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Rakow, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Adverum Biotechnologies, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;10, 2022</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.894%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Rakow</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Rakow</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Acting Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>advm-20220930ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7afe277703e740ddb49f651a18baf1da_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Adverum Biotechnologies, Inc. for the fiscal quarter ended September&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Laurent Fischer, in his capacity as Chief Executive Officer of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.508%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>advm-20220930ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i27fe1e5c205f4817a9cf3a619dca3587_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Adverum Biotechnologies, Inc. for the fiscal quarter ended September&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), John Rakow, in his capacity as Chief Financial Officer, of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Rakow</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Rakow</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Acting Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>advm-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:915153f8-5dd7-44a4-84da-67d592863439,g:2581671a-d3ba-4d70-a3e7-003e900c7a5c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:advm="http://www.adverum.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adverum.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.adverum.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Stockholders Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentation">
        <link:definition>0000007 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstruments" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments">
        <link:definition>0000009 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.adverum.com/role/BalanceSheetComponents">
        <link:definition>0000010 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.adverum.com/role/Leases">
        <link:definition>0000011 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwards" roleURI="http://www.adverum.com/role/EquityIncentiveAwards">
        <link:definition>0000012 - Disclosure - Equity Incentive Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.adverum.com/role/NetLossperShare">
        <link:definition>0000013 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.adverum.com/role/Restructuring">
        <link:definition>0000014 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000015 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsTables" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables">
        <link:definition>0000016 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables">
        <link:definition>0000017 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsTables" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsTables">
        <link:definition>0000018 - Disclosure - Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.adverum.com/role/NetLossperShareTables">
        <link:definition>0000019 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.adverum.com/role/RestructuringTables">
        <link:definition>0000020 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetail" roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentationDetail">
        <link:definition>0000021 - Disclosure - Organization and Basis of Presentation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails">
        <link:definition>0000022 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>0000023 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails">
        <link:definition>0000024 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>0000025 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.adverum.com/role/LeasesAdditionalInformationDetails">
        <link:definition>0000026 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsSummaryofStockOptionsActivityDetails" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails">
        <link:definition>0000027 - Disclosure - Equity Incentive Awards - Summary of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsAdditionalInformationDetails" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails">
        <link:definition>0000028 - Disclosure - Equity Incentive Awards - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails">
        <link:definition>0000029 - Disclosure - Equity Incentive Awards - Summary of Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails">
        <link:definition>0000030 - Disclosure - Equity Incentive Awards - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails" roleURI="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails">
        <link:definition>0000031 - Disclosure - Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringAdditionalInformationDetails" roleURI="http://www.adverum.com/role/RestructuringAdditionalInformationDetails">
        <link:definition>0000032 - Disclosure - Restructuring - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringScheduleofRestructuringCostDetails" roleURI="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails">
        <link:definition>0000033 - Disclosure - Restructuring - Schedule of Restructuring Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" abstract="false" name="IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashEquivalentsAndShortTermInvestmentsMember" abstract="true" name="CashEquivalentsAndShortTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedGain" abstract="false" name="CashAndCashEquivalentGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" abstract="false" name="DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" abstract="false" name="OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" abstract="false" name="AccruedNonclinicalClinicalAndDevelopmentProcessCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashAndCashEquivalentAmortizedCost" abstract="false" name="CashAndCashEquivalentAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_RemeasurementOfOperatingLeaseRightOfUseAssets" abstract="false" name="RemeasurementOfOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedLoss" abstract="false" name="CashAndCashEquivalentGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>advm-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:915153f8-5dd7-44a4-84da-67d592863439,g:2581671a-d3ba-4d70-a3e7-003e900c7a5c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="advm-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_78c8dc4b-9ce5-4784-a8a0-398c96262603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_159690ee-dd37-45a4-8af5-6c1738c02c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_78c8dc4b-9ce5-4784-a8a0-398c96262603" xlink:to="loc_us-gaap_LiabilitiesCurrent_159690ee-dd37-45a4-8af5-6c1738c02c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17d97f22-2b69-417a-8a57-d570006c6e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_78c8dc4b-9ce5-4784-a8a0-398c96262603" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17d97f22-2b69-417a-8a57-d570006c6e7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_032580b7-b3a1-440b-b1f7-6601df52155f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_78c8dc4b-9ce5-4784-a8a0-398c96262603" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_032580b7-b3a1-440b-b1f7-6601df52155f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5290405e-d8ec-429f-a643-fca739dc492b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_20ca995b-ae19-433a-89e9-9ae1fbea595b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5290405e-d8ec-429f-a643-fca739dc492b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_20ca995b-ae19-433a-89e9-9ae1fbea595b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e476cdbf-f70d-44a4-b8f0-64abc9019cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5290405e-d8ec-429f-a643-fca739dc492b" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e476cdbf-f70d-44a4-b8f0-64abc9019cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c7c01f20-2483-4c0c-ad33-2a213e3961f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5290405e-d8ec-429f-a643-fca739dc492b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c7c01f20-2483-4c0c-ad33-2a213e3961f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6c23f657-463f-46d6-9a59-4772de0e8a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5290405e-d8ec-429f-a643-fca739dc492b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6c23f657-463f-46d6-9a59-4772de0e8a92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1da9fa3e-2080-41c6-85cf-ad0084c56b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5290405e-d8ec-429f-a643-fca739dc492b" xlink:to="loc_us-gaap_AssetsCurrent_1da9fa3e-2080-41c6-85cf-ad0084c56b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_b650345b-2278-4d98-8896-5cca8e215bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5290405e-d8ec-429f-a643-fca739dc492b" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_b650345b-2278-4d98-8896-5cca8e215bfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9b9f64ed-b27a-4fde-b05e-ea554ca0a6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_382d7214-068a-4737-8eed-c8b1c6cee381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9b9f64ed-b27a-4fde-b05e-ea554ca0a6e3" xlink:to="loc_us-gaap_AccountsPayableCurrent_382d7214-068a-4737-8eed-c8b1c6cee381" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_496a8ff7-be35-4245-be11-78b1e90e020d" xlink:href="advm-20220930.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9b9f64ed-b27a-4fde-b05e-ea554ca0a6e3" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_496a8ff7-be35-4245-be11-78b1e90e020d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6c88d471-94e4-4dfc-88d7-ab74946af782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9b9f64ed-b27a-4fde-b05e-ea554ca0a6e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6c88d471-94e4-4dfc-88d7-ab74946af782" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1d484900-0621-46b3-b838-d6e7eeb58f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4093aa89-8709-4147-bec0-c55d3ba16600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d484900-0621-46b3-b838-d6e7eeb58f11" xlink:to="loc_us-gaap_PreferredStockValue_4093aa89-8709-4147-bec0-c55d3ba16600" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_07aef081-2f65-4f29-9e2b-9900f06c3ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d484900-0621-46b3-b838-d6e7eeb58f11" xlink:to="loc_us-gaap_CommonStockValue_07aef081-2f65-4f29-9e2b-9900f06c3ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_bbe0ec1a-b13c-4582-9563-4ecb11bbc322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d484900-0621-46b3-b838-d6e7eeb58f11" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_bbe0ec1a-b13c-4582-9563-4ecb11bbc322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5ba4a05b-b107-405e-a828-fb26abade2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d484900-0621-46b3-b838-d6e7eeb58f11" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5ba4a05b-b107-405e-a828-fb26abade2ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_efdac18f-4c49-471b-8b36-e06815bae423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d484900-0621-46b3-b838-d6e7eeb58f11" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_efdac18f-4c49-471b-8b36-e06815bae423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b7549bbf-ddcc-4eeb-8a9a-54a94635e6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_64275fe7-0a7c-4d3f-ae70-a989df8388c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b7549bbf-ddcc-4eeb-8a9a-54a94635e6ea" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_64275fe7-0a7c-4d3f-ae70-a989df8388c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_0e76d729-0a49-4f8d-b32f-ceb0b9f1710c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b7549bbf-ddcc-4eeb-8a9a-54a94635e6ea" xlink:to="loc_us-gaap_ShortTermInvestments_0e76d729-0a49-4f8d-b32f-ceb0b9f1710c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8133b92b-852a-4666-937f-f043046ecd03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b7549bbf-ddcc-4eeb-8a9a-54a94635e6ea" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8133b92b-852a-4666-937f-f043046ecd03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveToLessee_891de737-b553-4a81-b1ae-02602dc2f018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveToLessee"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b7549bbf-ddcc-4eeb-8a9a-54a94635e6ea" xlink:to="loc_us-gaap_IncentiveToLessee_891de737-b553-4a81-b1ae-02602dc2f018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f991f6ba-7626-4b07-849c-e024656e0430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0899b161-491a-4227-99ed-5aefd0b4213a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f991f6ba-7626-4b07-849c-e024656e0430" xlink:to="loc_us-gaap_Liabilities_0899b161-491a-4227-99ed-5aefd0b4213a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ca6fd831-3593-401d-8c5e-eb70a61195ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f991f6ba-7626-4b07-849c-e024656e0430" xlink:to="loc_us-gaap_StockholdersEquity_ca6fd831-3593-401d-8c5e-eb70a61195ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="advm-20220930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7f007fde-2545-4d70-807e-d1bce5ed01fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_542958d5-d464-470d-bcee-52403a3d0a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7f007fde-2545-4d70-807e-d1bce5ed01fe" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_542958d5-d464-470d-bcee-52403a3d0a9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ec6dd81c-9f47-426d-9d40-b38204769cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7f007fde-2545-4d70-807e-d1bce5ed01fe" xlink:to="loc_us-gaap_OperatingIncomeLoss_ec6dd81c-9f47-426d-9d40-b38204769cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f925f301-8b85-43e1-ab4c-54e8a09c4f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f9ad4211-e237-4c7b-aa9a-dfb99bf8bace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f925f301-8b85-43e1-ab4c-54e8a09c4f1a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f9ad4211-e237-4c7b-aa9a-dfb99bf8bace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_41fa9bb4-0f6f-4da6-bfc1-d747426b1679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f925f301-8b85-43e1-ab4c-54e8a09c4f1a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_41fa9bb4-0f6f-4da6-bfc1-d747426b1679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e18bd965-a8c7-4002-97e4-cdb7b925d1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_619010ea-e8cf-4a95-8f38-2e6d84062555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e18bd965-a8c7-4002-97e4-cdb7b925d1be" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_619010ea-e8cf-4a95-8f38-2e6d84062555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_065d328f-727e-40e1-9aa1-fb8d3c6c66ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e18bd965-a8c7-4002-97e4-cdb7b925d1be" xlink:to="loc_us-gaap_OperatingExpenses_065d328f-727e-40e1-9aa1-fb8d3c6c66ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ba30814d-7b3e-4097-ba40-fd82cd9ac471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_90c021e5-159d-4bab-a926-c93fca623c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ba30814d-7b3e-4097-ba40-fd82cd9ac471" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_90c021e5-159d-4bab-a926-c93fca623c3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0a93df14-4462-4f42-aa5b-44d0da9a5bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ba30814d-7b3e-4097-ba40-fd82cd9ac471" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0a93df14-4462-4f42-aa5b-44d0da9a5bf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0a95d802-5f0e-4bba-95ef-823ca3097190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7a806cc5-4948-4a15-bc00-17ab086d4968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0a95d802-5f0e-4bba-95ef-823ca3097190" xlink:to="loc_us-gaap_NetIncomeLoss_7a806cc5-4948-4a15-bc00-17ab086d4968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_32dee00e-cd78-4597-acbc-c3ff9fc4b999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0a95d802-5f0e-4bba-95ef-823ca3097190" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_32dee00e-cd78-4597-acbc-c3ff9fc4b999" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_de7b4943-5182-4899-96f5-58dc2689460d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0a95d802-5f0e-4bba-95ef-823ca3097190" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_de7b4943-5182-4899-96f5-58dc2689460d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="advm-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bbbb9b6d-43ef-49ce-917f-8f07717d3929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e9a87d87-2e77-4a70-8dd2-2fa4b089d7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bbbb9b6d-43ef-49ce-917f-8f07717d3929" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e9a87d87-2e77-4a70-8dd2-2fa4b089d7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4aaced02-58d5-4c95-a6f4-1232b8096639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bbbb9b6d-43ef-49ce-917f-8f07717d3929" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4aaced02-58d5-4c95-a6f4-1232b8096639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e74c7208-2325-4b28-ae1a-d03ad98f52be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bbbb9b6d-43ef-49ce-917f-8f07717d3929" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e74c7208-2325-4b28-ae1a-d03ad98f52be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52083ff2-c586-4034-8a6b-d32202a88d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8d1aa063-6939-45c5-af9f-fd756fb6cf26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52083ff2-c586-4034-8a6b-d32202a88d9b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8d1aa063-6939-45c5-af9f-fd756fb6cf26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_13895dec-b958-43af-a7ea-bfedd5e35eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52083ff2-c586-4034-8a6b-d32202a88d9b" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_13895dec-b958-43af-a7ea-bfedd5e35eb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5334e2bd-8593-48c0-a581-5863d8658d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52083ff2-c586-4034-8a6b-d32202a88d9b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5334e2bd-8593-48c0-a581-5863d8658d60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a74105cb-c6d6-4f7b-a570-072e572e5c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52083ff2-c586-4034-8a6b-d32202a88d9b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a74105cb-c6d6-4f7b-a570-072e572e5c98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ed975dc5-e7f9-4214-a9b5-9560fc0255e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ed975dc5-e7f9-4214-a9b5-9560fc0255e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4354f756-8592-4ec2-8fa7-70e1b63d46f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_us-gaap_ShareBasedCompensation_4354f756-8592-4ec2-8fa7-70e1b63d46f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e872acd4-66d8-4f26-becf-65d4107b215c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_us-gaap_NetIncomeLoss_e872acd4-66d8-4f26-becf-65d4107b215c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_6682def9-98e4-4f3e-b5e4-9446824a6d8f" xlink:href="advm-20220930.xsd#advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_6682def9-98e4-4f3e-b5e4-9446824a6d8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d6fa2d29-69f1-4a00-b031-ce09419a5e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_us-gaap_DepreciationAndAmortization_d6fa2d29-69f1-4a00-b031-ce09419a5e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_6d1ca1ec-4cf7-4e26-8634-2ae972141b84" xlink:href="advm-20220930.xsd#advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_6d1ca1ec-4cf7-4e26-8634-2ae972141b84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7dcca96b-03ca-4f42-962c-9cb8db108cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7dcca96b-03ca-4f42-962c-9cb8db108cfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_fe1a3597-d122-4f64-bf62-5ef559564121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_fe1a3597-d122-4f64-bf62-5ef559564121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_89f44c82-4d27-4052-88c9-b07f3e4e189a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_89f44c82-4d27-4052-88c9-b07f3e4e189a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_a7ba20e8-8d06-4292-a189-13564da474e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_a7ba20e8-8d06-4292-a189-13564da474e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_bf80b920-134c-4229-b45d-1ac67b0aae7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_bf80b920-134c-4229-b45d-1ac67b0aae7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_65316529-b600-444a-9e0d-a6f0c7e1ba9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_65316529-b600-444a-9e0d-a6f0c7e1ba9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_97dec4da-5964-496c-90e4-28e276253588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_97dec4da-5964-496c-90e4-28e276253588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_0143c4ff-9311-41ee-b97d-fb2bfdb2c04b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287e5da9-b513-481b-8eb5-ee08dc856c6f" xlink:to="loc_us-gaap_AssetImpairmentCharges_0143c4ff-9311-41ee-b97d-fb2bfdb2c04b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43c3d72a-f85a-483b-9ca4-5b215616c2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e402570-7105-46b1-a6c2-73eb5fb99410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43c3d72a-f85a-483b-9ca4-5b215616c2f0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e402570-7105-46b1-a6c2-73eb5fb99410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_2be76e8b-7516-4255-ae77-64264f4ec623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43c3d72a-f85a-483b-9ca4-5b215616c2f0" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_2be76e8b-7516-4255-ae77-64264f4ec623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a246049e-c75e-41a2-987d-f77ee373b743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_30aa4de5-7ab5-4841-9c43-8da80f4bef1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a246049e-c75e-41a2-987d-f77ee373b743" xlink:to="loc_us-gaap_RepaymentsOfDebt_30aa4de5-7ab5-4841-9c43-8da80f4bef1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_be95051e-2709-4ee8-9517-9e5e2ecc1324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a246049e-c75e-41a2-987d-f77ee373b743" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_be95051e-2709-4ee8-9517-9e5e2ecc1324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4052c8ba-b53f-4524-87da-73123bd469d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a246049e-c75e-41a2-987d-f77ee373b743" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4052c8ba-b53f-4524-87da-73123bd469d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_1aadccdb-b353-4984-916c-15b69231bf86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a246049e-c75e-41a2-987d-f77ee373b743" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_1aadccdb-b353-4984-916c-15b69231bf86" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7a7ecced-1f8d-4669-a3fe-d9b45b263d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_66274239-b8d7-4b87-a365-c450d4f455ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7a7ecced-1f8d-4669-a3fe-d9b45b263d45" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_66274239-b8d7-4b87-a365-c450d4f455ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_35a84e0e-4e1d-453e-98eb-139a0352ea18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7a7ecced-1f8d-4669-a3fe-d9b45b263d45" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_35a84e0e-4e1d-453e-98eb-139a0352ea18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a6821b28-49a1-433d-9407-69cb1fcc0c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7a7ecced-1f8d-4669-a3fe-d9b45b263d45" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a6821b28-49a1-433d-9407-69cb1fcc0c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_0997736a-aa54-4375-ba57-a07fa3678d2a" xlink:href="advm-20220930.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_d8e9175d-e536-46fc-9712-377d455c26ae" xlink:href="advm-20220930.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost_0997736a-aa54-4375-ba57-a07fa3678d2a" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_d8e9175d-e536-46fc-9712-377d455c26ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_94eaef60-5f23-4c70-ad76-528bd9e05271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost_0997736a-aa54-4375-ba57-a07fa3678d2a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_94eaef60-5f23-4c70-ad76-528bd9e05271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_0c380f07-9806-4e22-a472-e6792754b835" xlink:href="advm-20220930.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost_0997736a-aa54-4375-ba57-a07fa3678d2a" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_0c380f07-9806-4e22-a472-e6792754b835" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_80345d7f-b691-4f44-abee-817047cd4d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0181a2d5-f61e-4648-b73f-632eb5b13d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_80345d7f-b691-4f44-abee-817047cd4d96" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0181a2d5-f61e-4648-b73f-632eb5b13d25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_33da645c-870c-4c94-a9df-5694dfe0af49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_80345d7f-b691-4f44-abee-817047cd4d96" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_33da645c-870c-4c94-a9df-5694dfe0af49" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_6b043aee-1d35-4e8d-8451-0531c8b6598c" xlink:href="advm-20220930.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_31ccf894-2673-4180-bdb0-e52e21664f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_6b043aee-1d35-4e8d-8451-0531c8b6598c" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_31ccf894-2673-4180-bdb0-e52e21664f80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_27419fc0-3cee-495a-a408-985c55cbd6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_6b043aee-1d35-4e8d-8451-0531c8b6598c" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_27419fc0-3cee-495a-a408-985c55cbd6a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_3f7acbb8-ea84-467f-9a41-316f9c45915d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_6b043aee-1d35-4e8d-8451-0531c8b6598c" xlink:to="loc_us-gaap_TaxesPayableCurrent_3f7acbb8-ea84-467f-9a41-316f9c45915d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_45cc7c9b-5ac1-4e7b-8570-702ce6115aa9" xlink:href="advm-20220930.xsd#advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_6b043aee-1d35-4e8d-8451-0531c8b6598c" xlink:to="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_45cc7c9b-5ac1-4e7b-8570-702ce6115aa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_096d3d4d-5c61-47e0-9d38-3e7576fa71d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_6b043aee-1d35-4e8d-8451-0531c8b6598c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_096d3d4d-5c61-47e0-9d38-3e7576fa71d0" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>advm-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:915153f8-5dd7-44a4-84da-67d592863439,g:2581671a-d3ba-4d70-a3e7-003e900c7a5c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="advm-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i1e4603a388cf4714bf514c285cc91924_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b680ab55-dd90-43d3-b8d4-cab6a5d80f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b680ab55-dd90-43d3-b8d4-cab6a5d80f7a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_067f9956-9db5-4d43-b38a-e9b13ac69534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_SharesOutstanding_067f9956-9db5-4d43-b38a-e9b13ac69534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_704ea535-141d-41b1-8a12-444788b51ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockholdersEquity_704ea535-141d-41b1-8a12-444788b51ea6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_755b4b62-af9c-45db-829f-5f2ca5ad9dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_755b4b62-af9c-45db-829f-5f2ca5ad9dae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a5365454-3822-4104-a4e8-ea0352850065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a5365454-3822-4104-a4e8-ea0352850065" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_446df33c-34d9-4df4-a48d-3a25dab98775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_446df33c-34d9-4df4-a48d-3a25dab98775" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_22646620-a3a5-41b6-9ce7-9b58fb8c1f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_22646620-a3a5-41b6-9ce7-9b58fb8c1f1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_78462f50-7d08-443a-9931-dbad6b000acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_78462f50-7d08-443a-9931-dbad6b000acb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3fb27f2b-972b-48b5-9b89-8d7d88688ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3fb27f2b-972b-48b5-9b89-8d7d88688ab1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_7ffb541b-80bd-48cb-a14b-c8bc180f2d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_7ffb541b-80bd-48cb-a14b-c8bc180f2d6d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_486cd81a-e031-43c9-b2bf-a5d10bebe5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_486cd81a-e031-43c9-b2bf-a5d10bebe5a4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e09b589c-c259-4b6c-8d9a-02a7d02f2082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e09b589c-c259-4b6c-8d9a-02a7d02f2082" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5c6b7d58-9e19-48e1-adf6-52df375fbbca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5c6b7d58-9e19-48e1-adf6-52df375fbbca" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_3c911c83-a7e5-4a52-8a03-e1c5fae29057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_3c911c83-a7e5-4a52-8a03-e1c5fae29057" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49cf6b1c-b960-4cd9-8d40-11856d2aa6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_NetIncomeLoss_49cf6b1c-b960-4cd9-8d40-11856d2aa6f7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a34c8101-8f7b-4d66-a526-1e03fa2044e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cdd22912-5395-4e5f-b1f0-f504be396f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e4302d8d-0755-4300-955f-117553b9f021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b680ab55-dd90-43d3-b8d4-cab6a5d80f7a" xlink:to="loc_us-gaap_StatementTable_e4302d8d-0755-4300-955f-117553b9f021" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1f20e73d-9a1c-4139-b49c-7582f6d63c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e4302d8d-0755-4300-955f-117553b9f021" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1f20e73d-9a1c-4139-b49c-7582f6d63c07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1f20e73d-9a1c-4139-b49c-7582f6d63c07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f20e73d-9a1c-4139-b49c-7582f6d63c07" xlink:to="loc_us-gaap_EquityComponentDomain_1f20e73d-9a1c-4139-b49c-7582f6d63c07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_af982ce0-bad3-4e6f-a527-1d0f795409b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f20e73d-9a1c-4139-b49c-7582f6d63c07" xlink:to="loc_us-gaap_EquityComponentDomain_af982ce0-bad3-4e6f-a527-1d0f795409b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e35c5be1-9f30-44fa-9f7c-ade0708ebcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_af982ce0-bad3-4e6f-a527-1d0f795409b8" xlink:to="loc_us-gaap_CommonStockMember_e35c5be1-9f30-44fa-9f7c-ade0708ebcf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bf1e5f06-0136-49fd-ba07-0e40d05ccf35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_af982ce0-bad3-4e6f-a527-1d0f795409b8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bf1e5f06-0136-49fd-ba07-0e40d05ccf35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cc75950d-e39e-4e71-901e-7efd3c319c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_af982ce0-bad3-4e6f-a527-1d0f795409b8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cc75950d-e39e-4e71-901e-7efd3c319c29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5842fbf2-d036-4a14-a808-6c68f8f0fc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_af982ce0-bad3-4e6f-a527-1d0f795409b8" xlink:to="loc_us-gaap_RetainedEarningsMember_5842fbf2-d036-4a14-a808-6c68f8f0fc0c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="extended" id="ief5c3ef7f91b41cc8fc59e17fd0ffecd_FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_57ce97a3-0119-4fbb-a6c7-222ba713f365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_57ce97a3-0119-4fbb-a6c7-222ba713f365" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_65198667-247f-4f9c-8066-0102ee944d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_65198667-247f-4f9c-8066-0102ee944d19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d0bbd95-2541-47e5-8275-ecc67dab8c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d0bbd95-2541-47e5-8275-ecc67dab8c31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b3b7bd5-0ebd-4fa7-9396-d992e262b0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b3b7bd5-0ebd-4fa7-9396-d992e262b0d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_8c66c689-bb65-42c9-a100-cb2200492d5b" xlink:href="advm-20220930.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_8c66c689-bb65-42c9-a100-cb2200492d5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_5098424a-4ac2-4658-a2d9-13b804e6cb9d" xlink:href="advm-20220930.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_5098424a-4ac2-4658-a2d9-13b804e6cb9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_4ad3c198-10e4-4bde-8d43-e0881cab839d" xlink:href="advm-20220930.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_4ad3c198-10e4-4bde-8d43-e0881cab839d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_171a9555-0b4d-452c-b412-072258bc7dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_171a9555-0b4d-452c-b412-072258bc7dc8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50c687a1-53bb-46e7-948e-23d8beb01a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50c687a1-53bb-46e7-948e-23d8beb01a63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5488cb1a-9f21-442e-a492-b718e158f28a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50c687a1-53bb-46e7-948e-23d8beb01a63" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5488cb1a-9f21-442e-a492-b718e158f28a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5488cb1a-9f21-442e-a492-b718e158f28a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5488cb1a-9f21-442e-a492-b718e158f28a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5488cb1a-9f21-442e-a492-b718e158f28a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5488cb1a-9f21-442e-a492-b718e158f28a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ec7ae4d7-1429-47d8-9c23-b9e10b67364d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ec7ae4d7-1429-47d8-9c23-b9e10b67364d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f5f8951f-8466-4158-9e18-edc8759cf9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f5f8951f-8466-4158-9e18-edc8759cf9fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_01155226-692c-4d14-add4-94e5c1ad5c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:to="loc_us-gaap_CommercialPaperMember_01155226-692c-4d14-add4-94e5c1ad5c97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_83fa9579-c2a2-4533-877a-dac98407279a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_83fa9579-c2a2-4533-877a-dac98407279a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_b3687148-64b1-4d73-b4c1-601c5955aabf" xlink:href="advm-20220930.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_b3687148-64b1-4d73-b4c1-601c5955aabf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618d5a6e-48b4-42dd-8a67-3517b543e789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50c687a1-53bb-46e7-948e-23d8beb01a63" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618d5a6e-48b4-42dd-8a67-3517b543e789" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_618d5a6e-48b4-42dd-8a67-3517b543e789_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618d5a6e-48b4-42dd-8a67-3517b543e789" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_618d5a6e-48b4-42dd-8a67-3517b543e789_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eed23dac-5131-43f5-b399-df3c29ef9dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618d5a6e-48b4-42dd-8a67-3517b543e789" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eed23dac-5131-43f5-b399-df3c29ef9dce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_59b3a81d-cf71-4d72-bba5-45bfc2efc285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eed23dac-5131-43f5-b399-df3c29ef9dce" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_59b3a81d-cf71-4d72-bba5-45bfc2efc285" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0cf4a71b-bfc4-43fa-ab6f-aca6323afba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eed23dac-5131-43f5-b399-df3c29ef9dce" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0cf4a71b-bfc4-43fa-ab6f-aca6323afba5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended" id="i0cace81d53a54fb59352b0e4e55a2ff5_FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a4c55eb-0f0a-42b6-aec2-486a42bf63f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_17b21c0f-ea32-4360-8965-004a3fc07475" xlink:href="advm-20220930.xsd#advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a4c55eb-0f0a-42b6-aec2-486a42bf63f1" xlink:to="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_17b21c0f-ea32-4360-8965-004a3fc07475" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_79acbb61-33a6-4845-ac98-124e29c3cd27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a4c55eb-0f0a-42b6-aec2-486a42bf63f1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_79acbb61-33a6-4845-ac98-124e29c3cd27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a702116f-1d57-4bc6-8290-35dcdd87fc23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a4c55eb-0f0a-42b6-aec2-486a42bf63f1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a702116f-1d57-4bc6-8290-35dcdd87fc23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_dc05c5f3-8d34-4360-b67d-01b46c944fec" xlink:href="advm-20220930.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a4c55eb-0f0a-42b6-aec2-486a42bf63f1" xlink:to="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_dc05c5f3-8d34-4360-b67d-01b46c944fec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_fa827477-1e1b-42e4-8a23-68cc0953aa30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a4c55eb-0f0a-42b6-aec2-486a42bf63f1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_fa827477-1e1b-42e4-8a23-68cc0953aa30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b468014d-ecd3-4343-8bb0-9be754cd56f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_fa827477-1e1b-42e4-8a23-68cc0953aa30" xlink:to="loc_srt_RangeAxis_b468014d-ecd3-4343-8bb0-9be754cd56f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b468014d-ecd3-4343-8bb0-9be754cd56f1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b468014d-ecd3-4343-8bb0-9be754cd56f1" xlink:to="loc_srt_RangeMember_b468014d-ecd3-4343-8bb0-9be754cd56f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce422b0d-b77d-495f-84f7-d9904ab39618" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b468014d-ecd3-4343-8bb0-9be754cd56f1" xlink:to="loc_srt_RangeMember_ce422b0d-b77d-495f-84f7-d9904ab39618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_27c8e409-1627-4322-9128-f6bd3414c1be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ce422b0d-b77d-495f-84f7-d9904ab39618" xlink:to="loc_srt_MinimumMember_27c8e409-1627-4322-9128-f6bd3414c1be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_906ea90c-e4ec-4083-8222-96857e6fd580" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ce422b0d-b77d-495f-84f7-d9904ab39618" xlink:to="loc_srt_MaximumMember_906ea90c-e4ec-4083-8222-96857e6fd580" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended" id="ia10021469e8a4fde91871e8583e97997_BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f59ee49-2eb6-4b18-bddd-ec26f57aaca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_73e2c7b6-c183-4ca3-9081-531e0ad0ba45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f59ee49-2eb6-4b18-bddd-ec26f57aaca4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_73e2c7b6-c183-4ca3-9081-531e0ad0ba45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9a5b0d9a-1b37-4d6f-a088-8d1e8a52bd34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f59ee49-2eb6-4b18-bddd-ec26f57aaca4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9a5b0d9a-1b37-4d6f-a088-8d1e8a52bd34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5d4c9dc0-c0ec-4472-a0db-b4b78cd0d5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f59ee49-2eb6-4b18-bddd-ec26f57aaca4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5d4c9dc0-c0ec-4472-a0db-b4b78cd0d5f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9329c763-b6c3-498e-ac93-1883f6d4d7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f59ee49-2eb6-4b18-bddd-ec26f57aaca4" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9329c763-b6c3-498e-ac93-1883f6d4d7c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9ed33b38-f65f-475e-a0fd-27c41570f847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f59ee49-2eb6-4b18-bddd-ec26f57aaca4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9ed33b38-f65f-475e-a0fd-27c41570f847" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ea24c23-7605-4cda-8b9e-aa6f4d329290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9ed33b38-f65f-475e-a0fd-27c41570f847" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ea24c23-7605-4cda-8b9e-aa6f4d329290" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ea24c23-7605-4cda-8b9e-aa6f4d329290_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ea24c23-7605-4cda-8b9e-aa6f4d329290" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ea24c23-7605-4cda-8b9e-aa6f4d329290_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ea24c23-7605-4cda-8b9e-aa6f4d329290" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_de7157ff-6dad-465e-84b9-6ab46d5e75f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:to="loc_us-gaap_ComputerEquipmentMember_de7157ff-6dad-465e-84b9-6ab46d5e75f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_80a81675-6b71-4882-8984-62ad12a9429c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:to="loc_us-gaap_EquipmentMember_80a81675-6b71-4882-8984-62ad12a9429c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4df30023-9955-4cdd-9a33-c5869187bcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4df30023-9955-4cdd-9a33-c5869187bcfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4a83cbd3-c1d4-4c48-a4b9-05bc31036114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4a83cbd3-c1d4-4c48-a4b9-05bc31036114" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_aaafc540-fca7-4819-9150-616508a4c2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:to="loc_us-gaap_ConstructionInProgressMember_aaafc540-fca7-4819-9150-616508a4c2d1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#EquityIncentiveAwardsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails" xlink:type="extended" id="ic580d830e3da48c398964b6305bc9c6a_EquityIncentiveAwardsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45bd277a-af7c-4beb-93c3-63ebd64898fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd6d19ed-36ca-4aae-ab51-59c9f8baaee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45bd277a-af7c-4beb-93c3-63ebd64898fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd6d19ed-36ca-4aae-ab51-59c9f8baaee8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8b0733b4-a497-4e81-ab05-e51f4f478a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45bd277a-af7c-4beb-93c3-63ebd64898fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8b0733b4-a497-4e81-ab05-e51f4f478a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b15b681c-2a3b-48e6-b5a8-4934abc8c09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45bd277a-af7c-4beb-93c3-63ebd64898fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b15b681c-2a3b-48e6-b5a8-4934abc8c09d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a4d97347-08a8-425a-aae1-cf90c1073809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b15b681c-2a3b-48e6-b5a8-4934abc8c09d" xlink:to="loc_us-gaap_AwardTypeAxis_a4d97347-08a8-425a-aae1-cf90c1073809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d97347-08a8-425a-aae1-cf90c1073809_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a4d97347-08a8-425a-aae1-cf90c1073809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d97347-08a8-425a-aae1-cf90c1073809_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9821d81e-e2f9-464c-9140-30ac2467d48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a4d97347-08a8-425a-aae1-cf90c1073809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9821d81e-e2f9-464c-9140-30ac2467d48c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_62336c4b-5f79-4035-8762-df8c2ae665b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9821d81e-e2f9-464c-9140-30ac2467d48c" xlink:to="loc_us-gaap_PerformanceSharesMember_62336c4b-5f79-4035-8762-df8c2ae665b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails" xlink:type="extended" id="i1a9dc33570e44280be8e19183f2516c4_EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd52875c-1345-487a-be6b-9d29f49bb998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b576578-56d2-4d9f-a1bb-f44ff6c2318f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd52875c-1345-487a-be6b-9d29f49bb998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b576578-56d2-4d9f-a1bb-f44ff6c2318f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e39d1aa0-5a0b-414a-969a-93917a9d6bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b576578-56d2-4d9f-a1bb-f44ff6c2318f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e39d1aa0-5a0b-414a-969a-93917a9d6bc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0c344039-e7a1-4bf3-acae-8654a3eeb475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b576578-56d2-4d9f-a1bb-f44ff6c2318f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0c344039-e7a1-4bf3-acae-8654a3eeb475" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_66efe3bf-bdd6-4774-ba54-6f8d237a8f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b576578-56d2-4d9f-a1bb-f44ff6c2318f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_66efe3bf-bdd6-4774-ba54-6f8d237a8f78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4418bd3e-ade2-4c0c-ab0a-884d434b2d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b576578-56d2-4d9f-a1bb-f44ff6c2318f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4418bd3e-ade2-4c0c-ab0a-884d434b2d54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb2d37bd-8a3c-4c3c-87cc-61e531509bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5178aed4-0c0f-4f2d-9be3-475a21d3a7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd52875c-1345-487a-be6b-9d29f49bb998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5178aed4-0c0f-4f2d-9be3-475a21d3a7b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b449062-049e-4181-834b-6d2d03af34b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5178aed4-0c0f-4f2d-9be3-475a21d3a7b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b449062-049e-4181-834b-6d2d03af34b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75089e01-a1ff-48ac-9b10-8d8f3788eb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5178aed4-0c0f-4f2d-9be3-475a21d3a7b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75089e01-a1ff-48ac-9b10-8d8f3788eb8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_e3fd8b2a-215e-40b6-b71f-f8883461f25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5178aed4-0c0f-4f2d-9be3-475a21d3a7b1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_e3fd8b2a-215e-40b6-b71f-f8883461f25c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fa8c0946-7657-488a-93ce-ba4eade6685e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5178aed4-0c0f-4f2d-9be3-475a21d3a7b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fa8c0946-7657-488a-93ce-ba4eade6685e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2f685e4-8ac2-458a-aa83-bd195ee490b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d83793bb-6ce0-418d-8499-3bc08509cb58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd52875c-1345-487a-be6b-9d29f49bb998" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d83793bb-6ce0-418d-8499-3bc08509cb58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e8e3342a-f9c3-4fff-96f7-17bf72ed5c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d83793bb-6ce0-418d-8499-3bc08509cb58" xlink:to="loc_us-gaap_AwardTypeAxis_e8e3342a-f9c3-4fff-96f7-17bf72ed5c9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8e3342a-f9c3-4fff-96f7-17bf72ed5c9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e8e3342a-f9c3-4fff-96f7-17bf72ed5c9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8e3342a-f9c3-4fff-96f7-17bf72ed5c9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a834766f-01e5-4050-8314-572c6f5d0ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e8e3342a-f9c3-4fff-96f7-17bf72ed5c9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a834766f-01e5-4050-8314-572c6f5d0ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b8d2dbec-2244-47ae-9b94-305bc85c177a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a834766f-01e5-4050-8314-572c6f5d0ca2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b8d2dbec-2244-47ae-9b94-305bc85c177a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended" id="i9b9c208ccbed434195e7b4720797ab0a_EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f376f2a8-d7b5-4424-9fea-70008b9cc755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_39d81f19-9984-4c8b-9702-5c4000b3812c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f376f2a8-d7b5-4424-9fea-70008b9cc755" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_39d81f19-9984-4c8b-9702-5c4000b3812c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3a8752f3-e298-4904-a037-51a9ec73642e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f376f2a8-d7b5-4424-9fea-70008b9cc755" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3a8752f3-e298-4904-a037-51a9ec73642e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_efcd5d4d-b567-44b4-bf03-7e462afb42fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3a8752f3-e298-4904-a037-51a9ec73642e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_efcd5d4d-b567-44b4-bf03-7e462afb42fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_efcd5d4d-b567-44b4-bf03-7e462afb42fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_efcd5d4d-b567-44b4-bf03-7e462afb42fc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_efcd5d4d-b567-44b4-bf03-7e462afb42fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c322a3a2-2601-4635-946f-2a6fb111e44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_efcd5d4d-b567-44b4-bf03-7e462afb42fc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c322a3a2-2601-4635-946f-2a6fb111e44f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5a26e57c-9cf2-4aa4-826c-503359cac049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c322a3a2-2601-4635-946f-2a6fb111e44f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5a26e57c-9cf2-4aa4-826c-503359cac049" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5e4fb5b6-71da-444e-a95e-abce3bbf80af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c322a3a2-2601-4635-946f-2a6fb111e44f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5e4fb5b6-71da-444e-a95e-abce3bbf80af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails" xlink:type="extended" id="ib01c1965e0174b72b54f8386e502c6bd_NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_318b2bcc-6fde-49ab-aaa1-1bcacbfe50f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_72b1890c-9479-44c8-a1bf-dceaac7a6658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_318b2bcc-6fde-49ab-aaa1-1bcacbfe50f2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_72b1890c-9479-44c8-a1bf-dceaac7a6658" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98d3f49d-917a-4868-a0f2-c8b52b495a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_318b2bcc-6fde-49ab-aaa1-1bcacbfe50f2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98d3f49d-917a-4868-a0f2-c8b52b495a94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_99cadbf9-05db-429e-bfda-7f01c8c2d23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98d3f49d-917a-4868-a0f2-c8b52b495a94" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_99cadbf9-05db-429e-bfda-7f01c8c2d23f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_99cadbf9-05db-429e-bfda-7f01c8c2d23f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_99cadbf9-05db-429e-bfda-7f01c8c2d23f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_99cadbf9-05db-429e-bfda-7f01c8c2d23f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6181b4-c96c-491a-befe-33eed6096292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_99cadbf9-05db-429e-bfda-7f01c8c2d23f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6181b4-c96c-491a-befe-33eed6096292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5f17ca82-1c0b-4108-9ccd-24b9f3e9cd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6181b4-c96c-491a-befe-33eed6096292" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5f17ca82-1c0b-4108-9ccd-24b9f3e9cd0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_686bdffe-77f9-4609-8333-25168e5d3eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6181b4-c96c-491a-befe-33eed6096292" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_686bdffe-77f9-4609-8333-25168e5d3eeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c2e8cfc5-6c7c-4d27-91de-5c23a733f459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6181b4-c96c-491a-befe-33eed6096292" xlink:to="loc_us-gaap_EmployeeStockMember_c2e8cfc5-6c7c-4d27-91de-5c23a733f459" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#RestructuringAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/RestructuringAdditionalInformationDetails" xlink:type="extended" id="i767aab11a4074c8b9f763ec6f29ff1ef_RestructuringAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_92d7696e-1bf8-4fbc-8935-d2bd9fd30c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_70d5b98d-7aee-44d2-9c14-be9547f0bd08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_92d7696e-1bf8-4fbc-8935-d2bd9fd30c89" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_70d5b98d-7aee-44d2-9c14-be9547f0bd08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_3662e674-5996-472c-af69-2e78c17d649d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_92d7696e-1bf8-4fbc-8935-d2bd9fd30c89" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_3662e674-5996-472c-af69-2e78c17d649d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d475c2df-a714-4b58-abab-92be7f84655b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_92d7696e-1bf8-4fbc-8935-d2bd9fd30c89" xlink:to="loc_us-gaap_RestructuringCharges_d475c2df-a714-4b58-abab-92be7f84655b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_372c5fea-8548-41e6-96c0-ff1018a705a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_92d7696e-1bf8-4fbc-8935-d2bd9fd30c89" xlink:to="loc_us-gaap_PaymentsForRestructuring_372c5fea-8548-41e6-96c0-ff1018a705a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8dd76460-2cac-4ba2-825f-ae2642b2813a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_92d7696e-1bf8-4fbc-8935-d2bd9fd30c89" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8dd76460-2cac-4ba2-825f-ae2642b2813a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_13381393-b272-479e-9643-8443b2e11602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8dd76460-2cac-4ba2-825f-ae2642b2813a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_13381393-b272-479e-9643-8443b2e11602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_13381393-b272-479e-9643-8443b2e11602_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13381393-b272-479e-9643-8443b2e11602" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_13381393-b272-479e-9643-8443b2e11602_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8a1729c3-52cc-40ec-b083-64fcc3d0d8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13381393-b272-479e-9643-8443b2e11602" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8a1729c3-52cc-40ec-b083-64fcc3d0d8c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f0088780-cead-4da9-895f-eff64054cccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8a1729c3-52cc-40ec-b083-64fcc3d0d8c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f0088780-cead-4da9-895f-eff64054cccf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_da7acb47-1eb3-45d1-aae9-58ef0b0b6401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8a1729c3-52cc-40ec-b083-64fcc3d0d8c7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_da7acb47-1eb3-45d1-aae9-58ef0b0b6401" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#RestructuringScheduleofRestructuringCostDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails" xlink:type="extended" id="i41a5ba196cf44409901ce97dd26b3341_RestructuringScheduleofRestructuringCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d6f904be-47a9-4911-aed9-e2f5b170eaca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_4e40eaf1-781e-4ecb-a97e-f5f8d85e2bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d6f904be-47a9-4911-aed9-e2f5b170eaca" xlink:to="loc_us-gaap_RestructuringReserveRollForward_4e40eaf1-781e-4ecb-a97e-f5f8d85e2bcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c9548dc5-c6fb-4c19-b420-5209d1741ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_4e40eaf1-781e-4ecb-a97e-f5f8d85e2bcb" xlink:to="loc_us-gaap_RestructuringReserve_c9548dc5-c6fb-4c19-b420-5209d1741ffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ee7b6a5d-e51e-40e4-8dba-025ccca88ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_4e40eaf1-781e-4ecb-a97e-f5f8d85e2bcb" xlink:to="loc_us-gaap_RestructuringCharges_ee7b6a5d-e51e-40e4-8dba-025ccca88ede" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_31b2e758-5cb4-4c9d-bb4e-d0d494c898f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_4e40eaf1-781e-4ecb-a97e-f5f8d85e2bcb" xlink:to="loc_us-gaap_PaymentsForRestructuring_31b2e758-5cb4-4c9d-bb4e-d0d494c898f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_48dc26f5-f4c2-44bc-aae4-728e006fefda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_4e40eaf1-781e-4ecb-a97e-f5f8d85e2bcb" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_48dc26f5-f4c2-44bc-aae4-728e006fefda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_d683f1ed-556f-4133-b058-7a4ee449b9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_28f8a9fd-df00-44ee-a1ab-19f6e64700c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d6f904be-47a9-4911-aed9-e2f5b170eaca" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_28f8a9fd-df00-44ee-a1ab-19f6e64700c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_52487aac-26a4-43d0-a97e-a86b606b079c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_28f8a9fd-df00-44ee-a1ab-19f6e64700c7" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_52487aac-26a4-43d0-a97e-a86b606b079c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_52487aac-26a4-43d0-a97e-a86b606b079c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_52487aac-26a4-43d0-a97e-a86b606b079c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_52487aac-26a4-43d0-a97e-a86b606b079c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2105e134-5c66-44eb-9c90-25b24a83094d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_52487aac-26a4-43d0-a97e-a86b606b079c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2105e134-5c66-44eb-9c90-25b24a83094d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_a0c8ec51-4a94-498c-92ea-cc4b04f7cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2105e134-5c66-44eb-9c90-25b24a83094d" xlink:to="loc_us-gaap_EmployeeSeveranceMember_a0c8ec51-4a94-498c-92ea-cc4b04f7cd4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_1a195d38-3299-4463-a169-965965ab8589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2105e134-5c66-44eb-9c90-25b24a83094d" xlink:to="loc_us-gaap_StockCompensationPlanMember_1a195d38-3299-4463-a169-965965ab8589" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>advm-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:915153f8-5dd7-44a4-84da-67d592863439,g:2581671a-d3ba-4d70-a3e7-003e900c7a5c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e75796fe-6cde-491b-8d5b-4496c42cfdc9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5e1b1fb5-92ba-41aa-9258-619b7e8ad45f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d212873-a366-4aee-816f-0cb0b7ebffed_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_9306acaf-5097-4265-98e2-24f70cf56f00_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1393909b-9e21-4b3c-8eac-35327bfcfc64_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_39d390a9-554d-4a70-b5a5-d236e8a19014_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_402368f2-cebe-4ed8-93a7-c80142eb94e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_df74fb82-bd5b-4b18-bb48-def8abeb998d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_b05edcbc-3b2d-454b-9b3d-5ffa4fa7b48c_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_32be2378-3b19-4df0-bed1-97b200655a73_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7fe91f7d-a035-4868-ab37-2bb7dcb27056_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_aac1fba8-3f7c-442b-9b90-d625a45503cf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8265cc88-52fa-4465-ab34-657b6ccee0f9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares used to compute net loss per share - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2175ffa1-7f9b-4de0-a82d-a81d08149cbc_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_27ef9694-db0e-4c3e-9abb-9e1baf446c3e_terseLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash equivalents, unrealized losses</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Loss</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalent gross unrealized loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:href="advm-20220930.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ed20b034-a140-4f0b-af4f-fc48cbc94192_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_ab0da4a2-faa4-4d35-bcd4-8537126e8358_terseLabel_en-US" xlink:label="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_label_en-US" xlink:label="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years</link:label>
    <link:label id="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_documentation_en-US" xlink:label="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:href="advm-20220930.xsd#advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:to="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_22b71c6e-1a02-4542-a427-dc0ea9dd2bf0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_203165d6-4439-4292-8bf2-395fc73833cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_5c680e70-f6d8-4d85-9595-760cd0294294_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring cost, beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_41bdb2ef-9653-4cce-8a1e-d2fb570b8c85_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring cost, ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_d6b60e5a-0a4f-461e-9179-8c746ddcbcbd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_95c2fa5c-1376-4f9c-ab7d-7525a03ae072_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aab942da-00eb-4b3c-8c52-d82962621daa_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e34aeb6d-6dad-47ac-8cc9-177f21775c43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4f61cd6f-75c2-4e0e-a6c1-599a5c8079d9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_acc7b3fb-eb27-42e0-8b23-f78a05e4446b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f16c91d6-62c3-4c1b-8a30-3e55a80d1386_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_76781899-b8b5-4986-934c-4144e8e65c18_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b484c24a-46ce-43d2-b69f-192ee1389917_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon release of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_03a32140-25e4-4e4b-80bf-38f7aa623774_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_133310b6-89a3-4895-980c-b7ca51243e66_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_fad18d7c-5337-4901-bfcb-01641647fc17_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6eb5d8e6-5a32-4de1-b4b5-2a681688b904_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bac97d32-15c8-4c45-9912-084ca2bf3290_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6155fb3c-628c-4198-8bd7-88b8e0f894a9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_622c6717-87a6-4cd6-aa43-931dffe6a022_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_52976f9f-8738-4863-a088-f3eee507def7_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_78cd993a-0b12-44a6-8744-f04efbe34377_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_57f77627-81f7-4a7c-8fb8-94d832263d66_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock pursuant to option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_be468105-15a6-4b3b-aae4-657c3e87ccbf_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_34171e3e-97b5-4ae3-b97a-4e3364a9b8c7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_724b8c72-5104-4265-bb28-9b76092b26d0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_da9c2c76-2c83-4077-b129-95497507b693_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_beb6f57e-e4cd-4019-a4d9-5e7a54a53ae4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets in accounts payable, accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_87342e15-c1d8-423e-95a1-dcb6ce90c6b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0c6800a2-3508-4fb3-9f74-f277b879d90f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities in an unrealized loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_de66b75c-1308-49c5-b44a-cdf54f0572b2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9454019b-7fd1-4708-ac7e-51a7b66e50a3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7110d5d-3d7a-4d8e-949a-f6fd0eaea1a7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a5f995e4-754e-40f2-9af7-ead4e1ae64fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_50595c9f-71f3-4bb6-b7eb-99b937cab36d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_49c46021-9cac-4f86-919e-51d7f89f3fac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_e0ad6ed8-2d87-4506-94b6-6c04bd8ca26e_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1fbdc814-374a-4a5a-a4c0-72ba54b6173d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_af771cd1-87f0-45e7-b530-e75380f8827e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b109b4b3-5f21-481c-9c4a-6aabaf15e8a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit and other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_335d712a-8265-4130-aebd-24cb985f0fff_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_8e595c73-7319-4e14-9bea-b482f815fae5_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring cost paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_9666941c-684a-41eb-9250-5c16528e2d81_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments made</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cf21c6e0-d74d-4ba6-8ebc-8daa11584727_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_82003780-a60c-4350-8a92-99fac602274b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_de92c8a7-782b-44b3-84d1-71f39b4d1abe_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and Benefits Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5164cdf4-8f52-40fe-893c-2c2b734612c0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3056a209-e927-45b2-995f-bcae45c34c08_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4b360481-5947-4336-a0e9-3b836879536d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_694221e3-8b4b-43bd-a1ad-a02617aaac1c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_155ffb61-b084-489a-87e7-ad35c8126f4e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9ea39aec-be86-45ff-b873-6da8433d8723_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_64aaf973-2d32-4a47-a1b0-7eebaff102af_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_171ceab5-8cbf-4027-84f9-b8a6e21a7cd8_terseLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_28b998d1-ac54-4d82-8c97-e9a0ab4dc8a4_totalLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="advm-20220930.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d2c04389-fd96-4c35-82cb-be7eca2f42d2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b39953-529c-4f37-8e10-43b87b61f04d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_43315cd6-266e-4e5e-b7b3-6ec819fecd51_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a6fcc2de-8e4d-430f-8a3f-fa6a92d5dcd6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c1f0a0fb-f928-403b-9f0c-69b9c9403908_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_32cdcd44-324c-4b66-8439-424436c23bed_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_308d0d13-4194-42c6-a758-eb8e9868df22_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_66da5a23-55e0-46e8-a4bf-55fddd6f0fcc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6b86e276-db12-42f5-a35d-86b1e4cd0a2c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51b26fa7-62ae-4a73-a37b-b04602cdee20_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2f913977-aec4-428e-8876-b0674e47cee5_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cd7d3e32-e854-4f26-8f98-17aa5c2086a6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5b432c7d-65ee-4111-b29f-46dd7f06ae4b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_81f38bd3-c3d9-4e56-b1ee-7b4897237e48_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a320dacf-9fa2-4e43-8f36-5fc62f76f23c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e26d7932-9457-4b83-b76b-b150f6af2489_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747da130-f990-4997-ac6b-7af8fbb8b10b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_321647e9-18c0-49d2-b816-96da826dd732_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_928e54b8-7826-4150-aa1a-d6ef769c5f89_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_43e904bf-be49-4cb7-a972-616877c3eec0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0401caf3-88a2-4bc6-bbe6-6fc0d75a04d2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_aaec4bbf-83ad-458e-b3bc-e163b111676d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_92131c79-8b99-4a7d-90b4-a763a386cb2d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_409b2c6b-a500-47db-a8f7-0880ffebef47_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_8b82f50e-4f8a-4da2-9492-81a6bb9d3691_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c6eff897-93c3-4790-9357-eae35c463214_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_1de226b1-4451-4687-8caa-478de7e8b5d2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_e0b08c3d-6a33-4b93-8ad2-56de55b8bedf_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8f12a531-d098-42e7-ae4e-daeb9a5bcd3d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_afb7e1f0-dff5-4242-a384-7258fd7a946f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_da267104-ab8a-4225-9e64-e13af3353b9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant- Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1f091890-6360-4773-bc10-66fc3fa957bb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e6720af9-ee38-4822-9da7-37bf5773a537_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Units (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_30b96211-879c-4399-a389-4568d508e806_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_36251c53-8e72-48bf-8945-17931c122e74_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_cedb4097-addc-437f-8642-a80b6dc9355e_negatedTotalLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash equivalents, amortized cost basis</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Amortized Cost</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalent amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:href="advm-20220930.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:to="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_4a857a65-15ef-4cd5-9da8-9bb4ad75ef9c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_8b9509c5-3d30-4ee6-851e-3643c41e9008_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities term (in years)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e1ee232c-e36c-4974-94b9-63d5be51a2a8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b7507017-de7f-4282-98b1-249e40da2a43_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9d30e5c3-e2ad-4e9f-a1fb-9f939f3ee1c9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_145dcf7e-a32a-4064-83a7-24f0dfabd116_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_cc4b0611-a6d4-4987-8bc2-8739899b2288_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_15ce7787-9882-44da-a825-f77ee000dca7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_f36b5c21-7d28-406e-b357-88800f58a581_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_de8527bb-5aa1-431e-b617-bb025ddd35a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Negative sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7b7c03d9-821a-48c2-9dbb-b2b41339b04e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d5c8ac00-1247-4acb-8098-f27de5c251ca_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2114227e-f00f-4691-a8c4-dbe897432c0e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1dce7317-db25-4a00-9ab5-2a25fa0cbbeb_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b1aa2dd5-5003-4a62-905b-79d85e166d9f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentReceivablesNet_b46fce8a-106c-43fd-b98f-2885327e2fea_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent receivable</link:label>
    <link:label id="lab_us-gaap_DeferredRentReceivablesNet_label_en-US" xlink:label="lab_us-gaap_DeferredRentReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Receivables, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentReceivablesNet" xlink:to="lab_us-gaap_DeferredRentReceivablesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2f1fc579-4e76-453d-9aea-ea518ce1f8b6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_47d9fe56-2a11-45b4-bbd9-f1d54b5a9bb3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3eca2627-b6d6-4b66-84fb-3b03979691a9_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, additional issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2e41c027-4769-419a-a867-f03d861da6a0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_675af784-5add-4741-9e9b-0524a2fe363b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium and accrued interest on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ceef9a48-7390-406e-9099-93ff2373aac2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ac4c7044-c35a-4ba2-aa91-bf47e029dcdb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8f20250d-8802-4097-a009-09d3a5b532c7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_a43de598-a0c3-485d-9445-79944bd96100_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_446fdfb5-c023-48f9-ad20-957035d2d35a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d0e9db76-ce35-4299-af69-a3113f06d664_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d0a33479-8a9c-4b03-8c00-163c19562726_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_996a6133-5ec9-4f58-be0b-d18931a38b5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_deb811cc-1071-4dd4-9775-cd37a125518b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4d337695-e47c-48dc-af9d-9b0792fa3164_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0d4c6fca-ccd3-45fe-b557-560271db0031_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5b911496-7908-4b0e-b03e-ca5ea2acba42_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_10a9a1a1-ac00-4180-905a-511c5f31e525_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ae0adbca-9713-4d6f-82de-397777f1e5aa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_da91189e-1875-4e63-9f05-a4615b28b78d_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_d4d94d46-a54a-4b22-ae1e-aa01ba804d34_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5f927e79-3265-4f6d-8550-69af389054aa_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_26aa976b-ed7b-47d0-a56b-0a6c73c03567_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d994b93-7923-46e5-b21c-c621f3cea611_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7fec28ff-048e-4ea5-8c73-5121ff3855dc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7cc2ad34-9837-455e-b16c-934a6f82b42b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets_7ca18555-697a-43c8-ad47-c4d5a2900060_terseLabel_en-US" xlink:label="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of operating right-of-use assets</link:label>
    <link:label id="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement Of Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement Of Operating Lease Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_RemeasurementOfOperatingLeaseRightOfUseAssets" xlink:href="advm-20220930.xsd#advm_RemeasurementOfOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_RemeasurementOfOperatingLeaseRightOfUseAssets" xlink:to="lab_advm_RemeasurementOfOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncentiveToLessee_d2d0ee83-5231-459b-8fde-82775dd3bca7_terseLabel_en-US" xlink:label="lab_us-gaap_IncentiveToLessee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease incentive receivables</link:label>
    <link:label id="lab_us-gaap_IncentiveToLessee_label_en-US" xlink:label="lab_us-gaap_IncentiveToLessee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive to Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveToLessee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveToLessee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncentiveToLessee" xlink:to="lab_us-gaap_IncentiveToLessee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_431cc77e-5cc3-4999-916c-4fdddb82341e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c6405324-0549-43eb-afcc-c9ee00494468_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6447f6c9-ad89-4a1e-8d0d-e47c0ce1ea29_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from offerings of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a46983c2-bfb4-4556-bda7-e0079eaa4254_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares used to compute net loss per share - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b98ecdd8-8ea0-4e5b-b5c0-9b47426c5200_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_b04c4d8c-4625-4a92-9f6d-6bd356132d47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_7194c43e-d8a5-4dca-91ce-c5ec5a5e9630_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7bebee8e-379a-4a6b-8e58-e9840c85b963_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3e7dbf12-aa5d-4e4e-a631-9f2bc4dc4810_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_bf890cb4-5cd6-4d77-bff7-f23723275db5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7d117e93-5d32-4497-83ae-2624fa22d31c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3c9d6697-1df1-4882-916c-344372a50b1e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e4084d3d-d8eb-460c-bbae-cf21bbd4dd0b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_8d64a60b-aea3-4efc-bcd9-21066914e029_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees percentage</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_e1ed136a-a239-46d0-a9fd-96f0272e01dc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_bac3326c-f46c-4c59-9307-4b80e7522887_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_4960717a-90d7-493c-8776-47acd8b3c3be_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8e25e0bd-2ca5-47f3-afd5-def0707beb59_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_9d00d393-6b89-4903-9852-65d1129c2b30_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33cfe943-99b0-4ca9-a8f0-e2faf5dd8bc4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_c8593077-31a2-44df-a5ad-d6ab034d5771_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_adaefbdb-e49e-4205-9959-bbe6742dd2e6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_4df3a052-d9ce-4144-b8a8-8637cd087ff7_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_5fa68662-0e33-44ae-a4f6-3ff0ec9f560f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b4aa0a13-66c7-4086-a203-e3ff61507091_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_4a3785f7-59bd-4511-a20c-cec53223a2d3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a56a0d8b-245f-4de0-8583-feabbccdd37b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_8a5f7a4b-49ba-4e82-9c4c-d321400771a1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e589c627-e749-4b2d-8479-58b4cad5c101_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5944871c-5ae0-4549-aa3b-3daf9aaf5770_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_27f48be8-fc46-4a5a-944b-a581340d3da9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_338c5f4b-8a7f-4d38-ac56-036cb43331d3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b52c73bc-d838-4562-a789-f0966f84ab89_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_380e663b-dba1-4169-aa67-c4a54b93aea9_terseLabel_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities other-than-temporarily impaired</link:label>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_label_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Than Temporary Impaired Investments Available For Sale Securities</link:label>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than temporary impaired investments available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:href="advm-20220930.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:to="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_5ddd1e5a-019d-4a3c-862f-20050a762eec_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_18be9063-2885-42e8-b909-e56c1cc71033_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f9508406-09fa-40a0-9b85-74b7d8a1e7c9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_764e4f9c-04fe-406d-bbb9-38d748fbd5dc_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9c72679b-3c44-40a8-b952-2cb2e7cf1344_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_15d4a079-28d3-4d68-bc1e-7a4f546cf94a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_71f24a1a-93f8-4ad7-88d4-26815edab135_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99c3a6d8-7ad4-4ec1-98d5-5af4c7c2b0ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0bddeedb-f1e0-4d40-8cd3-bd7e1ebb3ec9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_e65a34cd-9265-4865-96ea-0ee70a0bebfb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_737f7449-c416-4048-9804-b7cc54ebc3a6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_46205113-0f04-4b8c-b11a-bb439cc79530_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8212; diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c249d920-c29b-441c-aa92-9ece05f0b33d_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_16ba2611-86dd-4df2-849e-029757b9a44f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash equivalents, estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0275f7ec-bc4e-4ff9-b3ab-a47b1d5dad19_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_63aec737-b228-4015-adb6-70916e175328_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_9031894c-5365-48a8-88e8-05f4dc0c8ee0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f4bb7ee2-2a47-4ce5-a26f-7b360d9c66b9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f1508e37-efe5-4e84-a0e7-5ce6c27f145a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_7e9f6b7b-4120-44be-9778-254442294b8f_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d18786bb-cce1-44c4-a148-a5d5497984e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_79a3c66f-e15b-4c5e-b3b6-fddfb81cba95_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9f5fa288-c167-428e-9e1a-ac19d751b488_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c1cd84e5-d428-4346-89c7-fed92e032381_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8212; basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2cbbd12c-d3ed-4946-aef2-ac8538a3af56_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_592712a9-c49e-4f8e-8e30-138290ed5918_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7db7d707-f947-49c0-9db7-e7d8e709e171_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_673a13ec-e7e8-4dac-8979-5a397840c629_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_6396c27b-edce-4a53-829c-c6b7565126d0_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_424b558d-fdcf-44dd-8dca-1d1ea5dfee62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_7137ae5e-33b2-41a1-9c35-5a10b64b08c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_73b9ed68-07e1-45c8-84c7-115b23cbf901_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_5190dc95-79f3-4c1d-95be-d6f64cc8ed26_terseLabel_en-US" xlink:label="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability and lease incentive receivable</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_label_en-US" xlink:label="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Liabilities And Lease Incentive Receivable</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_documentation_en-US" xlink:label="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in lease liabilities and lease incentive receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:href="advm-20220930.xsd#advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:to="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_ad61308c-a892-43b9-bffb-023babf3a5aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_59476fba-8bc5-42dd-a6d5-bfb1d11509a0_negatedTerseLabel_en-US" xlink:label="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Operating Lease Right-of-use Asset</link:label>
    <link:label id="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Operating Lease Right-of-use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:href="advm-20220930.xsd#advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:to="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ffee0240-ee9e-4e2b-895f-2dbc22c7bb3a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_faebc375-455a-4d7f-81b4-2390dc71a584_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_5623561e-a69e-4121-a573-61e82a2e113a_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2f58288-240f-4f31-9e78-f6355e2576cf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_636cd162-2098-4eae-9a8d-350e78698a55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_ff158be1-030b-4ff5-adcf-a5e0ce7523d6_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_e94db88e-fe04-4516-937b-437d913d4c7e_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_f457786d-ac2a-44e6-bf28-1d45a8ec6653_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d878ffbe-6fb8-4947-96f5-90f50c17bbf6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7638b8a1-016a-4ae9-9dd0-5168b51d32b8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_84aff687-8fbb-45d9-9ce6-5d013f80fab0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_655b8f6d-bb87-414c-b6b1-5508aa0c7026_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e8fdfe01-e3ee-453f-9227-8b9d624ff0ad_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_725faa8c-cfff-4b4e-8fc1-de2b1761ac6c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_f9d7ba5a-4e95-4bee-b888-b7067987541c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_7960f0af-65a9-4aa9-88ae-164850e44714_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c2e94395-e4a4-4c32-b1cd-667a4afc696b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_67c4b4be-00ef-424e-982d-306409c26a0a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_8adf03f4-ee34-4588-bea7-f0200944300b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d2526ab3-7032-48c2-8d41-190073e712b0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_0f072836-d5b3-4897-a311-c6f281d47619_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_6a45cadd-224c-4340-8e13-9be88546db51_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_13ca3726-1449-4741-ba02-d8140f714a38_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_bceaf0f6-56ee-490a-ba61-376f0c44a902_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_563402ef-22f0-46e5-aade-dd8ac32a45d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_389d5067-a27e-4cc2-ba49-5bfd5bf62ea4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_dd559749-e252-4381-9bd2-e02d86734b04_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b0713db1-9ca3-498e-a719-c8d796188c63_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_fce8f7df-78c8-4680-a427-a55b9e678ac5_terseLabel_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and short-term investments</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_label_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments [Member]</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_documentation_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and short term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:href="advm-20220930.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:to="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a19e8d2-d955-44b7-ac5b-ed1db33a84a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30035f7b-e648-497b-b828-47a7500a2c22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_9a9c6ad8-f464-4e76-80a4-4ce0e53f387b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d61baa76-0605-47b3-9339-bb136b4ebd68_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b07b82e-f1e8-4913-98bc-f1df8c9c9a7b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b3b80474-9d30-440e-80f8-2eb8c1940052_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_96cfaeb8-d657-4484-85c1-c5006ef0a295_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9379b824-f470-4d05-aa8c-ce12689c7212_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_81823f40-476b-4a22-a210-b9c89279e9c4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_957857fa-57e3-48ac-a537-cd0663a2c1c8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d69df2cf-304d-472e-8804-d84dc81101d9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30659ca9-ae30-4f8c-bad5-79e5a7a5bede_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_b67d5996-1178-4dec-8db6-5a16542a15ce_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ba325991-d88d-469a-9d3e-6d399d09b9cc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c50fe25b-e6b5-4e12-a08a-c72c02a23351_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_32e624d9-e9b7-4f0e-9504-6c3a259225b3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c4cadd3-4974-4eef-ba2b-d083a0b644e7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_61707f53-1e97-4ad0-8a23-0cba9e66bd29_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_63dee2b8-b9e0-4a91-9619-8695fad91eba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4f67df43-f680-4325-a51c-555c8f38dc77_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss)/Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4adb0d98-bb23-4cf0-8b83-cf59448e8253_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of noncash investing and financing information</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_054f5689-e668-4577-9309-b8ff6d3bc29f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_656ba84d-101d-4b8b-9aa1-03b48415ac8c_terseLabel_en-US" xlink:label="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued nonclinical, clinical and process development costs</link:label>
    <link:label id="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_label_en-US" xlink:label="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Nonclinical, Clinical, And Development Process Costs</link:label>
    <link:label id="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_documentation_en-US" xlink:label="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical clinical and development process costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:href="advm-20220930.xsd#advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:to="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_52f95772-7cfb-499f-8cc0-653ebcdc663f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_b1b8a0db-aeaf-42a6-8ba5-cc8292ca7731_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_3cb17a8f-3ae2-4def-840e-fbf41362f66a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_717c377b-1d91-4ea9-b353-ebaafdb49348_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cae640e7-bb76-4277-b2a1-9f909ff16db6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_f461bf7d-fb28-4e58-b323-2bd5ba374f83_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ef1ba487-798c-43c5-92b4-dab71002c2e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9ec73bc0-776d-4cfa-828d-7735b72ffdfa_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6af5d8f7-7cc3-4f59-92ad-5a04f78eb98b_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8ad21acb-ca0b-4b92-bdba-b9f1627a69b4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1e7cb58e-1680-4320-bf47-a3490bc38a01_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3b85790c-b335-4139-9a5d-2f7be27750a3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_c826a3ae-9c06-457b-bf41-75eed927c5ee_negatedTerseLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash equivalents, unrealized gains</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Gain</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalent gross unrealized gain.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:href="advm-20220930.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ee1b6544-24bb-49b0-9eff-a8b3ecb43e83_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>advm-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:915153f8-5dd7-44a4-84da-67d592863439,g:2581671a-d3ba-4d70-a3e7-003e900c7a5c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/CoverPage" xlink:type="simple" xlink:href="advm-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4ea6bc95-0358-4622-9e76-747545bdff73" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_DocumentType_4ea6bc95-0358-4622-9e76-747545bdff73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_02805aec-d6aa-4fca-9410-a7bada602345" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_DocumentQuarterlyReport_02805aec-d6aa-4fca-9410-a7bada602345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_272a92bd-ab12-49eb-845f-16a3ab9968c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_DocumentPeriodEndDate_272a92bd-ab12-49eb-845f-16a3ab9968c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c7218824-e9c9-4087-b806-6cf3b097ca1e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_DocumentTransitionReport_c7218824-e9c9-4087-b806-6cf3b097ca1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_536cd430-d54b-45fc-b812-a22f07c58709" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityFileNumber_536cd430-d54b-45fc-b812-a22f07c58709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_dc0bc32d-3264-4c31-a065-795356e6386d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityRegistrantName_dc0bc32d-3264-4c31-a065-795356e6386d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a159d361-f6c9-43c1-b0f1-41c1e98b215b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a159d361-f6c9-43c1-b0f1-41c1e98b215b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a933ea25-d1c3-43db-853a-df58698b58d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityTaxIdentificationNumber_a933ea25-d1c3-43db-853a-df58698b58d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c43717cd-4a5b-40fd-b23c-3b0b25dc6f6b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityAddressAddressLine1_c43717cd-4a5b-40fd-b23c-3b0b25dc6f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_775b806e-d812-47b2-8c85-7ea620a7b73e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityAddressCityOrTown_775b806e-d812-47b2-8c85-7ea620a7b73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1a71f737-f748-4a3b-bafd-e95ec458909f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityAddressStateOrProvince_1a71f737-f748-4a3b-bafd-e95ec458909f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_93a0b327-2fbc-4c6f-88b1-ed257e1a545e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityAddressPostalZipCode_93a0b327-2fbc-4c6f-88b1-ed257e1a545e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_64985a8c-cbab-4aae-99b2-172491b74c63" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_CityAreaCode_64985a8c-cbab-4aae-99b2-172491b74c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c8784670-c7b0-4e8a-8e24-30a39a3ad9de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_LocalPhoneNumber_c8784670-c7b0-4e8a-8e24-30a39a3ad9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_529c104e-52ac-41b9-b0ba-a3b6f93b3722" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_Security12bTitle_529c104e-52ac-41b9-b0ba-a3b6f93b3722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_55569af5-2f94-4322-8c83-348d265aec77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_TradingSymbol_55569af5-2f94-4322-8c83-348d265aec77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3b9b6107-2194-414e-b0df-dc12b45d0ada" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_SecurityExchangeName_3b9b6107-2194-414e-b0df-dc12b45d0ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_38b3339d-bcae-4a99-ba69-c5d1f6297b15" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityCurrentReportingStatus_38b3339d-bcae-4a99-ba69-c5d1f6297b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fa406b96-0f2b-49c8-9565-88ebb5cb741b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityInteractiveDataCurrent_fa406b96-0f2b-49c8-9565-88ebb5cb741b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_dca7bb3f-738e-4c45-b9b8-c5a2772d478c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityFilerCategory_dca7bb3f-738e-4c45-b9b8-c5a2772d478c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_de5f70f0-e769-487a-a67d-6fd6563ea727" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntitySmallBusiness_de5f70f0-e769-487a-a67d-6fd6563ea727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_dad85ed1-a330-46f1-bc80-33c05e537667" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityEmergingGrowthCompany_dad85ed1-a330-46f1-bc80-33c05e537667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_321e47d5-d6bd-4e55-90da-99db91868640" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityShellCompany_321e47d5-d6bd-4e55-90da-99db91868640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6f21925b-ea02-4adc-bbc9-631667b525d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6f21925b-ea02-4adc-bbc9-631667b525d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f23e616c-92c1-4c51-b43a-d071dbf2ef75" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_AmendmentFlag_f23e616c-92c1-4c51-b43a-d071dbf2ef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_192ae258-9475-45a9-8aad-4a1ffcfd1bda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_DocumentFiscalYearFocus_192ae258-9475-45a9-8aad-4a1ffcfd1bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ffffa6e7-f834-4232-9c31-9225a4476721" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ffffa6e7-f834-4232-9c31-9225a4476721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d370c974-fd9e-4179-9161-7f7ed41aaf51" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_EntityCentralIndexKey_d370c974-fd9e-4179-9161-7f7ed41aaf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6184e677-2c3f-41c0-b75f-854b17712663" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3aeb9aa9-9f74-473b-ae28-9d8164aa355f" xlink:to="loc_dei_CurrentFiscalYearEndDate_6184e677-2c3f-41c0-b75f-854b17712663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="advm-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c2e92cf8-ff2f-4e13-b7d7-67d9023df395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c6559529-e427-43c2-aaa1-47179c7c92b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c2e92cf8-ff2f-4e13-b7d7-67d9023df395" xlink:to="loc_us-gaap_AssetsAbstract_c6559529-e427-43c2-aaa1-47179c7c92b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e2e360ea-4c81-4195-a85c-36051fe71fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c6559529-e427-43c2-aaa1-47179c7c92b8" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e2e360ea-4c81-4195-a85c-36051fe71fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e266cff3-319b-475b-a9e3-9961de906637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e2e360ea-4c81-4195-a85c-36051fe71fb6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e266cff3-319b-475b-a9e3-9961de906637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_9161d9a0-8b4f-4b70-846e-6d88c952453d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e2e360ea-4c81-4195-a85c-36051fe71fb6" xlink:to="loc_us-gaap_ShortTermInvestments_9161d9a0-8b4f-4b70-846e-6d88c952453d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveToLessee_e6203ed3-6655-4d9f-ac30-baa092db2a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveToLessee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e2e360ea-4c81-4195-a85c-36051fe71fb6" xlink:to="loc_us-gaap_IncentiveToLessee_e6203ed3-6655-4d9f-ac30-baa092db2a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c72a3f26-6216-48e3-8d4a-eec4aa5e67e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e2e360ea-4c81-4195-a85c-36051fe71fb6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c72a3f26-6216-48e3-8d4a-eec4aa5e67e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c021a27a-6e08-4f13-8bd1-2cc5ccca046f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e2e360ea-4c81-4195-a85c-36051fe71fb6" xlink:to="loc_us-gaap_AssetsCurrent_c021a27a-6e08-4f13-8bd1-2cc5ccca046f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bd073dd0-708a-4763-ba52-274f9cad1110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c6559529-e427-43c2-aaa1-47179c7c92b8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bd073dd0-708a-4763-ba52-274f9cad1110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ae7e8d43-4220-4885-8b17-697ba512b879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c6559529-e427-43c2-aaa1-47179c7c92b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ae7e8d43-4220-4885-8b17-697ba512b879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_4553f0fd-76e6-4326-9be6-639736723bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c6559529-e427-43c2-aaa1-47179c7c92b8" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_4553f0fd-76e6-4326-9be6-639736723bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_5e723cdb-372c-4039-b235-3fc7b24ae03e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c6559529-e427-43c2-aaa1-47179c7c92b8" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_5e723cdb-372c-4039-b235-3fc7b24ae03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b617a375-a495-45fa-9d56-97a8f429da25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c6559529-e427-43c2-aaa1-47179c7c92b8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b617a375-a495-45fa-9d56-97a8f429da25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4ba47e9c-b37e-4ce5-9fc1-d358fe4b4f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c6559529-e427-43c2-aaa1-47179c7c92b8" xlink:to="loc_us-gaap_Assets_4ba47e9c-b37e-4ce5-9fc1-d358fe4b4f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_179bacdc-78be-4042-ae6c-8bb004c4bb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c2e92cf8-ff2f-4e13-b7d7-67d9023df395" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_179bacdc-78be-4042-ae6c-8bb004c4bb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_dc0a5a92-317e-4aac-90e7-9af66bb3db7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_179bacdc-78be-4042-ae6c-8bb004c4bb7d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_dc0a5a92-317e-4aac-90e7-9af66bb3db7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ecd1f7c6-74ae-479c-8b96-4092426aa7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dc0a5a92-317e-4aac-90e7-9af66bb3db7c" xlink:to="loc_us-gaap_AccountsPayableCurrent_ecd1f7c6-74ae-479c-8b96-4092426aa7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_7f5fb12c-da2c-498e-955a-014d15f6bbe7" xlink:href="advm-20220930.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dc0a5a92-317e-4aac-90e7-9af66bb3db7c" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_7f5fb12c-da2c-498e-955a-014d15f6bbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b17eb46-4472-4375-85c7-76a77407c6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dc0a5a92-317e-4aac-90e7-9af66bb3db7c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b17eb46-4472-4375-85c7-76a77407c6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bb0b17e8-e284-4339-ac0e-e2229e3001b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dc0a5a92-317e-4aac-90e7-9af66bb3db7c" xlink:to="loc_us-gaap_LiabilitiesCurrent_bb0b17e8-e284-4339-ac0e-e2229e3001b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3ca7328a-67ed-426a-b742-b5c6cf7fd200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_179bacdc-78be-4042-ae6c-8bb004c4bb7d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3ca7328a-67ed-426a-b742-b5c6cf7fd200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8a3aa5b6-90f3-481d-8e20-65e834dbe30a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_179bacdc-78be-4042-ae6c-8bb004c4bb7d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8a3aa5b6-90f3-481d-8e20-65e834dbe30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5aa7cbfe-0aee-48e1-b989-c1812e184849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_179bacdc-78be-4042-ae6c-8bb004c4bb7d" xlink:to="loc_us-gaap_Liabilities_5aa7cbfe-0aee-48e1-b989-c1812e184849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_344e32ba-2892-4250-9441-26586d7a1983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_179bacdc-78be-4042-ae6c-8bb004c4bb7d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_344e32ba-2892-4250-9441-26586d7a1983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_75d34576-0d59-4787-bf41-4dd9174fa771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_344e32ba-2892-4250-9441-26586d7a1983" xlink:to="loc_us-gaap_PreferredStockValue_75d34576-0d59-4787-bf41-4dd9174fa771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d5e93345-4a06-403c-a510-c42281ebb075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_344e32ba-2892-4250-9441-26586d7a1983" xlink:to="loc_us-gaap_CommonStockValue_d5e93345-4a06-403c-a510-c42281ebb075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2ef05824-7b55-478f-82cc-e0ba02640a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_344e32ba-2892-4250-9441-26586d7a1983" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2ef05824-7b55-478f-82cc-e0ba02640a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d675eb8c-6196-486d-9f4e-79ebca9120ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_344e32ba-2892-4250-9441-26586d7a1983" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d675eb8c-6196-486d-9f4e-79ebca9120ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d5667aa7-679e-4739-bbfc-33e33d272e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_344e32ba-2892-4250-9441-26586d7a1983" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d5667aa7-679e-4739-bbfc-33e33d272e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ed51ee58-5ecc-4aff-8422-5a0e7e54deb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_344e32ba-2892-4250-9441-26586d7a1983" xlink:to="loc_us-gaap_StockholdersEquity_ed51ee58-5ecc-4aff-8422-5a0e7e54deb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_df941cba-de09-4d89-947e-5e2fb25162fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_179bacdc-78be-4042-ae6c-8bb004c4bb7d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_df941cba-de09-4d89-947e-5e2fb25162fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="advm-20220930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4902fcca-52ef-404d-9592-fd68d2d17885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4902fcca-52ef-404d-9592-fd68d2d17885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1ebc9ba5-762d-4ec0-9dcf-2dda718aa96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1ebc9ba5-762d-4ec0-9dcf-2dda718aa96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3608153b-f070-4470-bfef-93070f769787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ebc9ba5-762d-4ec0-9dcf-2dda718aa96a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3608153b-f070-4470-bfef-93070f769787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_590143fa-0c5a-45bc-a7fb-937143ce73d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ebc9ba5-762d-4ec0-9dcf-2dda718aa96a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_590143fa-0c5a-45bc-a7fb-937143ce73d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0e89b6f8-75e4-4482-a38b-e019b461544c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ebc9ba5-762d-4ec0-9dcf-2dda718aa96a" xlink:to="loc_us-gaap_OperatingExpenses_0e89b6f8-75e4-4482-a38b-e019b461544c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fb93d298-f549-4515-acfe-642431ffa31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:to="loc_us-gaap_OperatingIncomeLoss_fb93d298-f549-4515-acfe-642431ffa31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3d4da3fb-5d37-428b-900b-ae311cf26ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3d4da3fb-5d37-428b-900b-ae311cf26ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c06aa852-69f3-415a-ae77-0ad77de2b138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c06aa852-69f3-415a-ae77-0ad77de2b138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ec702e2e-10a1-4353-9aae-4dbc2b7eb10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ec702e2e-10a1-4353-9aae-4dbc2b7eb10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1421d838-f164-46bc-b65a-f16a6f76a18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:to="loc_us-gaap_NetIncomeLoss_1421d838-f164-46bc-b65a-f16a6f76a18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_8330b61c-061b-4ccf-8cb8-c564871c2f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_8330b61c-061b-4ccf-8cb8-c564871c2f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_91fb7a1d-cb7a-4a36-81aa-87ada52f9067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_8330b61c-061b-4ccf-8cb8-c564871c2f88" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_91fb7a1d-cb7a-4a36-81aa-87ada52f9067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_262b725a-8228-4495-95fa-54b4b2a024da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_8330b61c-061b-4ccf-8cb8-c564871c2f88" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_262b725a-8228-4495-95fa-54b4b2a024da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ab0f201e-9ffe-454a-a948-a82bfa9128a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ab0f201e-9ffe-454a-a948-a82bfa9128a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b292bfc8-2921-491e-ae1e-c125d474fd53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:to="loc_us-gaap_EarningsPerShareBasic_b292bfc8-2921-491e-ae1e-c125d474fd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_75f57d54-2e1d-48f4-8b49-dd52aa1a87f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:to="loc_us-gaap_EarningsPerShareDiluted_75f57d54-2e1d-48f4-8b49-dd52aa1a87f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_51ddb65b-9f0f-4c3b-957b-736ae058e308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_51ddb65b-9f0f-4c3b-957b-736ae058e308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_676b5778-4df8-4457-a5ea-5635a2f3d37d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6a58627c-2daa-4697-8af5-7b5f281f89ee" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_676b5778-4df8-4457-a5ea-5635a2f3d37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="advm-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c5400e86-1b9f-4692-a179-736b7fdbc0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e4302d8d-0755-4300-955f-117553b9f021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c5400e86-1b9f-4692-a179-736b7fdbc0a3" xlink:to="loc_us-gaap_StatementTable_e4302d8d-0755-4300-955f-117553b9f021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1f20e73d-9a1c-4139-b49c-7582f6d63c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e4302d8d-0755-4300-955f-117553b9f021" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1f20e73d-9a1c-4139-b49c-7582f6d63c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_af982ce0-bad3-4e6f-a527-1d0f795409b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f20e73d-9a1c-4139-b49c-7582f6d63c07" xlink:to="loc_us-gaap_EquityComponentDomain_af982ce0-bad3-4e6f-a527-1d0f795409b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e35c5be1-9f30-44fa-9f7c-ade0708ebcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_af982ce0-bad3-4e6f-a527-1d0f795409b8" xlink:to="loc_us-gaap_CommonStockMember_e35c5be1-9f30-44fa-9f7c-ade0708ebcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bf1e5f06-0136-49fd-ba07-0e40d05ccf35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_af982ce0-bad3-4e6f-a527-1d0f795409b8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bf1e5f06-0136-49fd-ba07-0e40d05ccf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cc75950d-e39e-4e71-901e-7efd3c319c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_af982ce0-bad3-4e6f-a527-1d0f795409b8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cc75950d-e39e-4e71-901e-7efd3c319c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5842fbf2-d036-4a14-a808-6c68f8f0fc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_af982ce0-bad3-4e6f-a527-1d0f795409b8" xlink:to="loc_us-gaap_RetainedEarningsMember_5842fbf2-d036-4a14-a808-6c68f8f0fc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b680ab55-dd90-43d3-b8d4-cab6a5d80f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e4302d8d-0755-4300-955f-117553b9f021" xlink:to="loc_us-gaap_StatementLineItems_b680ab55-dd90-43d3-b8d4-cab6a5d80f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b680ab55-dd90-43d3-b8d4-cab6a5d80f7a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_067f9956-9db5-4d43-b38a-e9b13ac69534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_SharesOutstanding_067f9956-9db5-4d43-b38a-e9b13ac69534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_704ea535-141d-41b1-8a12-444788b51ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockholdersEquity_704ea535-141d-41b1-8a12-444788b51ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_755b4b62-af9c-45db-829f-5f2ca5ad9dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_755b4b62-af9c-45db-829f-5f2ca5ad9dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a5365454-3822-4104-a4e8-ea0352850065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a5365454-3822-4104-a4e8-ea0352850065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_446df33c-34d9-4df4-a48d-3a25dab98775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_446df33c-34d9-4df4-a48d-3a25dab98775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_22646620-a3a5-41b6-9ce7-9b58fb8c1f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_22646620-a3a5-41b6-9ce7-9b58fb8c1f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_78462f50-7d08-443a-9931-dbad6b000acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_78462f50-7d08-443a-9931-dbad6b000acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3fb27f2b-972b-48b5-9b89-8d7d88688ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3fb27f2b-972b-48b5-9b89-8d7d88688ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_7ffb541b-80bd-48cb-a14b-c8bc180f2d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_7ffb541b-80bd-48cb-a14b-c8bc180f2d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_486cd81a-e031-43c9-b2bf-a5d10bebe5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_486cd81a-e031-43c9-b2bf-a5d10bebe5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e09b589c-c259-4b6c-8d9a-02a7d02f2082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e09b589c-c259-4b6c-8d9a-02a7d02f2082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5c6b7d58-9e19-48e1-adf6-52df375fbbca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5c6b7d58-9e19-48e1-adf6-52df375fbbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_3c911c83-a7e5-4a52-8a03-e1c5fae29057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_3c911c83-a7e5-4a52-8a03-e1c5fae29057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49cf6b1c-b960-4cd9-8d40-11856d2aa6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_NetIncomeLoss_49cf6b1c-b960-4cd9-8d40-11856d2aa6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a34c8101-8f7b-4d66-a526-1e03fa2044e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_SharesOutstanding_a34c8101-8f7b-4d66-a526-1e03fa2044e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cdd22912-5395-4e5f-b1f0-f504be396f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e141873-c22b-4aa2-bb46-a59de0abab7a" xlink:to="loc_us-gaap_StockholdersEquity_cdd22912-5395-4e5f-b1f0-f504be396f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="advm-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_90308fa3-7352-4166-9e71-ded1cb444b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_64fb354d-65fb-4052-ba49-d9c09ecc1d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_90308fa3-7352-4166-9e71-ded1cb444b06" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_64fb354d-65fb-4052-ba49-d9c09ecc1d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="advm-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7782f310-97dc-4cf6-8f32-59ead6936f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5b8815b2-ded8-4c35-a9be-9e78ef07ffbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7782f310-97dc-4cf6-8f32-59ead6936f10" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5b8815b2-ded8-4c35-a9be-9e78ef07ffbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_88e38ea4-b15d-4a89-8797-aa901f7b7611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5b8815b2-ded8-4c35-a9be-9e78ef07ffbe" xlink:to="loc_us-gaap_NetIncomeLoss_88e38ea4-b15d-4a89-8797-aa901f7b7611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6c30ed6-c710-42c1-b3bb-19e66b07e4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5b8815b2-ded8-4c35-a9be-9e78ef07ffbe" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6c30ed6-c710-42c1-b3bb-19e66b07e4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_8cfd0953-f46f-444f-a0ee-3b5f858d2922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6c30ed6-c710-42c1-b3bb-19e66b07e4e2" xlink:to="loc_us-gaap_DepreciationAndAmortization_8cfd0953-f46f-444f-a0ee-3b5f858d2922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ddd1860e-5ec4-43a7-bdb2-abe5ee4dc34d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6c30ed6-c710-42c1-b3bb-19e66b07e4e2" xlink:to="loc_us-gaap_ShareBasedCompensation_ddd1860e-5ec4-43a7-bdb2-abe5ee4dc34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0c2df929-c4a3-4703-a1fa-97078537ff2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6c30ed6-c710-42c1-b3bb-19e66b07e4e2" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0c2df929-c4a3-4703-a1fa-97078537ff2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8beaee18-3e31-46d9-9d8e-bf5b0500044e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6c30ed6-c710-42c1-b3bb-19e66b07e4e2" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8beaee18-3e31-46d9-9d8e-bf5b0500044e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f94c67fc-6e2b-4e76-9842-1cc99ae8e28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6c30ed6-c710-42c1-b3bb-19e66b07e4e2" xlink:to="loc_us-gaap_AssetImpairmentCharges_f94c67fc-6e2b-4e76-9842-1cc99ae8e28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_09706293-0d78-486b-a8ea-2156503fe971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6c30ed6-c710-42c1-b3bb-19e66b07e4e2" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_09706293-0d78-486b-a8ea-2156503fe971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d649f3e-28bd-44d9-a747-b278a784ffe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5b8815b2-ded8-4c35-a9be-9e78ef07ffbe" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d649f3e-28bd-44d9-a747-b278a784ffe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a74ecc72-aa60-48f0-9b5f-d7b2717e0a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d649f3e-28bd-44d9-a747-b278a784ffe6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a74ecc72-aa60-48f0-9b5f-d7b2717e0a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_26163891-016a-4802-944f-42e90aad7a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d649f3e-28bd-44d9-a747-b278a784ffe6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_26163891-016a-4802-944f-42e90aad7a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_cc31867e-8d2d-4e82-969f-28a734e4601a" xlink:href="advm-20220930.xsd#advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d649f3e-28bd-44d9-a747-b278a784ffe6" xlink:to="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_cc31867e-8d2d-4e82-969f-28a734e4601a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c52c72fb-a8f7-40ba-b1dd-b04ca50154a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d649f3e-28bd-44d9-a747-b278a784ffe6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c52c72fb-a8f7-40ba-b1dd-b04ca50154a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b359748c-6530-438b-8aa6-97c939808bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d649f3e-28bd-44d9-a747-b278a784ffe6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b359748c-6530-438b-8aa6-97c939808bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_6569a6e1-eb57-4bce-ad43-a1516cfec0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d649f3e-28bd-44d9-a747-b278a784ffe6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_6569a6e1-eb57-4bce-ad43-a1516cfec0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_adea9b13-b727-4786-a6ef-4fb04b9b1691" xlink:href="advm-20220930.xsd#advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d649f3e-28bd-44d9-a747-b278a784ffe6" xlink:to="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_adea9b13-b727-4786-a6ef-4fb04b9b1691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e8c852c-cb1e-425a-a35e-8910f0a40f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5b8815b2-ded8-4c35-a9be-9e78ef07ffbe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e8c852c-cb1e-425a-a35e-8910f0a40f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e63d4c9c-1bf2-4a51-9ec0-c7ee4d4545a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7782f310-97dc-4cf6-8f32-59ead6936f10" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e63d4c9c-1bf2-4a51-9ec0-c7ee4d4545a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1c84e04c-029b-442a-9c9b-2ed3937220a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e63d4c9c-1bf2-4a51-9ec0-c7ee4d4545a3" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1c84e04c-029b-442a-9c9b-2ed3937220a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_49db3c12-7b14-4efd-bc46-3d7a8c11fe58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e63d4c9c-1bf2-4a51-9ec0-c7ee4d4545a3" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_49db3c12-7b14-4efd-bc46-3d7a8c11fe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_375b8fa1-5bcb-445f-a5ac-fcb965d0c62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e63d4c9c-1bf2-4a51-9ec0-c7ee4d4545a3" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_375b8fa1-5bcb-445f-a5ac-fcb965d0c62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e0e8c190-640a-4f1b-9067-d3f2b113b0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e63d4c9c-1bf2-4a51-9ec0-c7ee4d4545a3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e0e8c190-640a-4f1b-9067-d3f2b113b0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8eb17bfc-1ca0-4a64-9743-e29ff7386fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e63d4c9c-1bf2-4a51-9ec0-c7ee4d4545a3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8eb17bfc-1ca0-4a64-9743-e29ff7386fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88550c27-dc9b-4e52-a823-c13f581fbb14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7782f310-97dc-4cf6-8f32-59ead6936f10" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88550c27-dc9b-4e52-a823-c13f581fbb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fc8423fb-d326-4055-9eef-8fd563da6740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88550c27-dc9b-4e52-a823-c13f581fbb14" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fc8423fb-d326-4055-9eef-8fd563da6740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3e224baf-d649-4f8f-ae66-a5a84b1af163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88550c27-dc9b-4e52-a823-c13f581fbb14" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3e224baf-d649-4f8f-ae66-a5a84b1af163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_0a6c5610-f339-4b11-ad45-7796863aa164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88550c27-dc9b-4e52-a823-c13f581fbb14" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_0a6c5610-f339-4b11-ad45-7796863aa164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_8fdf9302-52a8-4d49-9ec2-87884bcdf062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88550c27-dc9b-4e52-a823-c13f581fbb14" xlink:to="loc_us-gaap_RepaymentsOfDebt_8fdf9302-52a8-4d49-9ec2-87884bcdf062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c0519897-17fd-4d4b-9878-1e3dd3582668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88550c27-dc9b-4e52-a823-c13f581fbb14" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c0519897-17fd-4d4b-9878-1e3dd3582668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fadfcc8e-4fcb-4a82-9aa2-fdff07790a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7782f310-97dc-4cf6-8f32-59ead6936f10" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fadfcc8e-4fcb-4a82-9aa2-fdff07790a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df5ca503-b597-4eae-8f64-78f7be76238c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7782f310-97dc-4cf6-8f32-59ead6936f10" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df5ca503-b597-4eae-8f64-78f7be76238c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e1e9889-1ae7-40cb-8fe3-7b6c6fdec952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7782f310-97dc-4cf6-8f32-59ead6936f10" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e1e9889-1ae7-40cb-8fe3-7b6c6fdec952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7f99049b-0555-4bf0-be25-aa3cb5971515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7782f310-97dc-4cf6-8f32-59ead6936f10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7f99049b-0555-4bf0-be25-aa3cb5971515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_295565ae-4d7a-41bf-8ab5-afdc16240379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7782f310-97dc-4cf6-8f32-59ead6936f10" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_295565ae-4d7a-41bf-8ab5-afdc16240379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b4159440-c636-472b-8e39-052f91e04e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7782f310-97dc-4cf6-8f32-59ead6936f10" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b4159440-c636-472b-8e39-052f91e04e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_43511bf8-2069-453b-b3a5-1aac4bdeb3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7782f310-97dc-4cf6-8f32-59ead6936f10" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_43511bf8-2069-453b-b3a5-1aac4bdeb3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_66c103bd-b458-47a5-9e3f-7ff2b5e927e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_43511bf8-2069-453b-b3a5-1aac4bdeb3fa" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_66c103bd-b458-47a5-9e3f-7ff2b5e927e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_RemeasurementOfOperatingLeaseRightOfUseAssets_21911273-16b4-48d1-aa43-0d2977520636" xlink:href="advm-20220930.xsd#advm_RemeasurementOfOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_43511bf8-2069-453b-b3a5-1aac4bdeb3fa" xlink:to="loc_advm_RemeasurementOfOperatingLeaseRightOfUseAssets_21911273-16b4-48d1-aa43-0d2977520636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d89c7b56-d38a-4dda-85ae-825f591554ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_43511bf8-2069-453b-b3a5-1aac4bdeb3fa" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d89c7b56-d38a-4dda-85ae-825f591554ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="advm-20220930.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e72d0c3d-3d10-42e8-8488-6a8e0304f20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7b26d480-570e-426a-be8e-5ddba364a0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e72d0c3d-3d10-42e8-8488-6a8e0304f20f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7b26d480-570e-426a-be8e-5ddba364a0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="advm-20220930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_421cb647-8710-4b14-a4e4-f9a170636e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e651239d-ef05-4c32-a098-064606a49368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_421cb647-8710-4b14-a4e4-f9a170636e75" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e651239d-ef05-4c32-a098-064606a49368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="simple" xlink:href="advm-20220930.xsd#FairValueMeasurementsandFairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_69deea09-da94-41ad-bc1f-9e72c4202e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_cc6a52b8-b897-4547-a677-b7c513d630ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_69deea09-da94-41ad-bc1f-9e72c4202e96" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_cc6a52b8-b897-4547-a677-b7c513d630ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="advm-20220930.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4bdc5318-fc59-403f-a18b-6e7835b9431e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_9974b2d3-6ba6-429d-bdca-994e8a220830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4bdc5318-fc59-403f-a18b-6e7835b9431e" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_9974b2d3-6ba6-429d-bdca-994e8a220830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/Leases" xlink:type="simple" xlink:href="advm-20220930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3b3ac99c-6058-4c09-8a9c-eb25e56f1f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_6c6c8765-8d67-4a03-b6b0-3f2a022a4cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b3ac99c-6058-4c09-8a9c-eb25e56f1f56" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_6c6c8765-8d67-4a03-b6b0-3f2a022a4cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwards" xlink:type="simple" xlink:href="advm-20220930.xsd#EquityIncentiveAwards"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1843a0c-5d3b-49ad-951a-5c336253fe09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_f64583ca-5c71-4b9a-8383-0f8c5899a242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1843a0c-5d3b-49ad-951a-5c336253fe09" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_f64583ca-5c71-4b9a-8383-0f8c5899a242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShare" xlink:type="simple" xlink:href="advm-20220930.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_24f01f5c-17ab-446c-b9c5-b69ae0998ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7ea7e9e6-6961-4262-9082-254397076a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_24f01f5c-17ab-446c-b9c5-b69ae0998ec4" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7ea7e9e6-6961-4262-9082-254397076a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/Restructuring" xlink:type="simple" xlink:href="advm-20220930.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3c46278b-47c2-4d47-aaac-942674b86849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_17839b83-de94-4d00-b7f2-8c5742a0e4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3c46278b-47c2-4d47-aaac-942674b86849" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_17839b83-de94-4d00-b7f2-8c5742a0e4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="advm-20220930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_471f6f65-5646-4da2-b293-773c08e3c258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e3025168-4e28-4e91-8498-3252c219c5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_471f6f65-5646-4da2-b293-773c08e3c258" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e3025168-4e28-4e91-8498-3252c219c5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_7ccc6977-4dd7-4ad1-81c3-39521a1d5110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_471f6f65-5646-4da2-b293-773c08e3c258" xlink:to="loc_us-gaap_UseOfEstimates_7ccc6977-4dd7-4ad1-81c3-39521a1d5110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9a3427c3-ebc1-45a3-8caa-af51bd1f5b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_471f6f65-5646-4da2-b293-773c08e3c258" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9a3427c3-ebc1-45a3-8caa-af51bd1f5b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="advm-20220930.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cb0aedc7-d4e7-4d07-934e-a483b66ac156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_416ed4de-d444-4e3f-a2c1-a6c7bdf55eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cb0aedc7-d4e7-4d07-934e-a483b66ac156" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_416ed4de-d444-4e3f-a2c1-a6c7bdf55eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="advm-20220930.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c65ff7bf-dbf7-445d-93f8-c0bfee9dad47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f144a4ec-b3ea-499d-9ce5-b3a9c0c2ca5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c65ff7bf-dbf7-445d-93f8-c0bfee9dad47" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f144a4ec-b3ea-499d-9ce5-b3a9c0c2ca5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7866f489-ead6-473b-8048-6da6dd334634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c65ff7bf-dbf7-445d-93f8-c0bfee9dad47" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7866f489-ead6-473b-8048-6da6dd334634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsTables" xlink:type="simple" xlink:href="advm-20220930.xsd#EquityIncentiveAwardsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9314fde5-af5b-43f1-b7d6-2baafd952ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ae813455-19ce-4d43-b1fb-5687f116682f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9314fde5-af5b-43f1-b7d6-2baafd952ffb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ae813455-19ce-4d43-b1fb-5687f116682f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_7d185214-9301-439e-b7a9-310760d4806a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9314fde5-af5b-43f1-b7d6-2baafd952ffb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_7d185214-9301-439e-b7a9-310760d4806a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0aeac9c8-f8a6-47ef-8847-f862061befc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9314fde5-af5b-43f1-b7d6-2baafd952ffb" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0aeac9c8-f8a6-47ef-8847-f862061befc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="advm-20220930.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_82595a98-7a11-494c-9e1a-4b38392ea1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1e88b11f-8692-4614-a80a-7e3e830099c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_82595a98-7a11-494c-9e1a-4b38392ea1e3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1e88b11f-8692-4614-a80a-7e3e830099c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringTables" xlink:type="simple" xlink:href="advm-20220930.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_653bef01-29d7-4c40-8039-82b9f97c4390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_5a6bc7f6-9d56-4cc0-a79f-bdd8ae8e0bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_653bef01-29d7-4c40-8039-82b9f97c4390" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_5a6bc7f6-9d56-4cc0-a79f-bdd8ae8e0bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentationDetail" xlink:type="simple" xlink:href="advm-20220930.xsd#OrganizationandBasisofPresentationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/OrganizationandBasisofPresentationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6bd2963-942c-427f-9303-700f9d54986e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_294bbf52-34c3-4d8b-8059-1d28c1be1434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6bd2963-942c-427f-9303-700f9d54986e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_294bbf52-34c3-4d8b-8059-1d28c1be1434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_620c5ede-087c-43a7-bdf5-a6cb9fcb7931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6bd2963-942c-427f-9303-700f9d54986e" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_620c5ede-087c-43a7-bdf5-a6cb9fcb7931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ceb46c8a-e674-46ca-a74e-28873f8cbd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50c687a1-53bb-46e7-948e-23d8beb01a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ceb46c8a-e674-46ca-a74e-28873f8cbd3d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50c687a1-53bb-46e7-948e-23d8beb01a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5488cb1a-9f21-442e-a492-b718e158f28a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50c687a1-53bb-46e7-948e-23d8beb01a63" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5488cb1a-9f21-442e-a492-b718e158f28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5488cb1a-9f21-442e-a492-b718e158f28a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ec7ae4d7-1429-47d8-9c23-b9e10b67364d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ec7ae4d7-1429-47d8-9c23-b9e10b67364d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f5f8951f-8466-4158-9e18-edc8759cf9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f5f8951f-8466-4158-9e18-edc8759cf9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_01155226-692c-4d14-add4-94e5c1ad5c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:to="loc_us-gaap_CommercialPaperMember_01155226-692c-4d14-add4-94e5c1ad5c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_83fa9579-c2a2-4533-877a-dac98407279a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_83fa9579-c2a2-4533-877a-dac98407279a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_b3687148-64b1-4d73-b4c1-601c5955aabf" xlink:href="advm-20220930.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd00d59f-282d-4abc-8e9d-bcd17c27ec8d" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_b3687148-64b1-4d73-b4c1-601c5955aabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618d5a6e-48b4-42dd-8a67-3517b543e789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50c687a1-53bb-46e7-948e-23d8beb01a63" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618d5a6e-48b4-42dd-8a67-3517b543e789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eed23dac-5131-43f5-b399-df3c29ef9dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618d5a6e-48b4-42dd-8a67-3517b543e789" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eed23dac-5131-43f5-b399-df3c29ef9dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_59b3a81d-cf71-4d72-bba5-45bfc2efc285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eed23dac-5131-43f5-b399-df3c29ef9dce" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_59b3a81d-cf71-4d72-bba5-45bfc2efc285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0cf4a71b-bfc4-43fa-ab6f-aca6323afba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eed23dac-5131-43f5-b399-df3c29ef9dce" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0cf4a71b-bfc4-43fa-ab6f-aca6323afba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50c687a1-53bb-46e7-948e-23d8beb01a63" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_57ce97a3-0119-4fbb-a6c7-222ba713f365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_57ce97a3-0119-4fbb-a6c7-222ba713f365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_65198667-247f-4f9c-8066-0102ee944d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_65198667-247f-4f9c-8066-0102ee944d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d0bbd95-2541-47e5-8275-ecc67dab8c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d0bbd95-2541-47e5-8275-ecc67dab8c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b3b7bd5-0ebd-4fa7-9396-d992e262b0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b3b7bd5-0ebd-4fa7-9396-d992e262b0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_8c66c689-bb65-42c9-a100-cb2200492d5b" xlink:href="advm-20220930.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_8c66c689-bb65-42c9-a100-cb2200492d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_5098424a-4ac2-4658-a2d9-13b804e6cb9d" xlink:href="advm-20220930.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_5098424a-4ac2-4658-a2d9-13b804e6cb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_4ad3c198-10e4-4bde-8d43-e0881cab839d" xlink:href="advm-20220930.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_4ad3c198-10e4-4bde-8d43-e0881cab839d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_171a9555-0b4d-452c-b412-072258bc7dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_31172bb9-290f-4b76-a939-42122b489143" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_171a9555-0b4d-452c-b412-072258bc7dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6056f379-fbc6-40c9-b01a-14cdffd2ab56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_fa827477-1e1b-42e4-8a23-68cc0953aa30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6056f379-fbc6-40c9-b01a-14cdffd2ab56" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_fa827477-1e1b-42e4-8a23-68cc0953aa30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b468014d-ecd3-4343-8bb0-9be754cd56f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_fa827477-1e1b-42e4-8a23-68cc0953aa30" xlink:to="loc_srt_RangeAxis_b468014d-ecd3-4343-8bb0-9be754cd56f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce422b0d-b77d-495f-84f7-d9904ab39618" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b468014d-ecd3-4343-8bb0-9be754cd56f1" xlink:to="loc_srt_RangeMember_ce422b0d-b77d-495f-84f7-d9904ab39618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_27c8e409-1627-4322-9128-f6bd3414c1be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ce422b0d-b77d-495f-84f7-d9904ab39618" xlink:to="loc_srt_MinimumMember_27c8e409-1627-4322-9128-f6bd3414c1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_906ea90c-e4ec-4083-8222-96857e6fd580" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ce422b0d-b77d-495f-84f7-d9904ab39618" xlink:to="loc_srt_MaximumMember_906ea90c-e4ec-4083-8222-96857e6fd580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a4c55eb-0f0a-42b6-aec2-486a42bf63f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_fa827477-1e1b-42e4-8a23-68cc0953aa30" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a4c55eb-0f0a-42b6-aec2-486a42bf63f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_17b21c0f-ea32-4360-8965-004a3fc07475" xlink:href="advm-20220930.xsd#advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a4c55eb-0f0a-42b6-aec2-486a42bf63f1" xlink:to="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_17b21c0f-ea32-4360-8965-004a3fc07475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_79acbb61-33a6-4845-ac98-124e29c3cd27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a4c55eb-0f0a-42b6-aec2-486a42bf63f1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_79acbb61-33a6-4845-ac98-124e29c3cd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a702116f-1d57-4bc6-8290-35dcdd87fc23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a4c55eb-0f0a-42b6-aec2-486a42bf63f1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a702116f-1d57-4bc6-8290-35dcdd87fc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_dc05c5f3-8d34-4360-b67d-01b46c944fec" xlink:href="advm-20220930.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a4c55eb-0f0a-42b6-aec2-486a42bf63f1" xlink:to="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_dc05c5f3-8d34-4360-b67d-01b46c944fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_fc249ffd-622a-4c47-9b40-ae931c73eaba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9ed33b38-f65f-475e-a0fd-27c41570f847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_fc249ffd-622a-4c47-9b40-ae931c73eaba" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9ed33b38-f65f-475e-a0fd-27c41570f847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ea24c23-7605-4cda-8b9e-aa6f4d329290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9ed33b38-f65f-475e-a0fd-27c41570f847" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ea24c23-7605-4cda-8b9e-aa6f4d329290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ea24c23-7605-4cda-8b9e-aa6f4d329290" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_de7157ff-6dad-465e-84b9-6ab46d5e75f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:to="loc_us-gaap_ComputerEquipmentMember_de7157ff-6dad-465e-84b9-6ab46d5e75f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_80a81675-6b71-4882-8984-62ad12a9429c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:to="loc_us-gaap_EquipmentMember_80a81675-6b71-4882-8984-62ad12a9429c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4df30023-9955-4cdd-9a33-c5869187bcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4df30023-9955-4cdd-9a33-c5869187bcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4a83cbd3-c1d4-4c48-a4b9-05bc31036114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4a83cbd3-c1d4-4c48-a4b9-05bc31036114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_aaafc540-fca7-4819-9150-616508a4c2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7021b1-0c53-4e7e-9a13-f89d1fb87f2f" xlink:to="loc_us-gaap_ConstructionInProgressMember_aaafc540-fca7-4819-9150-616508a4c2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f59ee49-2eb6-4b18-bddd-ec26f57aaca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9ed33b38-f65f-475e-a0fd-27c41570f847" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f59ee49-2eb6-4b18-bddd-ec26f57aaca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_73e2c7b6-c183-4ca3-9081-531e0ad0ba45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f59ee49-2eb6-4b18-bddd-ec26f57aaca4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_73e2c7b6-c183-4ca3-9081-531e0ad0ba45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9a5b0d9a-1b37-4d6f-a088-8d1e8a52bd34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f59ee49-2eb6-4b18-bddd-ec26f57aaca4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9a5b0d9a-1b37-4d6f-a088-8d1e8a52bd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5d4c9dc0-c0ec-4472-a0db-b4b78cd0d5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f59ee49-2eb6-4b18-bddd-ec26f57aaca4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5d4c9dc0-c0ec-4472-a0db-b4b78cd0d5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9329c763-b6c3-498e-ac93-1883f6d4d7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f59ee49-2eb6-4b18-bddd-ec26f57aaca4" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9329c763-b6c3-498e-ac93-1883f6d4d7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ec3cfbae-c159-40e8-8644-bb8989b0a6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_b8b87dde-56a9-42ce-bfb3-2f2680500c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ec3cfbae-c159-40e8-8644-bb8989b0a6b1" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_b8b87dde-56a9-42ce-bfb3-2f2680500c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_168fa990-36b0-44a2-8750-f98b58c8280f" xlink:href="advm-20220930.xsd#advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ec3cfbae-c159-40e8-8644-bb8989b0a6b1" xlink:to="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_168fa990-36b0-44a2-8750-f98b58c8280f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_999ca74d-7be5-4624-b358-19f6097c55da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ec3cfbae-c159-40e8-8644-bb8989b0a6b1" xlink:to="loc_us-gaap_TaxesPayableCurrent_999ca74d-7be5-4624-b358-19f6097c55da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0a251d58-6afc-43c4-a0b9-dd805099b76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ec3cfbae-c159-40e8-8644-bb8989b0a6b1" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0a251d58-6afc-43c4-a0b9-dd805099b76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f73c9ead-218d-46b7-a387-e8bf718046d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ec3cfbae-c159-40e8-8644-bb8989b0a6b1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f73c9ead-218d-46b7-a387-e8bf718046d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_edbb004b-f030-4620-9604-22f9353cb868" xlink:href="advm-20220930.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ec3cfbae-c159-40e8-8644-bb8989b0a6b1" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_edbb004b-f030-4620-9604-22f9353cb868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_71b8fc16-2903-4c4e-892e-ce261701c09f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_1c65ab58-2a65-413b-8f79-f4df78f8e953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_71b8fc16-2903-4c4e-892e-ce261701c09f" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_1c65ab58-2a65-413b-8f79-f4df78f8e953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_fb5f991c-799b-497e-a05c-540033dadcec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_71b8fc16-2903-4c4e-892e-ce261701c09f" xlink:to="loc_us-gaap_SubleaseIncome_fb5f991c-799b-497e-a05c-540033dadcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_531ff1f7-faa2-4802-957e-97f77a0600db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ec823d8-f8eb-42d0-b30e-a1418a010689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_531ff1f7-faa2-4802-957e-97f77a0600db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ec823d8-f8eb-42d0-b30e-a1418a010689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9cf845ac-d62b-446a-999b-8f3e2ed55b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ec823d8-f8eb-42d0-b30e-a1418a010689" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9cf845ac-d62b-446a-999b-8f3e2ed55b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f1e24d50-9f08-48f9-ba0e-8fc4e474972f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ec823d8-f8eb-42d0-b30e-a1418a010689" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f1e24d50-9f08-48f9-ba0e-8fc4e474972f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d47a3cf1-784e-4a27-becf-665c79c87362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ec823d8-f8eb-42d0-b30e-a1418a010689" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d47a3cf1-784e-4a27-becf-665c79c87362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a6413af2-b525-404a-bbf7-2d3850fc7920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ec823d8-f8eb-42d0-b30e-a1418a010689" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a6413af2-b525-404a-bbf7-2d3850fc7920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_807f38fd-88a5-47f2-a5a1-e08e225d628c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ec823d8-f8eb-42d0-b30e-a1418a010689" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_807f38fd-88a5-47f2-a5a1-e08e225d628c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_15064465-539d-4672-870f-6396548e6eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ec823d8-f8eb-42d0-b30e-a1418a010689" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_15064465-539d-4672-870f-6396548e6eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aae22c70-d70f-450f-8a0d-3e2bb33e514e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_531ff1f7-faa2-4802-957e-97f77a0600db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aae22c70-d70f-450f-8a0d-3e2bb33e514e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e0cf4191-7144-40ed-b9fb-a9b5afa1b0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aae22c70-d70f-450f-8a0d-3e2bb33e514e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e0cf4191-7144-40ed-b9fb-a9b5afa1b0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4914c5e8-346f-4f75-9a9c-836b45ad5f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aae22c70-d70f-450f-8a0d-3e2bb33e514e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4914c5e8-346f-4f75-9a9c-836b45ad5f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8604b8a4-8e5e-410a-8f9b-787e392c76f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aae22c70-d70f-450f-8a0d-3e2bb33e514e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8604b8a4-8e5e-410a-8f9b-787e392c76f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_769876ab-f3dc-4208-9501-1ac94266dab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aae22c70-d70f-450f-8a0d-3e2bb33e514e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_769876ab-f3dc-4208-9501-1ac94266dab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c4b941fb-0467-47d8-9ea0-618a3aba4933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aae22c70-d70f-450f-8a0d-3e2bb33e514e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c4b941fb-0467-47d8-9ea0-618a3aba4933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0d083388-9f53-4166-8e13-05c1d64c2381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aae22c70-d70f-450f-8a0d-3e2bb33e514e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0d083388-9f53-4166-8e13-05c1d64c2381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#EquityIncentiveAwardsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9eefd57d-20f9-49de-b2dc-fb73979d0e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b15b681c-2a3b-48e6-b5a8-4934abc8c09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9eefd57d-20f9-49de-b2dc-fb73979d0e78" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b15b681c-2a3b-48e6-b5a8-4934abc8c09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a4d97347-08a8-425a-aae1-cf90c1073809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b15b681c-2a3b-48e6-b5a8-4934abc8c09d" xlink:to="loc_us-gaap_AwardTypeAxis_a4d97347-08a8-425a-aae1-cf90c1073809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9821d81e-e2f9-464c-9140-30ac2467d48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a4d97347-08a8-425a-aae1-cf90c1073809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9821d81e-e2f9-464c-9140-30ac2467d48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_62336c4b-5f79-4035-8762-df8c2ae665b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9821d81e-e2f9-464c-9140-30ac2467d48c" xlink:to="loc_us-gaap_PerformanceSharesMember_62336c4b-5f79-4035-8762-df8c2ae665b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45bd277a-af7c-4beb-93c3-63ebd64898fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b15b681c-2a3b-48e6-b5a8-4934abc8c09d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45bd277a-af7c-4beb-93c3-63ebd64898fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd6d19ed-36ca-4aae-ab51-59c9f8baaee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45bd277a-af7c-4beb-93c3-63ebd64898fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd6d19ed-36ca-4aae-ab51-59c9f8baaee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8b0733b4-a497-4e81-ab05-e51f4f478a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45bd277a-af7c-4beb-93c3-63ebd64898fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8b0733b4-a497-4e81-ab05-e51f4f478a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9e82594-1900-4276-912d-5d3539c8b877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d83793bb-6ce0-418d-8499-3bc08509cb58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9e82594-1900-4276-912d-5d3539c8b877" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d83793bb-6ce0-418d-8499-3bc08509cb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e8e3342a-f9c3-4fff-96f7-17bf72ed5c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d83793bb-6ce0-418d-8499-3bc08509cb58" xlink:to="loc_us-gaap_AwardTypeAxis_e8e3342a-f9c3-4fff-96f7-17bf72ed5c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a834766f-01e5-4050-8314-572c6f5d0ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e8e3342a-f9c3-4fff-96f7-17bf72ed5c9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a834766f-01e5-4050-8314-572c6f5d0ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b8d2dbec-2244-47ae-9b94-305bc85c177a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a834766f-01e5-4050-8314-572c6f5d0ca2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b8d2dbec-2244-47ae-9b94-305bc85c177a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd52875c-1345-487a-be6b-9d29f49bb998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d83793bb-6ce0-418d-8499-3bc08509cb58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd52875c-1345-487a-be6b-9d29f49bb998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b576578-56d2-4d9f-a1bb-f44ff6c2318f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd52875c-1345-487a-be6b-9d29f49bb998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b576578-56d2-4d9f-a1bb-f44ff6c2318f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e39d1aa0-5a0b-414a-969a-93917a9d6bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b576578-56d2-4d9f-a1bb-f44ff6c2318f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e39d1aa0-5a0b-414a-969a-93917a9d6bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0c344039-e7a1-4bf3-acae-8654a3eeb475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b576578-56d2-4d9f-a1bb-f44ff6c2318f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0c344039-e7a1-4bf3-acae-8654a3eeb475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_66efe3bf-bdd6-4774-ba54-6f8d237a8f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b576578-56d2-4d9f-a1bb-f44ff6c2318f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_66efe3bf-bdd6-4774-ba54-6f8d237a8f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4418bd3e-ade2-4c0c-ab0a-884d434b2d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b576578-56d2-4d9f-a1bb-f44ff6c2318f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4418bd3e-ade2-4c0c-ab0a-884d434b2d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb2d37bd-8a3c-4c3c-87cc-61e531509bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b576578-56d2-4d9f-a1bb-f44ff6c2318f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb2d37bd-8a3c-4c3c-87cc-61e531509bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5178aed4-0c0f-4f2d-9be3-475a21d3a7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd52875c-1345-487a-be6b-9d29f49bb998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5178aed4-0c0f-4f2d-9be3-475a21d3a7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b449062-049e-4181-834b-6d2d03af34b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5178aed4-0c0f-4f2d-9be3-475a21d3a7b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b449062-049e-4181-834b-6d2d03af34b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75089e01-a1ff-48ac-9b10-8d8f3788eb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5178aed4-0c0f-4f2d-9be3-475a21d3a7b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75089e01-a1ff-48ac-9b10-8d8f3788eb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_e3fd8b2a-215e-40b6-b71f-f8883461f25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5178aed4-0c0f-4f2d-9be3-475a21d3a7b1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_e3fd8b2a-215e-40b6-b71f-f8883461f25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fa8c0946-7657-488a-93ce-ba4eade6685e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5178aed4-0c0f-4f2d-9be3-475a21d3a7b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fa8c0946-7657-488a-93ce-ba4eade6685e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2f685e4-8ac2-458a-aa83-bd195ee490b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5178aed4-0c0f-4f2d-9be3-475a21d3a7b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2f685e4-8ac2-458a-aa83-bd195ee490b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a30caee3-8b80-48d9-be28-dac67dde01ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3a8752f3-e298-4904-a037-51a9ec73642e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a30caee3-8b80-48d9-be28-dac67dde01ee" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3a8752f3-e298-4904-a037-51a9ec73642e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_efcd5d4d-b567-44b4-bf03-7e462afb42fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3a8752f3-e298-4904-a037-51a9ec73642e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_efcd5d4d-b567-44b4-bf03-7e462afb42fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c322a3a2-2601-4635-946f-2a6fb111e44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_efcd5d4d-b567-44b4-bf03-7e462afb42fc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c322a3a2-2601-4635-946f-2a6fb111e44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5a26e57c-9cf2-4aa4-826c-503359cac049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c322a3a2-2601-4635-946f-2a6fb111e44f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5a26e57c-9cf2-4aa4-826c-503359cac049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5e4fb5b6-71da-444e-a95e-abce3bbf80af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c322a3a2-2601-4635-946f-2a6fb111e44f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5e4fb5b6-71da-444e-a95e-abce3bbf80af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f376f2a8-d7b5-4424-9fea-70008b9cc755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3a8752f3-e298-4904-a037-51a9ec73642e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f376f2a8-d7b5-4424-9fea-70008b9cc755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_39d81f19-9984-4c8b-9702-5c4000b3812c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f376f2a8-d7b5-4424-9fea-70008b9cc755" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_39d81f19-9984-4c8b-9702-5c4000b3812c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_44c6cf91-485a-4f02-819c-c392c91352ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98d3f49d-917a-4868-a0f2-c8b52b495a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_44c6cf91-485a-4f02-819c-c392c91352ad" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98d3f49d-917a-4868-a0f2-c8b52b495a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_99cadbf9-05db-429e-bfda-7f01c8c2d23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98d3f49d-917a-4868-a0f2-c8b52b495a94" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_99cadbf9-05db-429e-bfda-7f01c8c2d23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6181b4-c96c-491a-befe-33eed6096292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_99cadbf9-05db-429e-bfda-7f01c8c2d23f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6181b4-c96c-491a-befe-33eed6096292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5f17ca82-1c0b-4108-9ccd-24b9f3e9cd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6181b4-c96c-491a-befe-33eed6096292" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5f17ca82-1c0b-4108-9ccd-24b9f3e9cd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_686bdffe-77f9-4609-8333-25168e5d3eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6181b4-c96c-491a-befe-33eed6096292" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_686bdffe-77f9-4609-8333-25168e5d3eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c2e8cfc5-6c7c-4d27-91de-5c23a733f459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6181b4-c96c-491a-befe-33eed6096292" xlink:to="loc_us-gaap_EmployeeStockMember_c2e8cfc5-6c7c-4d27-91de-5c23a733f459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_318b2bcc-6fde-49ab-aaa1-1bcacbfe50f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_98d3f49d-917a-4868-a0f2-c8b52b495a94" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_318b2bcc-6fde-49ab-aaa1-1bcacbfe50f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_72b1890c-9479-44c8-a1bf-dceaac7a6658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_318b2bcc-6fde-49ab-aaa1-1bcacbfe50f2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_72b1890c-9479-44c8-a1bf-dceaac7a6658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#RestructuringAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RestructuringAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9ac81253-c40a-46af-8988-8f8cf53e3948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8dd76460-2cac-4ba2-825f-ae2642b2813a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9ac81253-c40a-46af-8988-8f8cf53e3948" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8dd76460-2cac-4ba2-825f-ae2642b2813a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_13381393-b272-479e-9643-8443b2e11602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8dd76460-2cac-4ba2-825f-ae2642b2813a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_13381393-b272-479e-9643-8443b2e11602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8a1729c3-52cc-40ec-b083-64fcc3d0d8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13381393-b272-479e-9643-8443b2e11602" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8a1729c3-52cc-40ec-b083-64fcc3d0d8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f0088780-cead-4da9-895f-eff64054cccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8a1729c3-52cc-40ec-b083-64fcc3d0d8c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f0088780-cead-4da9-895f-eff64054cccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_da7acb47-1eb3-45d1-aae9-58ef0b0b6401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8a1729c3-52cc-40ec-b083-64fcc3d0d8c7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_da7acb47-1eb3-45d1-aae9-58ef0b0b6401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_92d7696e-1bf8-4fbc-8935-d2bd9fd30c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8dd76460-2cac-4ba2-825f-ae2642b2813a" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_92d7696e-1bf8-4fbc-8935-d2bd9fd30c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_70d5b98d-7aee-44d2-9c14-be9547f0bd08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_92d7696e-1bf8-4fbc-8935-d2bd9fd30c89" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_70d5b98d-7aee-44d2-9c14-be9547f0bd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_3662e674-5996-472c-af69-2e78c17d649d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_92d7696e-1bf8-4fbc-8935-d2bd9fd30c89" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_3662e674-5996-472c-af69-2e78c17d649d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d475c2df-a714-4b58-abab-92be7f84655b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_92d7696e-1bf8-4fbc-8935-d2bd9fd30c89" xlink:to="loc_us-gaap_RestructuringCharges_d475c2df-a714-4b58-abab-92be7f84655b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_372c5fea-8548-41e6-96c0-ff1018a705a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_92d7696e-1bf8-4fbc-8935-d2bd9fd30c89" xlink:to="loc_us-gaap_PaymentsForRestructuring_372c5fea-8548-41e6-96c0-ff1018a705a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails" xlink:type="simple" xlink:href="advm-20220930.xsd#RestructuringScheduleofRestructuringCostDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_694422b3-cfe3-4a87-ad3b-033b00541aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_28f8a9fd-df00-44ee-a1ab-19f6e64700c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_694422b3-cfe3-4a87-ad3b-033b00541aa7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_28f8a9fd-df00-44ee-a1ab-19f6e64700c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_52487aac-26a4-43d0-a97e-a86b606b079c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_28f8a9fd-df00-44ee-a1ab-19f6e64700c7" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_52487aac-26a4-43d0-a97e-a86b606b079c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2105e134-5c66-44eb-9c90-25b24a83094d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_52487aac-26a4-43d0-a97e-a86b606b079c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2105e134-5c66-44eb-9c90-25b24a83094d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_a0c8ec51-4a94-498c-92ea-cc4b04f7cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2105e134-5c66-44eb-9c90-25b24a83094d" xlink:to="loc_us-gaap_EmployeeSeveranceMember_a0c8ec51-4a94-498c-92ea-cc4b04f7cd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_1a195d38-3299-4463-a169-965965ab8589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2105e134-5c66-44eb-9c90-25b24a83094d" xlink:to="loc_us-gaap_StockCompensationPlanMember_1a195d38-3299-4463-a169-965965ab8589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d6f904be-47a9-4911-aed9-e2f5b170eaca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_28f8a9fd-df00-44ee-a1ab-19f6e64700c7" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_d6f904be-47a9-4911-aed9-e2f5b170eaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_4e40eaf1-781e-4ecb-a97e-f5f8d85e2bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d6f904be-47a9-4911-aed9-e2f5b170eaca" xlink:to="loc_us-gaap_RestructuringReserveRollForward_4e40eaf1-781e-4ecb-a97e-f5f8d85e2bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c9548dc5-c6fb-4c19-b420-5209d1741ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_4e40eaf1-781e-4ecb-a97e-f5f8d85e2bcb" xlink:to="loc_us-gaap_RestructuringReserve_c9548dc5-c6fb-4c19-b420-5209d1741ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ee7b6a5d-e51e-40e4-8dba-025ccca88ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_4e40eaf1-781e-4ecb-a97e-f5f8d85e2bcb" xlink:to="loc_us-gaap_RestructuringCharges_ee7b6a5d-e51e-40e4-8dba-025ccca88ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_31b2e758-5cb4-4c9d-bb4e-d0d494c898f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_4e40eaf1-781e-4ecb-a97e-f5f8d85e2bcb" xlink:to="loc_us-gaap_PaymentsForRestructuring_31b2e758-5cb4-4c9d-bb4e-d0d494c898f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_48dc26f5-f4c2-44bc-aae4-728e006fefda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_4e40eaf1-781e-4ecb-a97e-f5f8d85e2bcb" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_48dc26f5-f4c2-44bc-aae4-728e006fefda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_d683f1ed-556f-4133-b058-7a4ee449b9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_4e40eaf1-781e-4ecb-a97e-f5f8d85e2bcb" xlink:to="loc_us-gaap_RestructuringReserve_d683f1ed-556f-4133-b058-7a4ee449b9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976123887360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adverum Biotechnologies, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5258327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Cardinal Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">656-9323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,729,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976124138896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 84,430<span></span>
</td>
<td class="nump">$ 34,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">118,834<span></span>
</td>
<td class="nump">270,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveToLessee', window );">Lease incentive receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,979<span></span>
</td>
<td class="nump">6,248<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">213,243<span></span>
</td>
<td class="nump">317,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">79,882<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">36,579<span></span>
</td>
<td class="nump">33,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentReceivablesNet', window );">Deferred rent receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Deposit and other long-term assets</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">332,362<span></span>
</td>
<td class="nump">439,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">846<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">16,539<span></span>
</td>
<td class="nump">18,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">11,236<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">28,621<span></span>
</td>
<td class="nump">21,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">94,464<span></span>
</td>
<td class="nump">101,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">940<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">124,025<span></span>
</td>
<td class="nump">123,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">980,156<span></span>
</td>
<td class="nump">964,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,953)<span></span>
</td>
<td class="num">(714)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(769,876)<span></span>
</td>
<td class="num">(648,076)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">208,337<span></span>
</td>
<td class="nump">316,185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 332,362<span></span>
</td>
<td class="nump">$ 439,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental income recognized over rental payment required by lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123394697&amp;loc=d3e40879-112712<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveToLessee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive granted by lessor to lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40010-112707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40019-112707<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123388062&amp;loc=SL77916639-209961<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveToLessee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976123992288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">23,849<span></span>
</td>
<td class="nump">24,069<span></span>
</td>
<td class="nump">77,078<span></span>
</td>
<td class="nump">66,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">17,188<span></span>
</td>
<td class="nump">14,453<span></span>
</td>
<td class="nump">46,117<span></span>
</td>
<td class="nump">52,546<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">41,037<span></span>
</td>
<td class="nump">38,522<span></span>
</td>
<td class="nump">123,195<span></span>
</td>
<td class="nump">119,203<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(41,037)<span></span>
</td>
<td class="num">(38,522)<span></span>
</td>
<td class="num">(123,195)<span></span>
</td>
<td class="num">(111,703)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(40,114)<span></span>
</td>
<td class="num">(38,362)<span></span>
</td>
<td class="num">(121,745)<span></span>
</td>
<td class="num">(111,131)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(40,131)<span></span>
</td>
<td class="num">(38,362)<span></span>
</td>
<td class="num">(121,800)<span></span>
</td>
<td class="num">(111,131)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized loss on marketable securities</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(1,189)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (40,288)<span></span>
</td>
<td class="num">$ (38,468)<span></span>
</td>
<td class="num">$ (123,039)<span></span>
</td>
<td class="num">$ (111,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share &#8212; basic (in USD per share)</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="num">$ (1.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share &#8212; diluted (in USD per share)</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="num">$ (1.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares used to compute net loss per share - basic (in shares)</a></td>
<td class="nump">99,475<span></span>
</td>
<td class="nump">98,126<span></span>
</td>
<td class="nump">99,027<span></span>
</td>
<td class="nump">97,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares used to compute net loss per share - diluted (in shares)</a></td>
<td class="nump">99,475<span></span>
</td>
<td class="nump">98,126<span></span>
</td>
<td class="nump">99,027<span></span>
</td>
<td class="nump">97,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976121759776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss)/Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 434,347<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 937,134<span></span>
</td>
<td class="num">$ (261)<span></span>
</td>
<td class="num">$ (502,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">1,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,436)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,436)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">414,820<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">946,098<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="num">(530,972)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">434,347<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">937,134<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="num">(502,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(111,131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">346,000<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">960,180<span></span>
</td>
<td class="num">(523)<span></span>
</td>
<td class="num">(613,667)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">414,820<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">946,098<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="num">(530,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">8,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, additional issuance costs</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,333)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">379,142<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">954,854<span></span>
</td>
<td class="num">(417)<span></span>
</td>
<td class="num">(575,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(38,362)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,362)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">346,000<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">960,180<span></span>
</td>
<td class="num">(523)<span></span>
</td>
<td class="num">(613,667)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">316,185<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">964,965<span></span>
</td>
<td class="num">(714)<span></span>
</td>
<td class="num">(648,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(37,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,908)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,767,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">282,952<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">970,349<span></span>
</td>
<td class="num">(1,423)<span></span>
</td>
<td class="num">(685,984)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 316,185<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">964,965<span></span>
</td>
<td class="num">(714)<span></span>
</td>
<td class="num">(648,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(1,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(121,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,728,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">208,337<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">980,156<span></span>
</td>
<td class="num">(1,953)<span></span>
</td>
<td class="num">(769,876)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,767,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">282,952<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">970,349<span></span>
</td>
<td class="num">(1,423)<span></span>
</td>
<td class="num">(685,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,761)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">244,122<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">975,653<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
<td class="num">(729,745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(40,131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,131)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,728,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 208,337<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 980,156<span></span>
</td>
<td class="num">$ (1,953)<span></span>
</td>
<td class="num">$ (769,876)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976122830480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976124011520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (121,800)<span></span>
</td>
<td class="num">$ (111,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,816<span></span>
</td>
<td class="nump">3,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">14,826<span></span>
</td>
<td class="nump">20,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium and accrued interest on marketable securities</a></td>
<td class="num">(277)<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">2,011<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(1,526)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,468)<span></span>
</td>
<td class="num">(3,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">864<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">3,092<span></span>
</td>
<td class="nump">2,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(543)<span></span>
</td>
<td class="num">(587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(272)<span></span>
</td>
<td class="nump">3,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable', window );">Lease liability and lease incentive receivable</a></td>
<td class="nump">12,505<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(89,616)<span></span>
</td>
<td class="num">(82,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(81,782)<span></span>
</td>
<td class="num">(328,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">232,899<span></span>
</td>
<td class="nump">384,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(11,631)<span></span>
</td>
<td class="num">(10,771)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">139,486<span></span>
</td>
<td class="nump">54,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offerings of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock pursuant to option exercises</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="nump">50,235<span></span>
</td>
<td class="num">(25,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">36,698<span></span>
</td>
<td class="nump">63,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">86,933<span></span>
</td>
<td class="nump">38,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">84,430<span></span>
</td>
<td class="nump">32,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">5,284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">86,933<span></span>
</td>
<td class="nump">38,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of noncash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_RemeasurementOfOperatingLeaseRightOfUseAssets', window );">Remeasurement of operating right-of-use assets</a></td>
<td class="nump">2,842<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed assets in accounts payable, accrued expenses and other current liabilities</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">$ 2,675<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease liabilities and lease incentive receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Operating Lease Right-of-use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_RemeasurementOfOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement Of Operating Lease Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_RemeasurementOfOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976126802704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or &#8220;Adverum&#8221;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $769.9 million as of September&#160;30, 2022. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of September&#160;30, 2022, the Company had cash, cash equivalents and short-term investments of $203.3 million, which the Company believes will be sufficient to fund its operations for at least twelve months from the date of issuance of these financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s consolidated financial information. The results of operations for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2021 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976122876976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topic 326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company on January 1, 2023. Early adoption is permitted. The Company does not expect the effect of adoption to be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976122785744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value Measurements and Fair Value of Financial Instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance on the fair value hierarchy for disclosure of fair value measurements is as follows:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, and corporate bonds are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,817&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,987)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,502)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, $9.6 million of marketable securities have a remaining maturity between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMzg0ODI5MDcwMTczOQ_6a3d187e-f234-4fd7-9010-35776946dddc">one</span> and two years. The remainder of the marketable securities have a remaining maturity of less than one year. Management regularly reviews all of the Company&#8217;s investments for other-than-temporary declines in estimated fair value. The aggregate fair value of the marketable securities in an unrealized loss position as of September&#160;30, 2022 was $167.9&#160;million, which are highly liquid funds with high credit ratings that have final maturity of less than two years from date of purchase. Management determined that the gross unrealized losses on the Company&#8217;s marketable securities as of September&#160;30, 2022 were temporary. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. Management concluded that none of the Company&#8217;s marketable securities were other-than-temporarily impaired as of September&#160;30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, the Company performed an impairment test to measure certain laboratory equipment at fair value. The assets are measured at fair value using Level 3 inputs on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable. Refer to Note 4, Balance Sheet Components for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976122812640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,973&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,579&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,060&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an impairment analysis for certain laboratory equipment assets based on the identification of impairment indicators during the nine months ended September&#160;30, 2022. The analysis determined that the fair value of the assets, which was determined using a market approach, was lower than the carrying value. As a result of the evaluation, an impairment charge of $2.0 million was recognized for the nine months ended September&#160;30, 2022. The assets indicated as impaired were written down to their estimated fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical, clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,539&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976122847984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LeasesSublease income for operating leases is recognized on a straight-line basis over the lease term and is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. In the three months ended September&#160;30, 2022, the Company reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. The Company assessed the collectability to be less than probable and recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses in the three and nine month periods ended September&#160;30, 2022. The deferred rent receivable as of December 31, 2021 and September 30, 2022 was $0.8&#160;million and zero, respectively. As a result of the adjustment to eliminate the deferred rent receivable, sublease income for the three and nine months ended September 30, 2022 was a negative $4.1&#160;million and a negative $0.8&#160;million, respectively<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976122767728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Equity Incentive Awards</a></td>
<td class="text">Equity Incentive Awards<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s option activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,302&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.71&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the nine months ended September&#160;30, 2022 include 2.5&#160;million shares of performance-based non-qualified options with both performance and service vesting conditions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSUs activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant-<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted during the nine months ended September&#160;30, 2022 include 0.4 million shares of performance units with both performance and service vesting conditions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.332%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,826&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976122891472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, rights under the employee stock purchase plan (&#8220;ESPP&#8221;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,859</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,593</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,852&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976122785744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize its clinical development of ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, and focus its pipeline strategy on certain highly prevalent ocular diseases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the restructuring plan, the Company reduced its workforce by 75 employees (approximately 37%) as of July 6, 2022. Below is a summary of restructuring costs during the nine months ended September&#160;30, 2022 and accrued restructuring costs as of September&#160;30, 2022 :</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Benefits Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock-Based Compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments made</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the three and nine months ended September 30, 2022, the Company recorded $4.7&#160;million of restructuring costs, of which $3.7&#160;million was classified as research and development expenses and $1.0&#160;million was classified as general and administrative expenses. Substantially all of the restructuring costs were incurred during the three months ended September&#160;30, 2022, of which $4.5&#160;million were paid. The Company expects the restructuring to be completed in the fourth quarter of 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976123871664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s consolidated financial information. The results of operations for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2021 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. </span>The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topic 326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company on January 1, 2023. Early adoption is permitted. The Company does not expect the effect of adoption to be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976122785744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash Equivalents and Short-term Investments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,817&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,987)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,502)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976122755712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,973&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,579&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,060&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical, clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,539&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976123878032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s option activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,302&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.71&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSUs activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant-<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.332%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,826&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976122876976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,859</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,593</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,852&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976122831040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring Cost</a></td>
<td class="text">Below is a summary of restructuring costs during the nine months ended September&#160;30, 2022 and accrued restructuring costs as of September&#160;30, 2022 :<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Benefits Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock-Based Compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments made</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976123442000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 769,876<span></span>
</td>
<td class="nump">$ 648,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 203,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976121449376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 120,336<span></span>
</td>
<td class="nump">$ 271,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,502)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">118,834<span></span>
</td>
<td class="nump">270,993<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_CashAndCashEquivalentAmortizedCost', window );">Less: cash equivalents, amortized cost basis</a></td>
<td class="num">(72,987)<span></span>
</td>
<td class="num">(25,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedGain', window );">Less: cash equivalents, unrealized gains</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedLoss', window );">Less: cash equivalents, unrealized losses</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Less: cash equivalents, estimated fair value</a></td>
<td class="num">(72,983)<span></span>
</td>
<td class="num">(25,807)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">10,074<span></span>
</td>
<td class="nump">10,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">10,074<span></span>
</td>
<td class="nump">10,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government and agency securities | Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">81,323<span></span>
</td>
<td class="nump">62,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,165)<span></span>
</td>
<td class="num">(218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">80,160<span></span>
</td>
<td class="nump">62,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">99,867<span></span>
</td>
<td class="nump">177,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(294)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">99,573<span></span>
</td>
<td class="nump">177,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">2,059<span></span>
</td>
<td class="nump">47,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,010<span></span>
</td>
<td class="nump">47,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember', window );">Total cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">193,323<span></span>
</td>
<td class="nump">297,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,508)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 191,817<span></span>
</td>
<td class="nump">$ 296,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent amortized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent gross unrealized gain.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent gross unrealized loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976123806384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears', window );">Marketable securities</a></td>
<td class="nump">$ 9,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Marketable securities in an unrealized loss</a></td>
<td class="nump">167,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities', window );">Marketable securities other-than-temporarily impaired</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Marketable securities term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Marketable securities term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other than temporary impaired investments available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976047125728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 53,973<span></span>
</td>
<td class="nump">$ 46,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(17,394)<span></span>
</td>
<td class="num">(13,174)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">36,579<span></span>
</td>
<td class="nump">33,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Asset impairment charge</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">16,368<span></span>
</td>
<td class="nump">12,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">34,336<span></span>
</td>
<td class="nump">26,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,076<span></span>
</td>
<td class="nump">$ 4,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976045268864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation</a></td>
<td class="nump">$ 8,604<span></span>
</td>
<td class="nump">$ 9,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts', window );">Accrued nonclinical, clinical and process development costs</a></td>
<td class="nump">6,580<span></span>
</td>
<td class="nump">4,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">State income tax payable</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 16,539<span></span>
</td>
<td class="nump">$ 18,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical clinical and development process costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976123302896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentReceivablesNet', window );">Deferred rent receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Negative sublease income</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental income recognized over rental payment required by lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123394697&amp;loc=d3e40879-112712<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976047048000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Summary of Stock Options Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">13,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">10,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares) | shares</a></td>
<td class="num">(4,644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">19,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">5,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Grant- Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 9.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in USD per share) | $ / shares</a></td>
<td class="nump">1.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in USD per share) | $ / shares</a></td>
<td class="nump">0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">5.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">5.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in USD per share) | $ / shares</a></td>
<td class="nump">$ 11.71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976124115536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Additional Information (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">10,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="nump">400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976123838560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Summary of Restricted Stock Units Activity (Details) - Restricted stock units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">2,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(426)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">1,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Grant- Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 3.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">1.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested and released (in USD per share) | $ / shares</a></td>
<td class="nump">3.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">3.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 2.92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976121545328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,503<span></span>
</td>
<td class="nump">$ 5,326<span></span>
</td>
<td class="nump">$ 14,826<span></span>
</td>
<td class="nump">$ 20,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,432<span></span>
</td>
<td class="nump">2,207<span></span>
</td>
<td class="nump">5,195<span></span>
</td>
<td class="nump">7,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,071<span></span>
</td>
<td class="nump">$ 3,119<span></span>
</td>
<td class="nump">$ 9,631<span></span>
</td>
<td class="nump">$ 13,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976045270624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">21,705<span></span>
</td>
<td class="nump">16,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">19,221<span></span>
</td>
<td class="nump">13,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">1,724<span></span>
</td>
<td class="nump">2,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">760<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976121542752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 06, 2022 </div>
<div>employee</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate', window );">Number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent', window );">Number of employees percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Restructuring cost paid</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">4,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139976121717728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schedule of Restructuring Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring cost, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments made</a></td>
<td class="num">$ (4,500)<span></span>
</td>
<td class="num">(4,539)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring cost, ending balance</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance and Benefits Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring cost, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,539)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring cost, ending balance</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_StockCompensationPlanMember', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring cost, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring cost, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>advm-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:advm="http://www.adverum.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="advm-20220930.xsd" xlink:type="simple"/>
    <context id="i212f30cf841742a9837912319faa7a3f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0f50a0d4c90547b5a6e67d46b4c5995e_I20221104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="ieb2df3a435684436bddd5c51c154a23a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i44433fe8d4104d3a83fe0df026333455_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d6f32550ba1434c9e67090a8d16b28e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9842733bcbb49b2ac6dd8ef51160cf1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67846955d203444991996f8db5938a69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5fc4612654aa4870acef5f852550d561_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if0eb628814a04ad8971209780bc02232_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifc0d4ed39fb04b2089aee2f3e0739e42_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i00ced84e48d142babc4e6edcc897094a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia22a80d1fae54e15bac4c1582f12e26e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5d3a4780987e4e9692fdafbb646d0e5a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib5d6b6204c994327981fb6f38ee2e5ff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6e35090827424e029a917e87a3044012_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib90a0153e711486598954353cda4c4f6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia61c0616a34746bf8b0475dd12eece06_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6f8b7aaa691944a4a550b8ced951db24_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i972d3044b3264665a366176257e6f0a4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i65bbe7741c5844b19b5542e8c5caf343_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i46e83442dc5749b0a5d1ad0026c402d2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if4af61eabf3d42e09f408fb99c2367e5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i96f851ab82a443b5a834a5415c2880e0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i65c2b4e4a1b54fdf897b4c3015a17e3f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id191c6d1957d4719b9c5e156e348e8db_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idbb610db5124447a81519c9fddb553ad_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i19622582a11f4462a48573d5c32fb7c5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6388d78a0f704f1c86da5e1f4c37aa33_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i47c31b7bd48c4503a19ac8602ddba6ff_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic047966dbeb843b496329bb693a66b72_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ice288f0d914a4d95915117eb965b9fc7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib238c3743368488b9eb8ed8b364431e9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i480b594590b940cd851f225ae27fd622_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i90ba8498524046978db9a015fa44aeab_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id4af913e76594eaa821e5e62c4699428_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idbfe14fd14dc46eeae6028be0bedb756_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0dda90e2dcb84f4abf4d236b758309c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic53d2c3285b2405c89747aede88daf77_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2061f8740354460fbd6fa9e20be2522a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6353d7b319d44289aff3a0e8fcae2bac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe95493f3b5a4dc5b74fbbfe667afede_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i121cdd6f1a6b4029901948f5a1c143d5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idebb246dffde4b12a9cd6c4cf9a7f620_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaefcad51308b4b3790bcf428575004c3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i94109faeb1f44d1da072d36ea355382d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i841267b2dc374ac3ad96e04341fb587a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia5269eef549e4b18bb64d22f1b54e0ca_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i37097774df59414a8b4fe74f0511d45f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i23eb60965e1a4ce59cc12982fa1fc9fa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0fe7ae56850e4431a1e91bc6167ef963_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i475232b6968b4298945132136bd68a2d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib1230d7a79cd43ca8b3d88d5b06de1db_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i609ae2740da044548ec7c4c368af7b51_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iceda05b2f1b4410faf5aca6a1f9cb9c0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id9921ca0a5094f0bac938ac91d53078a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i07da0e72c1be41e7aaf42551fd516c9f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7bd7d22674a0458b874208ec2cf0c887_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i851c8e2358684ae6b21b416e2330cb70_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3d43fd4cf2a549a0b04c2f34890cb7ff_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2e6eb7bc0bbc467bbdb22d47d409103f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a18ede15a1b47778e90d6d5c7bb304f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45935ce9978f46239a14318be6d6f2ae_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if9809e3ed4b544acb18ad2a9ef94d4fa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib5ff1d37342b4c27865fff03a63c60c8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1c37575b017e43bf9a8ac40ac84a9957_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i021fc47f853242c2be3df72c455d228f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0b517ce4be034b4db4fafa152857e3ae_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if94ce7427b6d4ad3bf65c204029b5bb5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2b38d8b71f5349f99b74f3e4bd7dfb70_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9a51274da0d34c37ad110f512dfb6c25_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib282142f99284b73981803c872356bd9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i873db4f7c8b74c7fadbdceb695e76de6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie3979c9c68184f3089401c14ce8a48c1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i791b55383c7c4814974ebaa3df5a5e64_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15d7519e0368492d811f7889f8f65003_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ebe063f5210487eb63855bfa84821b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b8a5bca20fd4ab780190fe9cbc37eb6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45214185b5144da5833b2593032606d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifcc1c37af20f4e43b05ad926c9e5ef3b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i516fa99e52e24c8d83b6da7334ab3f9a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id6877ebb93e445a3a2cefb8eb73f1d51_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ica79f5395f3b4b1ba885cad3da2e3411_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b8bf7bd53f54d4c801f071028410a38_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic95b4f1bc3f54077994fca5c6a6559a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9da0b7851f7b452aa126439ff59ef51a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2b828ba25c3d418d8eda881a27399aa8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20efbf626199415a933fd647730ef5bf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8313d8ae20774ec3899f99bacdb83cf8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3befe5528eac478382c46f05cfe1a877_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i073bece618d24b9dade2383ac940ee3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79d4b72dd8084e709d360860964f3246_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i576e4bb113d94eed83356af145669908_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iac1959e2c1824ece92a8a5edf1bfaac6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i29b93864200e4683b63e032b6c30feaa_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4d0ce2c0d4824b3893f8f9741ffe6466_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65531dff90074634acb629953b46148e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i74b15a520ab64b8ba0d52607a8761034_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if5cc515fb7324c88b70e0087f46cd446_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8482f95dee2f458a9ec19baa5f1da9dc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5ee3bd88ea5a4bfab2257c3d73958b7a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i76d9330c6a204905a56b7b28a34889ae_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8e1fbe5196e04b16b259d139c7ef556a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie986bf5a8039432c815e7e22b77b230a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i849c716b759343fb82104acfaafcf33f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i027ecc53eb374b44b0ff45c72b438658_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i058b41effd8f43b9be1d05aaf73dfe08_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0d479b8fb7b044e3aa6c6ab883f2dd7a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i16076e8ab5354387af2ac1ec6fc8cbdc_I20220706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-07-06</instant>
        </period>
    </context>
    <context id="i71258ef0094f45c882375b7e1010e7ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58f2678ad14b4a3d881b892b268a77d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22948541eb864302a316aae361adb856_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie0c3eb26c891436cabc497ed5bd59128_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1ad217fa80da4c1da3ead4e449ee044e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id96f08f18d8844938eb17eab71c615ff_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>advm:employee</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80L2ZyYWc6NzlkMGU4NzA1Y2Y2NDBhOGEyMGJlNjY3MGNmZDAwMzcvdGFibGU6MGNkOWRjYTYxODMzNDZhM2JkNTk4NmU2OWYwYjdmY2EvdGFibGVyYW5nZTowY2Q5ZGNhNjE4MzM0NmEzYmQ1OTg2ZTY5ZjBiN2ZjYV8zLTEtMS0xLTI5MDk1_a12e8df2-1891-44ab-a846-f4458e58748b">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80L2ZyYWc6NzlkMGU4NzA1Y2Y2NDBhOGEyMGJlNjY3MGNmZDAwMzcvdGFibGU6MGNkOWRjYTYxODMzNDZhM2JkNTk4NmU2OWYwYjdmY2EvdGFibGVyYW5nZTowY2Q5ZGNhNjE4MzM0NmEzYmQ1OTg2ZTY5ZjBiN2ZjYV80LTEtMS0xLTI5MDk1_01ca5eb1-efb3-4197-94f8-686b94ad1c74">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80L2ZyYWc6NzlkMGU4NzA1Y2Y2NDBhOGEyMGJlNjY3MGNmZDAwMzcvdGFibGU6MGNkOWRjYTYxODMzNDZhM2JkNTk4NmU2OWYwYjdmY2EvdGFibGVyYW5nZTowY2Q5ZGNhNjE4MzM0NmEzYmQ1OTg2ZTY5ZjBiN2ZjYV81LTEtMS0xLTI5MDk1_bbfcb86e-493c-4a9e-892c-b3175c40ba66">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80L2ZyYWc6NzlkMGU4NzA1Y2Y2NDBhOGEyMGJlNjY3MGNmZDAwMzcvdGFibGU6MGNkOWRjYTYxODMzNDZhM2JkNTk4NmU2OWYwYjdmY2EvdGFibGVyYW5nZTowY2Q5ZGNhNjE4MzM0NmEzYmQ1OTg2ZTY5ZjBiN2ZjYV82LTEtMS0xLTI5MDk1_95a93698-8ecb-4387-8342-46f473319bd2">0001501756</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80L2ZyYWc6NzlkMGU4NzA1Y2Y2NDBhOGEyMGJlNjY3MGNmZDAwMzcvdGFibGU6MGNkOWRjYTYxODMzNDZhM2JkNTk4NmU2OWYwYjdmY2EvdGFibGVyYW5nZTowY2Q5ZGNhNjE4MzM0NmEzYmQ1OTg2ZTY5ZjBiN2ZjYV83LTEtMS0xLTI5MDk1_e5f83fef-4899-4849-968c-9fbd0324de5d">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ifcc1c37af20f4e43b05ad926c9e5ef3b_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMzg0ODI5MDcwMTczOQ_6a3d187e-f234-4fd7-9010-35776946dddc">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <dei:DocumentType
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDM2_edbf2aa1-3869-4380-97d9-5d95d5b8b3ff">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6MTZmZTBmNmI2NzcwNGY5YWE1M2QzNzc4YzRhN2Y5NjUvdGFibGVyYW5nZToxNmZlMGY2YjY3NzA0ZjlhYTUzZDM3NzhjNGE3Zjk2NV8wLTAtMS0xLTI5MDk1_672a6606-d7df-482e-a507-27a89cc2388f">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNjY_2ecef4d1-cb57-400e-baf2-84fb56e65884">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6NzFmZjQ3MWEzZDgyNDg2NmI1Njc2ZmRiMTE1MzZhNzAvdGFibGVyYW5nZTo3MWZmNDcxYTNkODI0ODY2YjU2NzZmZGIxMTUzNmE3MF8wLTAtMS0xLTI5MDk1_b08ef748-9c34-4e44-a0a1-b106e4dfdac2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDI5_270306e0-2f1e-4171-a0d7-b9dbcad8a7bd">001-36579</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDI1_7547b97a-d594-4a26-b4c3-d668ac7bfb09">Adverum Biotechnologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6MTk4M2I4NmYyZDFhNGZiMDgyZTQzNzgyZGNhYmM1ZTkvdGFibGVyYW5nZToxOTgzYjg2ZjJkMWE0ZmIwODJlNDM3ODJkY2FiYzVlOV8wLTAtMS0xLTI5MDk1_34c5dfc8-3de4-4719-8792-17db3eada0fb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6MTk4M2I4NmYyZDFhNGZiMDgyZTQzNzgyZGNhYmM1ZTkvdGFibGVyYW5nZToxOTgzYjg2ZjJkMWE0ZmIwODJlNDM3ODJkY2FiYzVlOV8wLTItMS0xLTI5MDk1_d327d595-ecd6-464b-b21e-28280e59fbf9">20-5258327</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDI2_cae1fad2-1797-40c7-aa3b-a62b0492a811">100 Cardinal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDIz_99eb7f8b-4a4f-4920-a431-a2ffb0508d78">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDI4_095698d0-2bb3-4dec-a8bd-d3f422d91534">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDMx_33967b27-0e85-49a1-82be-7676cc44bb7b">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF82OTk_1cc551f3-a9b7-4616-9f05-5ddd9863c569">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDMy_a5554e08-5062-4131-81e6-754d51c255b7">656-9323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6NmM4MzU4N2QzMjYwNDU0Yjg0MjNlZDFkOTljYmQxOTgvdGFibGVyYW5nZTo2YzgzNTg3ZDMyNjA0NTRiODQyM2VkMWQ5OWNiZDE5OF8xLTAtMS0xLTI5MDk1_b191dac3-3609-4c3b-ac4a-91e57451c381">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6NmM4MzU4N2QzMjYwNDU0Yjg0MjNlZDFkOTljYmQxOTgvdGFibGVyYW5nZTo2YzgzNTg3ZDMyNjA0NTRiODQyM2VkMWQ5OWNiZDE5OF8xLTEtMS0xLTI5MDk1_c01c513d-1cbe-44c7-ab61-0d845a18ba68">ADVM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6NmM4MzU4N2QzMjYwNDU0Yjg0MjNlZDFkOTljYmQxOTgvdGFibGVyYW5nZTo2YzgzNTg3ZDMyNjA0NTRiODQyM2VkMWQ5OWNiZDE5OF8xLTItMS0xLTI5MDk1_d100bb3b-8e75-49b3-ad5c-9424813fd249">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDI0_3ceb31ec-b409-4b07-95e8-a608bca6bc10">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDMz_d665cd6c-8d7e-423c-a22a-3c2cba99326f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6MGI1NzYxZjlmMGYxNDQ2YWI3NmU1NzU5Mzg0NzRlNTkvdGFibGVyYW5nZTowYjU3NjFmOWYwZjE0NDZhYjc2ZTU3NTkzODQ3NGU1OV8xLTAtMS0xLTI5MDk1_918c0deb-e2c9-482b-8dde-f9f7a64481db">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6MGI1NzYxZjlmMGYxNDQ2YWI3NmU1NzU5Mzg0NzRlNTkvdGFibGVyYW5nZTowYjU3NjFmOWYwZjE0NDZhYjc2ZTU3NTkzODQ3NGU1OV8xLTQtMS0xLTI5MDk1_125fbfe3-0830-4252-a3e7-035191748232">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGFibGU6MGI1NzYxZjlmMGYxNDQ2YWI3NmU1NzU5Mzg0NzRlNTkvdGFibGVyYW5nZTowYjU3NjFmOWYwZjE0NDZhYjc2ZTU3NTkzODQ3NGU1OV8yLTQtMS0xLTI5MDk1_f55838ed-4149-41e9-9303-2a31b3e3018a">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yNDM1_24c902ab-5f09-4964-9460-cb001b60bf5f">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0f50a0d4c90547b5a6e67d46b4c5995e_I20221104"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xL2ZyYWc6ZTRmNzJlYjUyNTk4NGVhZThhZTcwY2VlZDkxMzJmOTgvdGV4dHJlZ2lvbjplNGY3MmViNTI1OTg0ZWFlOGFlNzBjZWVkOTEzMmY5OF8yMzM4_5a9f4961-781d-4146-8602-4d75f6062782"
      unitRef="shares">99729025</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMy0xLTEtMS0yOTA5NQ_ec4c2eac-bd5e-4ac5-80d2-ae1f387a6fab"
      unitRef="usd">84430000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMy0zLTEtMS0yOTA5NQ_52796e2a-eeb6-4c51-a66e-81e0e997dc45"
      unitRef="usd">34195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNC0xLTEtMS0yOTA5NQ_39b3e7a4-fdfe-4087-ba6f-1b7411c76a70"
      unitRef="usd">118834000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNC0zLTEtMS0yOTA5NQ_8c39aa29-c8d7-4f72-9eaa-4c60afaf155a"
      unitRef="usd">270993000</us-gaap:ShortTermInvestments>
    <us-gaap:IncentiveToLessee
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNS0xLTEtMS0yOTA5NQ_328bc2b4-79dd-4074-a35c-f3ba7679714d"
      unitRef="usd">0</us-gaap:IncentiveToLessee>
    <us-gaap:IncentiveToLessee
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNS0zLTEtMS0yOTA5NQ_aa6022f3-c59f-45af-9fb3-d2267422b4aa"
      unitRef="usd">5709000</us-gaap:IncentiveToLessee>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNi0xLTEtMS0yOTA5NQ_dbbb45e4-1394-4eee-a7e8-41b2ee566d9e"
      unitRef="usd">9979000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNi0zLTEtMS0yOTA5NQ_266f8abc-a4f3-48c3-ae85-a8065194d24e"
      unitRef="usd">6248000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNy0xLTEtMS0yOTA5NQ_d2bdd80d-2af4-4a1a-8e0d-0013a6f53978"
      unitRef="usd">213243000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfNy0zLTEtMS0yOTA5NQ_b815d198-5a54-4c9e-85f6-b06108fc43e8"
      unitRef="usd">317145000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfOC0xLTEtMS0yOTA5NQ_30792cbb-1436-4e43-99c0-5804c037aa77"
      unitRef="usd">79882000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfOC0zLTEtMS0yOTA5NQ_1838b8df-22ae-46c5-98a9-dbb220e00a89"
      unitRef="usd">86000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfOS0xLTEtMS0yOTA5NQ_756221b5-674b-438c-89da-d6972f4afcc3"
      unitRef="usd">36579000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfOS0zLTEtMS0yOTA5NQ_174230e6-d74d-4f85-910e-4625cf3c2207"
      unitRef="usd">33060000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTEtMS0xLTEtMjkwOTU_c3d080fa-94ec-4913-affe-930783dd24c0"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTEtMy0xLTEtMjkwOTU_9145fa0d-6a6f-44f2-baac-b19b62213714"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTItMS0xLTEtMjkwOTU_818ed79a-7f16-44ed-b7ef-a7f5d197865f"
      unitRef="usd">0</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTItMy0xLTEtMjkwOTU_88367ff5-95c9-4185-9668-ae095ccec11a"
      unitRef="usd">769000</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTMtMS0xLTEtMjkwOTU_1dabfcb0-d74c-4d5f-bd57-3c1967416609"
      unitRef="usd">155000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTMtMy0xLTEtMjkwOTU_be0710f9-2f6a-4cb6-95d1-16cfd9fd194a"
      unitRef="usd">250000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTQtMS0xLTEtMjkwOTU_83e7dc5f-f94e-4ed4-823f-faca1cdbb946"
      unitRef="usd">332362000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTQtMy0xLTEtMjkwOTU_e84ba44c-7d51-4370-aed4-5050efc6f198"
      unitRef="usd">439727000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTctMS0xLTEtMjkwOTU_20e16617-20ef-4622-a495-09c87f2b39f3"
      unitRef="usd">846000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTctMy0xLTEtMjkwOTU_4bdca73c-bb0b-48e6-8fd0-beba9acf68b3"
      unitRef="usd">1387000</us-gaap:AccountsPayableCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTgtMS0xLTEtMjkwOTU_8b5bc63c-e91c-44aa-be18-a30047be86a5"
      unitRef="usd">16539000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTgtMy0xLTEtMjkwOTU_ae6d318b-84ad-47d4-8dc1-5fb1bc577cf5"
      unitRef="usd">18047000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTktMS0xLTEtMjkwOTU_48aecddf-6c7b-4efc-abad-7bd42c860dbb"
      unitRef="usd">11236000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMTktMy0xLTEtMjkwOTU_b9fa5a71-9c0c-4436-ba51-fec591796a84"
      unitRef="usd">1886000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjEtMS0xLTEtMjkwOTU_041df0ab-6acb-4071-8a3d-95d8c273485a"
      unitRef="usd">28621000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjEtMy0xLTEtMjkwOTU_fb78e248-4c6a-4a6b-a857-fda791bebfa3"
      unitRef="usd">21320000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjMtMS0xLTEtMjkwOTU_b1b35117-ef9f-4314-92d3-8a5964550bda"
      unitRef="usd">94464000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjMtMy0xLTEtMjkwOTU_ea363306-b87b-4cb5-a356-6f6b2449052f"
      unitRef="usd">101108000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjQtMS0xLTEtMjkwOTU_e30dca1c-393c-455b-a93f-1404601f5c5d"
      unitRef="usd">940000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjQtMy0xLTEtMjkwOTU_7b606c20-b086-45ce-9e2d-744ddec73d2c"
      unitRef="usd">1114000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjUtMS0xLTEtMjkwOTU_6cd4d663-c4c0-4e3c-acc8-52b282a8ea00"
      unitRef="usd">124025000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjUtMy0xLTEtMjkwOTU_0bc27ce4-af20-4dbf-a778-4eee28b57f7c"
      unitRef="usd">123542000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjgtMS0xLTEtMjkwOTU_00b4f3ab-02de-489b-a579-d68233936258"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjgtMy0xLTEtMjkwOTU_97f01ba9-37cb-4eda-ac00-67b481e7b8f1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjktMS0xLTEtMjkwOTU_14fdd95e-d806-4891-8289-18fb1fadbdbb"
      unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMjktMy0xLTEtMjkwOTU_78bb62ef-1f41-4abf-a12a-c8c6e8b38e15"
      unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzAtMS0xLTEtMjkwOTU_558efbaf-35ec-4084-88bf-b3a8be631d0f"
      unitRef="usd">980156000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzAtMy0xLTEtMjkwOTU_9b1753b0-ea10-4bc7-a8a7-83a7c9a8b537"
      unitRef="usd">964965000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzEtMS0xLTEtMjkwOTU_9ab7e53b-6102-402a-90d0-7fefa53e5e57"
      unitRef="usd">-1953000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzEtMy0xLTEtMjkwOTU_c432ea06-6cad-4e8d-ba4c-6f46adc9e4d9"
      unitRef="usd">-714000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzItMS0xLTEtMjkwOTU_d385ec9b-dd44-441b-a5f1-2ca07b7eed78"
      unitRef="usd">-769876000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzItMy0xLTEtMjkwOTU_5aa2d20f-a895-4d78-aa34-d83985fc87bc"
      unitRef="usd">-648076000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzMtMS0xLTEtMjkwOTU_f8397829-e444-43ac-ad5e-95c9d9e7dbb0"
      unitRef="usd">208337000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzMtMy0xLTEtMjkwOTU_7d9ef787-e573-4e2a-8b07-91e6c0df43c8"
      unitRef="usd">316185000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzQtMS0xLTEtMjkwOTU_d59174dc-886b-4f7d-ac03-c4c0f3f30504"
      unitRef="usd">332362000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xOS9mcmFnOmIyYzBjMjkwMWUxMjRlMDliN2NlZTM1ZWQ2YzZiMDE0L3RhYmxlOjNiODkyNTkzNTAzMzRlZmU4NWIxZmQzYWI0MDQyMTI1L3RhYmxlcmFuZ2U6M2I4OTI1OTM1MDMzNGVmZTg1YjFmZDNhYjQwNDIxMjVfMzQtMy0xLTEtMjkwOTU_6ee60376-5be1-4441-b30a-cea7235ec0a4"
      unitRef="usd">439727000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMi0xLTEtMS0yOTA5NQ_0d48ed87-f510-4aac-9074-aefe8d11b650"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMi0zLTEtMS0yOTA5NQ_4b5fc55d-b3f5-4ea4-91a3-25d52b247182"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMi01LTEtMS0yOTA5NQ_9d6e9f00-0f3c-4248-9aee-34cf350c6ee9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMi03LTEtMS0yOTA5NQ_b3b82786-8d9d-4586-99cc-4ca257680861"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNS0xLTEtMS0yOTA5NQ_e13068d4-97b2-48a1-91a6-3284ae939c55"
      unitRef="usd">23849000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNS0zLTEtMS0yOTA5NQ_4bc07b2e-848c-435b-8d2f-571d565afd53"
      unitRef="usd">24069000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNS01LTEtMS0yOTA5NQ_8ca5d464-c7cc-48d2-86f0-c5f41cf8470c"
      unitRef="usd">77078000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNS03LTEtMS0yOTA5NQ_27cd5993-4480-4f20-91b5-51d6114fe0ff"
      unitRef="usd">66657000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNi0xLTEtMS0yOTA5NQ_17f1031b-ef7f-43cd-8b49-4fad25d0d5fb"
      unitRef="usd">17188000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNi0zLTEtMS0yOTA5NQ_791e2f91-f4aa-4915-9b7f-3d1bac060d9c"
      unitRef="usd">14453000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNi01LTEtMS0yOTA5NQ_a0dfe16a-8213-43ef-ba53-ad9d18d71fbd"
      unitRef="usd">46117000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfNi03LTEtMS0yOTA5NQ_a6bf5ba1-3dae-4075-a520-e4f28eb49e0c"
      unitRef="usd">52546000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOC0xLTEtMS0yOTA5NQ_63ad6567-7ca4-4c74-a35d-fb5586bdda86"
      unitRef="usd">41037000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOC0zLTEtMS0yOTA5NQ_7a5bc699-ee77-414e-a060-727dd03d1a30"
      unitRef="usd">38522000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOC01LTEtMS0yOTA5NQ_2a555d1b-2dbb-4c6a-9f89-8102ee1204c0"
      unitRef="usd">123195000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOC03LTEtMS0yOTA5NQ_eddb10cc-4223-4e6b-876c-4b115f895c53"
      unitRef="usd">119203000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOS0xLTEtMS0yOTA5NQ_074f1292-1050-476b-8662-4f73b20cd65f"
      unitRef="usd">-41037000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOS0zLTEtMS0yOTA5NQ_f219954b-ab9a-4ec5-826b-f18e3492084c"
      unitRef="usd">-38522000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOS01LTEtMS0yOTA5NQ_e051fd47-e852-4b74-8946-84c4c5dec871"
      unitRef="usd">-123195000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfOS03LTEtMS0yOTA5NQ_67cd23f1-47c2-4204-aba2-1a3a3f504612"
      unitRef="usd">-111703000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTAtMS0xLTEtMjkwOTU_8f1c2721-232d-4a44-bd00-d8443ccb9f13"
      unitRef="usd">923000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTAtMy0xLTEtMjkwOTU_0a3ba30e-53ff-4753-accf-78e8749f1295"
      unitRef="usd">160000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTAtNS0xLTEtMjkwOTU_4d55c4ea-5ba1-4f76-9d8c-e62f5edfb2f8"
      unitRef="usd">1450000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTAtNy0xLTEtMjkwOTU_02fe2dfd-0626-498b-bd9f-64f679d08aee"
      unitRef="usd">572000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTEtMS0xLTEtMjkwOTU_f7257971-9912-4c2c-afbb-77a4ea66b307"
      unitRef="usd">-40114000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTEtMy0xLTEtMjkwOTU_ebb8d85e-b77c-4b0f-ad6d-99b59e483392"
      unitRef="usd">-38362000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTEtNS0xLTEtMjkwOTU_e66df4c4-5802-424c-b80d-08b3fff07db1"
      unitRef="usd">-121745000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTEtNy0xLTEtMjkwOTU_d938fde0-c151-44cf-9300-4e703cd58b34"
      unitRef="usd">-111131000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTItMS0xLTEtMjkwOTU_38b4037e-7531-48cf-9120-a9376407b454"
      unitRef="usd">17000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTItMy0xLTEtMjkwOTU_a079a649-34ed-4894-b263-aa9def733354"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTItNS0xLTEtMjkwOTU_b16b67ee-f628-42da-a169-441223b27fae"
      unitRef="usd">55000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTItNy0xLTEtMjkwOTU_0e94ca4a-8b3f-4523-92dc-dde61f0c040f"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTMtMS0xLTEtMjkwOTU_977de856-65a9-4cfe-97dd-c1cf30e58e59"
      unitRef="usd">-40131000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTMtMy0xLTEtMjkwOTU_ad932a15-5871-41ce-93bc-c5208b858b71"
      unitRef="usd">-38362000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTMtNS0xLTEtMjkwOTU_f6e85814-d86c-491b-b4bb-c2aedadf02aa"
      unitRef="usd">-121800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTMtNy0xLTEtMjkwOTU_82b5ae9b-cc26-48ac-a06b-feaa4acfb1ae"
      unitRef="usd">-111131000</us-gaap:NetIncomeLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTUtMS0xLTEtMjkwOTU_1c51e3b5-01ff-44d9-8445-ac5236504036"
      unitRef="usd">-127000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTUtMy0xLTEtMjkwOTU_61dba675-992a-4340-90ca-b3c3636a78bd"
      unitRef="usd">-55000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTUtNS0xLTEtMjkwOTU_4e21c159-dbe2-4191-8b06-9a386fde6486"
      unitRef="usd">-1189000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTUtNy0xLTEtMjkwOTU_6f566f6e-5e34-44da-94e8-5a327d11b21d"
      unitRef="usd">-139000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTYtMS0xLTEtMjkwOTU_c5265520-df49-4bfe-ac1f-6da712014957"
      unitRef="usd">-30000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTYtMy0xLTEtMjkwOTU_e9977933-baa0-4e4a-8905-c261458aceb8"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTYtNS0xLTEtMjkwOTU_c062cdd4-47f8-48f4-9a92-a8ea8d8edc7d"
      unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTYtNy0xLTEtMjkwOTU_495c353c-c3dc-4eb6-b23f-9e7e75dc69df"
      unitRef="usd">-123000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTctMS0xLTEtMjkwOTU_862dcc9d-1dc4-4fce-a0d5-57d0136ef53a"
      unitRef="usd">-40288000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTctMy0xLTEtMjkwOTU_14951c3b-496d-438c-8e82-770875cc21ac"
      unitRef="usd">-38468000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTctNS0xLTEtMjkwOTU_66f285dd-82c5-40c2-868b-4d28dc9b4918"
      unitRef="usd">-123039000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTctNy0xLTEtMjkwOTU_6502e029-1214-419c-b29f-b552afb09a6e"
      unitRef="usd">-111393000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtMS0xLTEtMjkwOTU_87336572-c005-4bf0-a9ea-d8612ac2276f"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtMS0xLTEtMjkwOTU_dd3d7927-521d-450f-afd3-e2eb89d6febb"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtMy0xLTEtMjkwOTU_c6c36f6c-cb08-4c8c-98fb-d5c588e1f1ed"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtMy0xLTEtMjkwOTU_d38d2c3a-0bab-4e58-8b89-a7e457c35839"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtNS0xLTEtMjkwOTU_388d3821-d037-4f2f-a7df-6b29ef710b8e"
      unitRef="usdPerShare">-1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtNS0xLTEtMjkwOTU_7aca5ad0-0c00-4a29-8c05-fc70c0527583"
      unitRef="usdPerShare">-1.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtNy0xLTEtMjkwOTU_178a4d38-a704-4cf4-8c08-c2b1c2f76937"
      unitRef="usdPerShare">-1.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTgtNy0xLTEtMjkwOTU_426f18de-801b-43de-8489-33d80961f8ea"
      unitRef="usdPerShare">-1.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktMS0xLTEtMjkwOTU_0cfc1c88-da0b-489f-aec1-2b38ac010361"
      unitRef="shares">99475000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktMS0xLTEtMjkwOTU_26f5fd44-9a5a-4b70-98cb-207ddbb803c5"
      unitRef="shares">99475000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktMy0xLTEtMjkwOTU_4b8aca36-25ed-4fee-ae36-5c1119cc156a"
      unitRef="shares">98126000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktMy0xLTEtMjkwOTU_6c4cf9b6-fa1f-40ba-a38e-f29b9151f2fc"
      unitRef="shares">98126000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktNS0xLTEtMjkwOTU_7d190921-2df8-465d-b4d2-0de853075651"
      unitRef="shares">99027000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktNS0xLTEtMjkwOTU_d6b51eaa-52bb-4625-a2ff-65d821f186d5"
      unitRef="shares">99027000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktNy0xLTEtMjkwOTU_778deac0-d98b-47db-96f0-b757b89222ec"
      unitRef="shares">97966000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yMi9mcmFnOmY3MjVjMmRkZTUzMzQ5Nzc4YTczNDM3MDNhZDdmNzE0L3RhYmxlOmEyYTIxNTgyYzJiOTQwYmZiMDg1YTQ4YTI1MDAyZWFmL3RhYmxlcmFuZ2U6YTJhMjE1ODJjMmI5NDBiZmIwODVhNDhhMjUwMDJlYWZfMTktNy0xLTEtMjkwOTU_b04a61fc-5bf8-4b14-a36b-d3be385099e6"
      unitRef="shares">97966000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i44433fe8d4104d3a83fe0df026333455_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMi0xLTEtMS0yOTA5NQ_1975b64b-2eac-4efa-971a-699a0262393e"
      unitRef="shares">98381000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i44433fe8d4104d3a83fe0df026333455_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMi0zLTEtMS0yOTA5NQ_753ce4f0-c319-4ff9-8cee-af3f6434bae8"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d6f32550ba1434c9e67090a8d16b28e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMi01LTEtMS0yOTA5NQ_5ccbad72-4cc3-4632-b870-93bdd78d9b82"
      unitRef="usd">964965000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib9842733bcbb49b2ac6dd8ef51160cf1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMi03LTEtMS0yOTA5NQ_01e908b8-3009-441a-9bae-9e38a678ec58"
      unitRef="usd">-714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67846955d203444991996f8db5938a69_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMi05LTEtMS0yOTA5NQ_8f91ced4-2a72-4c3e-9593-bbf8cdd2fe8d"
      unitRef="usd">-648076000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMi0xMS0xLTEtMjkwOTU_47aa9302-c088-4b41-a3a5-9c0d3273b6c8"
      unitRef="usd">316185000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5fc4612654aa4870acef5f852550d561_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMy01LTEtMS0yOTA5NQ_84468aa3-3b70-46e3-b1d8-96aa16a4ab2e"
      unitRef="usd">5381000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if0eb628814a04ad8971209780bc02232_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMy0xMS0xLTEtMjkwOTU_6da03428-1471-41b4-9ad1-b44cccea277b"
      unitRef="usd">5381000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ifc0d4ed39fb04b2089aee2f3e0739e42_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfNC0xLTEtMS0yOTA5NQ_57c50263-e270-471a-afed-92dfb812d2e5"
      unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5fc4612654aa4870acef5f852550d561_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfNC01LTEtMS0yOTA5NQ_49663a3a-9e60-4bb7-b8bb-66c947a2273d"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if0eb628814a04ad8971209780bc02232_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfNC0xMS0xLTEtMjkwOTU_47cdde7b-df8f-4cc1-a1d2-15274662a585"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ifc0d4ed39fb04b2089aee2f3e0739e42_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfNS0xLTEtMS0yOTA5NQ_ea3e701e-96bc-43a7-b1be-cf5c6814f0d8"
      unitRef="shares">371000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i00ced84e48d142babc4e6edcc897094a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfNy03LTEtMS0yOTA5NQ_90ed6fc4-b90c-4724-a684-5de51d16f544"
      unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if0eb628814a04ad8971209780bc02232_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfNy0xMS0xLTEtMjkwOTU_fa6c3368-da30-4c96-b55f-0b47840977c7"
      unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i00ced84e48d142babc4e6edcc897094a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfOC03LTEtMS0yOTA5NQ_ebc801db-c729-4e97-a08a-61b255801f49"
      unitRef="usd">-723000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="if0eb628814a04ad8971209780bc02232_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfOC0xMS0xLTEtMjkwOTU_1223aaca-d91b-4296-8694-7b6ce447f058"
      unitRef="usd">-723000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia22a80d1fae54e15bac4c1582f12e26e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfOS05LTEtMS0yOTA5NQ_f916a30c-17db-4d8d-93b5-b8e305e32625"
      unitRef="usd">-37908000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if0eb628814a04ad8971209780bc02232_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfOS0xMS0xLTEtMjkwOTU_6248fc5b-7129-43e4-a3db-267248f81bd8"
      unitRef="usd">-37908000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i5d3a4780987e4e9692fdafbb646d0e5a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTAtMS0xLTEtMjkwOTU_b400c8fb-cc8a-4059-a08f-ca6bc2861918"
      unitRef="shares">98767000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5d3a4780987e4e9692fdafbb646d0e5a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTAtMy0xLTEtMjkwOTU_5b39e6a4-6112-4075-853c-c035c9559ed8"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5d6b6204c994327981fb6f38ee2e5ff_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTAtNS0xLTEtMjkwOTU_c0dd3e76-afe3-439c-beec-d780ff9c7921"
      unitRef="usd">970349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6e35090827424e029a917e87a3044012_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTAtNy0xLTEtMjkwOTU_62f8dcda-3ffe-4e22-932d-d790746c48fa"
      unitRef="usd">-1423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib90a0153e711486598954353cda4c4f6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTAtOS0xLTEtMjkwOTU_54437c00-0d09-4c4d-9fb0-c26f707acae5"
      unitRef="usd">-685984000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia61c0616a34746bf8b0475dd12eece06_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTAtMTEtMS0xLTI5MDk1_bce61f29-717a-4cd0-95b2-180115291da3"
      unitRef="usd">282952000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6f8b7aaa691944a4a550b8ced951db24_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTEtNS0xLTEtMjkwOTU_4b8bf62c-2bd9-4707-b5ea-2f21ce60bfae"
      unitRef="usd">4942000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i972d3044b3264665a366176257e6f0a4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTEtMTEtMS0xLTI5MDk1_e13aa7ad-267a-45cd-9479-d5faae0cc208"
      unitRef="usd">4942000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i65bbe7741c5844b19b5542e8c5caf343_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTItMS0xLTEtMjkwOTU_90c71ff2-ae19-4ed0-9911-0f90e3280ac2"
      unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i65bbe7741c5844b19b5542e8c5caf343_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTMtMS0xLTEtMjkwOTU_27a59080-074b-458a-a3ce-9ffcc30a9969"
      unitRef="shares">499000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6f8b7aaa691944a4a550b8ced951db24_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTMtNS0xLTEtMjkwOTU_6b899923-39fc-4f5a-93cd-c7c0ffa8bedc"
      unitRef="usd">362000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i972d3044b3264665a366176257e6f0a4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTMtMTEtMS0xLTI5MDk1_af4f9bdb-aa7a-4350-99fb-32609e0efaa4"
      unitRef="usd">362000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i46e83442dc5749b0a5d1ad0026c402d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTQtNy0xLTEtMjkwOTU_614a2bed-aa21-4fb6-ad5a-c6a30f93c0c4"
      unitRef="usd">-34000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i972d3044b3264665a366176257e6f0a4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTQtMTEtMS0xLTI5MDk1_fb38f468-159f-43dd-a290-54b023f90851"
      unitRef="usd">-34000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i46e83442dc5749b0a5d1ad0026c402d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTUtNy0xLTEtMjkwOTU_266f30d1-7008-46cb-848e-052059318b51"
      unitRef="usd">-339000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i972d3044b3264665a366176257e6f0a4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTUtMTEtMS0xLTI5MDk1_bf983ae2-b13b-4004-b138-06a4b37faefc"
      unitRef="usd">-339000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if4af61eabf3d42e09f408fb99c2367e5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTYtOS0xLTEtMjkwOTU_d4040716-fe6d-4f22-935c-2545f35cfda9"
      unitRef="usd">-43761000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i972d3044b3264665a366176257e6f0a4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTYtMTEtMS0xLTI5MDk1_351c2913-9c99-4adb-b5ca-d82c0f5b3335"
      unitRef="usd">-43761000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i96f851ab82a443b5a834a5415c2880e0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTctMS0xLTEtMjkwOTU_8dc3686f-e395-4f76-9d40-49ce15e68c69"
      unitRef="shares">99271000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i96f851ab82a443b5a834a5415c2880e0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTctMy0xLTEtMjkwOTU_4efc0dca-1030-48db-8040-c0af0bb61a76"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65c2b4e4a1b54fdf897b4c3015a17e3f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTctNS0xLTEtMjkwOTU_bdd6d3ef-d6db-414b-ad2c-f3eb05a2c889"
      unitRef="usd">975653000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id191c6d1957d4719b9c5e156e348e8db_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTctNy0xLTEtMjkwOTU_6723965b-2c01-4a07-9cc1-13a01bdb1980"
      unitRef="usd">-1796000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idbb610db5124447a81519c9fddb553ad_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTctOS0xLTEtMjkwOTU_06adf5b3-8933-4c23-97cb-4bc82066e66e"
      unitRef="usd">-729745000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i19622582a11f4462a48573d5c32fb7c5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTctMTEtMS0xLTI5MDk1_7cee192b-973d-4e7d-ab02-1a972b08fb23"
      unitRef="usd">244122000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6388d78a0f704f1c86da5e1f4c37aa33_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTgtNS0xLTEtMjk4MjQ_b4c83de9-b82b-4a77-add8-4349cdf9d773"
      unitRef="usd">4503000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTgtMTEtMS0xLTI5MzAz_d497c69c-3baf-4c66-bf48-8736f9dbc3ba"
      unitRef="usd">4503000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i47c31b7bd48c4503a19ac8602ddba6ff_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMTktMS0xLTEtMjkzMDY_ab150423-a615-4fd9-a024-f2560f33b680"
      unitRef="shares">457000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ic047966dbeb843b496329bb693a66b72_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjAtNy0xLTEtMjk4NDY_7904c80b-f5e6-4aeb-a98a-f395a1654acb"
      unitRef="usd">-30000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjAtMTEtMS0xLTI5MzA4_3179e21d-2bec-49cb-8858-aa8a24b4cafb"
      unitRef="usd">-30000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ic047966dbeb843b496329bb693a66b72_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjEtNy0xLTEtMjk4NDY_c65aa521-904c-4ce0-ac86-68f49efdab4b"
      unitRef="usd">-127000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjEtMTEtMS0xLTI5MzEw_80ab23f0-6aac-4c53-9486-dd0853724da3"
      unitRef="usd">-127000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ice288f0d914a4d95915117eb965b9fc7_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjItOS0xLTEtMjk4NTU_f6a01d57-10af-4cbc-8a0a-365d0a638635"
      unitRef="usd">-40131000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjItMTEtMS0xLTI5MzEy_1c23e973-0d33-4d02-8ea8-5db6efe8a8ec"
      unitRef="usd">-40131000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ib238c3743368488b9eb8ed8b364431e9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjMtMS0xLTEtMjkzMTQ_7ba3507e-d62b-45f5-8eca-8af2c245d2cc"
      unitRef="shares">99728000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib238c3743368488b9eb8ed8b364431e9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjMtMy0xLTEtMjkzMTY_c2f17496-0050-4948-8c3b-1ebf9933ea78"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i480b594590b940cd851f225ae27fd622_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjMtNS0xLTEtMjkzMTg_24517356-bc7c-496f-b7d0-0c610e7a7f12"
      unitRef="usd">980156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i90ba8498524046978db9a015fa44aeab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjMtNy0xLTEtMjkzMjA_93aa4dfc-d611-4215-a5c5-87b9f89c64ae"
      unitRef="usd">-1953000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4af913e76594eaa821e5e62c4699428_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjMtOS0xLTEtMjkzMjI_48b48c71-807e-4418-b2b4-e43a5f6cb87b"
      unitRef="usd">-769876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjA3ODBjOGYzODBmMzQ2NjVhMjNhY2YwNmM0YjM3MjM0L3RhYmxlcmFuZ2U6MDc4MGM4ZjM4MGYzNDY2NWEyM2FjZjA2YzRiMzcyMzRfMjMtMTEtMS0xLTI5MzI0_20cd1880-68d9-4eaa-bdd2-19544d5d720d"
      unitRef="usd">208337000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="idbfe14fd14dc46eeae6028be0bedb756_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMi0xLTEtMS0yOTA5NQ_3e9fb6af-9a21-4ac1-925a-9885f84cf0f4"
      unitRef="shares">97549000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idbfe14fd14dc46eeae6028be0bedb756_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMi0zLTEtMS0yOTA5NQ_1d505e16-a229-4e77-9cb1-8a0d6950aa22"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0dda90e2dcb84f4abf4d236b758309c0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMi01LTEtMS0yOTA5NQ_fa5a64c4-d063-4ce3-8fa3-d33939f22ca1"
      unitRef="usd">937134000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic53d2c3285b2405c89747aede88daf77_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMi03LTEtMS0yOTA5NQ_aad74802-edc3-4510-bab4-a17217e6a064"
      unitRef="usd">-261000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2061f8740354460fbd6fa9e20be2522a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMi05LTEtMS0yOTA5NQ_bb7e26ed-848c-433b-b58e-4ca692f9bf81"
      unitRef="usd">-502536000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6353d7b319d44289aff3a0e8fcae2bac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMi0xMS0xLTEtMjkwOTU_99f5564d-4a9e-4c67-95e2-8455fef03fe6"
      unitRef="usd">434347000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibe95493f3b5a4dc5b74fbbfe667afede_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMy01LTEtMS0yOTA5NQ_1df77aad-d560-46ca-aaf6-0860a7089532"
      unitRef="usd">7224000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMy0xMS0xLTEtMjkwOTU_6a565d7a-7527-48c7-9287-6c2cb2d2e176"
      unitRef="usd">7224000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNC0wLTEtMS0yOTA5NS90ZXh0cmVnaW9uOmIzNTE3ZDE2Nzk3MzQ5YjNiNDkzOWE4NzkzMzcwOGMyXzU1_be037e27-9d6a-40aa-a473-db28686e9b45"
      unitRef="usd">5000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i121cdd6f1a6b4029901948f5a1c143d5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNC0xLTEtMS0yOTA5NQ_f43cec6f-7f66-4c36-8aa7-3c85c275c235"
      unitRef="shares">121000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibe95493f3b5a4dc5b74fbbfe667afede_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNC01LTEtMS0yOTA5NQ_69ff93b8-a048-4757-af22-67758b91e10a"
      unitRef="usd">1689000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNC0xMS0xLTEtMjkwOTU_bb970618-95d8-4895-945c-7edfc608b930"
      unitRef="usd">1689000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i121cdd6f1a6b4029901948f5a1c143d5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNS0xLTEtMS0yOTA5NQ_ee1c39e9-9046-4496-856d-eacc9e2c98a2"
      unitRef="shares">9000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibe95493f3b5a4dc5b74fbbfe667afede_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNS01LTEtMS0yOTA5NQ_1ba60f99-c026-4cff-9453-6497416fa0d1"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNS0xMS0xLTEtMjkwOTU_9aed5d37-2e04-4918-8130-fc60407ea1d8"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i121cdd6f1a6b4029901948f5a1c143d5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfNi0xLTEtMS0yOTA5NQ_c02921d8-8d48-4567-a704-e7f40930d60a"
      unitRef="shares">248000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="idebb246dffde4b12a9cd6c4cf9a7f620_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfOC03LTEtMS0yOTA5NQ_c664420f-99bd-446d-90f4-91dae100e2d2"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfOC0xMS0xLTEtMjkwOTU_426c5cb5-bb42-415a-bfd0-74ea37965a6d"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="idebb246dffde4b12a9cd6c4cf9a7f620_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfOS03LTEtMS0yOTA5NQ_bf7fb061-d876-47bb-959b-7d64c5b36cce"
      unitRef="usd">-22000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfOS0xMS0xLTEtMjkwOTU_3947c8c6-67dc-4d7e-bf9e-590406d0be63"
      unitRef="usd">-22000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaefcad51308b4b3790bcf428575004c3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTAtOS0xLTEtMjkwOTU_6c38d698-f475-467b-95f5-6c85af3a475d"
      unitRef="usd">-28436000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTAtMTEtMS0xLTI5MDk1_44f311a7-4ac1-45b3-a07e-afa2fe0d997e"
      unitRef="usd">-28436000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i94109faeb1f44d1da072d36ea355382d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTEtMS0xLTEtMjkwOTU_de825947-4983-4a93-88e6-077501641bcf"
      unitRef="shares">97927000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i94109faeb1f44d1da072d36ea355382d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTEtMy0xLTEtMjkwOTU_b32075ef-80c4-44c0-9e9a-dbf6a0dee36f"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i841267b2dc374ac3ad96e04341fb587a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTEtNS0xLTEtMjkwOTU_80b733be-60f9-4b97-8c88-02c489987845"
      unitRef="usd">946098000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia5269eef549e4b18bb64d22f1b54e0ca_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTEtNy0xLTEtMjkwOTU_e88c2580-279a-44e9-9800-566c8148212a"
      unitRef="usd">-316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37097774df59414a8b4fe74f0511d45f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTEtOS0xLTEtMjkwOTU_edbf1c70-74be-4132-b145-611bb59bee3a"
      unitRef="usd">-530972000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i23eb60965e1a4ce59cc12982fa1fc9fa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTEtMTEtMS0xLTI5MDk1_7bc3ecb3-f5c5-4ef9-9531-f72371a8b1ab"
      unitRef="usd">414820000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0fe7ae56850e4431a1e91bc6167ef963_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTItNS0xLTEtMjkwOTU_0416bbe6-7da1-42b3-a869-4682d471ce84"
      unitRef="usd">8234000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i475232b6968b4298945132136bd68a2d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTItMTEtMS0xLTI5MDk1_4b5f3380-3476-4864-a2e0-b11393948dfe"
      unitRef="usd">8234000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i0fe7ae56850e4431a1e91bc6167ef963_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTMtNS0xLTEtMjkwOTU_b1933c61-22c9-4316-bd0f-fb7250b3fe60"
      unitRef="usd">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i475232b6968b4298945132136bd68a2d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTMtMTEtMS0xLTI5MDk1_56ef8baf-2877-4fab-a0f0-44069c92087e"
      unitRef="usd">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ib1230d7a79cd43ca8b3d88d5b06de1db_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTQtMS0xLTEtMjkwOTU_59bfd43c-7f79-4110-9cc9-31188b2920f7"
      unitRef="shares">17000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ib1230d7a79cd43ca8b3d88d5b06de1db_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTUtMS0xLTEtMjkwOTU_4c1cbd3e-3213-4de8-8755-ebe6148705de"
      unitRef="shares">176000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0fe7ae56850e4431a1e91bc6167ef963_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTUtNS0xLTEtMjkwOTU_4a429a0f-43b2-41bf-b9a3-c8d18bbb9ba3"
      unitRef="usd">526000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i475232b6968b4298945132136bd68a2d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTUtMTEtMS0xLTI5MDk1_b97c7168-60d8-4a13-9af4-be8cd793dba3"
      unitRef="usd">526000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i609ae2740da044548ec7c4c368af7b51_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTYtNy0xLTEtMjkwOTU_f9ebc2e0-6b54-415c-8e68-40a2a12ae459"
      unitRef="usd">-39000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i475232b6968b4298945132136bd68a2d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTYtMTEtMS0xLTI5MDk1_78a05e89-d9f6-402d-8c04-220a141cc1bc"
      unitRef="usd">-39000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i609ae2740da044548ec7c4c368af7b51_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTctNy0xLTEtMjkwOTU_ad440136-6105-4d61-ba10-19fd077677db"
      unitRef="usd">-62000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i475232b6968b4298945132136bd68a2d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTctMTEtMS0xLTI5MDk1_a5742f7a-e39c-4ee8-8043-af68947fb85b"
      unitRef="usd">-62000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iceda05b2f1b4410faf5aca6a1f9cb9c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTgtOS0xLTEtMjkwOTU_1acd7a30-cad8-47b5-8b14-4eb9eb464f53"
      unitRef="usd">-44333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i475232b6968b4298945132136bd68a2d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTgtMTEtMS0xLTI5MDk1_48e04c93-1016-44c0-9f37-9d63da884dcd"
      unitRef="usd">-44333000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id9921ca0a5094f0bac938ac91d53078a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTktMS0xLTEtMjkwOTU_357fb94f-94c2-4514-9dfa-8ce074338722"
      unitRef="shares">98120000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id9921ca0a5094f0bac938ac91d53078a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTktMy0xLTEtMjkwOTU_646a2f74-d7d9-447f-b666-51aa877b4ba0"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07da0e72c1be41e7aaf42551fd516c9f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTktNS0xLTEtMjkwOTU_f3c5ecf5-4bb2-4dad-806f-ea0eb004870d"
      unitRef="usd">954854000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7bd7d22674a0458b874208ec2cf0c887_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTktNy0xLTEtMjkwOTU_74ac510b-4d64-46d2-8709-276aac0884fc"
      unitRef="usd">-417000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i851c8e2358684ae6b21b416e2330cb70_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTktOS0xLTEtMjkwOTU_a499971e-b6ef-4566-8a39-5fe97d87ee7a"
      unitRef="usd">-575305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3d43fd4cf2a549a0b04c2f34890cb7ff_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMTktMTEtMS0xLTI5MDk1_36f95dc9-494d-459a-9a91-95244c7e5f53"
      unitRef="usd">379142000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2e6eb7bc0bbc467bbdb22d47d409103f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjAtNS0xLTEtMjkwOTU_0b0ed41d-3c8d-4d32-b0af-91674927a246"
      unitRef="usd">5326000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjAtMTEtMS0xLTI5MDk1_8f0923c4-df50-43cb-b333-b6c411928b62"
      unitRef="usd">5326000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i0a18ede15a1b47778e90d6d5c7bb304f_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjEtMS0xLTEtMjkwOTU_75f659c0-5829-4a66-b613-b0076d3651b1"
      unitRef="shares">23000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i45935ce9978f46239a14318be6d6f2ae_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjItNy0xLTEtMjkwOTU_60c3aec6-a789-483b-bc19-a0311d69b6d9"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjItMTEtMS0xLTI5MDk1_ed49b07c-74bc-42c4-9c96-ce8cd44d4c0b"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i45935ce9978f46239a14318be6d6f2ae_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjMtNy0xLTEtMjkwOTU_26bb5663-491e-430b-b82a-52e157a64f14"
      unitRef="usd">-55000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjMtMTEtMS0xLTI5MDk1_5e4ec806-60d6-4a57-88ef-8b27a15991ff"
      unitRef="usd">-55000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if9809e3ed4b544acb18ad2a9ef94d4fa_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjQtOS0xLTEtMjkwOTU_89632904-950b-4105-8669-a5b2b133a0ef"
      unitRef="usd">-38362000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjQtMTEtMS0xLTI5MDk1_b4795c7d-f068-4d50-96e6-bdf7eaf642ef"
      unitRef="usd">-38362000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ib5ff1d37342b4c27865fff03a63c60c8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjUtMS0xLTEtMjkwOTU_3101166c-7fb9-463d-8d23-63f2e14e8708"
      unitRef="shares">98143000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib5ff1d37342b4c27865fff03a63c60c8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjUtMy0xLTEtMjkwOTU_6ef57696-cd15-4d75-afdc-be9f2004ddc5"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c37575b017e43bf9a8ac40ac84a9957_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjUtNS0xLTEtMjkwOTU_26d55a47-bd49-477f-9ba0-06793034ef84"
      unitRef="usd">960180000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i021fc47f853242c2be3df72c455d228f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjUtNy0xLTEtMjkwOTU_b60857d4-7f95-40e3-af52-d3ccdbaf7426"
      unitRef="usd">-523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0b517ce4be034b4db4fafa152857e3ae_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjUtOS0xLTEtMjkwOTU_f19af3df-fed7-46b5-a93d-d08dfa78d77b"
      unitRef="usd">-613667000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if94ce7427b6d4ad3bf65c204029b5bb5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yNS9mcmFnOjM1YTA3ZDRiMzVhZTRlZmFiYjQ4MmMwNmM4MTJkYjI0L3RhYmxlOjQxMTk5MzQ3ZWIzYzQ0OWE4YjlkYzRkZTA2YmVmZjJkL3RhYmxlcmFuZ2U6NDExOTkzNDdlYjNjNDQ5YThiOWRjNGRlMDZiZWZmMmRfMjUtMTEtMS0xLTI5MDk1_e7b0d22e-e0ae-45fa-9421-42155998753e"
      unitRef="usd">346000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMy0xLTEtMS0yOTA5NQ_63f4b250-7a9c-40f3-b69d-cd674a31daf8"
      unitRef="usd">-121800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMy0zLTEtMS0yOTA5NQ_b809aa24-2cab-40c8-8a66-d2b5e315e460"
      unitRef="usd">-111131000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNS0xLTEtMS0yOTA5NQ_5c6e94dd-6c2f-4b96-a345-60b329fc8f96"
      unitRef="usd">4816000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNS0zLTEtMS0yOTA5NQ_517834f3-ad97-48a7-88ae-7e293128c99b"
      unitRef="usd">3323000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNi0xLTEtMS0yOTA5NQ_1f9c7bf8-31b5-408f-9a2f-396a4db62de6"
      unitRef="usd">14826000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNi0zLTEtMS0yOTA5NQ_c31aa103-d4ee-489f-80c1-71416d8716f5"
      unitRef="usd">20784000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNy0xLTEtMS0yOTA5NQ_a34e5e40-94c8-4bbb-b1dd-4ddbac7b68b1"
      unitRef="usd">277000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNy0zLTEtMS0yOTA5NQ_cc2931f5-cd22-4756-887c-2dbf2a2131cb"
      unitRef="usd">-2273000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfOC0xLTEtMS0yOTA5NQ_76f33bf0-bd78-4645-a233-493f85d2fb0d"
      unitRef="usd">-101000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfOC0zLTEtMS0yOTA5NQ_2a8b3ec9-bb74-45c1-9ec6-b970556d6e39"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AssetImpairmentCharges
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfOS0xLTEtMS0yOTA5NQ_6e383f38-d3c2-4272-8742-cb0881baa0d7"
      unitRef="usd">2011000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfOS0zLTEtMS0yOTA5NQ_6e4f4f8d-4de1-4cc8-918d-02b723bc922d"
      unitRef="usd">1072000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTAtMS0xLTEtMjkwOTU_a33b8573-97e5-4e39-a350-3bfab19852c3"
      unitRef="usd">1526000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTAtMy0xLTEtMjkwOTU_38c100c2-dffd-4574-a535-a190f79a695c"
      unitRef="usd">132000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTItMS0xLTEtMjkwOTU_39582ba3-54c2-4860-b55b-877c562ad25e"
      unitRef="usd">3468000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTItMy0xLTEtMjkwOTU_ea0a29da-2947-4017-b7e9-4dfc135e7985"
      unitRef="usd">3493000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTMtMS0xLTEtMjkwOTU_30778753-6fa5-4c7c-b4b7-190b6d435ecc"
      unitRef="usd">-864000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTMtMy0xLTEtMjkwOTU_c859b3ec-9a45-4d24-a28f-c05ac0927555"
      unitRef="usd">109000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTQtMS0xLTEtMjkwOTU_4ec6f1cf-03a1-4b3c-b436-53c7e7e42dd0"
      unitRef="usd">-3092000</advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset>
    <advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTQtMy0xLTEtMjkwOTU_46856dc6-5478-4071-b831-5fdfa73a683e"
      unitRef="usd">-2825000</advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTUtMS0xLTEtMjkwOTU_ad987c60-034c-434a-9b8a-0962ae8a6b3a"
      unitRef="usd">-543000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTUtMy0xLTEtMjkwOTU_c31f8061-5772-4a82-ade5-a8c12c3de845"
      unitRef="usd">-587000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTYtMS0xLTEtMjkwOTU_913d41dc-8fb7-4bbd-b9fc-e89267f708e9"
      unitRef="usd">-272000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTYtMy0xLTEtMjkwOTU_f129cf61-2d82-4b80-921b-588e2f8396f2"
      unitRef="usd">3253000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTctMS0xLTEtMjkwOTU_fb734276-15cf-4ed7-9d8a-35c6cce18ea7"
      unitRef="usd">55000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTctMy0xLTEtMjkwOTU_89e0b514-ec22-450c-a372-0f0c9970d6f8"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTktMS0xLTEtMjkwOTU_002b9111-7509-455e-913d-cb77989440f6"
      unitRef="usd">12505000</advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable>
    <advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMTktMy0xLTEtMjkwOTU_7c0c063e-cdbf-4d10-a4e1-5575672975a3"
      unitRef="usd">-94000</advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjEtMS0xLTEtMjkwOTU_72f66449-1f7e-49b2-8c46-b3c7147caf84"
      unitRef="usd">-89616000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjEtMy0xLTEtMjkwOTU_f024d51d-47e8-4d24-a685-35203c2db8cf"
      unitRef="usd">-82016000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjMtMS0xLTEtMjkwOTU_05703e48-1e33-4537-992b-37a652386a1e"
      unitRef="usd">81782000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjMtMy0xLTEtMjkwOTU_e88d68a0-de63-4393-b03f-f4e7a957e0e1"
      unitRef="usd">328275000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjQtMS0xLTEtMjkwOTU_41108a6d-100e-49cf-98fe-db78dab18748"
      unitRef="usd">232899000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjQtMy0xLTEtMjkwOTU_c0ee0ab0-d40c-4e70-ba50-839cf5d33d07"
      unitRef="usd">384882000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjUtMS0xLTEtMjkwOTU_2bde1e81-7dc6-4370-bb13-ab7a1e66f9d5"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjUtMy0xLTEtMjkwOTU_e38cbd83-ead1-4bc6-a88c-403baa68fae9"
      unitRef="usd">8990000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjYtMS0xLTEtMjkwOTU_8ffe9ba2-3e1d-4682-92ce-28df806cbae9"
      unitRef="usd">11631000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjYtMy0xLTEtMjkwOTU_0d8f9142-89bf-43fe-ba94-e08ac0322199"
      unitRef="usd">10771000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjctMS0xLTEtMjkwOTU_0ecdc441-aba3-423b-a415-cb8cf477f7b7"
      unitRef="usd">139486000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjctMy0xLTEtMjkwOTU_85f81818-0c6f-4414-807c-2a70c5e49b1e"
      unitRef="usd">54826000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjktMS0xLTEtMjkwOTU_1a3ba636-b0c1-4653-958c-3bdaf42b979d"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMjktMy0xLTEtMjkwOTU_f142dbce-621e-4205-8eb5-148c455efcd2"
      unitRef="usd">1685000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzEtMS0xLTEtMjkwOTU_36125926-2e11-4ae1-933f-5544866d6969"
      unitRef="usd">3000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzEtMy0xLTEtMjkwOTU_7e276c20-524b-400a-b5b7-97b60ef845fa"
      unitRef="usd">51000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzMtMS0xLTEtMjkwOTU_1f643ed9-8bd7-4267-9ad7-6fcb0eb8bca5"
      unitRef="usd">362000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzMtMy0xLTEtMjkwOTU_84d2bbf5-e150-4a30-a420-7af69812e594"
      unitRef="usd">526000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:RepaymentsOfDebt
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzUtMS0xLTEtMjkwOTU_73835443-f49e-4c03-9b8e-68370c39ef9c"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzUtMy0xLTEtMjkwOTU_85c53074-09a5-4517-a330-472b0c251fb6"
      unitRef="usd">240000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzYtMS0xLTEtMjkwOTU_80844789-eb63-464a-bf4c-69460ef58b01"
      unitRef="usd">365000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzYtMy0xLTEtMjkwOTU_ce550b35-cb67-4f88-8670-2da7fcc3498c"
      unitRef="usd">2022000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzctMS0xLTEtMjkwOTU_fe1a41a4-bbb6-46b2-819a-c28230b12f5a"
      unitRef="usd">50235000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzctMy0xLTEtMjkwOTU_106fd9ce-763e-45b2-a2ec-931daa230f47"
      unitRef="usd">-25168000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzgtMS0xLTEtMjkwOTU_f3aa056e-0117-45a2-88b8-1e81bd614158"
      unitRef="usd">36698000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6353d7b319d44289aff3a0e8fcae2bac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzgtMy0xLTEtMjkwOTU_444fcef1-98fa-4690-8a86-6ba50f7d4927"
      unitRef="usd">63423000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzktMS0xLTEtMjkwOTU_0e56c017-221d-4a8f-8cc4-d308ce486b7e"
      unitRef="usd">86933000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if94ce7427b6d4ad3bf65c204029b5bb5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfMzktMy0xLTEtMjkwOTU_1370bd70-31e4-49c7-9a1a-672722ef0f43"
      unitRef="usd">38255000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDAtMS0xLTEtMjkwOTU_ec4c2eac-bd5e-4ac5-80d2-ae1f387a6fab"
      unitRef="usd">84430000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if94ce7427b6d4ad3bf65c204029b5bb5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDAtMy0xLTEtMjkwOTU_d7b93652-3fda-4127-96e9-fb21d0e9ab74"
      unitRef="usd">32971000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDEtMS0xLTEtMjkwOTU_c3d080fa-94ec-4913-affe-930783dd24c0"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="if94ce7427b6d4ad3bf65c204029b5bb5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDEtMy0xLTEtMjkwOTU_1aa7c103-ce82-49ee-82f0-ed63b865905f"
      unitRef="usd">5284000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDItMS0xLTEtMjkwOTU_52f86187-d213-4821-921b-7e8188a64ad4"
      unitRef="usd">86933000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if94ce7427b6d4ad3bf65c204029b5bb5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDItMy0xLTEtMjkwOTU_62c94155-e8d0-40f5-8065-2defa8f4b2d4"
      unitRef="usd">38255000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDQtMS0xLTEtMjkwOTU_121e14a1-c176-497d-bcf1-e9b532c603a9"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDQtMy0xLTEtMjkwOTU_ceb54b6a-4474-4525-af14-c8939781123f"
      unitRef="usd">84005000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <advm:RemeasurementOfOperatingLeaseRightOfUseAssets
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDUtMS0xLTEtMjk4Nzc_a1fff18b-dc01-4432-911e-b5b9e2ea350a"
      unitRef="usd">2842000</advm:RemeasurementOfOperatingLeaseRightOfUseAssets>
    <advm:RemeasurementOfOperatingLeaseRightOfUseAssets
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDUtMy0xLTEtMzAxNzI_0c1cf60d-0d9b-41f6-ac0e-75150ee35e44"
      unitRef="usd">0</advm:RemeasurementOfOperatingLeaseRightOfUseAssets>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDUtMS0xLTEtMjkwOTU_b141db96-8bc2-44bc-ae0a-1e09e20a9942"
      unitRef="usd">168000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8yOC9mcmFnOjk3ZmViMzVjODVjNDQ4NTQ4NDI4MTM5YzgzY2ZmOWUyL3RhYmxlOjA5YjQzYWE2ZDc5MDRjMzk5YWRlNDJkNGU1NWE1MTJmL3RhYmxlcmFuZ2U6MDliNDNhYTZkNzkwNGMzOTlhZGU0MmQ0ZTU1YTUxMmZfNDUtMy0xLTEtMjkwOTU_a274bb80-5252-43cd-acf0-9a3eab28c208"
      unitRef="usd">2675000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNC9mcmFnOjVmNmM5OGY2NjM3ZDQ3OTk5ZjY2MWM4YWY3OWZiODM2L3RleHRyZWdpb246NWY2Yzk4ZjY2MzdkNDc5OTlmNjYxYzhhZjc5ZmI4MzZfMjU4MA_cab10002-dd28-405e-a19e-7add333ce81c">Organization and Basis of Presentation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adverum Biotechnologies, Inc. (the &#x201c;Company&#x201d; or &#x201c;Adverum&#x201d;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $769.9 million as of September&#160;30, 2022. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of September&#160;30, 2022, the Company had cash, cash equivalents and short-term investments of $203.3 million, which the Company believes will be sufficient to fund its operations for at least twelve months from the date of issuance of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and follow the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#x2019;s consolidated financial information. The results of operations for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2021 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNC9mcmFnOjVmNmM5OGY2NjM3ZDQ3OTk5ZjY2MWM4YWY3OWZiODM2L3RleHRyZWdpb246NWY2Yzk4ZjY2MzdkNDc5OTlmNjYxYzhhZjc5ZmI4MzZfNjg2_4a7f27b1-b2bc-4c5b-ba8c-0a7224801d6e"
      unitRef="usd">-769900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNC9mcmFnOjVmNmM5OGY2NjM3ZDQ3OTk5ZjY2MWM4YWY3OWZiODM2L3RleHRyZWdpb246NWY2Yzk4ZjY2MzdkNDc5OTlmNjYxYzhhZjc5ZmI4MzZfOTM1_8bf1afef-22ec-42b7-aff0-b5ccdc54a435"
      unitRef="usd">203300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNC9mcmFnOjVmNmM5OGY2NjM3ZDQ3OTk5ZjY2MWM4YWY3OWZiODM2L3RleHRyZWdpb246NWY2Yzk4ZjY2MzdkNDc5OTlmNjYxYzhhZjc5ZmI4MzZfMjU4MQ_113d2d55-005e-478d-9b15-ae991b3592c7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and follow the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#x2019;s consolidated financial information. The results of operations for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2021 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. &lt;/span&gt;The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNy9mcmFnOjQwMDM1NTI3ZTRjNTQyOGNiNjBhOTJhMTIyNjNjN2UwL3RleHRyZWdpb246NDAwMzU1MjdlNGM1NDI4Y2I2MGE5MmExMjI2M2M3ZTBfMjI1Mw_8e73c07b-d40e-42d6-9f21-3b79cf02ed36">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Topic 326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company on January 1, 2023. Early adoption is permitted. The Company does not expect the effect of adoption to be material.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNy9mcmFnOjQwMDM1NTI3ZTRjNTQyOGNiNjBhOTJhMTIyNjNjN2UwL3RleHRyZWdpb246NDAwMzU1MjdlNGM1NDI4Y2I2MGE5MmExMjI2M2M3ZTBfMjI1MA_6c6ab359-2e40-40da-984a-8b9a9de75fdd">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8zNy9mcmFnOjQwMDM1NTI3ZTRjNTQyOGNiNjBhOTJhMTIyNjNjN2UwL3RleHRyZWdpb246NDAwMzU1MjdlNGM1NDI4Y2I2MGE5MmExMjI2M2M3ZTBfMjI1MQ_397b21be-efe8-4422-b6fe-a0dbc9174010">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Topic 326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company on January 1, 2023. Early adoption is permitted. The Company does not expect the effect of adoption to be material.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMjg3MQ_8dcd6cdc-207a-4456-91a3-816ef90d6d23">Fair Value Measurements and Fair Value of Financial Instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance on the fair value hierarchy for disclosure of fair value measurements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, and corporate bonds are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 1:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, $9.6 million of marketable securities have a remaining maturity between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMzg0ODI5MDcwMTczOQ_6a3d187e-f234-4fd7-9010-35776946dddc"&gt;one&lt;/span&gt; and two years. The remainder of the marketable securities have a remaining maturity of less than one year. Management regularly reviews all of the Company&#x2019;s investments for other-than-temporary declines in estimated fair value. The aggregate fair value of the marketable securities in an unrealized loss position as of September&#160;30, 2022 was $167.9&#160;million, which are highly liquid funds with high credit ratings that have final maturity of less than two years from date of purchase. Management determined that the gross unrealized losses on the Company&#x2019;s marketable securities as of September&#160;30, 2022 were temporary. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. Management concluded that none of the Company&#x2019;s marketable securities were other-than-temporarily impaired as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2022, the Company performed an impairment test to measure certain laboratory equipment at fair value. The assets are measured at fair value using Level 3 inputs on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable. Refer to Note 4, Balance Sheet Components for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMjg3Mg_7c3c2ed7-d3f4-49f9-833c-376c3ec9391b">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 1:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2b38d8b71f5349f99b74f3e4bd7dfb70_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNC0xLTEtMS0yOTA5NQ_1914152a-293e-44f4-8fee-6faef96356e3"
      unitRef="usd">10074000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2b38d8b71f5349f99b74f3e4bd7dfb70_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNC0zLTEtMS0yOTA5NQ_4c9a23cd-2815-4d3e-9aaf-a6d2ce09de01"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2b38d8b71f5349f99b74f3e4bd7dfb70_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNC01LTEtMS0yOTA5NQ_f94854a2-3f24-49fc-a2a3-ad57358c6c61"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b38d8b71f5349f99b74f3e4bd7dfb70_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNC03LTEtMS0yOTA5NQ_cd1755b3-3d3e-44ab-9075-54cc3c79f2a5"
      unitRef="usd">10074000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9a51274da0d34c37ad110f512dfb6c25_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNi0xLTEtMS0yOTA5NQ_9dd54f37-2856-4233-a322-db737491b844"
      unitRef="usd">81323000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9a51274da0d34c37ad110f512dfb6c25_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNi0zLTEtMS0yOTA5NQ_4386ed42-2b49-4d1c-845b-e46a5d788aff"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9a51274da0d34c37ad110f512dfb6c25_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNi01LTEtMS0yOTA5NQ_9241cbb6-59cf-463a-a671-8a6934a94a17"
      unitRef="usd">1165000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9a51274da0d34c37ad110f512dfb6c25_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNi03LTEtMS0yOTA5NQ_41b325ce-ce6f-45e0-ba61-22e1b26f63b1"
      unitRef="usd">80160000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib282142f99284b73981803c872356bd9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNy0xLTEtMS0yOTA5NQ_c579d60a-7387-42c5-a9ea-c54928530a4d"
      unitRef="usd">99867000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib282142f99284b73981803c872356bd9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNy0zLTEtMS0yOTA5NQ_839f5c76-d0d2-4a93-a704-b8d42dee2416"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib282142f99284b73981803c872356bd9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNy01LTEtMS0yOTA5NQ_f0b6c498-1706-47b1-bee4-e32c1bc7be81"
      unitRef="usd">294000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib282142f99284b73981803c872356bd9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfNy03LTEtMS0yOTA5NQ_2930bab6-f275-440e-980b-c4279879eeab"
      unitRef="usd">99573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i873db4f7c8b74c7fadbdceb695e76de6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOC0xLTEtMS0yOTA5NQ_c2e225e9-3692-4619-b2c7-ed50ca82a212"
      unitRef="usd">2059000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i873db4f7c8b74c7fadbdceb695e76de6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOC0zLTEtMS0yOTA5NQ_758e059d-345c-4d67-b278-01aa4a6741bc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i873db4f7c8b74c7fadbdceb695e76de6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOC01LTEtMS0yOTA5NQ_e2bcd36b-c95e-4be9-aada-6b07c0b38767"
      unitRef="usd">49000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i873db4f7c8b74c7fadbdceb695e76de6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOC03LTEtMS0yOTA5NQ_3cc57d66-8350-4a2b-bb6b-c6109ecb6335"
      unitRef="usd">2010000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie3979c9c68184f3089401c14ce8a48c1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOS0xLTEtMS0yOTA5NQ_cf689aff-08e4-4ebf-9fca-63c3bb13c78a"
      unitRef="usd">193323000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie3979c9c68184f3089401c14ce8a48c1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOS0zLTEtMS0yOTA5NQ_4f47668f-ce2d-4d18-9364-636b06f49f9f"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie3979c9c68184f3089401c14ce8a48c1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOS01LTEtMS0yOTA5NQ_22368786-52b1-4ee4-a52d-eb0bc4f18b30"
      unitRef="usd">1508000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3979c9c68184f3089401c14ce8a48c1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfOS03LTEtMS0yOTA5NQ_63eff477-ece1-4cc3-bd9d-2c9ee2565f89"
      unitRef="usd">191817000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTAtMS0xLTEtMjkwOTU_cd3ee2b0-4694-491a-86fa-11b3cdf6b259"
      unitRef="usd">72987000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTAtMy0xLTEtMjkwOTU_351c34a0-808d-49ae-825d-5fc064dc2857"
      unitRef="usd">2000</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTAtNS0xLTEtMjkwOTU_e40d30fc-0d59-4c91-8fd0-51b2063cdc5d"
      unitRef="usd">6000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTAtNy0xLTEtMjkwOTU_03f035c5-2869-43dd-8ef5-a109be317fbd"
      unitRef="usd">72983000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTEtMS0xLTEtMjkwOTU_69dfd962-e273-46c2-9cc9-bcbc404cdac1"
      unitRef="usd">120336000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTEtMy0xLTEtMjkwOTU_dde1acbd-665a-4198-b9d5-0faedee330ae"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTEtNS0xLTEtMjkwOTU_c8597a7d-3e64-4fef-a535-e89cf3e998dd"
      unitRef="usd">1502000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjhjZTZiZjJjYTNhOTQ1NjhiMjc5YTlmOTgxYjFmN2QyL3RhYmxlcmFuZ2U6OGNlNmJmMmNhM2E5NDU2OGIyNzlhOWY5ODFiMWY3ZDJfMTEtNy0xLTEtMjkwOTU_b444dec6-8e23-456a-880b-c30cc96c426c"
      unitRef="usd">118834000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i791b55383c7c4814974ebaa3df5a5e64_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNC0xLTEtMS0yOTA5NQ_c1042386-d6c5-48c3-b4e5-f844d45020b8"
      unitRef="usd">10311000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i791b55383c7c4814974ebaa3df5a5e64_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNC0zLTEtMS0yOTA5NQ_fb6006c9-21d4-4f87-926f-5efc4a91249f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i791b55383c7c4814974ebaa3df5a5e64_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNC01LTEtMS0yOTA5NQ_321fe48c-ca7b-4863-80d7-a6f39cd6b192"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i791b55383c7c4814974ebaa3df5a5e64_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNC03LTEtMS0yOTA5NQ_bbe3c309-1139-4ecf-8920-946d51ae604e"
      unitRef="usd">10311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i15d7519e0368492d811f7889f8f65003_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNi0xLTEtMS0yOTA5NQ_fab60d24-4631-489b-bea7-a30c5129ed01"
      unitRef="usd">62268000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i15d7519e0368492d811f7889f8f65003_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNi0zLTEtMS0yOTA5NQ_56eb0168-3b8c-4f78-a874-509acd9213e7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i15d7519e0368492d811f7889f8f65003_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNi01LTEtMS0yOTA5NQ_2dd532b7-e8b9-4815-a804-4d5cdef9cfc6"
      unitRef="usd">218000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15d7519e0368492d811f7889f8f65003_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNi03LTEtMS0yOTA5NQ_19e59563-c20c-4eb4-9d01-c486a48c9090"
      unitRef="usd">62050000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6ebe063f5210487eb63855bfa84821b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNy0xLTEtMS0yOTA5NQ_a92f7566-4147-4020-a329-bbd8c0ffc86c"
      unitRef="usd">177215000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6ebe063f5210487eb63855bfa84821b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNy0zLTEtMS0yOTA5NQ_449ec846-3eaa-44cb-9005-e36200e29e52"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6ebe063f5210487eb63855bfa84821b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNy01LTEtMS0yOTA5NQ_89293f57-ca9e-4010-b61e-f28c4d5b2c3c"
      unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ebe063f5210487eb63855bfa84821b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfNy03LTEtMS0yOTA5NQ_83edf786-8078-4c08-8f39-7d8728c8fc18"
      unitRef="usd">177155000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2b8a5bca20fd4ab780190fe9cbc37eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfOC0xLTEtMS0yOTA5NQ_93eb4cf4-4c59-4ba8-971a-5c938a75d4c0"
      unitRef="usd">47323000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2b8a5bca20fd4ab780190fe9cbc37eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfOC0zLTEtMS0yOTA5NQ_bfe94d0b-af8e-4b72-a0b0-c81d461bbf60"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2b8a5bca20fd4ab780190fe9cbc37eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfOC01LTEtMS0yOTA5NQ_98ec34cb-79f9-40b6-8be0-2494d598fd3b"
      unitRef="usd">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b8a5bca20fd4ab780190fe9cbc37eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfOC03LTEtMS0yOTA5NQ_982cbb28-fa92-4df5-9b23-4b8f365182d1"
      unitRef="usd">47284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i45214185b5144da5833b2593032606d2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTAtMS0xLTEtMjkwOTU_350a6fdd-5839-4077-aca0-fb815f641a18"
      unitRef="usd">297117000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i45214185b5144da5833b2593032606d2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTAtMy0xLTEtMjkwOTU_d26f7a66-20f8-4d3e-83cc-56465a246879"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i45214185b5144da5833b2593032606d2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTAtNS0xLTEtMjkwOTU_b8f47752-eacd-491f-bbd4-44d1c8f262a8"
      unitRef="usd">318000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i45214185b5144da5833b2593032606d2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTAtNy0xLTEtMjkwOTU_0644256e-6df5-48be-b56f-324baf567176"
      unitRef="usd">296800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTEtMS0xLTEtMjkwOTU_2c70c894-356f-4ce6-938c-59fe4845f5f2"
      unitRef="usd">25808000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTEtMy0xLTEtMjkwOTU_b9e6bf0b-2d47-4d59-9810-5018b91d8b34"
      unitRef="usd">0</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTEtNS0xLTEtMjkwOTU_321dc26e-bc0d-4863-a424-15708723822d"
      unitRef="usd">1000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTEtNy0xLTEtMjkwOTU_6fa078b6-f805-4a59-b1da-d657b081dd59"
      unitRef="usd">25807000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTItMS0xLTEtMjkwOTU_a061fc74-bfe7-456f-8bfa-83b53c2ec273"
      unitRef="usd">271309000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTItMy0xLTEtMjkwOTU_20e087a3-9593-461c-ac8a-e0519539d8ee"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTItNS0xLTEtMjkwOTU_b7d5bc10-0323-4903-b87c-c24dcb469906"
      unitRef="usd">317000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RhYmxlOjZhYWY2OGU3MDhlMzRmMzZiNWNlZTg4MTI1ZmJmNDY2L3RhYmxlcmFuZ2U6NmFhZjY4ZTcwOGUzNGYzNmI1Y2VlODgxMjVmYmY0NjZfMTItNy0xLTEtMjkwOTU_4b86c8a1-7b4b-4677-80a6-d5f286ae3c3a"
      unitRef="usd">270993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfNTQ5NzU1ODE2NzYz_0dd88c63-7553-4bfe-88c1-c920d772e5ed"
      unitRef="usd">9600000</advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i516fa99e52e24c8d83b6da7334ab3f9a_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMzg0ODI5MDcwMTc0MA_d66b1efe-662b-4342-93e3-6844a6959377">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMjc0ODc3OTA3Mzk0OA_fe93a4bc-041f-4d03-9e89-7b3403bd8789"
      unitRef="usd">167900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80My9mcmFnOjg5NzQ4NjM1NDNmNTQ0NzBiNjAyNTJlZWEwMTZhYTAwL3RleHRyZWdpb246ODk3NDg2MzU0M2Y1NDQ3MGI2MDI1MmVlYTAxNmFhMDBfMjM3Mw_85c842eb-f0e5-43bc-a613-002a6b236a5c"
      unitRef="usd">0</advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RleHRyZWdpb246Y2RiNzZkYTRiMzRmNDE4MmE4MDVmNzNjMjBlZjc1NDJfNzM2_de8e30ba-5a02-42c3-9501-d7672ae6747c">Balance Sheet Components&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an impairment analysis for certain laboratory equipment assets based on the identification of impairment indicators during the nine months ended September&#160;30, 2022. The analysis determined that the fair value of the assets, which was determined using a market approach, was lower than the carrying value. As a result of the evaluation, an impairment charge of $2.0 million was recognized for the nine months ended September&#160;30, 2022. The assets indicated as impaired were written down to their estimated fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued nonclinical, clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RleHRyZWdpb246Y2RiNzZkYTRiMzRmNDE4MmE4MDVmNzNjMjBlZjc1NDJfNzM3_8908bf50-eae8-449a-a37a-41bb82811a48">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id6877ebb93e445a3a2cefb8eb73f1d51_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfMi0xLTEtMS0yOTA5NQ_40d3787a-cb5c-4b88-b438-785825ae3b5e"
      unitRef="usd">1325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ica79f5395f3b4b1ba885cad3da2e3411_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfMi0zLTEtMS0yOTA5NQ_d2dbba9e-1ab1-444c-914f-17dcdb7ff2c9"
      unitRef="usd">1224000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3b8bf7bd53f54d4c801f071028410a38_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfMy0xLTEtMS0yOTA5NQ_cce88107-a2c4-4d18-b816-1bc13efe9830"
      unitRef="usd">16368000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic95b4f1bc3f54077994fca5c6a6559a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfMy0zLTEtMS0yOTA5NQ_c40fcd74-178f-4954-b007-102bb4f130e0"
      unitRef="usd">12778000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9da0b7851f7b452aa126439ff59ef51a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNC0xLTEtMS0yOTA5NQ_f1b079af-9c4a-40a7-9605-54cd04029ec5"
      unitRef="usd">868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2b828ba25c3d418d8eda881a27399aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNC0zLTEtMS0yOTA5NQ_169d5c2d-16c5-4aba-970b-3900d7d239bb"
      unitRef="usd">1136000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i20efbf626199415a933fd647730ef5bf_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNS0xLTEtMS0yOTA5NQ_ea5d71aa-e59b-46e1-afca-d84e4010526f"
      unitRef="usd">34336000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8313d8ae20774ec3899f99bacdb83cf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNS0zLTEtMS0yOTA5NQ_19da7c73-6865-4d6e-8276-06b29534bf2f"
      unitRef="usd">26701000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3befe5528eac478382c46f05cfe1a877_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNi0xLTEtMS0yOTA5NQ_1a14fbdc-c531-4699-8eeb-4a07df715780"
      unitRef="usd">1076000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i073bece618d24b9dade2383ac940ee3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNi0zLTEtMS0yOTA5NQ_b8001ddc-d1e0-4c89-85dd-a98bcacc8c4c"
      unitRef="usd">4395000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNy0xLTEtMS0yOTA5NQ_79b83b94-e0f6-426e-9e37-5a0f75e58dd8"
      unitRef="usd">53973000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfNy0zLTEtMS0yOTA5NQ_c4db7dc0-b84d-4198-bd08-b3416ea47ef1"
      unitRef="usd">46234000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfOC0xLTEtMS0yOTA5NQ_1fca1225-9a90-41ce-aaf3-86e317ece564"
      unitRef="usd">17394000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfOC0zLTEtMS0yOTA5NQ_51ff52db-9bdc-4a4a-949e-a23bfd2997ae"
      unitRef="usd">13174000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfOS0xLTEtMS0yOTA5NQ_8acd5199-9b9b-48d9-81c0-ac65c987a0a8"
      unitRef="usd">36579000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmUwYjUxMjdiNjRkNDRiZjQ5OGZmZDdiYWMzOThkOTI2L3RhYmxlcmFuZ2U6ZTBiNTEyN2I2NGQ0NGJmNDk4ZmZkN2JhYzM5OGQ5MjZfOS0zLTEtMS0yOTA5NQ_34c6f6b4-9248-4ae3-b484-25649343b626"
      unitRef="usd">33060000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RleHRyZWdpb246Y2RiNzZkYTRiMzRmNDE4MmE4MDVmNzNjMjBlZjc1NDJfNDg0_8371a063-0b36-4ebf-8439-2ffc97044f7c"
      unitRef="usd">2000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RleHRyZWdpb246Y2RiNzZkYTRiMzRmNDE4MmE4MDVmNzNjMjBlZjc1NDJfNzM1_035b2838-1771-41c8-a358-d456bb6bae93">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued nonclinical, clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfMi0xLTEtMS0yOTA5NQ_3d58b01f-ce35-4c19-8acb-c527894cb05b"
      unitRef="usd">8604000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfMi0zLTEtMS0yOTA5NQ_a8dc7491-3c3f-4dd1-b080-cff0d4da72ec"
      unitRef="usd">9209000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfMy0xLTEtMS0yOTA5NQ_abb8cc09-2f21-4ba3-95a7-0f9cf341c4f0"
      unitRef="usd">6580000</advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts>
    <advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfMy0zLTEtMS0yOTA5NQ_fd61b5db-a44a-42d1-9ffc-cdf0ce748745"
      unitRef="usd">4953000</advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts>
    <us-gaap:TaxesPayableCurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNC0xLTEtMS0yOTA5NQ_97536b62-867e-41ad-bef8-7e23d03bd578"
      unitRef="usd">301000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNC0zLTEtMS0yOTA5NQ_990ccc23-3078-4d96-89ba-7e17b213da73"
      unitRef="usd">1318000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNS0xLTEtMS0yOTA5NQ_46a32900-03fc-408e-b839-2faff05dc61b"
      unitRef="usd">469000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNS0zLTEtMS0yOTA5NQ_e1a5a4af-a43d-4e9e-ba8d-da41f29554a7"
      unitRef="usd">550000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNi0xLTEtMS0yOTA5NQ_4fbe26dc-afb0-4e78-a606-59816993ef4c"
      unitRef="usd">585000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNi0zLTEtMS0yOTA5NQ_dfbf2927-9aa5-4f94-b6eb-83eba38edeb7"
      unitRef="usd">2017000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNy0xLTEtMS0yOTA5NQ_d0f2b3a9-f39f-456e-a3fe-fa7305f458f1"
      unitRef="usd">16539000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80Ni9mcmFnOmNkYjc2ZGE0YjM0ZjQxODJhODA1ZjczYzIwZWY3NTQyL3RhYmxlOmJkNjRhMDMwNGRmZTQ4ZmZiODY2ZDc3YTVkNDdjOTI1L3RhYmxlcmFuZ2U6YmQ2NGEwMzA0ZGZlNDhmZmI4NjZkNzdhNWQ0N2M5MjVfNy0zLTEtMS0yOTA5NQ_8157ade0-f587-4a96-98c5-de4caea45c7c"
      unitRef="usd">18047000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xMTg2L2ZyYWc6NmQ4NzQ0NWE4YjkyNGU4MThmYzlhNjQzZjI3MzlhN2YvdGV4dHJlZ2lvbjo2ZDg3NDQ1YThiOTI0ZTgxOGZjOWE2NDNmMjczOWE3Zl8yNzQ4Nzc5MDcxOTM5_1b6a8e02-f6ab-4e59-9d6c-94a882f71333">LeasesSublease income for operating leases is recognized on a straight-line basis over the lease term and is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. In the three months ended September&#160;30, 2022, the Company reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. The Company assessed the collectability to be less than probable and recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses in the three and nine month periods ended September&#160;30, 2022. The deferred rent receivable as of December 31, 2021 and September 30, 2022 was $0.8&#160;million and zero, respectively. As a result of the adjustment to eliminate the deferred rent receivable, sublease income for the three and nine months ended September 30, 2022 was a negative $4.1&#160;million and a negative $0.8&#160;million, respectively</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xMTg2L2ZyYWc6NmQ4NzQ0NWE4YjkyNGU4MThmYzlhNjQzZjI3MzlhN2YvdGV4dHJlZ2lvbjo2ZDg3NDQ1YThiOTI0ZTgxOGZjOWE2NDNmMjczOWE3Zl8xNjQ5MjY3NDQ0MjIx_5e80dc58-0f6f-4822-bc2a-74ad79d9b986"
      unitRef="usd">800000</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xMTg2L2ZyYWc6NmQ4NzQ0NWE4YjkyNGU4MThmYzlhNjQzZjI3MzlhN2YvdGV4dHJlZ2lvbjo2ZDg3NDQ1YThiOTI0ZTgxOGZjOWE2NDNmMjczOWE3Zl8yNzQ4Nzc5MDcxOTQw_2655a5aa-69ab-4ba1-a2c3-a91b9e57f3fc"
      unitRef="usd">0</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:SubleaseIncome
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xMTg2L2ZyYWc6NmQ4NzQ0NWE4YjkyNGU4MThmYzlhNjQzZjI3MzlhN2YvdGV4dHJlZ2lvbjo2ZDg3NDQ1YThiOTI0ZTgxOGZjOWE2NDNmMjczOWE3Zl8yNzQ4Nzc5MDcxOTQ4_2349e8bc-f14e-48a4-ba4f-6bea265bad87"
      unitRef="usd">-4100000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV8xMTg2L2ZyYWc6NmQ4NzQ0NWE4YjkyNGU4MThmYzlhNjQzZjI3MzlhN2YvdGV4dHJlZ2lvbjo2ZDg3NDQ1YThiOTI0ZTgxOGZjOWE2NDNmMjczOWE3Zl8yNzQ4Nzc5MDcxOTY0_5d7f4bba-70c0-45ed-a2a5-3a995714d790"
      unitRef="usd">-800000</us-gaap:SubleaseIncome>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RleHRyZWdpb246NzkxMTFiZDUxZWY5NDUxYzk3NTNjYWVhYzZjYzRjMGZfNjg0_b11f362c-8e43-4fb7-8d30-6f15fe230288">Equity Incentive Awards&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s option activity and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted during the nine months ended September&#160;30, 2022 include 2.5&#160;million shares of performance-based non-qualified options with both performance and service vesting conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units (&#x201c;RSUs&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSUs activity and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Grant-&lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted during the nine months ended September&#160;30, 2022 include 0.4 million shares of performance units with both performance and service vesting conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, by operating expense, the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RleHRyZWdpb246NzkxMTFiZDUxZWY5NDUxYzk3NTNjYWVhYzZjYzRjMGZfNjgx_0c175639-bafe-4607-891e-c73bc67c8622">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s option activity and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfMS0xLTEtMS0yOTA5NQ_48a03442-a3ac-414d-9f70-cbc5f0d1114c"
      unitRef="shares">13288000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfMS0zLTEtMS0yOTA5NQ_c4173c18-4b9a-47cc-8cf8-89bdf81b36ba"
      unitRef="usdPerShare">9.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfMi0xLTEtMS0yOTA5NQ_2c497bf6-5888-47cb-9660-ce88dc1761c0"
      unitRef="shares">10592000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfMi0zLTEtMS0yOTA5NQ_b3cb5763-4c44-4329-a0fc-9af2be7bd57f"
      unitRef="usdPerShare">1.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfMy0xLTEtMS0yOTA5NQ_c4b011e2-8776-4084-9e93-dbfdda1f4be1"
      unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfMy0zLTEtMS0yOTA5NQ_c618f739-c3b3-4c26-ba04-b8528ba5555f"
      unitRef="usdPerShare">0.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfNC0xLTEtMS0yOTA5NQ_b9fc145f-2ae9-4052-bd15-c19cd608cc20"
      unitRef="shares">4644000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfNC0zLTEtMS0yOTA5NQ_1400d636-d32a-4387-ba91-478c2d6581de"
      unitRef="usdPerShare">5.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfNS0xLTEtMS0yOTA5NQ_c3d1e135-be04-4064-bff3-b356dd21d911"
      unitRef="shares">19221000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfNS0zLTEtMS0yOTA5NQ_97ef3c0d-c64e-47ce-a026-a989ded1f6ae"
      unitRef="usdPerShare">5.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfNi0xLTEtMS0yOTA5NQ_81359fcf-374f-4b6f-b09a-e832058c55ac"
      unitRef="shares">5302000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmNlYmNhYzUzMWQ4ZDQ4MzJhYWEzNDg0N2I1MmE1MDQ0L3RhYmxlcmFuZ2U6Y2ViY2FjNTMxZDhkNDgzMmFhYTM0ODQ3YjUyYTUwNDRfNi0zLTEtMS0yOTA5NQ_3e9f2366-1d17-4003-b662-eb4a8cd77a1f"
      unitRef="usdPerShare">11.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i79d4b72dd8084e709d360860964f3246_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RleHRyZWdpb246NzkxMTFiZDUxZWY5NDUxYzk3NTNjYWVhYzZjYzRjMGZfMTg4_9d427ba1-007c-44b2-aad5-fd393b98104a"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RleHRyZWdpb246NzkxMTFiZDUxZWY5NDUxYzk3NTNjYWVhYzZjYzRjMGZfNjgy_aabd97e1-d433-46a5-99d8-d1901c2dabc6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSUs activity and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Grant-&lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i576e4bb113d94eed83356af145669908_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfMS0xLTEtMS0yOTA5NQ_d251ea09-a4d0-47a7-9c21-e70d9e1e1af5"
      unitRef="shares">2126000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i576e4bb113d94eed83356af145669908_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfMS0zLTEtMS0yOTA5NQ_cf8d8063-4a35-41d2-8a64-eb55964e37c9"
      unitRef="usdPerShare">3.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfMi0xLTEtMS0yOTA5NQ_9e0f1673-f3a6-4bbc-896c-5f1a0154ff6f"
      unitRef="shares">857000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfMi0zLTEtMS0yOTA5NQ_d84343cb-5d94-437b-a434-6e582073f760"
      unitRef="usdPerShare">1.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfMy0xLTEtMS0yOTA5NQ_1f1342cd-e75c-4ae7-a8e6-60686cf97cce"
      unitRef="shares">833000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfMy0zLTEtMS0yOTA5NQ_d09dcd1c-fa86-4872-a8b6-e21ed9e077f6"
      unitRef="usdPerShare">3.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfNC0xLTEtMS0yOTA5NQ_a4029860-4b21-443f-ac8d-a850b67373bc"
      unitRef="shares">426000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i7bffc2b027c34641a5a1987b175b8643_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfNC0zLTEtMS0yOTA5NQ_b2603026-7433-44e2-b427-fb838684bba8"
      unitRef="usdPerShare">3.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iac1959e2c1824ece92a8a5edf1bfaac6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfNS0xLTEtMS0yOTA5NQ_f048c02d-b6b0-45da-afaf-61afee3b9d74"
      unitRef="shares">1724000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iac1959e2c1824ece92a8a5edf1bfaac6_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOjEwY2M1NTUyMzlkNjQ0ODJiZTRiOThjMzI2MTdlOWMwL3RhYmxlcmFuZ2U6MTBjYzU1NTIzOWQ2NDQ4MmJlNGI5OGMzMjYxN2U5YzBfNS0zLTEtMS0yOTA5NQ_95397f98-01d5-4b34-b145-f5aa45457895"
      unitRef="usdPerShare">2.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i79d4b72dd8084e709d360860964f3246_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RleHRyZWdpb246NzkxMTFiZDUxZWY5NDUxYzk3NTNjYWVhYzZjYzRjMGZfNDYz_e625cc40-3f5f-41b7-b973-68c97b9150e0"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RleHRyZWdpb246NzkxMTFiZDUxZWY5NDUxYzk3NTNjYWVhYzZjYzRjMGZfNjgz_a8bd42ca-55ac-4da7-9fea-1139870e7221">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, by operating expense, the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i29b93864200e4683b63e032b6c30feaa_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfMy0xLTEtMS0yOTA5NQ_5b41d156-02e8-4849-a6ae-81cef1a7e34a"
      unitRef="usd">1432000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4d0ce2c0d4824b3893f8f9741ffe6466_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfMy0zLTEtMS0yOTA5NQ_8cf22146-d2be-41f2-8be9-8d01bd02099a"
      unitRef="usd">2207000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i65531dff90074634acb629953b46148e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfMy01LTEtMS0yOTA5NQ_49c10927-9032-4e6e-a6f9-679c39450dce"
      unitRef="usd">5195000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i74b15a520ab64b8ba0d52607a8761034_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfMy03LTEtMS0yOTA5NQ_d8660514-876b-494e-9a26-92dab99ddf1b"
      unitRef="usd">7125000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if5cc515fb7324c88b70e0087f46cd446_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNC0xLTEtMS0yOTA5NQ_278ba22e-e757-4d3a-9bc3-6ed315962738"
      unitRef="usd">3071000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8482f95dee2f458a9ec19baa5f1da9dc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNC0zLTEtMS0yOTA5NQ_f17b8bbd-1ab9-44ba-b904-1c49e87201e8"
      unitRef="usd">3119000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ee3bd88ea5a4bfab2257c3d73958b7a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNC01LTEtMS0yOTA5NQ_b9915ce1-f01e-4f06-9a96-49daeffa164c"
      unitRef="usd">9631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i76d9330c6a204905a56b7b28a34889ae_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNC03LTEtMS0yOTA5NQ_73cdb347-bd99-49fd-a23c-7e8fec76bccd"
      unitRef="usd">13659000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNS0xLTEtMS0yOTA5NQ_30e0bcda-6d9e-44b5-afd4-267ebd2519a2"
      unitRef="usd">4503000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibd26e4830b1f447696438191d3d579bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNS0zLTEtMS0yOTA5NQ_a3e04ea6-7eba-4ffd-95e0-b228bad5a1ea"
      unitRef="usd">5326000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNS01LTEtMS0yOTA5NQ_4d8e6841-5fd8-476f-ab7f-d97343e3a7dc"
      unitRef="usd">14826000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV80OS9mcmFnOjc5MTExYmQ1MWVmOTQ1MWM5NzUzY2FlYWM2Y2M0YzBmL3RhYmxlOmJiY2ZjNjUxZGJiMDQ2MTQ5YzM3NzUxMzg5ZjlhOTkxL3RhYmxlcmFuZ2U6YmJjZmM2NTFkYmIwNDYxNDljMzc3NTEzODlmOWE5OTFfNS03LTEtMS0yOTA5NQ_a57734fa-51d1-4e6c-8896-cd2d2942404c"
      unitRef="usd">20784000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RleHRyZWdpb246MmMyYjZkYzBhYjUzNGM4MzgxZjY1ZTk4ZDY2ZTcwNGFfODM1_b23930b8-88f6-4ec9-a9ef-45936df99d8c">Net Loss per Share&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, rights under the employee stock purchase plan (&#x201c;ESPP&#x201d;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,859&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,593&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RleHRyZWdpb246MmMyYjZkYzBhYjUzNGM4MzgxZjY1ZTk4ZDY2ZTcwNGFfODM2_0eb6bd34-c3ad-4863-ac8c-e080639053ba">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,859&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,593&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8e1fbe5196e04b16b259d139c7ef556a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfMi0xLTEtMS0yOTA5NQ_34a90b08-6fce-4776-a875-341a1c1f9800"
      unitRef="shares">19221000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie986bf5a8039432c815e7e22b77b230a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfMi0zLTEtMS0yOTA5NQ_1ca23b86-a707-4dbb-84d0-6eca939b9f74"
      unitRef="shares">13859000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i849c716b759343fb82104acfaafcf33f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfMy0xLTEtMS0yOTA5NQ_3fb88740-dc43-46ca-8a7d-1496cc60e35a"
      unitRef="shares">1724000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i027ecc53eb374b44b0ff45c72b438658_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfMy0zLTEtMS0yOTA5NQ_963f3b70-c87a-46af-b53b-bd0bb3cf9ff7"
      unitRef="shares">2593000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i058b41effd8f43b9be1d05aaf73dfe08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfNC0xLTEtMS0yOTA5NQ_5623aaeb-8c07-473c-b9c6-002bb5128cc9"
      unitRef="shares">760000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0d479b8fb7b044e3aa6c6ab883f2dd7a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfNC0zLTEtMS0yOTA5NQ_51e64d7d-884d-4bbe-b9c8-464bffb39050"
      unitRef="shares">400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfNi0xLTEtMS0yOTA5NQ_3cd7eed3-d392-40e1-8416-6843c50bab52"
      unitRef="shares">21705000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3659ac98c350444699eab7faf3dbc135_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81Mi9mcmFnOjJjMmI2ZGMwYWI1MzRjODM4MWY2NWU5OGQ2NmU3MDRhL3RhYmxlOjBkMmFmMzc1NDM2NjQ0NjNhZjgwOTJmNGJhMThmY2JkL3RhYmxlcmFuZ2U6MGQyYWYzNzU0MzY2NDQ2M2FmODA5MmY0YmExOGZjYmRfNi0zLTEtMS0yOTA5NQ_508c9f40-c7e6-41ba-921e-aa0dc2b7069d"
      unitRef="shares">16852000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfODk4_36ffea94-0a4b-4d54-a8f8-f135ca91f0cc">Restructuring&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, the Company implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize its clinical development of ixoberogene soroparvovec (&#x201c;Ixo-vec&#x201d;), formerly referred to as ADVM-022, and focus its pipeline strategy on certain highly prevalent ocular diseases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the restructuring plan, the Company reduced its workforce by 75 employees (approximately 37%) as of July 6, 2022. Below is a summary of restructuring costs during the nine months ended September&#160;30, 2022 and accrued restructuring costs as of September&#160;30, 2022 :&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and Benefits Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the three and nine months ended September 30, 2022, the Company recorded $4.7&#160;million of restructuring costs, of which $3.7&#160;million was classified as research and development expenses and $1.0&#160;million was classified as general and administrative expenses. Substantially all of the restructuring costs were incurred during the three months ended September&#160;30, 2022, of which $4.5&#160;million were paid. The Company expects the restructuring to be completed in the fourth quarter of 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate
      contextRef="i16076e8ab5354387af2ac1ec6fc8cbdc_I20220706"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfNjUy_2ca24d4e-9401-4b3e-a43d-b179ea658e09"
      unitRef="employee">75</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent
      contextRef="i16076e8ab5354387af2ac1ec6fc8cbdc_I20220706"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfNjgw_65ef25d2-795f-4327-9fed-0ca34ee8b43c"
      unitRef="number">0.37</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfMjc0ODc3OTA3NDA0NQ_d874e181-da6e-4262-97aa-f359ebe5ce42">Below is a summary of restructuring costs during the nine months ended September&#160;30, 2022 and accrued restructuring costs as of September&#160;30, 2022 :&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and Benefits Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i71258ef0094f45c882375b7e1010e7ef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfMi0yLTEtMS0zMDkxOQ_dea720e9-f40a-4f25-a0cb-457969a1143d"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i58f2678ad14b4a3d881b892b268a77d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfMi00LTEtMS0zMTEzMQ_cecc875d-08cc-4647-901d-d2c52400ec3c"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i1ce599b6e3c3466c8ca651ad131d59f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfMi02LTEtMS0zMTEzMQ_bd91ebbc-e490-4677-9478-38b01647443f"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i22948541eb864302a316aae361adb856_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfMy0yLTEtMS0zMDkxOQ_d48e9edb-0b1b-4356-ae51-d841222c70da"
      unitRef="usd">4632000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie0c3eb26c891436cabc497ed5bd59128_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfMy00LTEtMS0zMTEzMQ_eeb89bd0-52d5-4564-bce3-525c6759d43a"
      unitRef="usd">53000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfMy02LTEtMS0zMTEzMQ_29ddf2e2-a907-4a64-861c-2f0e92bd2262"
      unitRef="usd">4685000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i22948541eb864302a316aae361adb856_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNC0yLTEtMS0zMDkxOQ_78452f18-f021-4ed4-b916-4550dfb220f3"
      unitRef="usd">4539000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ie0c3eb26c891436cabc497ed5bd59128_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNC00LTEtMS0zMTEzMQ_6cbdb3e5-ce67-4d64-868e-bbde9e4c4261"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNC02LTEtMS0zMTEzMQ_bf43f571-9164-4b48-b713-016d0bf4abc8"
      unitRef="usd">4539000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i22948541eb864302a316aae361adb856_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNS0yLTEtMS0zMDkxOQ_3e08ebca-1af2-40a8-991a-48fe57075b25"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="ie0c3eb26c891436cabc497ed5bd59128_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNS00LTEtMS0zMTEzMQ_e1b710c4-304a-4dc4-8dc1-74e1038546bd"
      unitRef="usd">53000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNS02LTEtMS0zMTEzMQ_560855db-2a5d-433d-b9ba-af2f91471deb"
      unitRef="usd">53000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserve
      contextRef="i1ad217fa80da4c1da3ead4e449ee044e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNi0yLTEtMS0zMDkxOQ_3eb624ad-1d6d-4e3e-b585-caf7fbfa424a"
      unitRef="usd">93000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id96f08f18d8844938eb17eab71c615ff_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNi00LTEtMS0zMTEzMQ_14cc7934-ce40-4c52-97c4-080e59cc3e8c"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ieb2df3a435684436bddd5c51c154a23a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RhYmxlOmY0NmMyZjM0MDU5MzRmOGJhN2IyOGM5MTA3MzRiY2I5L3RhYmxlcmFuZ2U6ZjQ2YzJmMzQwNTkzNGY4YmE3YjI4YzkxMDczNGJjYjlfNi02LTEtMS0zMTEzMQ_5e96048f-a80a-4d1f-b03c-d26928eef18b"
      unitRef="usd">93000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i212f30cf841742a9837912319faa7a3f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfMTY0OTI2NzQ0Nzk5Mg_d2d30699-e9b4-4bcd-9a77-489043b67181"
      unitRef="usd">4700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i65531dff90074634acb629953b46148e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfMjc0ODc3OTA3NTcyNg_34be0018-a38a-44b1-b146-2350e4781c21"
      unitRef="usd">3700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i5ee3bd88ea5a4bfab2257c3d73958b7a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfMjc0ODc3OTA3NTc0MA_2746e95d-409e-42a3-9edf-97091a9b727e"
      unitRef="usd">1000000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i60530e05c7914c9782b93e270c2a4057_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGZjODRkYjI1NzQ5MzhhNTJjMmI2MTljMGM2MDE5L3NlYzpkNzhmYzg0ZGIyNTc0OTM4YTUyYzJiNjE5YzBjNjAxOV81NS9mcmFnOjQ3YWIzNzJjZmRjOTRiOGE5MTU2YzQ4ODU5ZjQ0YzI3L3RleHRyZWdpb246NDdhYjM3MmNmZGM5NGI4YTkxNTZjNDg4NTlmNDRjMjdfMjc0ODc3OTA3MzY0OA_d3dc6574-8b70-4a2d-ba0d-8c784173091f"
      unitRef="usd">4500000</us-gaap:PaymentsForRestructuring>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #R":E4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  \@FI5[K%;XN\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9++
M:L,P$$5_I6AOC^7T <+QIJ6K%@H-M'0GI$DB8CV0IMCY^\IJXE#:#^A2,U=G
MSL!T*@CE([Y$'S"2P70UV<$EH<*:[8F" $AJCU:F.B=<;FY]M)+R,^X@2'60
M.X2V:6[!(DDM2<(,K,)"9'VGE5 1)?EXPFNUX,-G' I,*\ !+3I*P&L.K)\G
MAN,T=' !S##":--W ?5"+-4_L:4#[)2<DEE2XSC6XZKD\@X<WI^?7LNZE7&)
MI%.8?R4CZ!APS<Z3WU;W#YM'UK=-VU:<5[S9M%SP.W%]\S&[_O"["%NOS=;\
M8^.S8-_!K[OHOP!02P,$%     @ /()J59E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M*2\1^]Z:5:ZZ^1=ZQR1L+J>E[T).+* \3_,1M6V4D"AS4Z<]=>JE_BPTK5X
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M#Z"O9?V9HKY18EN=P]\*I41>76YXG/!2 ^#]G1#J\48WT'XLFOT#4$L#!!0
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MLFR^O+D6^@]E];&+<?=_4$L#!!0    ( #R":E5\<)/S0P(  -T$   8
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M((+>L.H_92'W5XML$11T1[I*WK'G?]#!H$3IRUDE]/_!\R ;+H*\$Y+5PV!
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M3O:W\PV)#\69L\$9K6[JL)T^E^.-MM)66AIQB44"+V,0?YW,0_1@UM]W5:@
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MB&#K=;!:+'MY)_%Z-J;%^3(!\7&@Q$$X7Q](9^LQ+44A^Z =&/X#R[-HG1P
MSL/5&"M1L(J64-3",?=XG2SC8+U:CH%PS!;M:S)N13\B!=:+PR!)%D<6]1+!
M!;O1*E@E,_8*I:6)@LA'0?0_14$218]' 6W^PRA8Q$&\6 V<&\'0"W+C Y$0
M+9=!',W1HTX6T=B_1O/YO2"8+;WC>IX)H@!K\6KV+\(@7D,(G Z9"6&+UXM@
M%8:/!D$\QS;H.NE1N[3\VT"(E\B(<$VFI!!(HN78KX;!>IVP2U_<[E>#@#U;
M3Q:X?!4%W2-!TSCMBP+(<HX!@*.*TUVX*9R.]O;H-NY.H 7#X^P5EK!'50M$
M@OH\W88$W88>%#ZH;PPNHGLX*-%Y)=:D\9YW5&;1==HIF*7".(!@!?>M5Z-2
MD@FK)DS<8 IHJFLW3IA^D,Z.R=I6T$URW;2+?HGY3#TW9 6OE^]-U*K($!97
MXZY$ZY1(A!_RMSU 9^1N)_Q)L/:SN\HP,[G.1BDW9D\O#XUS)=_[V7=#O3.E
M1""?3-A[L:4I7+.?T(G8+$#J%OYZ<>V_<Y UX0K5SFE=R_<=NOG,@;?)0S>S
MZ>"BC<39^<\)-,35RC5W[GZU_V)QV5S4#^3-YXZWW.RH?!1BBZ/A9#D?,=-\
M0FA>G*[\M7VCG=.E?\S1*X4A NQO-91K7TA _QWGXB]02P,$%     @ /()J
M5=695$JI!   BPH  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULK59;
M;]LV%/XK!UXPM( 0Z^)KEAA(TA0MT&Y!TVT/PQYHZ=@B*I$J2<5Q?_T^4K+J
M#FZP GN1*/*<[WSG*E[NM/ED2V9'3W6E[-6H=*ZY&(]M7G(M[+EN6.%DHTTM
M'#[-=FP;PZ((2G4U3N-X-JZ%5*/59=B[-ZM+W;I**KXW9-NZ%F9_PY7>78V2
MT6'C@]R6SF^,5Y>-V/(#N]^;>X.O\8!2R)J5E5J1X<W5Z#JYN)EX^2#PA^2=
M/5J3]V2M]2?_\;:X&L6>$%><.X\@\'KD6ZXJ#P0:GWO,T6#2*QZO#^BO@^_P
M92TLW^KJ3UFX\FJT&%'!&]%6[H/>O>'>GZG'RW5EPY-VG>QD.J*\M4[7O3(8
MU%)U;_'4Q^%(81%_1R'M%=+ NS,46+X23JPNC=Z1\=) \XO@:M &.:E\4AZ<
MP:F$GEO=B$JHG.DA5,"MKANM6#E[.79 ]S+CO$>ZZ9#2[R MZ;U6KK1TIPHN
MOM4?@]5 +3U0NTF?!7S@YIRR.*(T3M-G\++!U2S@9?_)U0]<"<<%O9(VK[1M
M#5OZZWIMG4&A_'W*_0Y]<AK=-\^%;43.5R-TAV7SR*/5SS\EL_B79[A/!NZ3
MY]!_*$W/(IWF^3UXNC=H?^/V)%1!=Y];V: A742_0NR;,_YZIG"6:[2M!8#>
MD"N9-KI"^TNUO2"DU7&]9C/DEEYQWN\D82>A%V\5]'1K@6U?!D:M@\!@)ABU
M>N-VPC"=41)EZ32\TW1"[\1:&^&TV1]I)+,HFRTH2:/Y?$&O6Z.D0]H#TD8^
MN5 ""R\1)=F,WC&:O=150;)NC'[D.D0DFT093M-9-(\3$%.HF+:;,%(1!+>
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MPK+$;9&-%\#Y1FMW^/ &AOOGZA]02P,$%     @ /()J57;0. .: P  [@@
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MV/,_"/V,?42S0M8UH'*%#B'L  S.@$/Z1-,)\H)^*^Y;D@#VJV"ULSJR0TP
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M?FY14^3Y )[SNV![P0:Z[W)7_P%02P,$%     @ /()J579,JLW@ P  :@D
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M.=/F>G\V;QY)7[A<Y72*%;@D5[_7I[:6S<.CF6A1V\M^(30]'>QP36\UE,:
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MB)P@%)A:Q\#H]X(S%,(1D8P_6\Z@">F ^^,=^V>?.^6R9 9G2OSDF<U'03^
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MT.CZ0R\ 77>WVK"J]!UEJ2SU)S_,Z4% [1QH?:64W1DN0//$C/\"4$L#!!0
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M0*6!>+XFA!\VTD'S7PW_/U!+ P04    "  \@FI5WX*T\G4#   6#P  &0
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M9O*&'7^'QJ&YYL4L$]4O.M9M%S,'Q:60+&^,U0AR0NM_?-\(T3'P_6<,_,;
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ML9*)EWM>Y4"RO-@VVC I658<QJ"JCNL)ZOJ6,?D\T#>H=QX7_P%02P,$%
M  @ /()J5<%+0WX5 P  "A$   T   !X;"]S='EL97,N>&ULW5AM:]LP$/XK
MQEU'"Z..X]6+USBP!0J#;13:#_M6E%AV!++DR4J7[-=/)SG.2W6EZX<MFT-J
MZ1[=<X_NSI7)N-5K3F\7E.I@57/1YN%"Z^9]%+7S!:U)>R$;*@Q22E43;::J
MBMI&45*TX%3S:#@8I%%-F @G8[&LKVO=!G.Y%#H/D]X4N-NG(@_C]&T8.+JI
M+&@>WI^]_KZ4^NI5X.XG;TY.!O?G5X?V,PN<AY&7]/(9I!<#G-=@&'6Z3VV7
MGQHBYWAJW:)NZY-Q*<5^!L!@>$E-@P?"\W!*.)LI!EXEJ1E?._,0#'/)I0JT
M2;T)%(.E_>G@V,V@*AU/S814-K:+X/[.NN4'P&8& AGGO<!AZ R3<4.TIDI<
MFXE=;(V/H* ;WZT;H[!29!T/+\.M@[V9(#.I"JKZ,'&X,4W&G)8@1[%J 7<M
MFPA K65M!@4CE13$:MAX= -#.Z><WT++?BOWN%?E3L4&4"_1#XV@;NAHW 3X
M=]D<]R[MX$6\0<,>I/ZX--L1=@X]1F\4+=G*SE=E+P!CCW%VTC1\_8&S2M34
M;?[9 2=CLO$+%E*QGR8:M,K<&*@*@P>J-)OO6GXHTMS1E=ZTTZK$-0__0<U_
M-L\5%501OBO:]/XQ9_G%BI-W?TNR_:]R*-BKL3N'CEWDY?&+3++CU]B=XD<G
M,NI.G9VC;>]@ZZT!O$#DX5=X$>';H,%LR;AFHILM6%%0\>A\,_2:S,R+WAZ_
M65_0DBRYONO!/-R.O]""+>NL7W4#B>A6;<>?87MQVK^]F%A,%'1%BVDW5=7,
M#@,S,%&["QP.D6M[^1',QV%^!# L#J8 \W%>6)S_:3\C=#\.P[2-O,@(]1FA
M/L[+ATSM!XOC]\G,Y=]IEB5)FF(9G4Z]"J98WM(4OGXV3!MX8'$@TN_E&J\V
MWB%/]P%6TZ<Z!-LIWHG83O%< ^+/&WADF;_:6!SPP*J ]0[$]\>!GO+[) E4
M%=.&/<$XDF48 KWH[]$T1;*3PL=?'^PI29(L\R. ^14D"8; TX@CF +0@"%)
M8L_!@_,HVIQ3T?;7C\DO4$L#!!0    ( #R":E67BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ /()J5=DZG/TS P
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MU)L%Z,VH-PO0FU%O%J WH]XL0&]&O5F WHQZLP"]&?5F 7H;U-L(T-N@WD:
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M<',O87!P+GAM;%!+ 0(4 Q0    ( #R":E7NL5OB[P   "L"   1
M      "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #R":E69
M7)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N
M>&UL4$L! A0#%     @ /()J5?!QXC3/!0  RQX  !@              ("!
M#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #R":E6V
M&W#E@@4   X7   8              " @1,.  !X;"]W;W)K<VAE971S+W-H
M965T,BYX;6Q02P$"% ,4    "  \@FI5OQV*4- %   X&@  &
M    @('+$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M/()J5>?906_O#0  EI   !@              ("!T1D  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( #R":E5\<)/S0P(  -T$   8
M          " @?8G  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    "  \@FI57K@V&<D'   4(P  &               @(%O*@  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ /()J5>!:DUAE!@  K@\
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #R":E6SN?$K4P0  %P*   9
M      " @<=.  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ /()J5;\TZ2"E P  > @  !D              ("!45,  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  \@FI57X%L.V0$  #O"0
M&0              @($M5P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( #R":E74J:;ODP<  *,3   9              " @<A;  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ /()J579,JLW@
M P  :@D  !D              ("!DF,  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    "  \@FI55:,^DMT#  #I"   &0
M@(&I9P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( #R"
M:E7>R"8L$@0   D*   9              " @;UK  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ /()J5372*IL! P  ;@8  !D
M         ("!!G   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    "  \@FI50P&TDM("  !N!@  &0              @($^<P  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( #R":E4EN:3YA (  "X&
M   9              " @4=V  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ /()J5=I0,;D-!@  52$  !D              ("! GD
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  \@FI53F'9
MA=8"  "/"0  &0              @(%&?P  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( #R":E4Z\"B39P0  '45   9
M  " @5."  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M/()J5<=, Z$J P  N @  !D              ("!\88  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    "  \@FI5D#J$OID"  ":!P  &0
M            @(%2B@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( #R":E5J,X#=;@,   H,   9              " @2*-  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ /()J51WH'.ZG @
M@0<  !D              ("!QY   'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    "  \@FI5%^*4$58#  #G"@  &0              @(&E
MDP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( #R":E5$
M YBML0,  .$0   9              " @3*7  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ /()J5=^"M/)U P  %@\  !D
M     ("!&IL  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M"  \@FI5?W\V"IT#  #?$0  &0              @('&G@  >&PO=V]R:W-H
M965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( #R":E5P& 5S^0,  (44   9
M              " @9JB  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!
M A0#%     @ /()J5<%+0WX5 P  "A$   T              ( !RJ8  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  \@FI5EXJ[',     3 @  "P
M        @ $*J@  7W)E;',O+G)E;'-02P$"% ,4    "  \@FI5V3J<_3,#
M  "C%@  #P              @ 'SJ@  >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ /()J5> ]"5=H 0  2A0  !H              ( !4ZX  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ /()J51R:"5V, 0
MYQ0  !,              ( !\Z\  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     "D *0 6"P  L+$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>120</ContextCount>
  <ElementCount>176</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>27</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Stockholders Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Equity Incentive Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwards</Role>
      <ShortName>Equity Incentive Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.adverum.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/BalanceSheetComponents</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsTables</Role>
      <ShortName>Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/EquityIncentiveAwards</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/NetLossperShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/Restructuring</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Organization and Basis of Presentation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/OrganizationandBasisofPresentationDetail</Role>
      <ShortName>Organization and Basis of Presentation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adverum.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Equity Incentive Awards - Summary of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails</Role>
      <ShortName>Equity Incentive Awards - Summary of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Equity Incentive Awards - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Awards - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Equity Incentive Awards - Summary of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Equity Incentive Awards - Summary of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Equity Incentive Awards - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Awards - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Restructuring - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RestructuringAdditionalInformationDetails</Role>
      <ShortName>Restructuring - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="advm-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Restructuring - Schedule of Restructuring Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails</Role>
      <ShortName>Restructuring - Schedule of Restructuring Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtSecuritiesAvailableForSaleTerm -  advm-20220930.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:SubleaseIncome has a value of -4100000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:SubleaseIncome fact are: Context: i60530e05c7914c9782b93e270c2a4057_D20220701-20220930, Unit: usd, Rule Element Id: 7095. advm-20220930.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:SubleaseIncome has a value of -800000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:SubleaseIncome fact are: Context: i212f30cf841742a9837912319faa7a3f_D20220101-20220930, Unit: usd, Rule Element Id: 7095. advm-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="advm-20220930.htm">advm-20220930.htm</File>
    <File>advm-20220930.xsd</File>
    <File>advm-20220930_cal.xml</File>
    <File>advm-20220930_def.xml</File>
    <File>advm-20220930_lab.xml</File>
    <File>advm-20220930_pre.xml</File>
    <File>advm-20220930ex311.htm</File>
    <File>advm-20220930ex312.htm</File>
    <File>advm-20220930ex321.htm</File>
    <File>advm-20220930ex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="462">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>51
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "advm-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 120,
   "dts": {
    "calculationLink": {
     "local": [
      "advm-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "advm-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "advm-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "advm-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "advm-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "advm-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 265,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 10,
   "keyStandard": 166,
   "memberCustom": 1,
   "memberStandard": 25,
   "nsprefix": "advm",
   "nsuri": "http://www.adverum.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://www.adverum.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Balance Sheet Components",
     "role": "http://www.adverum.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Leases",
     "role": "http://www.adverum.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Equity Incentive Awards",
     "role": "http://www.adverum.com/role/EquityIncentiveAwards",
     "shortName": "Equity Incentive Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Net Loss per Share",
     "role": "http://www.adverum.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Restructuring",
     "role": "http://www.adverum.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Equity Incentive Awards (Tables)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsTables",
     "shortName": "Equity Incentive Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.adverum.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ieb2df3a435684436bddd5c51c154a23a_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ieb2df3a435684436bddd5c51c154a23a_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Restructuring (Tables)",
     "role": "http://www.adverum.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ieb2df3a435684436bddd5c51c154a23a_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Organization and Basis of Presentation (Detail)",
     "role": "http://www.adverum.com/role/OrganizationandBasisofPresentationDetail",
     "shortName": "Organization and Basis of Presentation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ieb2df3a435684436bddd5c51c154a23a_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ieb2df3a435684436bddd5c51c154a23a_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Details)",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ieb2df3a435684436bddd5c51c154a23a_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ieb2df3a435684436bddd5c51c154a23a_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ieb2df3a435684436bddd5c51c154a23a_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ieb2df3a435684436bddd5c51c154a23a_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ieb2df3a435684436bddd5c51c154a23a_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ieb2df3a435684436bddd5c51c154a23a_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ieb2df3a435684436bddd5c51c154a23a_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ieb2df3a435684436bddd5c51c154a23a_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredRentReceivablesNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://www.adverum.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i60530e05c7914c9782b93e270c2a4057_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i1ce599b6e3c3466c8ca651ad131d59f3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Equity Incentive Awards - Summary of Stock Options Activity (Details)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails",
     "shortName": "Equity Incentive Awards - Summary of Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i1ce599b6e3c3466c8ca651ad131d59f3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Equity Incentive Awards - Additional Information (Details)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails",
     "shortName": "Equity Incentive Awards - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i79d4b72dd8084e709d360860964f3246_D20220101-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i576e4bb113d94eed83356af145669908_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Equity Incentive Awards - Summary of Restricted Stock Units Activity (Details)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails",
     "shortName": "Equity Incentive Awards - Summary of Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i576e4bb113d94eed83356af145669908_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i60530e05c7914c9782b93e270c2a4057_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i60530e05c7914c9782b93e270c2a4057_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i60530e05c7914c9782b93e270c2a4057_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Equity Incentive Awards - Summary of Stock-Based Compensation Expense (Details)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails",
     "shortName": "Equity Incentive Awards - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i60530e05c7914c9782b93e270c2a4057_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Details)",
     "role": "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails",
     "shortName": "Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i16076e8ab5354387af2ac1ec6fc8cbdc_I20220706",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Restructuring - Additional Information (Details)",
     "role": "http://www.adverum.com/role/RestructuringAdditionalInformationDetails",
     "shortName": "Restructuring - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i16076e8ab5354387af2ac1ec6fc8cbdc_I20220706",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i1ce599b6e3c3466c8ca651ad131d59f3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Restructuring - Schedule of Restructuring Cost (Details)",
     "role": "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails",
     "shortName": "Restructuring - Schedule of Restructuring Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i1ce599b6e3c3466c8ca651ad131d59f3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "idbfe14fd14dc46eeae6028be0bedb756_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders Equity (Parenthetical)",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "ie5dc85d79f034bdd8444bb2de63ea7f8_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.adverum.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220930.htm",
      "contextRef": "i212f30cf841742a9837912319faa7a3f_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 27,
   "tag": {
    "advm_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.adverum.com/20220930",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical clinical and development process costs.",
        "label": "Accrued Nonclinical, Clinical, And Development Process Costs",
        "terseLabel": "Accrued nonclinical, clinical and process development costs"
       }
      }
     },
     "localname": "AccruedNonclinicalClinicalAndDevelopmentProcessCosts",
     "nsuri": "http://www.adverum.com/20220930",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent amortized cost.",
        "label": "Cash And Cash Equivalent Amortized Cost",
        "negatedTotalLabel": "Less: cash equivalents, amortized cost basis"
       }
      }
     },
     "localname": "CashAndCashEquivalentAmortizedCost",
     "nsuri": "http://www.adverum.com/20220930",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "advm_CashAndCashEquivalentAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent gross unrealized gain.",
        "label": "Cash And Cash Equivalent Gross Unrealized Gain",
        "negatedTerseLabel": "Less: cash equivalents, unrealized gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentGrossUnrealizedGain",
     "nsuri": "http://www.adverum.com/20220930",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "advm_CashAndCashEquivalentAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent gross unrealized loss.",
        "label": "Cash And Cash Equivalent Gross Unrealized Loss",
        "terseLabel": "Less: cash equivalents, unrealized losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentGrossUnrealizedLoss",
     "nsuri": "http://www.adverum.com/20220930",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashEquivalentsAndShortTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and short term investments.",
        "label": "Cash Equivalents And Short Term Investments [Member]",
        "terseLabel": "Total cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermInvestmentsMember",
     "nsuri": "http://www.adverum.com/20220930",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years",
        "label": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears",
     "nsuri": "http://www.adverum.com/20220930",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in lease liabilities and lease incentive receivables.",
        "label": "Increase (Decrease) In Lease Liabilities And Lease Incentive Receivable",
        "terseLabel": "Lease liability and lease incentive receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable",
     "nsuri": "http://www.adverum.com/20220930",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Operating Lease Right-of-use Asset",
        "label": "Increase (Decrease) Operating Lease Right-of-use Asset",
        "negatedTerseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.adverum.com/20220930",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other than temporary impaired investments available for sale securities.",
        "label": "Other Than Temporary Impaired Investments Available For Sale Securities",
        "terseLabel": "Marketable securities other-than-temporarily impaired"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities",
     "nsuri": "http://www.adverum.com/20220930",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_RemeasurementOfOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement Of Operating Lease Right Of Use Assets",
        "label": "Remeasurement Of Operating Lease Right Of Use Assets",
        "terseLabel": "Remeasurement of operating right-of-use assets"
       }
      }
     },
     "localname": "RemeasurementOfOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.adverum.com/20220930",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r195",
      "r200",
      "r216",
      "r217",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r337",
      "r366",
      "r367",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r195",
      "r200",
      "r216",
      "r217",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r337",
      "r366",
      "r367",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r161",
      "r179",
      "r180",
      "r181",
      "r182",
      "r195",
      "r200",
      "r207",
      "r216",
      "r217",
      "r246",
      "r247",
      "r248",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r337",
      "r366",
      "r367",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r161",
      "r179",
      "r180",
      "r181",
      "r182",
      "r195",
      "r200",
      "r207",
      "r216",
      "r217",
      "r246",
      "r247",
      "r248",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r337",
      "r366",
      "r367",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r21",
      "r306"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premium and accrued interest on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r8",
      "r157"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r15",
      "r30",
      "r31",
      "r32",
      "r357",
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r29",
      "r32",
      "r38",
      "r39",
      "r40",
      "r71",
      "r72",
      "r73",
      "r271",
      "r303",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss)/Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r253",
      "r254",
      "r255",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r219",
      "r257",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r202",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Issuance of common stock, additional issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r60",
      "r154"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r10",
      "r68",
      "r108",
      "r111",
      "r117",
      "r141",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r268",
      "r272",
      "r282",
      "r304",
      "r306",
      "r341",
      "r356"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r20",
      "r68",
      "r141",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r268",
      "r272",
      "r282",
      "r304",
      "r306"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r125",
      "r148"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r123",
      "r126",
      "r148",
      "r345"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Fixed assets in accounts payable, accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r6",
      "r62"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "advm_CashAndCashEquivalentAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "negatedTerseLabel": "Less: cash equivalents, estimated fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/OrganizationandBasisofPresentationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r57",
      "r62",
      "r66"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Cash and cash equivalents and restricted cash at end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r57",
      "r283"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of noncash investing and financing information"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r71",
      "r72",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r12",
      "r306"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r34",
      "r36",
      "r37",
      "r43",
      "r348",
      "r362"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Term",
        "terseLabel": "Marketable securities term (in years)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r133",
      "r149",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "verboseLabel": "Marketable securities in an unrealized loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentReceivablesNet": {
     "auth_ref": [
      "r290",
      "r291",
      "r294",
      "r302"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental income recognized over rental payment required by lease.",
        "label": "Deferred Rent Receivables, Net",
        "terseLabel": "Deferred rent receivable"
       }
      }
     },
     "localname": "DeferredRentReceivablesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r60",
      "r155"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r44",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r84",
      "r86",
      "r88",
      "r89",
      "r90",
      "r94",
      "r95",
      "r277",
      "r278",
      "r349",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share \u2014 basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r44",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r86",
      "r88",
      "r89",
      "r90",
      "r94",
      "r95",
      "r277",
      "r278",
      "r349",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share \u2014 diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance and Benefits Costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r38",
      "r39",
      "r40",
      "r71",
      "r72",
      "r73",
      "r75",
      "r81",
      "r83",
      "r97",
      "r142",
      "r202",
      "r203",
      "r253",
      "r254",
      "r255",
      "r262",
      "r263",
      "r276",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r303",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r196",
      "r198",
      "r199",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r279",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r196",
      "r208",
      "r209",
      "r214",
      "r215",
      "r279",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1:"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r196",
      "r198",
      "r199",
      "r208",
      "r209",
      "r214",
      "r215",
      "r279",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2:"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r196",
      "r198",
      "r199",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r131",
      "r132",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r151",
      "r152",
      "r153",
      "r197",
      "r201",
      "r275",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "verboseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails",
      "http://www.adverum.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r60",
      "r154",
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "verboseLabel": "Asset impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncentiveToLessee": {
     "auth_ref": [
      "r292",
      "r293",
      "r295"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of incentive granted by lessor to lessee.",
        "label": "Incentive to Lessee",
        "terseLabel": "Lease incentive receivables"
       }
      }
     },
     "localname": "IncentiveToLessee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r41",
      "r108",
      "r110",
      "r113",
      "r116",
      "r118",
      "r340",
      "r346",
      "r350",
      "r364"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r160",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails",
      "http://www.adverum.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails",
      "http://www.adverum.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r69",
      "r82",
      "r83",
      "r107",
      "r261",
      "r264",
      "r265",
      "r365"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r23",
      "r68",
      "r112",
      "r141",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r269",
      "r272",
      "r273",
      "r282",
      "r304",
      "r305"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r68",
      "r141",
      "r282",
      "r306",
      "r342",
      "r359"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r25",
      "r68",
      "r141",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r269",
      "r272",
      "r273",
      "r282",
      "r304",
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized loss on marketable securities",
        "verboseLabel": "Unrealized loss on marketable securities, net"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r57",
      "r58",
      "r61"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r33",
      "r35",
      "r40",
      "r42",
      "r61",
      "r68",
      "r74",
      "r76",
      "r77",
      "r78",
      "r79",
      "r82",
      "r83",
      "r87",
      "r108",
      "r110",
      "r113",
      "r116",
      "r118",
      "r141",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r278",
      "r282",
      "r347",
      "r361"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r108",
      "r110",
      "r113",
      "r116",
      "r118"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Deposit and other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r266",
      "r267",
      "r270"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r56",
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Cash payments made",
        "verboseLabel": "Restructuring cost paid"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalInformationDetails",
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r49",
      "r51",
      "r124"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r11",
      "r306"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from offerings of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r53",
      "r252"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r49",
      "r50",
      "r124"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r252"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock pursuant to option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r7",
      "r156"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r158",
      "r306",
      "r354",
      "r360"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of loan"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r260",
      "r338",
      "r377"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails",
      "http://www.adverum.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r9",
      "r66",
      "r374"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails",
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r163",
      "r165",
      "r168",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "verboseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent",
        "terseLabel": "Number of employees percentage"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r60",
      "r162",
      "r171",
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Charges",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalInformationDetails",
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "verboseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalInformationDetails",
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r165",
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Restructuring cost, ending balance",
        "periodStartLabel": "Restructuring cost, beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "auth_ref": [
      "r165",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.",
        "label": "Restructuring Reserve, Settled without Cash",
        "negatedTerseLabel": "Non-cash"
       }
      }
     },
     "localname": "RestructuringReserveSettledWithoutCash2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r14",
      "r203",
      "r306",
      "r358",
      "r371",
      "r373"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/OrganizationandBasisofPresentationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r71",
      "r72",
      "r73",
      "r75",
      "r81",
      "r83",
      "r142",
      "r253",
      "r254",
      "r255",
      "r262",
      "r263",
      "r276",
      "r368",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r105",
      "r106",
      "r109",
      "r114",
      "r115",
      "r119",
      "r120",
      "r121",
      "r205",
      "r206",
      "r339"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "License revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r129",
      "r130",
      "r134",
      "r135",
      "r136",
      "r137",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash Equivalents and Short-term Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r250",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r167",
      "r174",
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalInformationDetails",
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r169",
      "r170",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "verboseLabel": "Schedule of Restructuring Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r224",
      "r239",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Units (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Grant- Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetails",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r204",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Equity Incentive Awards"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r19",
      "r343",
      "r344",
      "r355"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r67",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r27",
      "r38",
      "r39",
      "r40",
      "r71",
      "r72",
      "r73",
      "r75",
      "r81",
      "r83",
      "r97",
      "r142",
      "r202",
      "r203",
      "r253",
      "r254",
      "r255",
      "r262",
      "r263",
      "r276",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r303",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r97",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r11",
      "r12",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Common stock issued under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r11",
      "r12",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Common stock issued upon release of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r11",
      "r12",
      "r202",
      "r203",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "terseLabel": "Common stock issued upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r11",
      "r12",
      "r202",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Common stock issued under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r202",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r202",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Common stock issued upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r12",
      "r16",
      "r17",
      "r68",
      "r122",
      "r141",
      "r282",
      "r306"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r298",
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Negative sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "State income tax payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r131",
      "r132",
      "r138",
      "r139",
      "r140",
      "r197",
      "r201",
      "r275",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r85",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted-average common shares used to compute net loss per share - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r84",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares used to compute net loss per share - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e40010-112707"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e40019-112707"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123394697&loc=d3e40879-112712"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123388062&loc=SL77916639-209961"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r378": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r379": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r380": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r381": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r382": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r383": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r384": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r385": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r386": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r387": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r388": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r389": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r390": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>52
<FILENAME>0001628280-22-029499-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-029499-xbrl.zip
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MNN$@,R#M70=>2NGN=[O5\=:%Q8&![# /)![VOZ+%@&VS8LL:ANCVNK=,TA\
MM[EB/H_PTWFO/XA'^FR]<M0+T!U48-:O[%L)DN^SY;CX5+ \N.E^V%>%LAM7
MF<,!X/\R>Q1&+I_X%* IW+I[,\O=1<_<3J-3%*T70E0.?'.WZJ,)C#TFG#A>
MG75>@;"QL$0_^):NTK&3BO@VKO!H2*)0 X]&)6IQFZJXC:WQ8YP=R.!4"%;=
M9_!@T0.6*V/+0$X'/%#T08"ARA##:/"-:+M[_9 7 RZHU&[%_=5M$[RO\D'7
MY?T0UE)E&"2@QGN3&0'+(JCBU44O+Z#&Z.5 ;-NJ, B3]Y4!CN[U>LG;QH7I
M/P)&:IZ;&L\]!@>?]- Z@ Q*@-@#O3&HE$([*VZ$Z0V],H-2?U?XH0IY/:7&
M[\(.=T\?,=8C&APL#H"5P)+ "7?FIYS:8]&+R;"%&FGNFG]>E']*2D_$N?Y3
M-FK)RBJ+,7;H%PCR+AQAP!0^P1@=YP9W7%$8]+!]4]JID1\"=(?WM.LAX.K&
MK@";ZL!W72]5$BC'8>"3<@.D#'],<$_--"\<>E!5N"B KKS<F"DW68;ZK JB
MCX?/*R-P"Q3!DHQB[9-Z)XP[J/:3GG*!1]%^5<8V@>+=87%4![ F<(D-<PD/
M*H#39>"6]O68,Q/^+#>#C.H'+19\DG#T+SP/N+X:H?2< O8=O>*38]^:RU&$
MY9;;QVQ?'J+,>=EL<+VXHWB'T1L8=:Y,-BA-Y^VOO0(E^VI]BVNK7;,,#'VY
M37 _ZE/^.)ITO_QR6..\Z;+_)*MW NAZR,C@E(#QT\."[\<W'"<W&R<C0\"G
MN5-]5XE7?U :R#*,WQ^>!T(_'1^JJ3SM/<4 D,)V70'=;W<(QT6]U"]%1"_+
M;0&Q*]\Q^%^!0.76<QE94Z6;-J)A&?48D;+8CJRPUV0L1O7[ZGKRJQ'Y)QCO
M[NM*C19?#'JPE/<&+#U"\$9,ZU;9]=V]EQBI-O 70W9YU <EWB\5$I"A9K>I
M;PT5!N6;O#3N6X[,92#A>.BVK;K=8%DF<7BUI_B0TK97$+JP6^6NH+)AZ@5R
M+PS19=BL&NTKC:931(<J%[8_LG)V_9O1EWZE_+0KH3[,%)XS[-XY+Z-M^4=V
M.;X>YR[B1\_8C (E[+J53)>/K[;0:JZ>YF[(:(^CW <IX%.@QQA\"0IJE%D#
M'JIKM^'3$(@9@L0NAXM&<',\:@RWM+KP;J=9;?>F2++7;96!=.KK^RHH!(4O
M0\#(!SOC*J Y3I$\#%W:C#)45$2*LA&E@VA:U5&GI4XY+WRZ(C6A<O8G<Q%4
M^\&V<NE!5#D*-<U?:"]Y3 6'))%"UQ;^6'X;00H?[_('*KH'Q?RXHAVT\M[P
MM!4I ^:AS#PN46W6C<N@4"W"4]:Z=S3YWAR-"><F;"6" BAB*JTJVZ0:J=I:
M*)#LB(@1F/;NH(S!# LE4KJPP4%5W5$$?-C-0DYE$4^JR3[5_8=S-:A UJ#:
MF"N23F^_[3M3NJ-!&8\R8K_"!Z71+M3T/4Q:$V[:ZE=/Q!1,:8=-"Q"IZYZ.
MLJ5#0F(WA(-:V7F!S"_#=D[QH2)D0>M2T'K5+NLCD*HFWQ3E;B06UR-)J[1O
MZ>+<;F7<>5&/)I6//+9Q;ZE(1U5EO<-CN\^WPEOX5#517SB]KG(\'W=2*J*7
MT9QO.#0C\UP"H]#</@CW92]O?R5SJJ[[FA;3T;KN:Q&F\N)U7[7:^U[OOZ6Z
MP3\')?=AXW!C9,_:ZG)DS#)@^*Q?IH5=J/:P-$T5Z(#;0@5$'M*@@K%SX %D
M /VS?+2A]T38I][*>/%-_BK 6YFPBK!%D0NL7D@B#;Y<< M&Q#0] "E/;\3>
MRP2N$&R="/QR= QI7_UA_[PD%LC=^FWPK!"]<K=Z/$>W]+S;;C"Z_GY6SM/9
M/96\WP7R1AN3MMJ5+%S\]3MT6Q4:3<IXJ0T&;I3 4>Y2/(9^QW) [FHD:]Z9
M%N^$\]':X\FH$QLFCW- $0-VT9N=[5OOY:E$64"P10IQN+XP''YB$Z;(!ZXT
M1+7=LWZ;^U#P<+?:9!W;';\L&/!19GF,P^[J/"M>J[EG:MRS"PL:DCN+C)<G
M\SJ+O*_^(&QC/N([/5UY,IZS^IB=&67BC'3(:"OBEO1%$64&.BFXRF-IJ+=;
MC!6KU1PQ34Q1:>US4"A%?M(HT#P ,U&5S([JI0?@!KK!>&+[5^*.!7E5F24:
M<N+M>J6W0L9?+W<3G%29P X,.<A5%7H.D33E77Y;4%56-A39U'D$1BR#WXI<
MU0+,AE1F>&CWJT!G3)GUSD.C@6$W:*!1 =0H)3&,'[@M)!_6_/8B&JA"L$_8
MLF_H$N#&ZSN],!9O!: #F,C<UF:$O#F;J\LP[*A&NWSD^GAFPN0@ ,U4NS"(
MV405[GB"WA-)@>&9Y4TA(R'/BI*=83?DA9GLO.!L>!_0I9TJI^_)I.R0U5!L
MKMU6:,'<.Q,253/F]#SFX"6%ZKDRH2KKZ"' E0)^5_PQAG. GK=UW*%^JJK6
M*_DJZKO3.[7Y-'G'VY1\@7$&X)2'3.V T\.=PP*; V1J/Z5A;]M2U-L TV.$
MICLM#RX]'^IV9L!*@&VI-N#N?*<QZ>^;? CZJY#0B;X1X8[P1:BV&Z7H%<Q4
M9D^,'@!:HFIA\A5C&C3B-Q#T*)5KPIT/'/B4GOT:@]8,->T\XWM;L"X4<5YD
MYF[WYPM8-'=5;.Q>5#OLMVY^L7]4U'"$5/Q0Y^O]^L@Z5)4?1=E9!=)S5]"\
M3!#LN)!6?_N<SNV!W%5]5SX$W3/66>+N@O4G9P!,VP]5H^W'"LE#Q8G+:Q::
M]BX68(G>,&RWW%F*K SR%B0;Q?A.\]XE (LJTUD5K4CN-069P-XUH:::NV%Z
M.8C119:# ?^M:H'V>O_CWDZ,9=7U[/<HD,5U0)!:JE^$ULO<U<E28/BR4! C
MQWE4V V"G W&.X&4 XQ2,N^ZFGVE@=ECU<7C?2Y";LF#NM,[W**Z55B@JG"M
ML>B4N0B\8%M6<&9FU.\NZK=4?F<P)KKT!3[2KG(92E@Y7MP E&K!4P$\7/3"
M+G/;57WLA@!* -'DCX]:#E3U4;NK;ZGZJ"THR8L1-T-SI,Q,4.#Q[HT+R@3E
M;D\!_[]"]I#^=7=*%E"\Z#A<^B4AT2$/D"(W6;_L<1<N?WJP[%;F*^W0/0UU
M=>&W5J]M Y,49NC.L<TZ'1#_$+NS67LX2E0+92Z1JK1/"1#*!Y3,7$!@%Y!%
M'=N=;K;HJ#%,V/T+7@4 27O[Y;WXA;NJVD?U;CL,M-5E831&19[]];L"Q/7
MBCZ>\'M: !(+!JGZ3ZV/9:OUP+<YK<!&D=A2AO2  RZ4N5X/??+46'YCU>$F
M?%GQ\W7TVUWCFMOOX*LL<$#_]THW/6BAL1%%^U5$LYT5)>Q5\%*5N3O/61M
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M2Q(CC$HX5A93;+GTM%!0&!.*:P6U6 KJYIZ"XB25B2,J=DXG,0,C$ZLD<;'
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M8N11IK2*1E<CWIZZ'\P9<4]#$%&K,CU59 ?#>N)B]"1D=$[)>FTYRT9<T[X
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M8+57UA/A,!'P2A&7P!"CA<KVU?G\_>Y9V"T;]'+'"SPWMCEWN9I T%XPIUT
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MJ,;MJI2JE*J4.DGOUN>+UYGH:^!ESQ:<:*\DHN2,%&>:@(^4E*H9HDP"&U-
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M!?$FE"9]9QV*G5W)*^!NF"I7P*U2JE+:_+KM:A;OQ ^93R4[J[UFRA!%@R&
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M91CC8L%##>P\%!UN/;!S4]6]S#_2X*\8R)<X'E657DZEYZD'1^-$])8XIX&
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M$5."8?G3?'%BJPM/9N8_& W&8<GQ)W1F,,B[#_IGQV^)(S"'<E/#V.H"Z-V
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M7M7JEPL]7/JT,%(7-?:8_M_SE5BM2=_K'0,:,RH?-QYQRM\,>KHWV=F#D1L
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M^=NO_U4)^ZH*^PK(>N5%>P!QGO6B<>(8%3XB'R6(LX@8.2M)OKZ*."J39(X
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M.XJL#0*EP QS1A/,[=HFW;CJCJA)":1R;V23XSCVB]GN^GR772Z@"$^A_XY
MX(JZEKWQ7CUI#9LUD+_F]!-%?8'Q/:RU'W%0%#2$_1:*DM"#!35S%I3YT"M4
MYN,3C '@(PME6?'C"TC3H/9'+K! \5^?/G\9%#^2O_[U5(J 7 RI&%$QH$(
MJXH@9460TV_6NF!4)"APQA"75B!C@D:!&$P\#=9Y^50K@N0M6]4#J>J!O.QZ
M("6.5Y5 ?ED)I%;PL?)/V[E.YSO;ZM?^L>W1RZL(,G5R454%6:IW5B@9N7.$
ML&!XC$$S)J1-A LIC<'ZWJN"E.7P=KI C49%*%-QG<]>TW;'9DFCU\U\-H87
MX[4]>GL"?R,-:+M^UO[>./J(=[<_M [V/K5V]YI'];/<O]#>_5H_F75,U/=>
M Z'Z L_NG.U^_4@;V:G1^=!NO-\1N^_K9_6C_9\-^B7W=5&UD$ %B18;9'G
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M-1CVBW"X%Y:_?0N$2L)[041RBE'NM78*1XRU2ESZP,]C6RO_U*HBU(*<;*I
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M_6/K>D$JP,N@.D^P\L"G.!CV6SY[6$KW3W$+4%5UX#K.PX'> -51PC#.DM.
M;]SZ9&WRB?U.9%"%?2N%??-U,_,J:\4Q"IXSQ*6W2%L5$.%&>B]Q9,(NZ<+3
M%<YPO!OT/76QQU1%[P6+CBGN.'<X)2Z\HHXS+86N*,^3%_NY:S4E2\PIC+Q6
M%L3>)N0$<\@%[!SSR:2D<A%*4 0OE/$\0>=./AZN?#K7 9W0CA,8:M"),V=<
M) $+8#>*A12Q?BQ^4V'9C;%L06DE(2FS-H+1YK/YIIA'SGB),*;."4*U]V9M
M4TE<^6R>*X$)7!FGDU,.<QYA-T@O+1!;EF@(ZM%\-I5<WT:N9SF*(%'R +:(
MUCP@[ES,<JV!K7"7DLM!)WAM$_;/BV HJ]?AI_+-NSJ[[E(79QFWR3]+*K;\
M)+3*YEPI/%]PO.:#BC$P%)BAB.-($*R^1%)SY@5VUN7 ?DK6%;YSE=XEBM^J
M^*@JM/E]M%E^-E:%-BN&-G/L$6MO$L?(JR@1)\XB0TE$UN+@J5-8FES?2ZYK
M<><;H586;9X<&5N]#C^5;_YNGMZU"7E+R=83*YNMI^\]6Z\XA![Y(2B([N%6
M-WR*1=;4%L#,CT)E;+<&OMT;C%8GO:1QGIS[D0'. _[FI%G ^KU/K=WW;T5]
M[PO=/_O(=[>_B / \_VS'3:;7M+8#LW]HSJK=QH=T!>B\7X'WO?]9V/OX*BQ
M?<@;>^U.8_O34?THI-WM[_P;DRE%:SC"ECO$@^#(ZJ11 N7LK2$)^[E$/J:I
M)DPG#@O#E8TZ8AD,49'!7[7SL^DHE];B-W+X?OF^U<OAV^G6/HS:IT5<^GJ1
M?I)IB>V>UEJ=XW;LE+DMMM:?GIJ<R-([CGT[SEB[R$OIQS J%&1.7ZF! FK6
MFM$&G\E,D50V+L<(#PU[M>-^JY=YT5FLM8:#FH?N9?4U?>5J?E7K9\_%?N\P
M=B,HQ7[OV/9_]'Y$?Y[UMO.SA^#W2>+;>L&:8A^&U8\I]L?Y;G90V]K^IXZ*
MD>:^I)X?#8HW'[>.8YZ;6G'U1#P\K<&2>M"F%D;1A.F"IH[[L4P-JO5R0D^_
M!A@;+0P%(.)6J/@X"_WE/)'P\E+F],'+"U^L8<[V@XDYZ?6_PV3ZF!,FKV34
MD]3$&4X-#$G)J,%J8X(SK6RBUI/H):@#[X+_MC,NARBGJ?1.X]T-,?)-;S!L
M%+FBN^GOWJ!5[+NW[5:GU<T?[W1]+,*8]WK;\/LY7<8O##X;1U].OU%O*0_Y
MUAL.RH@[!CR7LX <46#I2 %0E8] YLWJ\[S30>T/>WS<[_V$=1K&]C7;H<S?
M7<IFH/>R%<#(ROD1YSL"T1>W)0Y/ODD1$Q6!(F5$0ISE:]Q2# A[RWB,VG$&
M&HO-WS'Y?_^5L12 N= <LDQJNG>B=)&E>\T>&+Q4CE0_@OYL>P:V+6ML;^'B
MRBO%(]$$!2LCXE129)2U*#%AHHO"1TYG&9-B%C-+C)' V!5GQFGB352*2H55
M_OYEQO0:]/1)3NJVM<&H XSF-.^+RQK&YW6IA?*7H@! UK0=>&]SD%-J0=6<
MIWV59O4D4:Y,0_<>7A46-EINPZN>?G4]A;N:Q_UR%IY0,JV0&TS<1]8KT_SI
MI.A6G:4; M\X37GE$B)?0IIPKGX"/*4 O==@ZZ1,P NE]G )PT\KI;3(541%
MI;/:=*FS:KX6SU=Q5<*]ASX\H*P3\>M$Z:>U1 ^<)?VD@UYO-J.O;;N$U6'M
M@P6:!Q25W+@.0W4I='4I]/B&)T*%C@ECPW/J@]:4*>%4S&?"4<54^"](MFFO
M/Q>^9+S"+['_8Z8F9VK]!"O\+/9[*W/"^YO6[+@<YSYN=.JG!T=U7(?/ZV>?
M.KOO/S0;=.=T%ZS:.EBL\+?6/MT1LR>\T!:T^Z%3/_MXTMC[?M9XO\_W.V\9
MC)'OGWW_6=_V\+</1_M'[9RV>3H^X3VK;W__N0L6<+2*XFA0XCC7E:?B_V?O
M39O;QI)TX;^"J*YWKBL"9'&75+[3$6HO/9Y;7MIV==UYOW2 P"&)-@BPL4AF
M__J;VUFP4*)D+92+$S'5ED0"9\D]G\SL!8-PWIM,3\YF9\%P.!E'/_P9P\;#
MT?/O#_M[E$7?J2R:GBY&LY/3(!I.YI-@')V>#N>G9Z/Y:'8:G)Q$9T=9]/BR
M:&!DT>=7_W[[MW^$*@Q/3Z91;W :AHA0/NF=#891+QJ%TQ%0A HQVGJ414=9
M= ![NX$L&H9J>G8VGZEQ.)[,9N%I&,RF0Q!-XV$T/5N,C[+H\671J"&+YM'9
M4,WG84]-S@8@BTY %DU.3GOCT_E@"))I,ADOGHXL.C:ZN(Z=7ZR"?*GV"2,>
M1P#??FC.Z&QR.IT 8YW.)N/!*!@/9T&@QC,0AO/3Z>S&]0HUB2A7^#0 P4]"
M+&[;[N+D5)VI:-X;S(?@)(ZGLUZ@IL->=#H9CD:C\&00!3CJ<3:^*SSP$ZTB
M^+X960W"L0)?*CP]&T[&LS"8AY.S$Q5-YV#0#$<WKP'O9N0CK]Z$5YONE (Q
M>S:/!KWI*)KV)M/9I#</U1A^G(:SD^E9-!GCR,!OGLEZ9-3#9=0[KQ \:MQ[
MYN*F(S(ZBZ+%2(UZP1DV9@B BT]GP[ W6@S4V6@>C48S&JX\.[VK>K_OQ@TY
MI$3<OFY(4*R\3;!=TWR%=1"I^\C ?>?];)X]IDOR02[O=9;79.512-Z5D'SW
MHN66G)Q.IJ/%\+2W&(QPJ%P$IL[9< 9&SW00+>9P;XLQ3: ?MWN/MA $3RAD
M_)TS\F-Z)/OQ\3'@>EL6;GHKLW >S<=JV@O5#/L'DYUSJGKS>:3.U"2<C&;#
MIQ-P/7+R-ZCDN_99CBKY ?BYE4!93,:+Z<FP!WIXTIO,)Z>]^<EPW!L,9]$
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MXY-YXB.01(+O2GL9,ANY*7EP$9>@MA/[IK]_-B02I_\4W=;)VI$JXF7*[XO
M(@%^\I(,/%A0+6O#V2ZK)DB]9/X$BR2>XV#738F4G0%'E=K8!O,EFP/K^XX
MP$66E P .0 6%O(/C3XV<5GS@7F5@\/,,Z,3C*4%9L3U.F#Q!;^/H]9[%[GZ
M5T5/R!*TTT#Y]2Z"@K\"D@M-B 0Y?YEGE_AYTN[FY/[^ZJ^OS='!,=KC S&I
MJ16.(0&B*<@&2H$J%:CQR,<SW>2Q*G'@D<@HD&)%#'\Z/_][_V1]ZJ.$SK=L
MS]3.+\S(/"EH]7"OE1D>+;S-,M-]A2-/0S@&598B-3F* 721%G*XX-*!FY5X
MH4K@ZBC89*C)(:;:AM$0 Z+3A!+797^\1NFO>. X$E_O,LO!9+F(C:NCA1.L
M)8D7L*:J!,FKV(X%>R1&$\Z>*OI$+ <3-&!QV2(H563<44LA\%3]#+[Y2[#+
M,*"FW5!-)Y'BS +QP#/C7I3>^=N7YJHO5QD9DT*8:-(B R+U($EHMNDRG Y)
M/OW.VV)A@8**DB%D1<)Y@1611BDJ)6 C<WBH0KW9E#Q]9NLE\*4PL38:0GI
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MFH9A#6&%6AP/D>PY60ABHN)<"FDH#P^V!_I4CER. KA,#<NBPA&LD H(">V
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MBKM7'C9Y[9ISI7MOPN]"$+X%W.:/@_[(4"'0S8^C<?_4_$*380G29"\Z''E
M<VMXRJ0ODR)N_:AA'^G+RRYPW$%BEDR$OLEC.&@X."\"9D%RAU?V!V;=YL-
MZHL@C!/0S<KRAVY!RD,4O!^'#B>Z7RV"!-X"GY.W)-FERKV5"J(0C)P2]I3
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MA.I]29RSYNZ^U88=@M]Y:ZXZ=('3, CW.N6]3,("K;DUOI!,01E)!#1/1F@
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M!V2Z3RB86TZ>GMF6<F[OTT:W?7QBDG%?A!^'([>WO\P\83 W-;['_F/V-8+
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M]J#K"TM)$.,HT()QT;,U7"?#)^IV6E=&,6OML%[2#O)@O4>OR<=7\UVF;6Y
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MFX&@1VT%8K//".Q)8G,F)H<OM4)'UX98RJ6;H9ZHN'SS=:=?66?[03.WD1"
MC6)SFS1 ^[GP[*B@SA(1&<=3<'X3;!]5 ,D%NHIQ>U4>Q^\F$(<X[$X:404Y
M4TRISA$"R7>!;G1L0BO-4H6;DT([GE=KYN!4W-)ZX$B(#]FMP:21'D12<K"2
MG")U0;RAUVB]4F$ !Q#6]]ZB!X-<@%WR75N ^NBD"8^S#QD(PQX2SU")EX%$
M>RQ<-'?W1CG.7@%7#GSR884!HW&7>L>87"[.64N.4PHFY1I\BGSYL@BZ>GSA
M.H@:C44,%U%O!-?3Q+7H((B0"$^%[>BDZZ@(G:W3!M(^57LLM0MC>%'V;@$R
M9X6!#T6>N'O>_BV-L082T G4$T4VAO?MM7(4F#3)(Z-I:!)V,^FP_1Z"D7?A
MS,X2-;\[;8HFU!>K2B[_H-;/[Z0)36C<TB(&15*UY*X7HDE)8FG[.VCP$&<>
MJZ)T;!"X1#93G!QR=X3)'3A"?A6U=-BK[S,/RC"\B$-!4PQQ:96VJ_F(5AT[
M*C5M5B+!^^<CD+%(3M;"R29H6M*1?0XVTV#$>(4MN%G+=1^K#]N^[I2X\PS)
M9-IT47]$H6D;K*NZ<;/C:>(CZ=8WE2MQJ:8QHS\:IH*C_H2\Y#R?1U'802I=
M&(?=O,LU[A$(*<Z^BP1HF#ZE>[U\M]9@D92=:7Y&L@+$'MP/_ 9^RT8$I4Y8
M_\J1.2JO=O+R0&H=$Z(Y5#+&0'G;K*JW0W/RZP%>"A>L[C3!=S&493IN.&:X
M$2%59HPX-__$T#>8U]0BCG=\&=382RPG']Z84V02P1B-]=^Z.SM(N T.6Z<^
M9.1=7L3J4ELEEE&U^4:GQ UKV'LG6(>>D<>&X**^82=HW&3</823[N8/F^2S
MC8LV-Y@CXO1 +,T\:[DL9Q/"5)LD"+D3@UD7-O?R=Y9&MQ^A\TI$Z4CS!ZX<
M:FY?[%Y4C0N_\<;(P&H-5D1ZB?+@TD[C%2TCXV9D=F:IUCB%B7)(56JM,Z1.
MSM?UJHTXEZ[;&*\W@71QDQ%+\ 6"CS(%<\)6F298C45H0>^!QY%*LUZ)KF]R
MIKR;2$([RO1F:NQJM!/*0AG+*\U$]E9D',?(RYC2_,F6MLKOQ2=Z[S]\?O-"
M^(Q7J0&!%FKHUH+$/)25\^R2]SXF"!X@07!R3! <PE(>N%;ZL/J>S*LXH6 2
M.-!IUG-: KNI2H,B.C__NT$1Z2PQF6]%#&L.<AGOC&:MAII8G()\H3Z:8I$$
MZ[7N;+(M,PJ8>)][H:(N*V33<#ROC'OP>OK'/#-!7P(Z*/-)'2XL<S@K>KN!
MSNKX9O/9NE>+^V#L3E7HH=$8W"QHD'U6JCAM6,!F-)#KMW0$$'R.#&ES,&.0
MEGL G.W^DF*EKA,$<(V5.FH#7BXS<:,J-RF'VB,E; RFJ[&L&LU!M4XDW9UB
M_(6!5^Y3.)F-!1I9'-F>AWPIYI.H3K%&E* G:SAU4;$6U\3*BSK,&9B/#>6C
M[9P$$@=L+H%L1PN0TC@;67+]HSEC6!BA*QXK^'CBC.;Q&E/QFRK?9#9/]>MO
M[\YU')8(6->G,$@- Y]@U,S%-F;</&;V5]L$T36A/ATJ95DK7G D+]#7Q[TH
ML<4;<&[!F:/:0VK[8#2.0;BM:?2QD@)M"L$+U*V[.92Y35+L[OEL&)) +M$N
M4/*",?.F\X\;];VUCZ+?H]-=\M"^]\I!ITM!2[LM G(0BQS]')-V\-O9'?Q[
MA>.8]<HEM+ K9&U"R9%2/)"<AXM2IDZ@:+5C9+L-SMO4")I* R<10S2K.ZSK
MI=10<%V"1Q"L6*(/)V@DU"*!O>;X.BN,.-;@/(,?#D?#8# )J>OU<!]CBLE9
M1""\KL=RS!'8L6IV#=^1:]+!YF1;WRU)2>2QR"J$G6_:^TCD+,@[:)]'/6.:
M*[AD\LT51N330";EML!H#HVX$1.X7#M:VR0'-)ZN<!S6OO=),I&D#@G1N,@J
M[?!B!W?X?8I!8.S 2+WP<("%@)A0L6E]"A]?8; 7A4?1R*,U\A,F>@*[7V]*
MI1&N#%^*'!RMSI/&Z466T,T[[X"%N LH5KHA[SI+8_@5I1\Q6XWR=,&]Y%:-
MM>PBCF5,K)TN*IY^)V JN2[N*?!/01' WQI4P5X,:V L87-BW_H)SC06B1%[
MJRUB.Q$M)FA.<V.^68G[.]R11.@; %V3V$%S(EC3/$#L7(SDC0:$%/?L"J'I
MG":G<HUW;)*Z!-LNE ;S$FENE2ZDH3H=FY2P*K,;Q^'6 A&YQ<B-B3U?:P+E
M*%@)%U&"N&4('- +*")8<H*I*SR5MH4")AKXWMC7&\E _VZ9!!4L)0#Y'*Q)
MY61"A_@6YJD\50$+:9"32FP_O6%@GIW(%/Z#[X+QFR#J)@X%GWHE D5XO-&Z
M\ ^14["M^5'U9U>4>!A[,4:1A4A$*;!#.&8/XX1(3P6*+Q5I'M6F40J_P.H0
MO%,CF1UQ+1I?B@]>_<^OK\[_XT_#D\ES[YGSJ9]LFUYWZH,&V'=;'<U\+!@J
M_N[RD_.W+S6[:=ZLY3^;TZ$<C<-,;=V#H%7B8-\&UC"%K\A2(RYLI5D;.4+/
MR1%VI_$Z<S5.KOWF23U:6.MKSXJ?6,D<;B;OZ57#?:[/D=T%:6+$?FN*C#@X
M' I"^RN*&9L-CY+;EX<SQKA-)S<KG(PN DZ!8V5#8S':UB82L?WNG8HISNVW
MFY21)> S$FXG>N/ Y>F;*R.\-(!FA?Z\#!%JH>EK[A>J:RRD1V['^;I&A7'J
M3U> UV80@$CY ,8?#R9QR4A?@*XNU1*L.\%;A\I);P';C]Z$=^2A-.^#8'GV
M(84#^Z#BNB9,RO6I%L9^<S2'N'Z"S@IT\(FZ%[A;HU6Z<A[^V.-Z/O+N2R4;
M\:U0KP'IX0()/2)1=EK4=6MR=O6)3P,U*+]5ZKP+$Y]1:#-?@:PP!FL+ZT%H
M(X+W.(BC%I"1O$'465QG05:O;(="#KN^V]EF7;H']-B114U6>YUQVFT:-5=L
MI2G9OQBQE(+F_L4[H;UQND.H19EBR"26]O%9= J.CD)Q'S-.G*+I<.M% /4Z
MP456)39;R]I:;)T[S6UM(>+/L%(>A)ZT;5Z*%:#+>QK-H&64N#NDFRM/G9B!
M+6+\V7T7CP_:S;V$.T",EJ3=0'(&%(3<BTFMIX8[YE8I#([D6DEU02U ] 77
M6BEP$P,:D2Z&GV@1-PW6I7SD!KEC,Z'7-EGJ'#]%&UL74*ON-#Z&K'!'"(JQ
M<"%['"9>!19LQFZ=4ZMCHFP=*<#?9=%<%ZE'K6E,LL:U;>*+K*Q5!K/94TNY
MZR_/N<-7("5B#GC->+]4Z 1O1)V 5C?*+#A[=-4VL'[6K@::H_LR.MT]*-KJ
M)#@#[R^_GO>]%S39#]^PR!FP@ W/Z?IK5:N%*N=!^*60R ./'&[I<1(BC*?3
MR,@FDW&*@!3AQB@K8Z'41-*N#B:U(DLJTG5-E:O[F]1"B:8CR2T:B>@P95?.
MM]86@J9,,-+97A9%3MJD[)MXJG#^S6.J3)9AENJ07[ +5(X.%0I91]1%V &&
M@(2A+KO]60,+3;<S=\J1(ZFE/8GA0CWLAUG_:9AP%DMD[1TZ06WLF & G569
MEP0_23O5DLYV=&@0O"R58Y"CIJNW5T$VM.U'%9?T#5MS*04QIM[6>%("!KH)
M]"O6=H2%WCBO.F(#'@ ;<'K$!AS"4OZPQ8,(%Z@W&0 6QI@O38+2*6]TR]!U
MLMZHQ7%]04'BCI3D7#-&*C@4A[E,[D)<E(YZ=Y15L[&T!5B:V2,[ZLL/7^60
M241*(!4MC,(81\D&N;1G=K</>@,KS#3.H/MJ NG.)5:XGC'$9G;1&#V$O: ;
M(<4N?(B^:DHCZS?IQAU7MOIJ%%T";ZP).D<[=W&UDA>IU5HX:<<60%UOE\UI
M+'(CWZ^[96$]A4>#KV62*&;%N/:^8YVR,U!"%XAYECF(E-9SUBFOL4WZ&'PO
M87$4!U@/RL<:TT]$QJ#2251TS_[!Q6&Z":QQJ7X,2O-'G#W]%41]*JV;.[O'
M8Q.W&J)28SPJ,6;T3!;I4-!1C^,:O[N[9]8&CQ*^$LQ%KA*2,:08Y..AKX?-
MD:V)M/4SZ:R;I,S"J[?GM7:R^QGM&D6! Y@P!R59>HOFIVNKBD;=*'Y%@+#^
MKIY'70[W!0)>ZIU9 MT<T""FMAOE"V5\I1>0;)<WF Y,E9B%TIQ05Q[9#O#B
MI#'8IGLL%9/R@J#WJ#ZZN]GH9"60GN%'BG?5.X&4.+M8>\<8 EMD39 ';LWP
M ^=C2W17&6JERYAH!D;!S8YT@A9/GP( GS7D)4VXV)!TD/$725K%>4$NZ$5\
MD342V;[WZV__]_-O']_I-!>N_/]__^M?7[W[]%9^Q\*!_$#3):6>$7<.1Q;F
MM)VR-3%D\ =<!<JY98H=Z<9GS=[PA44X"X:('0R69=*>R[;E<M##_%PWC:8K
MTGJ$F-G87MD-M+W3&'-)::Z\UFFKFXWZWL<&.07ARLP_<_@3#Z#[V-QFE@J1
M$,HZ:;I&60 @M*RV4I'N,V+):!S=(K/4UK1:#.$'12WB4QLCS"=)!+I#AM!-
M<[S7F3EGE=&!"]AS4)V^[@S4K$\3]E[&E"C1J'6LRD%5YGL*>X[9:#+\[G\5
MWINT*..R$G3$1RIW\?Z28?3!="'\^)=:WUBL8J]_[2]Q)G+T!6B\N*3AN^[L
M4"ZCT2XUHYD:BR_)_"&$BD76Z3%Z.D;8H5,"Z9.'^VE$P1HXG^[:])TDCO_@
M5#G)P:(Q%/U6T#W<"C&(!'P:[,:Q9&.^9B16W2!0HXM21ZG@8=/OY[J"WFK"
M"#79%+JA=5S@GY=Y5FT*WVCZ914C\"OERD.ZKW65+$WE8*+298D!>W8#FJ\Q
M7:[J4\R!^=GRMS AR;7XIIBCU;!7C&#[=S>X)Y<,@G4=<T_IFFWIB\M&G<J*
M&AWXIAV+TTVCL1L=WRF,49&#)"UUMY-6H8Z5G;5Q-;K!].X05I:;U;@BO#X2
MH-:3F9POK$D4G7A.SHI.?5_1T9?$157P9.Y&XS<<BXR^K\8E%1JIJNVE1'C4
MKS%BFY#T 9AF'DX[3H>T.)?NH/_,X%B3XX(#R3R!P\CRY A:EM0EVUHT"4A9
M2(?;UT[NR_:;V ^G LMZV6QY9KI1^^RW&;P7T2N2*X+KN:QM;N8#E#NL3-W
MD.NKI"JZ9:8Z/;XU -5A&@<EW]6C63_#Z=5<FZ_^='LU,\F 58'5=YAJT4$<
M5 VLGLECU79@=QF<O[L)D_39M,#?>@6F%4?- 0&'7Y=IQUH0SSIC+RPF/),"
M/HI*["HBU F%YI!>B=^P3U(BK'E)4.(KNJVX3[1C<BD8M,%T)*8QS%1!TN-@
MC&/Z9_>*=::7L]A7CO<][ O[4"N;92QL4%,:/$5#!Z6<$V\AF@I#I6A\K6F"
MHQG!X8(2<8%T4VE QZC=Z%879%];GE]15VUKWI<+QI*0#P%JDW@9B^0R\04+
M@(QUHV8&=>I7-QM&V.E3K6WR+V(X<^DU6BN^T+_;,$R2E;WN_.1(8-*L9LAV
M=[:RW@*+.O3KYM"ZH* C;UYKYYERYV*>IL'U-ZS':KG>THYCH 6+(^PTN1%V
M;C:_%>?!9O,NI \KLXK@G-O]..P*3<L.H/T(C*[0H@T:VM94)%'(QY3V6H74
MKN\UE<@-UV/W0$9L3VRG^37J:?#8I&TM-E.(@V5*#A%R!R\NUC@SHC 3?]#"
MI1Y=D,!O+96,X? &W9K:;K3*:OAEZ@A46R6Y;:FJREQ'+MU2$G@%/E>CT#A_
MJ\MER."$):PY1BKP7J>8ON6U7EOF;2KB:7M,L#)]%6OS9)-D:]+4,<YN8*V@
ME4:[U(.0L8[J(+8@R2XE6$V!:@JJ=^MP[-W;4%0=:ET@1[9EKK3\=MQ<6P[2
MK7-,Z+Q17J;?[AM=LS]12_P>$]277(@A/$*]&PKZ)[@@6*8 QPO\&W(K1RDL
MB[#ZID#IR&.1J"GW8>NH-QK'Q54-M>">7V_3WJST1ZEV$4>5,ZJ _/EGC'HA
M.W\T&/BP@9]8YE'W!149US6GF(U&R7-'9B$ZJZ^RA+F&.1U= ^H/T>[EV?=>
M6=*&];&V2E2#ZFB+R/OY9A4X53([J-XZ+#;;0\@_/$33YY Q12T=JZNBCFT/
M'@3:<':$-AS"4OX8;0]^%W06QH&4^F)@N.WJXNOP4#9SAQ@]GEDFO?N[%%QC
M2A0'@5N KH5X7/CEJY5?6TZV?;*V'5]8Y2@#723XB__$U.6-X\"M1*E)6R^P
M9"<RDQK9.*S9$YR*S@CX4)3)]L"UK@%FQXY!S7%+IQ.;5-VCP2[9U [?OA:J
MUVAX#5H7]70WC4.ILLL\U[1UVE3SA)_'[9+*CFZG\L1YG%D\C]=,I4FU@$'S
MFS$63L$/[GC_SMX+AP:#0HITM7<D;BCMH:O+DBY,Z=+JF>L=NJE:[29R<)K,
M3P.!<6U,I^=TJP0+0[0V/+A[@-PU+39!8JQP9FQ^\(&MSRY6GDLXR(Z6HNY<
ME=B7PAEO83MQE6J9,S.4F6-68C^]I$0&0[);(0P,.[,8W_KENW.?';J$'6!=
M^$G34H2B_]V:!<23RSK.FZ$+5.IN:O"++3#3VG?SK[00O6CTTTP1:B)R+M#^
M?M][EZ781S"AW(PK)S3G8>12%Y'N'GTH#G.#(6WS%M//MS/GY_1I"U<9R@CJ
MTYU=W:6L7I3);0OLH".S%.E!4P]I,^3EJ10]<SB;=FB\X*WC\%X71''2N"WY
ME>ZL_R.X7)I2]:N8",I)F_@"ULZXJ(.;4W0[T6:NI-O;XF87=L^S= \J>[&#
M_8.\ACLQ<!]G,KC?FB$N(JP0BX6%%R)7*76V-AE1"H'8!SD9]SH T0(3G8@3
MU[]NC*-J;#8+!-ISV/*!,R)F+)J%<5WYH8ZD<Y!L2[=N#M@GF&/6$_Y5@+H!
M?Y%B25D>];XHM>&O(4^45&[D4\8]DWZ9V)BRI)E2]+^.-\!C VP#W:M;.%Y#
M3Z[1'?!0148 28GTWB:W_K>O@ZC4_0C%1EGJ1EB,Q]NA^H $46]>56EMR_Y@
MN;I7EK'MKX1;(X,85)XO37Y+@H!3$F0+]H*DL'&<1!N-R#!CJ@+LPB)RJD3@
MB/5L@0W>U)KFTU/:D\F<$+YC*O:]<P-.S-"HT)GTI;$E6;<BK,%".JX":KD8
M+4R.8R^4+-4F-F8C6H#(9N,*Q[QL*HQ(I=M&85\[>;+@CFY;;59CRIVK5FOP
M>[XWG>M@QZ(S9]L)$/=WD4.*MIJMJ#IXZ]:ZQK?@4*3J.[DCAP9^V3>PMT%_
M/%WV$K4H?QG/=*@OILK:7WK#TT<[5,+>S9[KC3S\$NIG,YSTIW@6#"QV[I,J
M\N/":8;MYD>QHR'((>2!&NIH[_X9.B/:L.J>'R_XGB[X1LU-Q MW!\,[PSHS
M*0L'(V(1F"YEMT=1\I2!CA8<.T=MXC:L"CL2S7T1S:WOU.F/@6VAZG.EV:82
M^(VI/[ 87<0C8$XVU7-TS->!W%#_V[89E,BEP-OEBOM]*%MOC2&J@--S+K80
MW5V>Z2[&76"<#%J[1()OM.$C"=XG"3H>^:Y.2_5IPJJKNMR-^K?4G0O+/E[F
M$U!".Y2&"936_&GF9:G#*>SL*/Q!*(6:=!]O_A'M2V[JY:+?S6 +$M3[94^.
M5WA?5]CL8[@D+S;B\K]%5NN'X9DVK_4N8U2K98KN")XB_4(0N[\5XXZRR4P3
MQ+@N\-0M2," ;BTP175HA3K2P(.R,::X03ASLB!T6F1WUG+SX()VZ)+4@;'O
M?*Z"L.8>&FAQ'O50/6R=)Z.FH'0!8ZZ38(ZPCBQO%!#>2/-0*8\T]*TK$G=F
M8H75)JIX#@\^TML]6G_!=7'(;-&VYZ@#5$WT2!$7X1O7F(/"AV"669?RWSYV
M03HJ3IV$V7ZMGHX NKLBW_'@"* [A*7\00!TC5;WB 7&L"CGFU"_U=(8$0B2
M@C,\ 7@P2R=J 3K%YTZ"TLU9@FL!/A*%#OP.FTNC<^)32%TR.[4F^+IN3ZM2
M=R(.Y;6X7!:;:4<"TT&S>VVAQ1LPJ2C5YW86:+5%Q?G; 3<J_%>%+Z/TT3RK
MRIK/O3#=:2P8PTWC4!>U!$=5;W7)%9^<WYCL8$:O8=JX1*P'X2P:"<1;Y"8(
MEJ1'0>Y(#YHN/[PMWVDHTA$-P]0WO,)%"]3WTM&)QRW:[$H92:-J+BBM5W@R
MS*R)M?+="MBN!S8*.[BS^IY&D6Z2LT<+G*<'C_B0RS"4W+9VR>.UXWUVE9OH
M7H?4!DD&T1., 6%8Q4KBBYA41+;&_[4I4TS(UELX</V,:9M[Z+B%U\W-^5<=
MQ<8YX"S?[WRQBW?WM3@!P58!DD8"Z&)GG+39Z 9/<SY,J]4K[[X!:*!H)+9Q
MZ9IW7H,:@\S!SL-LB3I3->SMUV>32A<"KA=G#*A,F]*?X_&@7K7AB<HB9/#=
M^A.T8MWQ6*,\&PW'<9@F-6/6Z"]6"[CFQ%Y=%P<T*YMEIJ8[8!3;V6( /TE,
M<QNM"II3>G#.;<(HC2Q2 H5D-",U6C*5-6G6[$%:ZX1FVPV8AOMN W!$%?2X
M?9AT^.GM6%'LM'WN&E!E)\7<#IB,1U8')C<T+*8S9/11"^OF]'VJG[LM90+B
M67$[/!>9G2M;KD>[L=D/6!]5FMH J>V"5!LVC8V%1="7&8@7/5^K]BATV1V@
ML7_=8TE0,"ROQ3.NN2!&A;1-*MR(?OU&+$:1/'/.33N3?BSL__^Q]ZY-;AQ)
MMN!?@?7N7)/,LC@BI7Z-[*Y9B:34G&DU:2+5NOLQ 22J4@0RL9E E="_?L./
M/\(C,Q)59%=)8#<^S+2( O(1#P]_'#^G8,)UHF213<LC)SV';!B*Q&2-[$+4
M@R(W0@>7W91&H#F4K%K7BN%AN!&38C5)*:R<K=O%>P+"A8_([;#V6W( 1]!'
M9F6.V_M[13LZBI'!;3S%TC%+S"C*@3# M"#)IW?.?UOVN]F[KER\%R@#YYEI
MO"]?_/U[BNR_^//77SQ[9H4E94P)<U7VNY1B.P'ZB)?MZ7T,Q,0\2Y$DVFAF
M:)X@>5Q?MZWHH@T>!+9-(6J9%AUMQ&F04WV[^P0@CS\YW9PC,Z)'2'C#MR3"
M@/W][(NG?SHJ711YZ6@*D:2>N@FF%;@S/E?Z2.E'9SU=G'#0IL/E)7=\-<)G
M";&/AM7(V.%/MUPN(=VV;S85-7GC[ 4.NH_/OH6@)=D[$-COFUBF5'YZWKHJ
MNV<0'27GJLJ-B VXM]^J\&LTL,$>7+B>?D24R@Z0<,,;@=C?7AB!&/5PAXOT
MD$J[:%<76]#^/W5_X!YF]\=G]L?XT/3*5.&K^\4^# V5=PXR506C2#'%<AA@
MC#T+@-+\>U5,Z,J* *Y2$11:(:"+S>L6VZDCPY\9I,AN.J]BJQF(! 4CST-=
M..P!O0=_2IB#SO*34WS[POW&K"/ANV@<GV_J72\'$SA)*_^;$]_;?PD>X WU
MK]QC8T>-']-RS%A9S_,U,K'IR1;IWA",5RGGOK@RX:\WG%D)'\E>TR0-H,YJ
MI<'?6\T(B@+]'+M.3$!D>O_4\I ,:ZW"L/<P<BO\DN5=C-U48DS]4O"%A8N*
MMA"O$4>FDS!$Y._YZ1W9*5>"(VH6GUI9H#T9B+)OW:"A;Y0H^Z1Z Y2Q6E(T
MYH4I@S5K-U.4"S=SP-$5.26BC.QRT#9A^R:1[39*:2^K]=KS<2-546Y2O: X
M!QR\CMC%7(HM*:_Y'<_G5O3H#:V=A+().7@X2Z_;)?=G&G(D72V>W>/H<RD1
MS+'O*&FK*IFM::/%R 2!*+G.=&^O:&7T)_@&#]*(F$,I>8@Q/@7V!Z<!!PFG
MSHD2#N[C@6DYIYS$$U_FKXP&D_FR)")'FL/3[(5EL1!EH'F8"5FH.4IX4UFB
M!2HLW%BKQ:_4+U8,&L9F/XQVC=\L#=-9#A>9$EOZS@EL1]HQ_G'H9D8W&IYY
M4466F56[V/>)J61R8/D>O66RTOGIVFQ2W%:F'HIK[5Y7Y>^XY<YUSU^A[OET
MNNY)3U\O__?O[J[%/7WV]'?G:NF_=K7T<7VZHQ[<#U2]# ;0%"N^][B@3\XA
MY<YI9KC(,IMX3\O(3[LV'",[,;WK>EKK0ORB(^2Z(V"L$O)FB"3"*U4-PA@7
M0L;Z9'*H&G-M[+VV,_3$/8AWUR..W>CC$BO#\0'?';92 *G[&3@0$HD>84D#
MF27W<>([J>8"QWQ\7B-C06DDK;F3:Q/>5QF4Y5$+YM^A^NV6*#3_(8V4[$:P
MYQ=CY<RCQ^*'>('A&U7T$$19I686P@7YF6OBU*9U9 5K&I=%N:7EKRS8"1NS
MIP>HC095^X*OZTX4OU6ZII"(M.;7[TF(?JWB.#ZEXMB,XQ/3RE<G"DV3T/D4
M/L@H=IL,QB+$ V4XBM5I0;@4O-Z:Z9[CWT>EL/7L.TJ[)O9H]@8Y-?*,-./U
MW?=O(F5^9.DMN;7XAVIY2U=Y#B89ABP>).^ELC2#UNV(U!BV5D=]Z;3PZ.$#
MUQ45\0SA8-(0]/O; 30E'2ETZ2H[[0359=:\H=?K(.YYDO3V7.=43LC]&H 5
MY&NC[QJ7I2\5Q15*28M%&!8JU,U;)PJ=6#Z' TT9*U #.L)":38V1V)S'\LX
MC#S4<1[2<;JBS)3U^<Q1^U38RR':^+R8T=B*.4NPL.[[FQ9:N^F5'1R62^M1
M/=%=A>Q:H]*ON2\@A/*@V[BVD85&Y2KW=QBTW"4_3XSD/B$1&;/U#UL^%.?#
M]_ JK\<:^$5B(1VA3;O$9HJT]K'L1^1C" Z=IE7Z:X'OB ;5_52D])UJ)P[%
M*-1/1P]*XDG*PO:6EF %+@'"B#B3WY5Z?F5I+[_A]+?\LI1++^VZN5(XF0'R
MI#A/[J'DZ0)!D4 @&UI>&#80^7?0C<ILN93^7;-DN2M#&7(8OX8CKUE:<[#D
M]D,\2(IT>2-EDO3M8'SU>2T-#7@]TGI'7S4:OYB'YH6\79>BUO#J;R\HW+>[
M7K?K9>3!R&S%J2I7>G]=W*E8M8WPV(41(1;D[](95[D^(W>R/\![,!@-V9"P
MO?&V/J.34FBPW=X-G$.YI!YU2+(IV$97@2R<":]KRC([4:<!2"6M#'@#.&WB
MYM7NEBBV\N,GJD$$YH3.-%8;GG[@YJ2+06^>G\'<)LG>GM*I5&D1@GTW!G4_
M<XC,<,'L[\-UE==IT%)Q8-[VT[>%RQ;;DP33J +([(&-ZS/-#[&PF).N4T*'
M-=!!1Y_37D8+[5"B?" E08:F+JZKY1ZY\$[/$+4A+BW);EO^<8PX!QFU&VZ3
M(3Q;@W:MX(41",3_M5X). LN:LKU[KTTU:Y(8*X9 (.O@K4='D:H S-?UI?T
M?%8C'1\.,3!BAK1@QS2K4VD><583^A-$N>1<>!ZL1*LEQ&G-S@R7\Y,1VG#K
M/H>''!9F'7 B<?='1(P;W<8.-@5(]S5!XN(W1"1&JB5AH>_)W^91[86VTWGA
MGUY:XL7>Z#(<<5,8[('#[H8^$N.EW+G>I\K/X0?.!N^A!$6N:Z1J@!!-^'D$
MLX&@F:3MP7G/2P2I)RT]9U:.)W[KK5#P<2N(*FT3BRC\:7(=\4U=0.>TF0 B
ME-<\\?5T1_;H-TH>?2))H]8K^$ZED!XZ&$RZ)0Q)3!&?<.\6K!>\_==0"29+
M-I7FP%+3E!8;@I*ZHFII&D)GSJJB947YH1T,?5@MZY9F;UW>:N$R=GY>$<*C
M47*X/2G)B2@9GL;93$>(&'SDY=KQ&@;?AO,$U^4_RFY)08<&&GS'6X(D];(F
M+*L2[EAW?$_'L>=<WW7P\7I)RPT?7#N2/.^,*MQ U"U)^*G8FXC=T2-$\;SL
MR)SXFODNJ]+)KBB)'YNP7_4+&PQ@)<@CA7X%TP<L('X!$N)A:$%JXE4_&S3D
M;NN;=I=F^D;RB2%VHE(\(3>"-=QKM"W]X&G;.259!4)3-Q/*H\R+B$X LA A
M9H#7O&/5L:B/[M1CXHZ!;%F,K.@=UL3?>('WTYO@J;-9VVJ!O*BRD0]-WK9T
MY.?[+O>:3%7/*6G-[^*K'/<QC3]^% :^7[<RBPOR"=!S -*_& =HQBZ\*IKS
M_E%%6>J?J\64E_DASFLNR9M-U)[A"8\/3WAV;LL^A4?YUP$:?#AX5#.*:JC:
MX\6U!ZVE_50IQ$P/K8AI#)[BDIZ%;J04)<'"'!PV'XU*T'-;L*H5M5Z'N6'D
MEEXADN^: 9^ZM@667O,= =AD3<^@BO'8Y7,C!V148<?8& <GR8687JZ7_Z@/
M+=T ^U/W7<*<QM-/ D[QNJ[KK0G$C2=<"&.ZWMI7CBPH/M)8-2*[M%Y#]52O
MZ-/*#/F0A(#+&DA9D.-=FH>VX<;'E87 ZG=(3K"];:)(3KQ9:[J?K#<1O)H-
M=Y]'Y9_D^ [SV_2K"A0K/7X"=N4=!"9WY"B$)V3P88BR0,86QKO7:V&0AYN1
M6_^L&%_XPJU#QBP40$E4]+AJH1D9:2O1VI6D<Y68@+7NKZM33S%=!D>R4D](
M:;]M?KJ*HA%'T1J\4WBU?:X@-PB10UA4^4XA0$A_J7F%CFS-,=#2/6CAGX3C
MQI8D,D\KXK"X-G4:/+9='2(@X_)@[ V1WH_!ZW#I<%X-(@;9>2)IN2#"_"AW
M\-WW;Y+02KI?QW'H9.0K4&!M,G'U>R;GGPDY_^=FR0?LRHFR"(T.LB4[E6K1
M0CKISW-%B#M7K#V$ ^QAEU<2I,1_^.&C,2/UT[:SZT?*<^!5["6)G$2;)65G
MQZ_1A"YO>)U2@!T\/LRS,FG0Q4M*[IJ490L=)9(J0%H_;6T50R$HA7[GBJX3
MD8 !ER6M2ATV"\ZWD'!SG>%1.?&-_U.E?0H3X:E4R5%2@_ZEJ;\OV\4^+B[R
M,:1_#OONF[]><DY*8 K(1[%Y!8)QR=UN5EDWRLW!1@EF21*NCK!E=]TAMTS%
M0U\T;&#8944!M.^2*@G;RNC2'\9,_'IZP*SR+^'F$J)&$45X85N#Y))TM22*
MH/$:ARHAI5V.5%2&H_70M-JO4S1/J;KKSFJHM;GC:^2[D!-*MG5MXET>^>-]
M:RR2;4DE>_26ND9EFV.QS,EX> C%.C6OI4@!2_LM&H(^0%3,2J(&4#)L1>XY
MJ22[<T];')\#=_ND4\<X*2)59J9;<&(V-R2;0.G?YB#<*F4X,';L>K$/-$8U
MV>MYOZE56> [ILU<!YN,@?,P85C%E34]K_'RF9KL9(;CQ"L#5L19LNJT\8,_
MF;UE\H6/WAK67ADQ*C9VM7;HCYXYOSB+@2=?*<2[*N.@3_2/R>K8MGU/O<6%
MQ:K6Y+=0E@E*2)Z\8,CS>$I;4II=(R'C, 9'6Y[A(6.S5>)EI:U^S>R_PQ#3
MX?7ETV+V[(MG7Q2>]N!_P@H)48@A=G_\'P/LTMPMN_"")N7#.J7ASN''KJ_]
MY8_Z&\CL;)!O#F:]ZJ2_.)BA;SHJX0:/:-_UE(#4U4J-DN']^%[E+4@Z.AH,
MYE@#W=K2 #UX\/\Q\_ORQT(_NBU[[RB7'#JQV6,LN<"U7H3#'(%E' [9B>_B
M+][@%X56PC@5\/+'6;>G[+CF /C=R$U@^H$?_^<B?"=<9LEK^7D;7<]+Y8U3
MU!7I &)C4/ZWIKW"O"5+M8>9QS%N \3!95AJJXL5T4#O<,_PPZNV78:=-=_O
ML$?"<KPA0'9Q; 3GS$(G]<)K;D-'!3V!LUWP#:6FPB\1]B3N@^"&<],6)!YY
MD[!&50VUCQ8I/):"R9:DIWA5N97WH^)FG:FB>N=6Q"U0*UT;.X620T1P #^]
M,PS;/8@@6D'Y);"S$S<7ETI%14\\;Y<&FKS7"I3 M.JEY+<&/L04)>#VZA!Z
M]SX,XA7HG=!F3UW+!*1"HN4"%1TJ=DL)N>YUL7)D&&[?--4ONCCL67CC\-]L
M=1/<L]Q4MVWWWC(^%.]=->;&D \8'0TI^"CWSR]*%48!741:T)&"*DAX)?J]
M.O-"'A(6%G&RJ8=3Z$XH8E,*%U0T&E4.I7FY@UP?'US$1&40Z2>S2_!61HBA
M0G[9Q[GE5EV$^?C\.U"G?!/.7X)Q??:RN5H#O?%VT>[6>)_P?S]1C>YS [8I
MYQ:</7@IPI-Y($51;*AF]HIV!V69PH\*S0E=D=A'>"FR;/Y@]DE.(4^33>BS
MG60+4?4GG^B#5F"AEU,S1 9<V'IHEO]1C29X$8X%,I5$F2E1$;LN;^"0Z87N
M,]V\1I>9RWR &6=<1=6$D:;B>._XX3Q?43M?UU<")862<Z4I!Q!W$-@_]A(@
M.J>:.K<X2QJ@2BO:#F9K,(ZD0-X-8D)9KGXIEH3L0\PZ[RL9J\T>F42_SVA5
M\N+6["ID!_URUQ'#<;9O:K!P,"$>G]R27]'5)+(V87SON' 8LMM6I/[" -6+
MRM:[&1;I4)#=;JE-=I;"9!JCBJRV2!*HYS9]"H<+FT_SP'<\&L:>H,_)P1&N
M%%X];-RVPSH*%G 37"5-H(R,Z<R(_B6!YKQ?2T.&@=6\6U<EW[NPK]Y>AV,=
MM4J%<X1'$0''02)OWW,C'>_\WL-$V>O_AUJ U YAY*4>TW-LDP1@Z"CH>Y?6
M&C+Y"D#=_=PTBB8>8M)VF5GVZPKXWIO*2=-/O9NI+\CWS*=]'L9)7L(<V^?J
MV)YKWK]"S?O+<\W[%![EWX.*_)TA\6-14O64F]FB:_O^8BZP&[@"DQ$4?$#)
M.U29V#TXZ$@0+LNMA;T^R$6U>UALM^I0?#K4H<G]M<2_IJ#FZ9G!A_)89Y*X
M4O)9!9>$@FO(T;JG&J5G"XX1W\G=6R4=)BK54ZF?6,BQNECJA&KJ\3" 9H5C
M<-\U=AMDF11?538>08V&IGH7[*F,)261)'$D]#$U*$VEO%%=P5X35&ZS+>65
M=5Y=Q)HI@DX-CJKWPM7(%+MUCLV%**SCQ*6%RT/2?:'X8-1NK;_6,;XKYI&;
M.[EW1%&9#H"9N?F',_S<<TF(R\9Y>LE), I"'RQ\Z>0!#.^FT\Z(!L:YY\=)
M.6-OT"7A[SIOG^H,R';;^D8P'4+U/1>>[MZ:L15=Z;!O2R;I+F<W=;O.9K4U
M^H^7F-[WS+XF5!.091@]?B&B0QSWKZL;!R_R W](T!L$O%D"H![V 0)T*UW.
M&6L/FFY(9-'L7" (VV RB _,]VW/>,PI"E,KRA@-;) -5 600\$S[BI2@!=:
M8-)1+QONI.]!<R%5W"$9\;C&;C6!B0LNUBVJTUSDEP7T9/:65H'-C6:XL"(C
M/^0B6(*UOOZB X]Q. "J\/]9L^)2U]-X'&.Q^?A%:+!:DU[?R^OH<#I=J6"#
M;AWHBA_8]:B.F)-/W# PAEB*RE-U(N7YB\0V7@0CGF4?79R!R EF((G-PE5Y
M73AT'*NI",GX-=/-!J=OWPO1+I=K*90.>W5(O2H<@V'HYC71!D9P"8A&VX79
M"*X/V@D?26;KYN=](S7"OJK_(:O:+C-8<?G5!AA."U$5KR<P3>E@Q=I!K\J=
M5'7*^S9FJU/S,EB\)U]P2JDVN#%53^:88)D?X%-I\7YR9.,R5RKHKMMO=^1=
M<6'!DNYE*N=2]_0]P5*,^IG#-*U! X,,O]]+?#W7]!N;H!0GP7",R&B?.#?1
M+EK%@1PI2P1/5);5J/*!DR'>(%)+'I!<.[H-I)Z;<0B-]7#P>9P+[E4O_5AS
MXHL;GK ?[SE!GEQ_D"'RG1$H2J:_[N7L8R4E3ZXH[<-$U][//+-F)"B.<CQH
M+.BYU7M")! 0&MJ1)[Z1&-*V2M8E=VSNKBMUST?JRT4^>X;/I0<^2@\E,R1I
MK.GZ>(';T[3M)8U,!8;K\,@(&F/'(;?<R1<_0*,HH6RSN(A,;Z%-+@ZPJX<>
M>E5E'7&>V6.E!?^:[<+QMKVKD'/=&%$1;D+ :LE".( =4] GK!:1^P(C461Y
MC-(F?)Q%ULR8[Z#]]/K<?ZJ&R-+-.$0946R)F)HPSDZ3AQAU "<TU#  V'TG
MO]3I[W?+:!]K1_<;1H@]UM4O!3;BVHC'))WO.RHHMTU+B\?:?+;_NN>PG)52
M/U0I]<.I!G*TDA]#.F#@T9R"UPMCV1A"I&0'"0_0G;V',=561J=7R[7/7__]
MU8N+IW\.WP\+9$.<<N;G\#'FV#Z&+2GR(,AG;JCB/-S5VB$@R0T6%D"FT[77
MX(]"H Z<O'2I^];#Z U\&/>"3=0DNT)T4-QY'>GJY*C-\]6=M^0C;<EWV1:?
MY"QB&1)$GS"P84#)FR 2I'U/\UPG'; [.KJ)V:#2BG2I\^M)J2155E <#:0\
MI:?"H:IIKRYM)K ?%IIBMF\0!J_KVH[1902 HJUNEY&>^AAB*MV0\6G,7MY0
M?W;=H!'XII9XDP7E.J-XG.J<&,8YRNWA'*1#7:T)+!;9@(1G/[)*R@Z/<1KG
M'H.=Z-HY9-1N:I .C/L1!)=#2G(B*!'5W/)HV*SV>827JLF8N #3G"TKT3:;
MN IG^BULI/R!:ITT0_)9Y9YE+UH[0!2F&F+\@_4.VAO?RWLY"YH_B$U(NB#N
MMSA<(H++&6LM<'&V8V0)PFY8EW/:L"1T5RJ'BVNYZ<I;5\9P7PL+8M^!T*6'
M,@]D_F[1ZZF7II74[$/,19T]22/H&6_P*^ -OCKC#4[A47Y-O,'9]'Z$Z<W!
M$S(=<X,.]:,=;@!)[.NE>O7WN 65P1L 6P$0CU5P;CTEHOD:^NK<1..[.O4S
M='<"'*H]SZZP;J:;KI<EU;K[(0=)%0]@_6#M]5J1'C^'XZZ'"K-TNX6;K^IN
M<X\^FR$K 9?Y7$%8T+TT/;EZD_^M*IXC1BIBEI_IJ_3'@O\6<"/1'8_<NHIJ
M+.OU!;<IAU.Q7+POKY $-ZJIMANY^U-'>QK4QG+WB$3;&CU2JFY7S($+[NJ5
MQ;!F?F1HN"&N.>2F\^"KW#FI6$*<U-U0@FQ:>&RJ78]AIV%=:S]Q4FWQD;SJ
MX%K[;Y8"W@4D+I:6;-^BFN2"MSJVBZ([)DU&@VSZ?9L8"[\U.:UEQ+!>I*+A
MNP:SRI#'^NG/WOEC'1%OW3HCZNMHF;)HA!WCT\0198%2*5/[A-6*#@=?+2;O
M&Q5AJP(7?K]/6-*P#UC-=DR+>YQ]@7=,D2 Y.M^KUJ[BE0KE#W%%<*MN]\R1
M2U(IO:M3D$UB\P-* S)X^I[8]%;T[EJJAMB?1@GX!.$R6Y8;2BXP3?AVORN'
M5&?@Z[!4Y7$\0IK@)#1*O1,Y(D&93PU?0M8HJ!%5_XN'I/Y21B<.63+Q*08@
M#L=Y2S_6EGX]'4K'S!OG0K@>+LDG6LHAWMVZ#@?4[I26,'S:",S-BITK%/C(
MA[RF)#1-<4(D&(ZV[\,U6N#^6;EQ\JO2;'-]Z&-=V;[JZ"_H7#$ B_9R33@9
MTBA'K'V&(55VP/7!R5#^ RDV:8-,TQ7P/'P+R "%0DB+OB_MW#46%WT>:;!V
M!S4QPC1"6!)%&?!EM&R$=X40J5I<U>AF+89P?Q"V$#76H5"2;R&:"7/5'H)?
M'XSLEL"T/*'MK-P1.&WG>5,FJ4M31I7! ^;8F6;P7I9T.S*$8LW F=OO& 2=
M:2_?Q9+<V1H\8@SH^VW4-1TG;'7NF7-S5UWT.R2ZU>,SC)>%4J*$H#^D3C+>
M8A7!<]:C_97RAI"RV+8"(CP6YHD<5]E!:.%)]5Z<8DYT$Z;( *SFT0K9J+3O
M ;:0H%O/*^RQ5MB;K@T>R<9IVP^TO[1F<N_8,&DSF*ZFH.I(5$AKL;<E=1]S
MQG981AG42AC#GB:E.;FK'87ZPW7K<\HCG\>J5+6&9(MU60O33 @>H\VOH<%.
M38;GE?A8P0PX>T0,)$GOF\,BA:R)8X^*7N$7X *C%:9N!B$%56,8J.WTZEPL
M<_*)=$&M^GLN=^<])]6G&&2$LSVV;FAFJQ@6/OF[_"N+/2A"WS$IN*^RBBP0
MOY79RSZ3WCF2K)%@T&HOVFG3:8DQPRM]VG@@RJ=I:XQ#"?125LIHS,5TTW3H
M.8 F4,L0JE(:D)H1\ 6GO(F)T:J/07W&SB7R;#KO1&FI1C:6)%,^2E=T?+9;
MDK:X:(EU@\T8(1&C</N5-,NQ&JBPFB30$7J;*,^1=ID4K"*&6TKH*YT+6,2B
MV(WWA-J#Q"#XX@!;$$'&\;UBJGFKYU+Z*V>2.U$HORC,S;DH4MCFQ15Z"%V_
M$W>%A]?Z]L5E,7OYO0/\NSPN[;(E>K7I/=(V&YR3T3GV=!?SA.1<*OWB3/>[
MC)M\O(YW7S'LKW[W6V(@/TQ*^34$2"6."&/T#HG?-YSX_10!G<JH6TNVQ45S
MWG-GIF38>-^9XP0E/65=B;2U,<6GM+HX0_30<\:OD$ V^4@W]L"I&U!'XH-=
M&P9R<$%NP, V,]IF@*S]2VB>2N->HP1LNS ))WZ21&&T.'&N78X5 Y@X\;X3
M\T\,N'TJ8\FY0#\-,)5I=_)'K+LA.S%/:TW\=V:+!]A*8 :8NJE4.I88-8P6
M!8Z>E1 5?]AO+=5Z;+'!'U-$/,OSK:F^%5F\/>X=A#"Q3Q("3]=M*ZPBIM/%
M/ZR:J_+*/^.^]_VEFM%50)-_.=<XXWO-T>[,7I@46R;DX"*+($,N.V<J<Z-!
M9_=O9AWN7JR>%5&8A@ :M5HNY;%N6 RR3SD4]\;6M&/S>@,U+MEXM'3I"(Y5
M.\G(C8JSZW4,'X:-[D>6V8B)7HQ$WL9%::K@#'%27YYOS=4Z/)V*C$Z#RL\H
MHP=#&?W^C#(ZA4?YE5E-SEF7#\VZ5.7B6JVJ5T\VO=5F.=:<[TQ\.4]!CU@V
M7.  <F)MLL1A(>6).S$S7Y_S;(\TX_=W6GUSK/&RW37W;FH9?N8 .Q'B?H\%
M0-\^+X)'6@2*.=/8+N\Q<B$Q]1H_: 6$"=CWN^[@]?Z0/[,$"\#8P:.Z5_#_
MVX6)"?@CWWRV;$\_U(6/.HP/+3P4^HP$7*GT1$1=16G!<X?DK[5%&3O@@(E-
M==7NZK$RXCBD]I$,?+%$%V)&;<*M-'P3!_'YK'VL.=3^+X-%I[!99@R8W'LL
M:9//"PZ6@$7.Y[E\M/V8PFJ#L]Q5376KH-C[[TC0<C 8"!.[$^T:KDZ@;1WU
M$JK/$:00:X2(VLXNT6/.KVNWU,[T%*0^I)E*]VK;)=P8$/R:'WRKZ;[I8B$D
MD<U(\/ >/\'DVL$I[D6#15B7@<>"24'%:UXV[^G9%P9C\\_F'TU!WS4?"?6.
M5VEX(.M)OPG^7-U4!O@Q!397VMJ*_&TD>Y/,GN#;UU/JO2?N(EWZC"# \/T
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M8Q_%$>:]&3U"Y'SA\AJ'</T,.4?JDV"7SV#3E+R(C@OH$)&-I&VV+F_/$_R
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M1_0[^O$/[L>7"YBCIW_^TU>SS\#0_,77">HH? $?/_WZ<^_3BM@;SD$4[DF
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M*A=AZU51 J#3N@%Y_+.H!FGI2YWS<)W_',\[D=JU:V'%QNL@)K(<G+7NU=E
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M4442$5J2%4-MY:AQ8!Z9'T:KA(8A7+>6E>&.#FT(E('@^43X?>)V5))=&^"
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M3W"GQ9#[*$JG,4V]GBWZP1I#38I15X U6>4/K?R/YEZKJ1IGH,;H %[U0U%
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MERL5\2F<J&B.J9Z5;TM>E$PY\7/K%YPTZI[MQH.ZX7H26VY<@-?B0VG[3^*
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M!AK]G1?_@T+X.;;N'91D/'\<NXV /4@2]P3U.\_) P8\=;>\8&H7.X=9]X?
M0@0Q6+<FB!E9E+4%?<"['CZDQ&A>E) < KV2)M?;@3!8,!:H,C/F)BR6Y;J:
M].R01>0[&E)N$(NKJF(C_A\Q6TN8STF-AH"&E:@3YX*RF(#]KFV7L^?ZUS=
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M%UBK*\[4$EU#DK1+1U<:W!/1C$ZH A*/)W?3#.]*I-/BS""S Q KN1?<\-<
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M?S]]\HS:C==K4,S+>4*&LJ?W^-+,#/M'-$+[1JO%X141 TMZD2)]SL*%2/!
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M*XQ#^?'EU8QN*4(*WB/0O-]9?.)AYC%1A5\IAIQXA*,QI/_-)QE"?GKF,&5
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M.<J/TPW<4($G<77 @U"QJQ%#TJH=<&= L$^%XGYU\*HLQ9H[^Q]Z0\?E&>@
M;E-1:QOG2281?3 U6"R"=NU89TD_DQU^GG#RUDC=<]%:E@8E6D1)$SQ?S+%@
M)@P3.R"U5C%XF*P%.;;N@ &H "87%(U7B[0/]8,/4;Y0XE#[^)E5](I&+JE/
MC[!P+Y?B7[HHHLPY'\,D(JL1"GF6MH*S#Q5 8Y,W7,X7PK0?W,V%XDB-DKL_
M3@!@- <5P(JU^YA/CP*)<TP75S[5A0A^P6K+@;OF"Q02CUY^\L+21@98BQ+2
MML,&Y]+*=^B70MD.N\^]!Z)R11[-AED7F+GY ICO_FC^!<+H01[$NN.[;$<?
M*5'98B:?&"; C@DE2Y4V$)&!"L-%"D5710=!7'I>D; B+#+VIE#R ?.NE+2;
M(8X@S7/E:'[][BBF<<O3B95Y /J6+1IE-Y6*P<3^ZJ8VPN %(FFF 2IL*!O0
M9%B^D7=H:W8;3"WBZ.A?-<$ ."\Y<!UZUO)R2UZ9%+ $\(W(W"I%H_2I *E5
ML/:80Y;&6'?M&?!,U_&J>TQ*W.))9,<:UD5&'=[+NDGGA("6[#-SBG>&2;2L
MB05GXNS1%F:,"1GT&21 EA$KXSP[V=W%K[C N&[\&+QY]].;=V\^_B]EL6,6
M[H%V"^;.P&75.TP-CP@!#\B*,24$_+T$?A$T3SZYT(?U=9+HG<)%(UKD8=^#
MC(KVF02C8C+BZ>=%24]7KA"J9^J0!6R#&CG7A9V:R=,NN&D%GD \"!7PT>(#
MY#S=0N6DCUX=%QNND*I:#EYB@TSX"LB$O0TR81T>Y6LB$[XE445@C,!UI&,7
MTA?<ZLCQ 7G&K0$D<PD2^_J\U\K>H?* )7,JUC$HTIUK<$"4S7+A<9'4G\C=
M/34FW(6[!*RSR9Y#3@PRG-H!M-+/P/QQ<#O-D:3S15XN1<<;TKYX<-(!W[@/
MNGSF/GX+0)?>(8M=6. K?+T +;;G@04CNB/!=T&GM11G;.EN54\5N8C ]92
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M8*<.1@.70GF)='Z6P-N6R#1_&*Z)=3<!9T"P@2<13%305T^TD=RCXG$'HM6
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M#LV<</>"DG<[*PB, 4HY;K8[/T:951SW8"=P*KJ3&S7D(7-WEKE%S("HF1L
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MKPD&HVXP&%\1&X>!-GI"J11O2/8&_'V3^\68WO;==/O5.WG@WE(/'%BNS94
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MO9D\22'('2;L</5CS4?IO_\M.*NZ ?%UOY97W_?0GMXCQK; !O7C$E1J6.#
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M*(P8VC(0(YZG$]P5T&E.=CA-M8P"D:1(B7B;1!VD/.O<EV2_1_$HY'SEP?2
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MJ$8J+</D9<)42$Q-,];_@OHVM:+J$7+T1@\06'FD:S0I%TB6R2I.9&]E6Z\
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M8!0YN+EV6 =OMNY;#]HP_GC#%,9I;C3'GW).7U#:+ZR8!5U:TZ2>X<5P%^/
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MN0VUC01V>8MGY-4C";T Q(N]]</+ !85%3EU&2D'K%%QTP5EJJ*:T[^@-GV
MG#?9W.:)M>QCUO>ENFE5=GXN7*\P5-A2Z^4@@6]6@>/!S3IL+9$S<ZW_*GZ%
ML@DW'SY;Q^,'#=]OZ,' ,*K"&TIECU+J),-"_)<\ SHR\B"PQ5/DO=$5P>P>
MX7,D_,AHR8/'ABY^.*&(/67*2!Y"H+!@.0H4(W-9T1EE.#;D)[T/A3FE+2A=
M0PNE2N=HDS@OX\$KW .TBA'ZUEMRJ.:*2ZY2&B&E-K+%1]F2B.ZY8D\N^5!J
MB+.T6X'R2LM5"55.C]3"MBAJ5X5S>*52?9UF_S:+5@:%6@+SA&AJ^(3$+0C8
M*R*<GOJ>-/)K']QA^3[4] 8V?SSWBR;,3"\J-^39 MU%*=>6OHQM4MK4ITS:
MX+B1.!L(6HY9+;!OGWF3*--GP.STA@0LNKC&)?67F,N9I6.:V@LUY22=OM[G
M(9>%T-?T77N^[;3\1K-EMEMGX'V9)Z;,>)OSTW2F.4RP+K>CM_[R=.K R<>Y
M8NUG02<>>X$IO8ZTQY]R5OA]0JSGV#*I][2D5;RMV\(P2H7YZY9=*=:HKU]%
MCW8?HUVZDB2UT^R#LV09W)JJ!3UX;+WA\-9%7"T7H(,6C&$W)(X>[3T.Q4\M
M_^^C_<<KI:$C9'2C,@7>>-36*VI^;J0>/7U,G^$P>+>G\T(>!]"IK".\1-XM
M=_-Z9N*P&,5@:Z.L0\ZNIY,#,=5S#UV$^]JW4)Z*+MGZ9VD/'WPO7#$3P0K2
M,8D#$D>?LO&G43+^A(8_GVY-W-TD3\ LXO!TF*IG")H 8%:&ZMH81S0.5"Y,
MG+5RB[<BX-@4=3](PA86?EN(D*Y(#G'_/&D.\<"A5TMD@;'B*6 QPGZX\ +@
MYND'AQ9BU!Z)-5D7?2]P=P2CK4:9G85@SD?,ZZ8,5L)3WB.PLD K'\180ZWQ
M#,/+L9:,44Q/ =&Y)IX@#A/Q@,%"_G+,5A(AW9+/;1!;G@<6QM?/3#D\) >4
M[!?X>DG+E;B4/ \$<)!01^&U-Y"&5FR:U2P)6'6X)H_KK"V@^(-;IRU(EFV"
M%IZTJ$K$]K+,!2.YJ,$ '3A?X MLNVQF7L!C_8/*A .T<JZICD R><3/&)ZR
M6)7"E>'/5FY+H^!7RU8X?;A7B4D1;*P1(L<$FZ="#*,VPL1PO,9BO67%,L6:
MST ^L%B"';YE &^RV#7!\87 HM"&=[W# /L&GF+L'4NBR7#_S?7'BS10/J!4
M3>Q=2\&OR>)4J1 :>Z6C%ZC_6PP#(7M)_Y5-;'E3K'Q(UHF[/J1YUP<9*$=/
M,GS\&>4HIAF?^Y*03)!3JM:$I=O@N>#00I318-_I((>(U<QAY%6 \Y+,U""9
MR*8&^A5JH+N;&N@Z/,J?M@9ZS(T!X$<DGX?.FDCI>+$2DUI30[X[HZI]#YJF
MS*Z%O/J#89S4LVB:EY<K^([*6UNIM0@F?S9D>L*2XO[S=3I.D1UN;P\:IG:?
MQQ%Y))S"^^CFXKAU[_I?R7QQ&/VC'(54G!^/_^&I..6Z<_0(["'JNSZP30J0
M0S++V]%/=/"(QHE/3KT1*9-35@,ZX]Y.X[,!3LOF:SLTI_@.[AFMR(+X(9*3
M38BE2E(^^'4M?;CSTYVUE$6;EQ/W1N3L^OX>&=9.\0U]VWH!@"_E]WS_KS>O
MMW9?1DB,.L_&0CA9N=/Y(JO<$CZ"\_XT=<M[2@^IK.5G MH/F%"/3D_.X"\Z
M!Y<)M>/@4P(S67*);@6VRBI;;Z0_E)?RY+D\##)G<T#)<288AF8[,EO56; %
M->?"1%3$/DCA8J XYYPA].XJK*DPMJX)$0:P#7%EA X&.>$N?'.>>\9NA+LB
M=[I:DC-XND#K@9]:WS4V=5=\WA39RBW/Y#!,WCN1<#V".;(W-/!6<2_(L7O!
M.89;A(1PWIA8O%DZ4!IV5T0#C]V-(J,24'N8;*SN*6T!AFF&3"J1?V7<3>4S
M].B[D5?)K&!]$QRO&)![,Z)]"LD>;>J;8LJ3=4J+@JA9B;Y_;T\2136A8&M3
M((/B'D^EFB'QJ*%9;DYCKDEB7MS=I \%"Q"D1^!(S]LYCA>OCA%P9?/5#%EP
M#I,=7)+3ZA 1  $,7\)3T\C.(J%0\./=%D[J-"CWC3AV(6O.:$:YA?^1]GOB
MQ;J62MJ(I48UE3:[2U(*Q 9"T3ID0E_6;,)4@#6TUVQ ,NN#$QC[F+5(+\V$
MRQ3AHC3V]D&FUTTD!.D4,(R\_)$F"&3J #_AAO52<];FJ&NXWJ< $VE3D:$N
M)^FZ=R$*[!GE7:N0(%QR'A-N;'$C-LMJRH="*D=!M7R^<\F-XEBTEFQ."VB)
M9\/&20?J1471V?$L2R_\SW!*G,7D)EY:\%ZHS*L.B9J>VF9Z7(!28TV6GYXV
M!^)@>"+Q@)M.@>RK8]W)5,2,(H K-5E.FS6\J'OI#/(" .]88*UUHK7-4>IL
M[9I[H+]T#FK9UN_>_US[M4"'CS_W0#(A*Y#E&D-.=%*Y^5F&DK[(&P*&'7PT
M&7@HB[@S*&NPD05:U ;]"1SPX)$0'G[-H^SM@.GD/=@QJ^28B+K9_HL]\:Q@
MC\;=M$CK9AV@X>[6'0N@5C$T  /J)? %YQE(>R0U1YLWZ-H, JK#9G(CAK+$
MA73ZN!# '?"S;,%>P38[F$+ #&.9A"_7^4540AF @0S*?SENYRWKMGDO9DI\
MBJA[<K!#3;-% X6G19F96@"=A/Y&X#H4!*J$W^/'H$_-V)#SJFP7Z& $GUS.
M2K@&<J< "U\3'?P?JM:;HU-I/>B>C"A(!%<&_EY*?(I$1;$=G5'W:52U.5MG
MXM"F94 E&1_SO.G3O.*"&/_>9CX1>504B3O!BX1<^"4L_F<(%L.<]APS[X3]
MY+,;5RXW&]*BH RXENIKNTIPC8_*9C90/G+W1;DC=S=4^ 2MEGSIVR(+UL4#
M%Y/:K@EB$*9?&9+FWN7:)PL?#&+ %?YU'^6H<;Y?R^A:]=9D@L2]Y)>KVN"H
M0C4*X/BFV;JL0&&FT&8EX5\0S=ER/B\+6AFQLASP&I4LJM]4W8?@E^,ORL4M
M$:;QPV=I9[V+<ORZ'_)'?J3)Z_,K ?[57PTT\QW;QP(3="Y@M*/1!*[2N>EM
M-H9-YH2.3#A'R;IV332M=$(WUH)O;D+I#_#2X&GCH<?EMGF2!^E:= [05KUJ
M;7P"-0_&): MEGP>:@*Z.M6<3?[RP_4)Q-W]9S]\2^?Y2E?Y%&M@IY[D!7SG
M8]IX9[#^'YSS_Y%X/8F'NLK&"C%"<8UZR+A8R5&)_3L:F#-W!V>5+Q!WD3-X
M6B+%:OBJFD0 6])SO=?<BWPO!I ',1@B],4^<4*X,U(R1)08H4M0O1ULBX#*
M)=_$G^#YF)6-5Q+T?;^9)>/J'S\NB@"8D=P7C0*<U/# Y12.%WSLMNBP<OMH
MD-7T!%QF;J8/02_##TL#(EQMP90K(] T;^GQ1DM*TTX%)=0%M0 PH45ZVV14
M7IB<J]+TOKKA2CE<@,4MSK?R=-J\VG\F9:\,L4JOMG9??+/5A%[ML\-OQU<0
MCLWNT^T#&(O.2<*\_A0 (S"JT:9J:M<*\?Q:*"F++<S^Q82_I'@65"$MYVK@
MN!RNG-/-)/ZQ2>2VYL%&BPZ_HH'@>N I.H@&J,'7H[TH5]I,WYU.'PJHVKUB
MN(( BRK[KF[:22:\+AR843(8A&K@;,%8*5DL[=12#PB:=P2_:"2TF<4[FT53
M91BPE$9DQW]/FJ+4<UJD348J2Y4GGNM2R')\PD<QD5ILYO'.YI'0;<*HMJ#^
M&:R?)/FRSC1PLU6E?J=;AR"1F!4YU\M:.9?%9M;N</?I81>DH(32MLMNI'H,
MFSFXLSF NIT"H3LY%-TMQK!YDZ9N9$#@.%(A2$IR;*;JSJ:JD_CS]-]N6BSB
MD_B8/$6J[24K7 3,HG:"*""80XB^,9>CRZR>Q@W(\LY EGL;D.4Z/,J]@RPW
MEN^6E@]8*@" 0NY!P)$;.. A-M]4RZ <"GC\]#P;:S?J+%NXO_\&-43H:FM0
M61YZ-A-D0*-^F@;ON3G%[FPN38Y"9>2Q55$4Z"QY#%.Z<8);>(_1NU<6^\W<
MW-G<<"8)^CF#9D+544/J'NWT[N>C-G-Q=S:O2_+;DT(-$D><63CW^ N?L>^B
MGL,^=*H)E=@V2ZWQ]&?)'M*5-U-[=U/+<Z6 5T]_"AU8R3AM&^+R(FHO4UZB
MQ!&K.]1U*\4?IFPGOEE(>30U0U2X,Y>[)9#XI)A0P+>9T?M*Y@<'V[NDGB2_
MNZ,,C[?-H-_9H%/7LT6]@&N8D<HF=PD;9-=FY.]LY 6H<.'"]7DZA"+8#/;=
M#?9,0<;(K(T]%9K1[C4-;4;^SD9>4!\I-UG%AF("(63=8YP<*V:>PGHLHR?F
M02<TI-5&Z;(4OKT2._XW$W>'OK/.2.65]W#/?$J7GJ8;U50VPWYW5;@F15F(
MEN((IN>4,-$S<BJ6U2CQ>!J(-8>8==LXT7%/ZB8.<>3<P^*^)WI"=<U\%)YI
M0UXZ]/(Q( M# 5]VF98@H>BAY;BJ#8J,G\B"ON2P0%TFOHZ$!P:F+'4;,RD*
MGQODZ]B.SI#XPW^?08C(:*DZIQT<(; Z,W %] 6:B(A-()>CL'J0UBBTBFLX
M2BV5Q&V[#@=;#0?[#(5?ASI_O_UZO"66E&CY:FCDO (]"LI*/FQT0P*3D1'
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MP/>;,]W&/*N=NSZAW),>\!CM,;J;;VJ\W$#[UQ,7Q\#N#@Y6PSJZB$.'Q_P
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MH.O1OXG["[!:Z0W5&9B'&YU4(DNX@Y^YNP/^BHSD W$@G&C?G4,@46I>,_X
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M%*)EP7#N-3:W?F[@\LZLSK5GP)8"N$"$G_<O]M<;>MURT]6'.?U<&&VSLEI
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M57__CR_'HR>?<3(==N-?GO*?V-,G.$Y='HX/?WGZQ\=7X)[^QS_^]K>__Q^
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M&'&=\;+)S/=Z.CW!_.)D0E/Q*<S3&?IW_&O^J^F QJ312BN03M!HY$Q!4.@
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M3WPX.3X.DZ]=>1ZF1U5[G\-H\9<?CKK);(:3X]?CS[@H 7E1M3&:WJ>M<;L
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M! Y]AI@RMTE83*YU2_G^,_6.(L"])^HZ1NV!H+]U8_QZVK;TZF2<SXH4,-F
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M4((Y:9WJ:V!O*P>U]]VF7%[RW\ZT$6[OBE*8MJLMTCOSLW*"M:*)QA*P.,T
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MZMHW*EK+'7TXY2MU :ZR.6VJ)MGP^&YUWS/.=M79^7JCNPKGG2_X+Y<O29T
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M2E ;_--QO(,9B[PC6JH"),-MZC)M+G5U69.E >A4JMR]T.;JD<KY*;)8U3N
M$>32[6O\7SH#;W"]?HR\O7T-9[!LO[T)Z&<BE(OEY+.5M<D/AW2>")EK8)9B
M")"*%6"Y2$!&*<L$B3&53LG@=]H=V_)H\_(7Y;*PZ:!^5ZQ\7#0U$KQV5;O@
MG5ZB+H"D[P6B*QK.]'Q$]U/D:%[9($;SKS4I[K8V""4=4:$EA&._OMC)<K8L
MJH0KQ=.&E]/;[V+Z*)5\9\1[7>5JJ7CG1K]E"WO96QK6J'AG[</"A, \U1PH
M#FWY.Q4#PF$*-"8LSA1"*.<=/3$#B3@ZDMCP3MK4<<.Q,&JUC.R'$FWH:5]J
M-;764&U==?;H#/45.%K1+SJV?;-=^&$=R TJ]&"$=SL-)>!+^:8&!OB$ VOH
MGCJN,_9VH+Y]>5/Y#=369IV0J/IE8XV^_:X6HC V[$0GN:")S$$.A77^23@@
M+(U!JK*,D5@F*7%*M-I=A+&M$YO7>U%1:1(]/IB?J$9B2QKU;^=-X:#N!8/\
M!PSGF"2$4L )SP"B) <T10*@!"%%5)Z)A/@E<>IIR 9-U]26<&K'Z)(B3OYC
MXK@,]SHUQG_JM#I7:O7;.%H*N+YV1CG4^NDOP+#K8V> ]M:_[BWUL+ZMLY16
MCU4?W4>UO-'OY@NMBJ79!I<3C@@2$#& <J$ 2B4$/*<:)!0J9=8Z2A,<;+ES
MD>B'6?T6:EI5PS:+WV*=D;=^[G%6+/M:!9V&-0 !AQZLW@]Y+/"U,E&MS>J4
MOE;H*MK(G%P_WA"Q4<L.XX9B ]&O#\9#L+&3/.,A9Q_XO+C:J^'.^8^$4K*T
M>R$;XG<]DVUP\XU>)\]8;YXF<<I2:+,AP4PA@!0R.Y.8:Y 2C1G+88JQ5T5D
M;PG&1LU6Z-).W/ONN4:Z#X<;Q?8*<L^4VLI>GQ)50<4V/FZ5XL$@OY'EY<MY
MY+MD6.J&7KBD2Y[]#YV'J1L\!U(S=6RH&_F]*4HQG=N+F!N]N7GZK*J\HZ_G
MY;*LF)AOW"N6JQKF29JF2<QS0"A+ 2(T Y3$ G L6)9 E*K<ZXSF,G%&1XO5
MCI-O[S@W-J5=*\I?.&AN?#G<4 QX/M!Q%+SI,@QX@;CS0F$&)=(PP.VR:J!6
M@Y8BW/":GV@F$R*Q %F:8H!HG "N!0=QDB/S?ZR%W][_?)=CH\J- GL/38$]
M$; HX2;8;O07%L*>*6ZG/&&T+D]X%6W&P?1>H_  //T6*MSL< S5"@\ X%BR
M\-";'</@]C,E;-=),D;E]@\VGISDBF>2J!QD9I-K2W$8+D(\ Y#E),D)X33N
MD-O@(IE\9MIP21".9<RN<Y=LG$16OV?+C0P)9K_V</IRH8>!Y4Q0+,V8)ID@
M  ED;'6:0! 3)!CD.H4T]DVF,/"P]I]UP7M0E?GQBPQGGF29MO%L.23VCI42
M0+C$P,Q0HF)-*&)TLK3IJT<VE&N9_O]A=#V\&FQP>C94#B=[VKH/J!^QP[3S
MP\TW D;PAD V5+CO1;(,&QL< K:]0.(@C7;-\_30;/MNM$WJ.,DA%#E.#*%B
MEIOE4N: ,90"FB92:Y4S,WI^WBR[78S/5V4EH>7"Z9QY9AG9P]"-W#KA,E1J
MH58TBX@5+F1>H<-J!\LIM-/\P/F$#BNWGTOHR'/=9G$5VV++P!IN>#\3\WOU
M]KL][5&3#%*<:ZK-=$Z)+=N> A83 G2JE,IB+)7&?M/Y:%_CF]>5J'YS^3B2
M;I/Z,G2&F=UU9&$C9%1+&?W<R'G<4\1[II_%(M"4/][/H'/_K+J[)'#^A6YL
M\*%@O)A6UV1-@J'5'0@F0E*:,A!SLP5&R"SQ!",$=(R4YBI%*?8Z<3W>U=A.
M6AOQHNE:XM_\J.$$K&[<$ :LGLEA0\A5VK!>[HK.HQ&('DYT-"@_G%=XER <
MW@C@^W/0@3K#&N,<FFU HC% # M -"> (DE2"/-4^MUPG^UQ;'RQ[7MB_2YM
M[E%K#HM-A\R'QX7]S=(6=:^##U8>[Y<X %W@U!X4Z9[)9L?!IT*T#1Q8R=N3
M-\\ CN?G^WLY;QT?MW+W%[O1T4>UK.V?JO H5R@G29R!)+,G$#SE@#&%0)YA
MD2J"A>#:YX1WJ_6QG=A:S]^I<P77PX"E*,&)LI6'L0U 8BH%G&(&D$K3'#'*
MB? RZKH#-@ OAP#,C4@[P] S:5H$VDV;%>V7Z'JY7!3\L7:#- O1)Q8VV>M!
M) )QY';;@_+A0;5VN>_P0QU=8BX+2OVP*BZ$(;*3&H(LB1% ,,\ Y]!89QSG
M,84<YM*KZE,HP<9&%L'"SS]T+1H5;,C=..LE!K)GNAMT#/T=@@(#'LIM*)18
MPSH7!09SSP4I=/LOL@Q<W\\?;7$ 1@44. =0D!2@&&/ $T@!S1#%68QY3KU2
M/0:1:M0+P#HTQ^S1-\ECUMB4ZRR.W4,GPPSN(&SO/V0_!M5?1;5FHV'Y;:#'
M0?&-3#\2OV_#&)C<=QKOZH):^;16USBRCM(TFP=[="M?/2X_SI?_I9;6^W7"
M%<]UAA502$A#W@D%#$D*,H59AEB6,N452NG:\=CX^5WQW99O+DM5IS5E0MAA
M,$S,GNUN]LK^I"IJHNJKL=J3;5[=8(K]*QU?%S;'X7*CXSX&H6?&;42.-F6.
M6J$C_KB,C-C1LUD?K> AW<_\H KF:>;8[<!.97Y@[/N/>;[?C=SJ8Q";R[(*
M(/M@!]E0:5.L@. 4095D0"2V-B"TQY$92X 4/!>*QB+G7H>0)WL;&XTUQW$K
M::-67#\^.HVP&PD%PZUGYCD*60\U'IPP"40QI_L:E%><U-XE$[>7.D9=*[Y<
MFV:[-::_SA:*38M_*&F/6C_-RRI<:!+;HJ,Q@R#-8D,LFJ> :HR AAAS8O,E
MQWKRI!9\[AQMW4$,GYFS*4Q_$^CW0SDG*AMJ%CVN=.AP5])IE-S(J6_D>^8L
MAZKW5]%:B\BJ$;5Z!(RRO@#%4+'57408-J+Z I#VXJ@O::L;5=;IZ^V.=3XS
M--R8 %+EQHRJ"OM9+J0B QPA!H34&=)QAB'W*NQWL)>Q&5=-;8R5E'YL=AA(
M-[JZ&)Z>^6@7F1Y,IY,0!"*3PWT,RA8GU=RE@],/^\UWJ8K)M3&TI#6VWDW9
MW82BS)X'<8"U3 #"9J(S@17($H9YGJLL9D[G^GLMCVU>KX2+K'1NLWH?KM,S
M^2(0^C[M=M/?><H>U?7 -#46XU_NYD^_FG?J&6K^LIZ8^RT-,AF/*M!.P.,/
M=/8[L]%TGQ;SIT(J^>KY:ZGD^]G[V9,JE\7L[EHLBZ<ZV9K 21++3()46L\J
M212@B#*@<RUCQ10SL]/3*<VQZS%ZK%6!(P^-[#;)<-'*';&5X-X>6JYCX;9X
M]X-PSYQ@P:V"?C]M@/NSE=Q _$NT$CZZ/@]S%S<O3\3"^8"Y=CRT@Y@G( >\
MQWQ;")J(N2I=U58=KY[Y9#[5;ZQ4G\QW-V&9IM0F\\094@#%&@+*- :*2:02
MIG*DO<H$=Y)B;';)P83+,S,4D6I46/O^5TI$#U/?D.%NP^5&?+T/0L\<>"J1
M<E//O%6C"1EH%8D^G1J(4)F3W8#L-UOR&1G&D"'9#2;'K,B.C76\M3<[N87Z
MIF9E\:3J\^\JU_(M^S[)XHQF@FJ $YT"Q'D..%8<4,IIB@7C:2Z]TLT<[VML
MAMZ6J!W.D4_!ZL9D@<#JF:^V<=KRS%]E=C<27_7NIN\ 5ZA[]!,]#7MU?E[E
MO=MRAU<ZQEVKLE3JYD$MF+7M/MCJ#.6Z-!RB N4Q3  53 "D;9V@A-J#'8DU
MH3K53'C%7I_L;FQ652V>9\3U:4#=2"0<3#WS2"VHK<K3B!K5LD9_]%+VS@V7
M4#'8ISL;-@[;2?&]6&RWM[I:(%6=8F$OCM[/S&[QSGQ895/U5L5,YDH2 "7!
M &6QX0UD[)!<Q(A+(AC,E9>OX(G.QL8:F[+:N^V'1EI?2^0$O*ZF2!C0>K=%
MMO%J!8W^J$4-R!\NB 0S-TYT-;"]<5[I?8/#X9V.D20[5]$[%]5"/-X_5JF^
M_[HPYNCZHOJOK)B]4GJ^4-883S27@B0(I-C6X6(9 PR)&&#(66:8)L&I](HD
M"2'5V)AHPZW#RNG)0&$&RHVJ!H>_9TYS\KK94"NJ](IV!NPJXI5N=BL6,# D
M)-:A D."R#1L8$A(&/<"0X(V[G^]_W:VM.X"=;#"9_4P7U@#TGI8/I83IC%.
MA$P P3HVQIW"@&=I#!3.4A)K0B!V,N[.=30V.JUE72686DD;U>*Z>P.<1/<T
M88;$K&<.[ J7E_. "Q:=? E.-CR8:X&+>IN>!D[/7Y"O\[J*>K+Y_^HN)CR)
M*4<\!9F&"4 D$8 *8Y'EC'&FDTP11GSLL(.]C(T(WAA@RV*Y$=8UG<_N@.GZ
MOHD+ZY# <P]:-\OI8L!Z9H$Z<6<MX%6T%C%PRLYC"(1,U[G7Q_"I.H^I>3!-
MY]&'PVS<UO;(MG4R2=-,X@0R0&R2%Y08TX I+@%$@E.2Z5AK?<G>[%C'8Z.)
MM^6RN*^L^W>L6-3WP)=MP8Y"WFV7%0+(E]](];<S.H=/3YN?H]V^Z/[F'!CG
MMC!GW^^8%K3)26YZJ>H-/(IE=0<_(<K>@N,4X#2A *D$ <H5 QP1J$F2::8R
MOQBL8UWY3)=AXJRVQ(O$O%Q6I=H\DWL>0Y;F>4Z1L?1R8L_>$NM: +,89"+)
M,T@4E"1I\[/?>J1;O03>[1SMMT,<\U?^I&W)@7LF/;G]*+QN7![B8^R9NUL1
M(\/4T9:0 =.CGH$A5%;48]T,FPSUC+)[.5#//=_1;]/F'JF*M&X6Z-RHT_KJ
M>?U((T-5#7X[!:M=&SX^5O=9PFP>1:YB(#&2 '&;XEUQ 8AD+$DR@C#T"L0/
M+N'H3,NU@-W3/H4?1S?J>M'1Z9GS-BL8;VJW5<:8/T<'*QU;':_:9-)7T8:>
M9N=<:1K04;2O00CE1!I<OF$=3/N"=\_YM+>.>EH<RC,"F<5*JS8C3.U)^S=5
MW'TS9MVUL9[9G6I3>']:%$)-B!T>3&+ \E@ E!I#E# * :6:B=Q\5ACQH&M'
M8 7&MK2TN>QUK8;A)[O ?/WR9IUI,/0Z$_J3"+0,O>! CV"5*EV7J0T8*O>=
M)NRAA2)JL%@51X@J- 9<R7H:QZ$6NM#BCVL=[&EPO)?)ON3HF$JC#1M1MFV#
M=./X)Q6%@C ,,($<('OQ1I!,JD@/RLW?3&M>R30.]S.V-6DE7G7E]DK-E"X,
M0;V>E[Y7;<> =5LR L#5]Z7[*LIL!5EX-\HS,(1*L7&DEV&3;)Q6=2_-QIG'
MNP;*-IG-;K0]=7PWG?]9KNJX94F.A-0($)U!&P^K *&I %! CE.4)U!XU54X
MU=GH>&&5B6^NZQCT2ER7VF_^0#M:E8'@Z]L"[(Y<AYC4\Y $"ST]T=7 $:;G
ME=X/)'5XIZLSW[64UH>[ZN-F447W&T4F:9SE#,84&,O"1FIPNW/.-.""*92)
M%(G8R8'G7$=CHX[&.ZT1]JI.ZFD@C5J!?=WYCN![FC5"HM:W9=$9L X.?:?1
MN,"A[TC# SOTG59OWZ'OS//=K KKE%+YI+R?/3PNRP_&9)DFC3EL-A9YC$@"
M,HH,*Z1I#EBL*$@Y27.":5:%D+L;%2?Z&ALQ5+)%B6>AW5-@NAD.@2#JF076
MGDQ742WH5=0@UL-&PP&30(;#J9X&M1L<5-XU&UQ>"9JAISHH*8^FMB@G.440
M)BH%A"-NZ(-+P!)F_A/#/,&,,9%XA8UWE&-LU-(M2\\%%[P=A\]UI]/[H/2^
M"3J>M:=6XW3:GH!YS"X$L]_,/6>E&$/N'E>H'+/W.#=WX0&O;;BQ$Y(LTYKG
M"> Q00 1R@#!"@,FTTR0!.8:=3O<7?<Q-D9\^^73IXX'N!O >1[>=H-CL(/;
MBF=Z/+3=5S_T@>U&#R]S6+NOXM&#V@./OHQ7W(TQW99L)@T#-=Y45+&4,B4
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M.-1EU%;;PUXU'5)K[R+IX$/=9NHM^ZY*8R#:-'/M)Z=B'A.12I"SU-@(G*:
M, E!EDN599QP);6/C7"@C[%9!'4AP:*^9EVR[]%#+:[?S#T$IMO\O1"BGF=Q
M)5W4B-?#9#ZA?: I?:B'02?V"15WI_>I1P,7&-J(RM<)9%F: !E3 A!4-K,C
M4D RQ2G+N)!IF#)#HZUUMID6=JLLCF-QEZ[(NQ%$6#Q[YHN3)7*:7+G]E#US
MAZGOLCDO%$7O#H!S"9U+(^3MY<^;N:A2DMR:5R=,<ZP2'0.I=68+F4' 4H(
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M DH^KN(LX8?$NV)+#R)T= [:*6-JBY=N7"77_L[U,EPE]YL@F:8XIQE0" N
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MG2:3F%&6L 0PZ[2#$A+;U-\,9$DB,ITF*H.95P#3T:[&9E:O)8U:43O'4Y\
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M7@6LP%$M<52+O"K#5TM]%1FYZR<"YB#R RIDTL7SG0Z?@-$9B(/)&-W?#N"
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MJ1#J2,'2:34P%8]\5F)^9RA'R;JDGRT!57Y8I>ZG L,<4PY2@9"UU>R6,(,
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MSM<8!WZ@4F$_S*B[K8UC',D!#R\VE=X\P8CX\V%/)JOZ51/_MQF;'6WXHS8
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MBYU'7=X[O:!OND0#0=.!.6SSZOFLIVG1*+BD!<(LH8J8?:RD" $(N5DM!.)
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M2@_EVXNBD_S:J@M6&CR:O[ .":OM6+OYT& (#NP;#^ 5BMY$GW?H&66C0MN
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M.A>C<G<T*A=/!P\F#7)0& K?4,U2^ZHS;E_50."=M6 -]=Z0)5BS&$&-,*%
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MN+XW/_WMWW;_8OZP'#)_^[?_ U!+ P04    "  \@FI5"HV20-E&   =,@,
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M?!**=R)A?5\N2U!H"IW8P@+/K%A/&\XW?\7X7D(ZP<SABKX=+1XL]0Z@<VV
MPM^QNH 3E#KIB)R"#5EKQ>MC"(5\S)"16>8PIM+\,=K;1(P+F0:*?7@4RAY2
M[@ F#XS?.&<F%HZZ, .,2P/*ETQ"8A88*I:93JD<:PS*#O 9+%_0'C[MI-\#
ME+X_4..<L92L]IIE0%EG':"EW5+S_A9+EDERGT3K88);$S=N(?8 $!M$*QW
M[?9,C7,NM%.BQ"(@L[II E<0''-@DG'%%582:UW.?S\EXY9EMP=2 WEW@)I+
MK_$U\;(IL9U$XUBHDZ5R]G1B2Y),=%E!"M$$G1V)IG6UPUTJQAX4US[^VD_
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MRW,F&.=:"U'' ]5T2*Y7I3DK<I10)QZR3KYUL\J]A(Q;]],-#@]74A=(.]M
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M^;TT4'D5?K\R9>-%X>96 GA/H#TNZC3 &XB\V,X@WJGKP:%M2I'47<M&!/P
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M,L5S8Z&W19ZY55M_EA=\]JKQ^&]02P,$%     @ /()J5;(+GZ#1!   ^1,
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M4$L! A0#%     @ /()J58X#%<VL1P( J$P4 !$              ( !
M &%D=FTM,C R,C Y,S N:'1M4$L! A0#%     @ /()J5?:HR.L-"0  ^U$
M !$              ( !VT<" &%D=FTM,C R,C Y,S N>'-D4$L! A0#%
M  @ /()J51Z%A,^F%0  [\0  !4              ( !%U$" &%D=FTM,C R
M,C Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( #R":E6S-Q@/UA\  -M5 0 5
M          "  ?!F @!A9'9M+3(P,C(P.3,P7V1E9BYX;6Q02P$"% ,4
M"  \@FI54B)B@X=[  ",(@4 %0              @ 'YA@( 861V;2TR,#(R
M,#DS,%]L86(N>&UL4$L! A0#%     @ /()J50J-DD#91@  '3(# !4
M         ( !LP(# &%D=FTM,C R,C Y,S!?<')E+GAM;%!+ 0(4 Q0    (
M #R":E4(SK>D20@  %@G   6              "  ;]) P!A9'9M+3(P,C(P
M.3,P97@S,3$N:'1M4$L! A0#%     @ /()J516XFQUJ"   ;"<  !8
M         ( !/%(# &%D=FTM,C R,C Y,S!E>#,Q,BYH=&U02P$"% ,4
M"  \@FI52#66X= $  #%%   %@              @ ':6@, 861V;2TR,#(R
M,#DS,&5X,S(Q+FAT;5!+ 0(4 Q0    ( #R":E6R"Y^@T00  /D3   6
M          "  =Y? P!A9'9M+3(P,C(P.3,P97@S,C(N:'1M4$L%!@     *
-  H F@(  .-D P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
